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Thesis 
 
 
Depression is a common psychopathology in patients with End-Stage Renal Disease that is 
associated with maladaptive illness representations. Moreover depression and illness 
representations predict adverse outcomes in End-Stage Renal Disease.  
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Abstract 
Depression is a substantial psychopathology encountered in the dialysis population yet its 
association with potentially modifiable psychological antecedents are not well known. Of 
these potential antecedents, individual’s perception of their condition are likely to play an 
important role in how they adjust to their illness (Leventhal, Brissette, & Leventhal, 2003). 
The Common Sense Model suggests that illness representations guide the self-regulation of 
illness (Leventhal, Meyer, & Nerenz, 1980; Leventhal, Nerenz, & Steele, 1984). The model 
posits that the interpretation of illness (illness perceptions) influence the response and 
procedures adopted in order to regulate the illness threat. The overarching aim of the work 
here is to examine whether illness perceptions predict depression and its trajectory in End-
Stage Renal Disease (ESRD) patients, and to establish if depression and illness perceptions 
are associated with adverse clinical outcomes in these patients.  
In order to achieve these aims it was first important to establish how best to assess 
depression and illness representations in the context of ESRD. A pilot study investigated 
whether the Beck Depression Inventory (BDI) and the Revised Illness Perception 
Questionnaire (IPQ-R) could be administered to haemodialysis patients (HD) while actively 
on dialysis. Patients completed the BDI and IPQ-R while on-dialysis and again at a time 
when off-dialysis (n=40). Level of agreement revealed no discernable difference between 
BDI and IPQ-R scores across the two conditions, although there was a slight bias with 
regards to scoring on somatic items of the BDI while on-dialysis. Given these data, on-
dialysis assessments were employed in the studies reported. Furthermore the BDI was 
compared against a diagnostic standard for Major Depressive Disorder (MDD) in order to 
define an adjusted BDI cut-off score that would indicate potential depressive cases. The 
data revealed that a BDI≥16 had optimal sensitivity and specificity for MDD. This cut-off 
score was employed to define patients with “probable” depression. 
The factor structure of the BDI was the focus in the following chapter. BDI data from two 
larger studies (reported later in the thesis) were pooled in order to conduct confirmatory 
factor analysis, testing several proposed structures of the BDI. The analysis revealed that 
two and three factor solutions had relatively poor fit to the data. A relatively novel bi-factor 
model proposed by Ward (2006) had the best fit. In this model there is a general 
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depression factor that loaded onto all of the 21 BDI items, and two smaller orthogonal 
cognitive and somatic factors. These factors collectively explained 91% of the total variance 
in BDI-II total scores, suggesting that the BDI provides a good overall measure of global 
depressive symptoms. 
The first study to examine the association between illness representations and depression 
was a cross-sectional study of established HD patients (n=215). Nearly 30% of the sample 
were depressed (BDI≥16), highlighting the extent of depressive symptoms in this patient 
group. Significant differences between depressed and non-depressed patients with regards 
to illness perceptions were evident. In logistic regression illness coherence, perceived 
consequences and treatment control perceptions predicted depression. Interestingly 
clinical variables including co-morbidity were unrelated to depression. This suggests that it 
is not disease severity or extra-renal co-morbidity per se that are vulnerabilities for 
depression, rather it is the interpretation of the disease that appears to be important.  
The proceeding chapter extended this cross-sectional investigation by examining the 
trajectory of depression (i.e. change in depression) over the first year of dialysis therapy in 
relation to illness representations. An incident cohort of dialysis patients (n=160) were seen 
at a point soon after dialysis initiation and followed up 6 and 12 months thereafter. In 
particular, differences between patients who start dialysis via planned route (i.e. those with 
progressive renal failure who had been “worked-up” to dialysis) vs. those who started 
dialysis suddenly (unplanned starters) were sought. Unplanned starters were more 
depressed than the planned patients and held different illness perceptions. Structural 
equation modelling of the baseline data revealed that illness perceptions predicted 
depression, and that path to dialysis had an indirect effect on depression as mediated 
through illness perceptions. Over time, depression and illness perceptions appeared to 
remain relatively stable although there was some evidence of a non-linear decline in 
depression scores over the follow-up period. In addition, illness identity decreased over 
time, while illness coherence (understanding) increased. Clinical and demographic factors 
were not associated with the trajectory of depression as assessed using Latent Growth 
Models. However several illness perceptions were associated with a change in depression 
over time, suggesting that patient’s illness representations assist in the regulation (or 
under-regulation) of mood.  
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The first of two clinical oriented chapters examined the utility of illness representations in 
explaining fluid non-adherent behaviour. HD patients were categorised as either fluid 
adherent or non-adherent based upon Inter-dialytic Weight Gain (IDWG). Patients in the 
upper quartile of percent weight gain were defined as non-adherent (IDWG≥3.21% dry 
weight). The data revealed that non-adherent patients had lower timeline perceptions as 
compared to adherent patients. Logistic regression models were evaluated in order to 
identify predictors of fluid non-adherence. After several demographic and clinical variables 
had been controlled, lower consequence perceptions predicted non-adherence. This data 
points to the utility of understanding dialysis patient’s personal illness representations in 
relation to maladaptive health care behaviour.  
 
Finally, the potential association between depression, illness representations and short 
term survival in incident dialysis patients was evaluated. Patients were followed up for a 
mean of 545 (±271) days in which there were 27 deaths (16.9%). Patients were censored if 
they were lost to follow-up, transplanted or recovered renal function. In Cox survival 
models after controlling for several co-variates including co-morbidity, depression 
significantly predicted mortality. Furthermore, survival models including illness perceptions 
revealed that treatment control perceptions were also predictive of mortality. These results 
suggest that depression and beliefs surrounding treatment control contribute to the 
survival of dialysis patients. Possible explanations regarding these associations are 
presented. 
 
In conclusion the empirical investigations offered here support the thesis that illness 
perceptions predict depression in dialysis patients. Moreover there is evidence that illness 
representations are associated with maladaptive health behaviour (non-adherence) in 
dialysis patients. Depression and illness representations also predict short-term survival in 
incident patients after adjusting for important co-variates. Recent studies have shown that 
altering maladaptive illness perceptions via psychological intervention can have a positive 
influence upon outcomes (Petrie, Cameron, Ellis, Buick, & Weinman, 2002). Given the 
evidence presented in this thesis, testing interventions that target maladaptive illness 
representations in order to improve clinical and psychological outcomes seem highly 
relevant in this setting.  
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Prelude 
Thesis Structure 
 
In order to defend the thesis offered here the following empirical works are organised into 
three main sections. Following introductory review chapters surrounding the topics of End-
Stage Renal Disease, depression in renal failure and the self-regulation of illness (illness 
representations), the first of the empirical sections is presented and concerns the 
consideration of the applied methodology. Specifically attention is devoted to the 
measurement of depression via the Beck Depression Inventory in the context of End-Stage 
Renal Disease. This work includes examining the procedure of on-dialysis depression 
screening and examining the psychometric properties of the Beck Depression Inventory. 
The second empirical section concerns the relationship between depression and illness 
representations in two studies of dialysis patients. The first describes this association in a 
large cross-sectional sample of established haemodialysis patients. The second study 
addresses the longitudinal relationship between depression and illness representations in 
an incident sample of dialysis patients, examining changes in depression and its predictors 
over the first year of therapy. 
The final empirical section presents two clinically focused studies. The first of which 
evaluates the utility of understanding illness representations in relation to maladaptive 
health behaviours (fluid non-adherence). The second study of this clinical section examines 
the association between depression, illness representations and mortality in incident 
dialysis patients.  
The following introductory chapter concerns a basic overview of the kidneys, renal failure 
and dialysis. The aim of this introductory chapter is to describe the nature, consequences 
and treatment of kidney failure in preparation for the empirical works that investigate the 
psychological aspects of End-Stage Renal Disease. This introduction does not seek to 
provide an exhaustive account of advanced kidney disease and its management, but rather 
to define the population of patients with ESRD and to identify the major consequences of 
the condition.   
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Chapter 1 
An Introduction to End-Stage Renal Disease 
1.1 The Kidneys and Kidney Failure 
The following introductory chapter is structured to provide an essential overview of the 
kidneys and their function. Furthermore the consequences of renal failure and its 
treatment are considered. In addition a brief description of the UK End-Stage Renal Disease 
population is provided.  
There are two kidneys located retroperitoneally in the posterior part of the abdomen. 
Healthy kidneys weigh approximately 150g each, and are highly vascular receiving 
approximately 25% of the cardiac output. They are responsible for the maintenance of 
homeostasis, including the regulation of body fluid volume, maintaining electrolyte and 
acid-base balance, and excreting waste products including metabolic end-products such as 
urea and creatinine. The kidneys are also responsible for secreting and producing several 
enzymes and hormones, which regulate blood pressure (Renin), stimulate the formation of 
red blood cells (Erythropoietin, “EPO”), and regulate bone and mineral metabolism (1,25-
dihydroxycholecalciferol – the active form of vitamin D). In healthy kidneys, these functions 
are carried out continuously.  
The nephron is the functional unit of the kidney and has two main components, the renal 
corpuscle and renal tubules. The renal corpuscle acts as the initial filtering component, 
comprising of the glomerulus and Bowman’s capsule. The glomerulus is a capillary tuft that 
filters the blood under the influence of hydrostatic pressure. The glomerular filtrate is 
collected in the Bowman’s capsule and then processed and modified in the renal tubules, 
consisting of the proximal convoluted tubule, loop of Henle and the distal convoluted 
tubule. The complex functions of the tubules involve the regulated reabsorption of salt and 
water, and the selective reabsorption or secretion of many other substances.  Over two 
thirds of the glomerular filtrate consisting of water, sodium, potassium, bicarbonate, amino 
acids, calcium, magnesium, phosphate and glucose are reabsorbed by the proximal 
convoluted tubules. This reabsorption is essential as the glomerulus filtrates 170-180 L of 
water and small molecules a day. The distal tubules are responsible for fine-tuning salt and 
water balance under the control of aldosterone and antiduretic hormone (ADH). As a 
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consequence of this complex regulatory system, 1-2 litres of the filtrate are excreted per 
day as urine, removing excess fluid, toxins and metabolic end products from the body.  
1.1.1 The Progression of kidney Failure (Chronic Kidney Disease) 
Chronic Kidney Disease (CKD) refers to kidney damage or reduced kidney function which has 
persisted for a minimum period of 3 months (KDOQI, 2002). Kidney damage can be 
identified by renal biopsy, imaging the kidney (looking for structural abnormalities), or 
more typically via the detection of markers of kidney damage in the blood, such as the 
concentrations of urea and creatinine, and in the urine, such as the presence of blood and 
protein.  Proteinuria is the presence of significant amounts of proteins such as albumin in 
the urine (albuminuria), and is regarded as a prominent marker of kidney damage (Keane & 
Eknoyan, 1999). Microalbuminuria refers to the excretion of excess albumin in the urine, 
yet in levels below the detection limit of standard dipsticks tests.  
The best overall measure of kidney function is glomerular filtration rate (GFR- Smith, 1951). 
GFR is defined as the volume of fluid filtered from the glomerular capillaries into the 
Bowman’s capsule per unit of time (mL/min/1.73m2). GFR is dependent upon several 
factors including age, sex and body size.  A GFR of 120-130 mL/min/1.73m2 is considered 
normal in healthy adults, though this declines with age (Rowe, Andres, Tobin, Norris, & 
Shock, 1976; Smith, 1951). The gold-standard measure of GFR is Inulin clearance which 
involves an intravenous infusion and precisely timed urine collections. Inulin is a small 
molecule that is easily filtered through the glomeruli with no re-absorption in the renal 
tubules. However, Inulin clearance is rarely used in clinical practice because it is time-
consuming and costly. Alternative methods including the urinary excretion of exogenous 
radioactive markers  such as 125I-iothalamate and 99mTc-DTPA  (Perrone et al., 1990) and 
plasma clearance of exogenous substances (Cr-EDTA) are also reliable measures of GFR 
(KDOQI, 2002). These methods are also costly and are more appropriate in a research 
environment rather than tools for use in clinical practice. Creatinine clearance is another 
method of estimating GFR, which is more applicable to clinical practice. This requires a 24 
hour urine collection and an estimate of creatinine concentration in the serum.  
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Creatinine clearance is defined by the following formula: 
Creatinine Clearance (mL/min) = U x V/P,  
where U= urine concentration of creatinine; V = urine flow rate (mL/min) and P = plasma 
concentration of creatinine. Creatinine is a small molecule resulting from the metabolic 
break down of creatine phosphate found in muscle. Creatinine is a middle sized molecule 
freely filtered by the glomerulus, with little re-absorption in the renal tubules. Elevated 
levels of serum creatinine (>120 μmol/l) suggest renal impairment. Serum creatinine is 
affected by factors other than GFR, such as muscle bulk and protein intake, thus there is 
variation of serum creatinine both in patients with normal and impaired kidney function. 
Furthermore serum creatinine concentration does not rise out of the normal range until 
around 50% of GFR is lost. Hence serum creatinine alone is insufficient to determine the 
severity of kidney function.  In addition, creatinine clearance estimations generally 
overestimate GFR due to tubular secretion of creatinine. Variation of laboratory techniques 
for creatinine estimation, and inaccurate 24 hour urine collections are additional problems 
with this methodology. As a result of these issues, estimates of GFR are commonly used in 
clinical practice. These are derived from predictive equations. The two most common 
equations are; the Cockcroft-Gault equation (Cockcroft & Gault, 1976) and the Modification 
of Diet in Renal Disease (MDRD) study equation (Levey et al., 1999), which are defined 
below: 
Cockcroft-Gault equation:  
Creatinine Clearance (mL/min) = ([140 – Age X Weight] / [72 X Serum Creatinine]) X 0.85 
if female 
Abbreviated 4 variable MDRD equation: 
eGFR (ml/min/1.73m2) = 186 X [Serum Creatinine] -1.154 X [Age] -0.203 X [0.742 if female] X 
[1.21 if black].  
where eGFR is estimated GFR, age is measured in years, weight in kg, serum creatinine in 
mg/dL. The MDRD equation was validated against the urinary clearance of 125I-iothalamate 
(Levey et al., 1999). It is generally preferred for routine clinical use, since it does not require 
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the input of body weight, which is usually not available at the point of estimation by clinical 
laboratories.  
Renal failure can follow either an acute or chronic course. Acute Kidney Injury (AKI) is the 
loss of renal function in a setting in which the loss is potentially reversible. The onset of AKI 
is usually sudden with a time course of hours or days. CKD is the progressive deterioration 
of renal function resulting in irreversible kidney damage. CKD is defined by either of the 
following: 1) Kidney damage as evident by markers (e.g. proteinuria) or structural 
abnormalities with normal eGFR, for a minimum of three months, or 2) GFR<60 
mL/min/1.73m2 for greater than three months (KDOQI, 2002). CKD is classified according to 
the severity of renal impairment as measured by eGFR (table 1.1). Stage 3 reflects 
significant renal impairment and identifies individuals with CKD. It is from this point that 
the complications of CKD become more apparent, which are discussed later. eGFR falls with 
age and many patients with stage 3 CKD do not have progressive disease. The presence of 
proteinuria is a good marker of the likelihood of progression. Many patients with stage 4 
CKD (GFR<30 mL/min/1.73 m2) have progressive disease, and preparation for renal 
replacement therapy is often usually appropriate. Stage 5 CKD is referred to End-Stage 
Renal Disease (ESRD) or Established Renal Failure (ERF). In ESRD survival is limited without 
the initiation of renal replacement therapy (RRT).  
Table 1.1: Stages of renal failure according to eGFR 
Stage GFR 
(ml/min/1.73m2) 
Functional Description Prevalence (%)~ 
1 ≥90 Kidney function normal, but indication of 
underlying disease due to an abnormality 
3.3 
2 60-89 Mild loss of kidney function, or other 
abnormality 
3.0 
3 30-59 Moderately reduced function 4.3 
4 15-29 Severely reduced function 0.2 
5 ≤14 End-Stage Renal Disease (ESRD) 0.2 
~prevalence estimates based upon NHANES III data (Coresh, Astor, Greene, Eknoyan, & Levey, 
2003) 
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1.1.2 Factors that affect the progression of CKD 
In progressive CKD data from the MDRD study suggests that GFR declines on average by 
4ml/min/year, a rate unrelated to baseline GFR (Hunsicker et al., 1997). However, as 
identified in a review by the National Kidney Foundation, the rate of GRF decline is varied 
across studies (0 – 12ml/min/year). The rate of decline can be used to estimate the onset of 
ESRD, although this can be challenging. A rate of GFR loss of >4 ml/min/year is considered 
“fast” according to current guidelines (KDOQI, 2002).  
Despite the variations among the literature, several factors have been shown to impact 
upon the progression of CKD (KDOQI, 2002); 
 The degree of proteinuria  
 Blood pressure control 
  Glucose control in diabetes 
 Angiotensin-converting enzyme inhibition or angiotensin-2 receptor blockade 
Diabetes is the most common cause of ESRD (USRDS, 2003). Indeed, the rise in ESRD 
prevalence rates over the past 10 years is partially attributable to the growing incidence of 
diabetes (USRDS, 2003). The evidence regarding the benefit of strict glucose control upon 
preventing or slowing the progression of kidney disease is robust (DCCT, 1993; MACSG, 
1995; UKPDS, 1998a). Data from the Diabetes Control and Complications Trail randomised 
type 1 diabetics to either a conventional treatment group, or a intensive glucose control 
group (DCCT, 1993). The intervention group received insulin more than three times per day 
in order to maintain normal HbA1c levels. The standard treatment group received insulin 
once or twice per day. Patients were followed up for an average of 6.5 years. Albuminuria 
(protein leak) was employed as the outcome measure, which indicates nephropathy 
(kidney damage). Patients were also grouped according to the presence of mild retinopathy 
(damage to retinal blood vessels as a result of high blood sugars). A primary prevention 
group had no retinopathy at baseline n= 726, whilst a secondary prevention group had 
retinopathy at baseline n=715.  
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Figure 1.1: Cumulative Incidence of Urinary Albumin Excretion ≥300 mg per 24 Hours (Dashed Line) 
and ≥40 mg per 24 Hours (Solid Line) in Patients with type 1 diabetes Receiving Intensive or 
Conventional Therapy. Panel A = primary prevention cohort, Panel B= secondary prevention cohort. 
Reproduced with permission from the New England Journal of Medicine (DCCT, 1993). 
 
The data revealed the benefits of intensive therapy upon the subsequent protection against 
albuminuria (figure 1.1). For patients in the primary prevention cohort, intensive therapy 
reduced the adjusted risk of microalbuminuria by 34 percent. For the secondary prevention 
cohort, intensive therapy reduced the risk of microalbuminuria and albuminuria by 43 and 
56% respectively (p=0.01). 
 
Although this data does not show that tight glucose control prevents GRF loss per se, it 
does demonstrate that increased control protects against kidney damage. In addition, a 
elegant analysis conducted by the United Kingdom Prospective Diabetes Study showed that 
strict glycemic control had a significant impact upon the prevalence of microalbuminuria 
and reduced the incidence of declining renal function, as compared to standard therapy 
(UKPDS, 1998a).  
 
High blood pressure is known to cause kidney disease. Evidence also suggests than poorly 
controlled blood pressure is a prognostic factor for declining kidney function (Levey et al., 
1998). The largest study of blood pressure control in patients with non-diabetic kidney 
disease comes from the MDRD research group (Klahr et al., 1994). Patients were 
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randomised to either a standard treatment group (target blood pressure <140/90 mm/Hg), 
or the strict blood pressure control intervention group (<125/75 mm/Hg). The results 
revealed that the intervention group had a significantly slower rate of progression of CKD, 
but only in patients who had proteinuria >1.0g/d, as compared to the standard treatment 
group. The benefit of tight blood pressure control in type 2 diabetics has also been 
established with data showing that better control is associated with reduced 
microalbuminuria (UKPDS, 1998b).  
 
The degree of proteinuria is the major determinant of progression in CKD irrespective of 
aetiology. Angiotensin-converting enzyme inhibition (ACE inhibitors) and Angiotensin II 
receptor blockade (ARBs) have been shown to slow the progression of renal failure in both 
diabetic and non-diabetic renal disease. The specific benefits of these agents over and 
above standard antihypertensive agents are essentially limited to their use in proteinuric 
states (syndrome cause by renal impairment indicated by blood and protein in the urine). 
These medications disrupt the Renin-Angiotensin Aldosterone System by inhibiting the 
production of angiotensin II (ACE inhibitors) or it’s interaction with its receptors (ARBs). 
Angiotensin II modulates intraglomerular capillary pressure, and causing increased 
glomerular hydraulic pressure. Blocking or inhibiting this system via the use of ACE 
inhibitors of ARBs serves to protect glomerular filtration, by preventing hyperfiltration, cell 
proliferation and fibrosis (Weir & Dworkin, 1998). In addition to this affect, ACE inhibitors 
and ARBs reduce blood pressure and have antiproteinuric properties (Ruggenenti & 
Remuzzi, 1997). Studies have shown that in type 1 diabetics with normal blood pressure, 
ACE inhibitors slow CKD progression (Lewis, Hunsicker, Bain, & Rohde, 1993). A meta-
analysis of trials in non-diabetic patients has also provided evidence for the efficacy of 
these drugs. This data revealed that patients receiving ACE-inhibitors had lower urine 
protein excretion, improved blood pressure control, and approximately a 30% reduction in 
the risk of development of kidney failure, as compared to the control group (Jafar et al., 
2001).  
 
In addition to tight glucose control, blood pressure management and the administration of 
ACE-inhibitors or ARBs other factors may also be important. Restricting protein intake, 
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reducing lipids and correcting anaemia are several interventions that may slow the 
progression of CKD, although evidence is contentious (KDOQI, 2002).  
1.1.3 The consequences of CKD 
Early stages of renal impairment may be asymptomatic. Various “uraemic” symptoms can 
result from severe renal failure, though this is difficult to define in purely biochemical terms 
(table 1.2). The adverse consequences of CKD typically start to manifest once GFR<30 
mL/min/1.73 m2 (i.e. Stage IV CKD). Anaemia is a common consequence of CKD. The 
kidneys produce the hormone Erythropoietin, with is essential for Erythropoiesis 
(production of red blood cells). In kidney failure there is Erythropoietin deficiency causing 
anaemia. Haemoglobin (Hb) is the preferred method of assessing anaemia, although there 
is no CKD specific definition (KDOQI, 2002). Current guidelines recommend that Hb levels 
should be in the range of 10.5-12.5 g/dL for patients with CKD. Evidence suggests that 
anaemia progresses with CKD (Levin et al., 1999; McGonigle, Wallin, Shadduck, & Fisher, 
1984). For example, in the USA it is estimated that 1.2 million women and 390,000 men 
have Hb< 12.0 g/dL that is associated with CKD (Hsu, McCulloch, & Curhan, 2002). Data 
from the Third National Health and Nutrition Examination Survey (NHANES III) 
demonstrated a decline in Hb with falling eGRF (figure 1.2). Although anaemia is strongly 
associated with a GFR<60 ml/min/1.73 m2, there is also evidence of anaemia with higher 
levels of GFR (KDOQI, 2002). Anaemia is associated with negative outcomes including, 
increased mortality risk, hospitalisation, cardiovascular disease and reduced quality of life 
(Collins, Ma, Xia, & Ebben, 1998; Foley et al., 2000; Furuland et al., 2003; Levin & Foley, 
2000).  
Renal osteodystrophy is another complication of CKD caused by reduced renal activation of 
vitamin D, phosphate retention, lower ionized calcium and increased parathyroid hormone 
(PTH). CKD patients experience several forms of bone disease, with most having mixed 
bone diseases, including hyperparathyroidism and adynamic bone disease. Other issues 
relate to skin diseases (itching), endocrine abnormalities, gastrointestinal complications, 
and damage to the nervous system.  
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Table 1.2: Symptoms of CKD (Uraemia) 
Symptoms of CKD   
Loss of energy  Vomiting, diarrhoea, and nausea Mental slowing, seizures* 
Loss of appetite Peripheral or pulmonary oedema  Erectile dysfunction 
Nocturia  Rest leg syndrome- need to 
continuously move lower limbs 
Anaemia related symptoms – headaches, 
fatigue, pallor, tachycardia, palpitations 
Paraesthesiae Bone pain Amenorrhoea 
*typically associated with serve uraemia  
 
 
Figure 1.2: Blood haemoglobin percentiles by GFR adjusted to age 60 (NHANES III). Median and 5th 
and 95th percentiles of haemoglobin among adult participants age 20 years and older in NHANES III, 
1988 to 1994. Values are adjusted to age 60 years using a polynomial quantile regression. The 
estimated GFR for each individual data point is shown with a plus sign near the abscissa. 95% 
confidence intervals at selected levels of estimated GFR are demarcated with triangles, squares, and 
circles. Reproduced with permission from the American Journal of Kidney Diseases (KDOQI, 2002). 
 
The most significant complication of kidney failure is cardiovascular disease (CVD). Dialysis 
patients are 10-30 times more likely to die of CVD compared with the general population 
after controlling for sex, race, and diabetes (Foley, Parfrey, & Sarnak, 1998). Controlling for 
age still leaves a 5 fold increase in CVD mortality. Features of CVD including left ventricular 
hypertrophy (LVH) and atherosclerosis are significantly more prevalent among patients 
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receiving haemodialysis (Foley et al., 1995). LVH appears to develop early in the course of 
CKD, affecting around 38% of CKD stage 4 patients. At dialysis initiation around 70% of 
patients have LVH (Foley et al., 1995), which is a significant independent predictor of 
mortality among dialysis patients (Silberberg, Barre, Prichard, & Sniderman, 1989). Vascular 
calcification, including coronary artery calcification, is another significant concern among 
patients with kidney failure. Conventional risk factors associated with the development of 
accelerated atherosclerosis, and renal failure specific risk factors relating mainly to 
abnormal mineral metabolism and its treatment, both contribute. Coronary artery 
calcification is common among dialysis patients and remains a significant independent 
predictor of all cause mortality among dialysis patients (London et al., 2003).  
1.2 The treatment of End-Stage Renal Disease 
The treatment of kidney failure essentially involves attempts to prevent or to manage the 
consequences of impaired renal function. As renal failure progresses dietary modification 
and specific medications are required but when ESRD is reached renal replacement therapy 
become a necessary addition to this regime. 
For example, hyperkalaemia (high serum potassium >5.5 mmol/l) is generally treated by 
diet modification although levels greater than 7 mmol/l often present as medical 
emergencies requiring specific treatment. Dietary limitations are required to maintain 
adequate potassium levels, often involving specialist advice from renal dieticians. Similarly, 
phosphate control is regulated by dietary control and the ingestion of phosphate binder 
medications. Metabolic acidosis (acidification of blood where pH<7.35) is corrected by 
dialysis (using bicarbonate, described below). Anaemia is corrected by the maintenance of 
adequate haematinics and the administration of biosynthesized erythropoietin (EPO).  This 
is normally administered by subcutaneous injection in the predialysis setting, though the 
intravenous route is often preferred for haemodialysis patients. EPO administration is 
associated with many benefits including improved quality of life, sexual and cognitive 
function. Most of these clinical aspects of management continue to require rigorous 
attention even after patients have initiated renal replacement therapy.  
The control of blood pressure by dietary sodium restriction and antihypertensive 
medication is also a major aspect of predialysis management, which persists into the renal 
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replacement therapy phase. In fact, once dialysis has commenced, these and other 
management strategies, usually become more intrusive. With continued loss of residual 
renal function most dialysis patients eventually lose their urine output. In this setting, while 
dialysis is capable of removing some excess salt and water, the patient is required to 
restrict their salt and water intake more rigorously – with fluid intake usually limited to 0.5-
1 litres/daily. If patients ingest too much salt and water, they become “overloaded” and risk 
complications such as pulmonary oedema and congestive heart failure.  Such complications 
require hospitalisation and can prove fatal. Fluid intake restriction is a particular a 
frustration to the patient. Indeed fluid non-adherence has been identified as a particularly 
prevalent issue (Bame, Petersen, & Wray, 1993).  
1.2.1 Renal Replacement Therapy 
Dialysis is the most common form of renal replacement therapy (Grassmann, Gioberge, 
Moeller, & Brown, 2005). Essentially, dialysis replaces some renal function acting as an 
artificial kidney. Dialysis allows small and middles sized-molecules to be removed from the 
blood (e.g. metabolic end-products), whilst also removing fluid. There are two basic types 
of dialysis, Haemodialysis (HD) and Peritoneal Dialysis (PD). Both modalities essentially 
serve the same purpose but differ in their application. 
1.2.2 Haemodialysis 
HD is typically conducted in a hospital or clinic, for 3-4 hours thrice weekly. Essentially 
blood is removed from body, filtered and then returned to the patient. An Arteriovenous 
Fistula (AV fistula) is the preferred method of access. An AV fistula is fashioned surgically. A 
subcutaneous vein – usually at the wrist or elbow is joined to a suitable artery. This causes 
the vein to increase in diameter and “arterialize” – allowing frequent puncturing for dialysis 
access.  Two needles are inserted in the fistula at each dialysis session, one in which the 
blood leaves the body to circulate around the machine and dialyzer (“A” needle), and the 
other through which the blood returns (“V” needle). The dialyser consists of a semi-
permeable membrane separating the patient’s blood and the dialysis fluid. Membranes 
vary in permeability, high-flux membranes permitting good removal of larger molecular 
weight toxins such as beta-2-microglobulin (i.e. middle sized molecules) in contrast to low-
flux membranes which only permit removal of low molecular weight substances. The blood 
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and the dialysis fluid are pumped through the dialyser in a countercurrent fashion to 
maximise concentration gradients. HD works by the principles of convection and diffusion. 
Waste products are mainly removed by diffusion down the concentration gradient between 
the blood and the dialysis fluid. The composition of the dialysis fluid is devised to optimise 
the removal of toxins and excess minerals and electrolytes, such as potassium and 
magnesium, prevent excess removal of sodium, and to allow acidosis to be corrected by 
infusion of bicarbonate. Fluid is sucked from the blood into the dialysis fluid by convection, 
brought about by application of a negative pressure to the dialysis fluid side of the 
membrane. Convection also facilitates the removal of middle molecules.   
Dialysis systems have been devised which maximise convection, and require infusion of 
replacement fluids into the patient (haemodiafiltration). This allows a modest improvement 
in small molecule clearance and a significant improvement regarding middle molecule 
clearance compared to high flux haemodialysis. Empirical evidence suggests that HDF may 
improve haemodynamic stability and mortality rate (Canaud et al., 2006).  
Haemodialysis adequacy is assessed by either the urea reduction ration (URR) of 
normalised urea clearance (Kt/V, where K is the dialyser clearance, t is the duration of the 
dialysis treatment in minutes and V is the urea distribution estimated by total body water). 
A sessional URR of >65% or Kt/V of 1.2 is the target adequacy for haemodialysis (KDOQI, 
2002). These adequacy criteria relate to thrice weekly treatments, which are currently the 
norm, though significant benefits may accrue from more frequent sessions.  
Haemodialysis can take place in-centre, in minimal care units or in the home. In centre-
based therapy, nurses or health care assistants undertake most of the work associated with 
the treatment. In minimal care units patients are responsible for most of their treatment. In 
home haemodialysis, the patient with or without a carer assumes all responsibility for the 
day-to-day performance of the treatment. In-centre treatment is by far the most common 
current means of dialysis delivery. The majority of patients studied in the following 
chapters were receiving in centre-based treatment usually by high-flux haemodialysis with 
a smaller number receiving Haemodiafiltration. 
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1.2.3 Peritoneal Dialysis 
Peritoneal dialysis (PD) removes metabolic end products and fluid from the body via a 
naturally occurring semi-permeable membrane. This refers to the peritoneal membrane 
which lines the peritoneal cavity and surrounds the intestine. PD requires the insertion of a 
peritoneal catheter (Tenckhoff catheter) into the patient’s abdomen. Dialysis fluid is then 
introduced into the peritoneal cavity. The same principles of diffusion and convection as 
described above also operate in peritoneal dialysis, except that convection now occurs 
down an osmotic gradient created by high concentrations of glucose in the dialysis fluid. 
Peritoneal dialysis is a home-based treatment. Continuous ambulatory peritoneal dialysis 
(CAPD) is typically conducted throughout the day and involves four dialysis exchanges. 
Automated Peritoneal Dialysis (APD) involves the patient dialyzing at night, with a machine 
managing the exchanges over an 8-10 hour period. The self-care aspect associated with PD 
tends to mean that this modality is generally suited to younger patients with less co-
morbidity, though older independent patients may also do well on this modality (Brown, 
1999; Brown et al., 2010). Of the potential complications associated with PD peritoneal 
infection is a prominent concern. It usually responds to antibiotics but in rare cases may be 
fatal.  
1.2.4 Transplantation  
Renal transplantation if the preferred treatment for ESRD, though only a minority of 
patients are suitable. This reflects the increasing age and co-morbid load of the ESRD 
population.  A successful transplant often reverses some of the complications induced by 
kidney failure, including anaemia and infertility. Furthermore, the need for tight dietary and 
fluid restriction is no longer required. Transplantation involves the donation of a kidney 
either from a living related donor or a “brainstem dead” or “non-heart-beating” donor 
(cadaveric). The benefits of renal transplantation are well established, improving both 
survival and quality of life. However the demand for donor kidneys outweighs the supply, 
which prolongs patient’s reliance upon dialysis therapies. Successful transplantation 
generally relies upon matching blood group antigens, though exceptions are increasingly 
common. HLA matching may improve outcomes but mismatching is generally not a barrier. 
Following a transplant, immunosuppressive medication is required for the duration of the 
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transplant. Advances in this regard have led to transplanted kidney surviving longer, with 
around 50% lasting 10 years or more.  
1.3 Referral to a nephrologist and when to start dialysis 
Referral to nephrologist for specialist assessment should typically occur once GFR = 
<30ml/min/1.73 m2. Renal disease can remain asymptomatic for some individuals until the 
disease is very advanced. These individuals then present to nephrology services in need of 
urgent dialysis. Such patients are often termed “crash-landers.” Other patients may have 
been seen in primary or secondary care with known kidney disease yet for some reason are 
delayed before referral to a nephrologist (“late referral”). Further, patients may have been 
referred and clinically assessed by a nephrologist, but go on to need dialysis far sooner than 
initially expected (“failed planned”). These several pathways to dialysis initiation are all 
characterised by a sudden start to dialysis. Starting dialysis within 90 days of referral to a 
nephrologist is often used to define “late presenters,” although there is no accepted 
definition. For the purpose of this body of work, such patients are termed “unplanned 
starters”.  In comparison to unplanned starters, most patients start dialysis via a planned 
entry (approximately 80%). This implies that patients were referred to a nephrologist when 
their GFR was around 30 ml/min/1.73 m2, and were followed up over a period of time 
(usually many months or years), until a treatment decision was decided. Critically, these 
patients had time to adapt, seek support and to be educated. Such patients are termed 
“planned starters” in the work to follow. An unplanned start to dialysis has been shown in 
several empirical works to have adverse consequences upon patient outcome (Arora et al., 
1999; Innes, Rowe, Burden, & Morgan, 1992).  
 
Selecting a point at which point to start dialysis therapy is a complicated issue with no 
definitive answer. Dialysis is currently started when eGFR is at a mean of around 7-8 
ml/min/1.73 m2. KDQOI guidelines recommend considering starting dialysis when GFR <15 
ml/min/1.73 m2, whereas the Renal Association (UK) guidelines recommend dialysis 
consideration when GFR <10 ml/min/1.73 m2. The need to initiate dialysis can also be 
indicated by a variety of clinical features including symptoms of uraemia, fluid overload, 
and nutritional status. These features tend to be more important indicators of the need for 
dialysis than the eGFR.    
15 
 
There is little debate about the survival disadvantage of late referral, but whether starting 
dialysis early confers any survival advantage is still controversial. Data from the Netherlands 
Cooperative Study on the Adequacy of Dialysis suggests that a prompt dialysis start defined 
by a GFR>10 ml/min/1.73 m2 confers a survival advantage after 3 years on dialysis of 2.5 
months (Korevaar et al., 2001).  This advantage was explained in terms of treating patients 
at an earlier stage of the disease (i.e. before ESRD) hence there is potential lead-time bias 
(Korevaar et al., 2001).  
1.4 The incidence of ESRD in 2007- Data from the UK Renal Registry 
The UK Renal Registry (http://www.renalreg.com) was developed by the renal community 
(The Renal Association) as a resource to improve patient care. The registry collects 
standardised data from all UK renal services quarterly, relating to incidence, clinical 
outcomes and management of CKD.  
 
Data from the UK Renal Registry shows that in 2007 6,644 patients started renal 
replacement therapy (Farrington, Udayaraj, Gilg, & Feehally, 2008). Indeed over the last 17 
years the incidence for RRT has increased progressively (figure 1.3). 
 
Figure 1.3: UK Renal Replacement Therapy incident rates from 1990-2007. 
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Figure 1.4: Incident rates by age and gender in 2007 both figures 1.3 and 1.4 are data from chapter 
3 of the UK renal registry report 2008, reproduced with permission from the renal association 
(Farrington, Udayaraj et al., 2008). 
 
In the 2007 incident dialysis cohort the median age was 64.1, with the majority of patient 
being male (61.8%). The acceptance rate was highest for both males and females for 
patients aged between 75-79 years of age (figure 1.4). The majority of incident patients 
were white (79.8%, Asian 10.0%, Black 7.3%, Chinese 0.6%, and other 2.3%). Diabetic 
nephropathy accounted for the most common diagnosis in incident patients (21.9%), 
followed by glomerulonephritis (10.7%), renal vascular disease (7.4%), pyelonephritis 
(7.1%), polycystic kidney disease (7.1%), and hypertension (5.8%). Other causes and 
unknown aetiology accounted for 15.1% and 25.0% of cases respectively.  
HD was the most common treatment undertaken at the very start of dialysis (<90 days, 
74.9%), compared to PD (20.6%) and pre-emptive renal transplant (4.5%). This data is 
somewhat biased as most patients who present late (late referrals and crash-landers) start 
on HD. The established modality by 90 days was; HD (64.7%), PD (21.3%), pre-emptive renal 
transplant (5.2%), died (5.7%), and stopped treatment (0.5%). There were no significant 
gender differences between those who start on HD and PD, although age was a significant 
factor. Older patients (≥65 years) were more likely to start on HD as compared to PD (82.7% 
vs. 17.3%). Figure 1.5 shows the time of referral before dialysis initiation. Twenty one 
percent of dialysis patients started treatment as a late presenter (unplanned starter). 
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Figure 1.5: Time of referral before dialysis initiation from the 2007 incident cohort. Data from 
Farrington et al (2008). 
 
Renal registry data of incident dialysis patients between the years 2002-2007, revealed 
several differences between planned and late presenting patients (Farrington, Udayaraj et 
al., 2008). Late presenters were significantly older and more likely to be white. In addition, 
fewer late presenters had “no co-morbidities” as compared to planned patients. 
Specifically, there was a significantly greater prevalence of malignancy in the late 
presenters as compared to the planned patients. Estimated GFR was significantly lower in 
the late presenting patients as compared to planned patients.  
1.5 The prevalence of ESRD- Data from the UK Renal Registry 
Between the years 2000-2007 the prevalent RRT population has grown by 40% (5%/year).  
According to the UK renal registry 45,484 patients were undergoing RRT in 2007 
(Farrington, Hodsman, Casula, Ansell, & Feehally, 2008). Of these, 19,706 were treated with 
HD, 4,646 with PD and 21,132 with a renal transplant. The mean age of the HD and PD 
populations were 65.2 years and 60.3 years respectively. The mean age for transplant 
patients was notably younger at 50 years of age. The overall UK peak crude prevalence rate 
(correcting for the age and gender distribution of the UK) occurred in the age band 70–74. 
The crude prevalence rate for males was greater than females across all ages (figure 1.6).  
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Figure 1.6: Prevalence rate of RRT patients per million population by age and gender on 31/12/07, 
reproduced with permission from the renal association (Farrington, Hodsman et al., 2008). 
 
The median treatment vintage for HD patients was 2.8 years. PD and transplant patients 
had median vintages of 2.1 and 10.4 years respectively. The majority of established RRT 
patients were white (65.3%). Glomerulonephritis (biopsy proven) was the most common 
diagnosis (15.3%), followed by diabetes (13.2%) and pyelonephritis (11.9%). Unknown 
aetiology and other causes remained high accounting for 21.6% and 14.5% of the RRT 
population.  
Among the prevalent UK RRT population in 2007 renal transplant was the most common 
modality (46.6%) followed by HD (42.1%) and PD (10.1%). Analysis of treatment modality 
via age (<65 years vs. ≥65 years) suggests that age is a strong determinant of modality.  Of 
the prevalent HD population 66.4% were aged ≥65 years, compared to only 11.9% of the PD 
population and 21.6% of the transplant population. 
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1.6 Summary 
The kidneys serve to maintain fluid balance and body homeostasis. Kidney disease reduces 
the functionality of the nephron, signified by low GFR. Renal failure is associated with high 
mortality, particularly related to cardiovascular disease. In order to replace the functions of 
the kidney, dialysis or transplantation is required, with transplantation offering the better 
quality of life. In order to maintain life, regular dialysis is required for as long as the patient 
lives. However the dialysis is only one aspect of the treatment regime. Dietary and fluid 
restrictions are also required, accompanied by an extensive list of medications. These self-
care behaviours are critical to the management of ESRD. The chronic nature of ESRD, 
associated complications, and life restrictions have a sizeable effect upon the lives of 
suffers. Indeed, patients are required to self-regulate not only health related behaviour but 
also mood. As reviewed in the following chapter, ESRD and its treatment is associated with 
depression, which remains a significant co-morbidity in this population. Further because 
ESRD is a complex disease understanding patient’s common sense representations of their 
condition may help provide a theoretical basis to the understanding of illness, mood and 
behaviour in this patient population. 
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Chapter 2 
A Review of Depression on Dialysis1 
 
- “If you be sick, your own thoughts make you sick” 
Benjamin Jonson (1572-1637) 
 
2.1 Introduction 
The relationship between depression and physical illness is highly intimate. It is evident that 
depression, or sub-syndrome depressive disorders are implicated in both the aetiology and 
consequence of physical illness. Co-morbid depression has profound effects upon 
morbidity, mortality, self-care behaviour and health care costs in patients with chronic 
physical disease (Stein, Cox, Afifi, Belik, & Sareen, 2006). At any given time it is thought that 
2 to 4% of the general population suffers from depression, rising to between 5 and 10% in 
primary care (Kessler et al., 2003). Among patients with ESRD the reported point 
prevalence of depression or significant depressive symptoms is estimated to be between 
20-30% (Cukor, Coplan, Brown, Peterson, & Kimmel, 2008; Drayer et al., 2006; Kimmel & 
Peterson, 2005). However, the use of different depression assessment tools has lead to 
wide variation in estimated prevalence rates (Craven, Rodin, Johnson, & Kennedy, 1987; 
Craven, Rodin, & Littlefield, 1988; Smith, Hong, & Robson, 1985). Most notable regards the 
difference between estimates based upon screening questionnaire cut-off scores used to 
define “caseness” and clinical diagnosis. Furthermore, there are discrepancies in prevalence 
estimates between patients receiving HD and PD modalities, although methodological 
factors may contribute to this mixed evidence. Despite this depression is thought to be the 
most common psychopathology encountered in dialysis patients, the under recognition of 
which in day-to-day clinical practice is of considerable concern (Wang & Watnick, 2004). 
This concern is exacerbated by the growing body of empirical evidence identifying the 
adverse consequences of depression on clinical outcome in ESRD patients. In this chapter I 
                                                          
1
 To note, parts of this review chapter have been published in Chilcot, J., Wellsted, D., Farrington, K (2010). 
Depression in End-Stage Renal Disease: Current Advances and Research. Seminars in dialysis (23): 74-82. 
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review depression in the context of renal dialysis, consider the prevalence and associated 
adverse outcomes, treatment options, and the psychological and clinical correlates. First 
however, the thorny issue of assessing depression in physical illness is considered. 
2.2 Assessing depression in ESRD: diagnosis, screening and overlapping 
symptoms  
The assessment of depression in ESRD, and indeed among chronic illness states is 
challenging. Firstly, it is important to distinguish the diagnosis of depression from 
depression screening methods. Diagnostic approaches rely upon professional evaluation 
typically by structured or semi-structured interviews using diagnostic criteria such as the 
Diagnostic and Statistical Manual of Mental Disorders 4th edition- DSM-IV (APA, 1994). The 
DSM-IV defines Major Depressive Disorder (MDD) as having a loss of pleasure/loss of 
interest or depressed mood for 2 weeks accompanied by five or more psychological, 
somatic and behavioural symptoms. Sadness, loss of pleasure, a lack of energy, sleep 
disturbances, loss of concentration, intense guilt and thoughts of suicide are some of the 
symptoms associated with MDD. The Structured Clinical Interview for Depression (SCID) is 
one diagnostic assessment based upon the DSM-IV criteria. Other diagnostic methods 
included, the Diagnostic Interview Schedule (DIS). Formal diagnosis has implications for the 
management and treatment of depressive disorders. However as will be discussed, 
diagnostic criteria for depression among physical illnesses are complicated by the somatic 
symptoms of illness. 
 
In contrast screening approaches lack diagnostic capability. Depression screening tools such 
as the Beck Depression Inventory (BDI and BDI-II) are typical self-report scales requiring the 
patient to rate symptom frequency or severity (Beck, Steer, & Brown, 1996; Beck, Ward, 
Mendelson, Mock, & Erbaugh, 1961). Such tools assess the patient’s mood based upon a 
continuum, with higher depression scores often reflecting greater depressive symptoms. 
Self-report scales like the BDI are useful research tools which allow depression to be 
quantified across a population who do, as well as those that do not meet diagnostic criteria 
for depression. Although screening tools are not diagnostic, several have been validated 
against diagnostic criteria. This involves assessing the sensitivity and specificity of a defined 
symptom cut-off score against a diagnosis of clinical depression. The suggested cut-off 
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score for the BDI in ESRD patients is between 14-16, which is higher than the original score 
of >10 (for BDI-IA) and ≥13 (BDI-II), proposed for the general population (Craven et al., 
1988; Grant, Almond, Newnham, Roberts, & Hutchings, 2008; Hedayati, Bosworth, 
Kuchibhatla, Kimmel, & Szczech, 2006; Watnick, Wang, Demadura, & Ganzini, 2005). 
However caution is noted as different groups have used difference versions of the BDI (e.g. 
BDI-IA and BDI-II, see chapter 4). Furthermore although the employment of screening cut-
off scores is widely used such methods do not have diagnostic properties; instead they 
serve to identity patients with significant depressive symptoms or to assess the severity of 
depression. The use of the BDI, its structure and validation, are discussed in detail in the 
general methods chapter (chapter 4) and in chapter 6. In addition the non-somatic BDI for 
use in renal patients (Cognitive Depression Index, CDI) will come under scrutiny (Sacks, 
Peterson, & Kimmel, 1990). 
  
The cardinal issue concerning both screening and diagnostic methods is criterion 
contamination, which refers to the overlap between the physical symptoms of depression 
and those of illness. For example uraemia causes several symptoms that are also associated 
with depression including fatigue, sleep disorders, and reduced appetite (Israel, 1986). 
Other confounding symptoms include anaemia and electrolyte disturbances, which may 
produce symptoms similar to those of depression (Brown & Brown, 1995; Nissenson, 1989). 
The cause of such symptoms may be attributable to physical (or organic) factors, 
depression or indeed both. For these reasons many depression questionnaire cut-off scores 
are higher when applied to patients with chronic illness, as compared to psychiatric 
populations. It is inappropriate to use a depression screening tool to define probable 
“caseness” among physically ill populations unless the cut-off scores employed for such 
definitions have been derived from the population under investigation. Failure to adjust the 
score will lead to inflated estimates of depression (false positives). It is still important to 
remember that such cases do not translate into disorders, thus positive screens should be 
supported with diagnostic enquiry. Although adjusting cut-off scores attempts to control 
for the impact of physical symptoms on scoring and improves sensitivity and specificity, the 
higher order issues concern what to do with such symptoms when faced with diagnostic 
enquiry? According to the DSM-IV somatic symptoms that are judged to be caused by 
illness or its treatment should not be included in the diagnostic assessment, although there 
23 
 
is no specific guidance regarding this etiological procedure. This problem then relates back 
to the scrutiny of screening tools, which in order to demonstrate validity, are compared 
with apparent “gold-standard” diagnostic criteria.  
Table 2.1: A summary of the DSM-IV criteria for MDD and alternative schemas for physical illnesses.  
 
Scheme Concept Symptoms 
All approaches Core symptoms -Dysphoric mood 
  - Loss of interest or pleasure 
  -Psychomotor agitation/retardation 
  -Feelings of worthlessness/guilt 
  -Recurrent thoughts of death/suicide 
   
DSM-IV (etiological) Symptoms judged to be due to  -Diminished  concentration/indecisiveness 
 physical illness excluded -Weight loss/ gain or a decrease in appetite 
DSM-IV (inclusive) All somatic symptoms included  -Changes in sleeping pattern 
 regardless of  aetiology -Loss of energy 
   
Substitutive  e.g. (Endicott, 1984) Somatic symptoms are -Fearful or depressed appearance 
 substituted with additional  -Social withdrawal 
 cognitive-affective symptoms -Brooding and self-pity 
  -Cannot be cheered up 
   
Exclusive  e.g. (Cavanaugh, Clark, & 
Gibbons, 1983) 
Removal of somatic symptoms -No somatic symptoms considered 
 
If these criterion are actually more bronze than gold the question remains as to what is 
being compared with what? Until the diagnostic dilemma is satisfied efforts to pursue 
reliable screening methods for “depressive disorders” may be compromised. In response to 
this problem several schemas for depression diagnosis among physical illness have been 
devised, which are summarised in table 2.1. Although recent research has suggested the 
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utility of alternative criteria for diagnosis among physical illness (Akechi et al., 2009; von 
Ammon Cavanaugh, Furlanetto, Creech, & Powell, 2001; Whooley, Avins, Miranda, & 
Browner, 1997; Zimmerman, Chelminski, McGlinchey, & Young, 2006), the potential for 
false positive cases remains a concern (Koenig, George, Peterson, & Pieper, 1997), 
particularly as depression is a heterogeneous condition.  
 
Some evidence suggests that the cognitive-affective symptoms of depression (guilt, loss of 
interest and low mood) are better discriminators of depression in ESRD patients than 
physical symptoms (Craven et al., 1987; Hinrichsen, Lieberman, Pollack, & Steinberg, 1989). 
Similarly, it has been suggested that depressed mood, morning depression and 
hopelessness are symptoms which differentiate depression in patients with physical illness 
(Hawton, Mayou, & Feldman, 1990). Using DSM-III criteria for major depression in ESRD 
patients, others suggest that depressed mood, anhedonia, feelings of guilt or 
worthlessness, slowed thought, and weight loss distinguished depressed and non-
depressed patients, whereas loss of energy and sexual disinterest did not (Craven et al., 
1987). Although such evidence generally supports the thesis that cognitive symptoms 
discriminate depression better than somatic symptoms, it is reported that somatic 
symptoms of depression do increase in severity as one nears the threshold for “caseness” 
(Clark, Cavanaugh, & Gibbons, 1983). Others suggest that somatic symptoms are useful 
discriminators (Moffic & Paykel, 1975), including data from a sample of HD patients (Drayer 
et al., 2006). Whether this is due to biased somatic reporting owing to increased negative 
affect is of course arguable.   
 
While the best procedure for assessing depression among chronically ill populations 
remains contentious, it is still important to consider the possibility of depression when 
presented with physical symptomatology typical to mood disorders. Indeed in clinical 
practice an inclusive approach to depression assessment is advocated (Cohen-Cole, Brown, 
& McDaniel, 1993). After all, the pitfalls of false positive cases are far less than those of 
false negatives. Given current advances, the BDI has shown promise as a regular screening 
tool providing cut-off scores are adjusted (see chapter 4 and 5). The advantages of 
screening tools are that they can be used to assess larger populations, and monitor more 
easily depressive symptoms over time. Regular assessment may prove to benefit 
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psychosocial outcome among dialysis patients. However, the utility of regular depression 
screening was not supported in a systematic review of randomised control trials, in non-
psychiatric settings (Gilbody, House, & Sheldon, 2001b). These data suggest that routine 
depression screening does little to improve psychosocial outcome, although interestingly 
depression recognition improved if screening questionnaires were administered by a non-
clinician, with subsequent positive screens identified and then passed on to a clinician 
(Gilbody et al., 2001b). The heterogeneity of patients used may have influence the results, 
therefore the benefits of regular depression assessment among chronic populations 
requires further research.  
2.3 Prevalence of depression and depressive symptoms in ESRD 
The montage of research in the area suggests that depression accounts for around 50% of 
the psychopathology encountered in chronic physical illness. As in patients with ESRD the 
estimated prevalence of depression among patients with other physical illnesses is varied, 
and depends on the definition of depression employed and the type of depression 
measurement administered (Meakin, 1992; Rodin & Voshart, 1986). As a consequence, 
estimates of the prevalence of depression range between 15 and 61%, among the medically 
ill (Martucci et al., 1999). As stated previously, screening approaches generally inflate 
estimations compared to diagnostic assessments. For example, Smith et al (1985) 
compared three depression assessments among patient with ESRD, reporting varying 
prevalence rates across the assessments. When using the BDI (cut-off >11), 47% had 
significant symptomatology, compared to 17% when using the Multiple Affect Adjective 
Checklist and 5% after a professional diagnostic evaluation. In a recent study of ESRD 
patients treated with haemodialysis and peritoneal dialysis (n=128), 45.3% had a BDI≥14, 
while no differences between treatment modalities were apparent (Simic Ogrizovic et al., 
2009).  
 
Investigations employing diagnostic criteria among ESRD patients generally reveal lower 
estimates of depressive disorder, yet there is still variation across studies. A large 
epidemiology study reports that ESRD was associated with nearly a fourfold increase in 
depression prevalence as compared to healthy individuals (Egede, 2007). An early 
diagnostic study found that 8.1% of dialysis patients meet the DSM-III criteria for MDD 
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(Craven et al., 1987), of which half had a history of depression. A recent investigation 
reports more than 70% of predominantly black ESRD patients had some form of 
psychopathology (Cukor et al., 2007). Among the 70 patients assessed with the SCID, 29% 
had a depressive disorder (20% Major depressive disorder, 9% dysthymia or other 
depressive disorder not specified).  Moreover as is common in patients with ESRD, only 
12% of the patients assessed were receiving treatment for depression or anxiety disorders 
(Cukor et al., 2007). Grant et al (2008) revealed a 12.3% prevalence rate after applying ICD-
10 classification for depression to 57 HD patients. Others report a 17.3-19% prevalence of 
MDD in HD patients (Hedayati et al., 2006; Watnick et al., 2005). Analysis from the Dialysis 
Outcomes and Practice Patterns Study (DOPPS) cohort (n=6987) found a 13.9% prevalence 
rate of physician-diagnosed depression, compared to a 43% when using a CES-D cut-off of 
≥10 (Lopes et al., 2004). Of the 12 DOPPS countries analysed, the USA had the greatest 
prevalence of physician diagnosed depression 21.7%. Variation in prevalence was not only 
evident across countries, but again dependent upon the assessment criteria. Italy had the 
highest prevalence of depression when using the CES-D≥10 (62.3%), yet only 15.5% had a 
physician diagnosis. Similarly, Japan had the lowest physician diagnosis of depression (2%), 
yet 40% had a CES-D≥10.  
 
Empirical evidence demonstrates that the variation in prevalence is not only due to 
different methodologies employed in research, but also to population differences. In 
addition, studies based upon the DOPPS cohort suggest that some of the discrepancies 
between estimates obtained from diagnostic and self-report assessments may be due 
physician under diagnosis.  
2.4 Prevalence of Depression in Chronic Kidney Disease 
As described above there is considerable data concerning the estimated prevalence of 
depression in ESRD. However, in comparison there is a scarcity of research in CKD. 
Hedayati’s group in America have recently attended to this need by investigating the 
prevalence of Major Depressive Disorder (DSM-IV criteria), in patients with various stages 
of CKD (Hedayati, Minhajuddin, Toto, Morris, & Rush, 2009). Depression was found to be 
constant across CKD stages, with 21% of the sample meeting the criteria for MDD.  This 
figure is indeed similar to estimates observed in ESRD. However, this data should be 
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appreciated with some caution as the sample consisted of mostly male veterans. Despite 
this limitation and the paucity of research in CKD, depression may be a prevalent 
psychopathology in early stages of kidney disease. This finding is pertinent as it has long 
been known that past depression predicts subsequent depression (Lewinsohn, Hoberman, 
& Rosenbaum, 1988). Indeed this has also been upheld in studies of depression in ESRD 
(Cukor et al., 2008; Sensky, 1989). The activation of depressogenic styles during CKD may 
be potent precursors of later depression, particularly after starting dialysis therapy, which is 
a significant stressor to the individual (c.f. Beck, 1967). 
2.5 Dialysis initiation and depression symptoms 
Data regarding depression symptoms following the initiation of dialysis therapy is limited 
(Korevaar et al., 2000). One if the first investigations to consider depression symptoms soon 
after dialysis initiation revealed that 45% of incident patients screened positive for 
depression on a three item measure derived from the diagnostic interview schedule 
(Walters, Hays, Spritzer, Fridman, & Carter, 2002). Similar findings were reported in a later 
study, with 44% of incident dialysis patients scoring ≥15 on the BDI (Watnick, Kirwin, 
Mahnensmith, & Concato, 2003). Of the depressed patients identified by Watnick et al only 
16% were receiving treatment for depression. However it should be borne in mind that 
adjustment disorders and inadequate dialysis following the early weeks of dialysis may 
complicate the assessment of depression further.  
There is a lack of data regarding the nature of dialysis initiation upon psychological 
functioning. Indeed, only one study to date has approached this problem in terms of 
depression symptoms (Miura, Kitagami, & Ohta, 1999). Miura et al (1999) assessed 
depression symptoms before and after dialysis initiation, comparing those with “ordinary 
introduction (OI)” with those who started as an emergency (emergent introduction- EI). The 
results indicated that both before and after dialysis introduction patients with an EI had 
greater depression symptoms as assessed by the Zung self-rating depression scale, as 
compared to those with an OI. While of interest it should be considered that this 
investigation suffered from a small sample size and lack of clinical data. In this instance the 
potential for confound maybe substantial.  
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2.6 The course of Depression in ESRD 
A recent longitudinal study of HD patients, reports a 29% prevalence rate for depressive 
disorder using the SCID at baseline assessment (Cukor et al., 2008). Interestingly, 43% of 
patients diagnosed with depressive disorder at baseline, still satisfied the criteria 16 
months later. A persistent depressive course was associated with reduced perceived health 
status and quality of life and a depressive history (Cukor et al., 2008). These results may 
imply that depression is relatively stable over time in ESRD patients, or that depression is 
not detected and treated adequately. Although this study had a relatively small sample size, 
it provides insight into the course of depression over time among HD patients. Other data 
suggest a trend for a decrease in depression symptoms in haemodialysis patients (House, 
1987). In contrast a 3 year study of elderly dialysis patients found that around half had 
stable depressive symptoms, with around one-third worsening with time (Husebye, 
Westlie, Styrvoky, & Kjellstrand, 1987). In peritoneal dialysis patients quality of life appears 
to decline over time (Bakewell, Higgins, & Edmunds, 2002), although this appears to be 
mostly due to decreased perceptions of physical function, rather than deteriorating mental 
health (Merkus et al., 1999; Mittal et al., 2001). Others have shown that mental health 
component scores of the SF-36 improved significantly over the first year of dialysis therapy 
(Korevaar et al., 2002). Given the paucity of longitudinal data specific to the assessment of 
depression symptoms, the trajectory of depression over stages of the dialysis career 
remains undefined.  
2.7 The impact of depression in ESRD 
The impact of depression upon health related outcome is tangible. In a recent study of HD 
patients, depression symptoms were associated with significantly more hospital admissions 
and emergency department visits (Tavallaii, Ebrahimnia, Shamspour, & Assari, 2009). In the 
general population depression is associated with increased mortality risk (Wulsin, Vaillant, 
& Wells, 1999), although methodological issues confound certain studies. A recent study  
investigated the impact of depression and anxiety symptoms using the Hospital Anxiety and 
Depression Scale (HADS) upon mortality in a large population survey (Mykletun et al., 
2009). In a comprehensive analysis, the authors were able to demonstrate a significant 
effect of depressive symptoms upon survival after controlling for several factors including 
somatic conditions, physical activity and smoking status (OR=1.37, 95% CI 1.19 to 1.58). 
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Interestingly the adjustment of somatic conditions led to an attenuation of the depression-
mortality association. Physical illness is therefore an important confound in this context, 
and suggests further the intimate relationship between depression and physical illness.  
 
Cardiovascular disease (CVD) is a prominent co-morbidity among the dialysis population 
and one of the largest contributors of mortality (see chapter 1). There is also a 
comprehensive literature linking depression with CVD (Steptoe, 2007). Pro-inflammatory 
cytokines appear to be heightened in HD patients and predict mortality (Kimmel, Phillips et 
al., 1998). There is evidence that depression is associated with these cytokines including IL-
6, IL-1β and TNF-α and CRP in both the general and ESRD populations (Appels, Bar, Bar, 
Bruggeman, & de Baets, 2000; Kop et al., 2002; Miller, Stetler, Carney, Freedland, & Banks, 
2002; Simic Ogrizovic et al., 2009; Suarez, 2003). In a recent study, ESRD patients with a 
BDI≥14, had significantly higher IL-6 and hsCRP as compared to those with a BDI<14 (Simic 
Ogrizovic et al., 2009). Pro-inflammatory markers are associated in the pathogenesis of CVD 
(Ridker, Rifai, Rose, Buring, & Cook, 2002). It is proposed that immune functioning and 
inflammation mediates the link between depression and CVD (Lesperance, Frasure-Smith, 
Theroux, & Irwin, 2004). Efforts to investigate the complex pathways between depression, 
immune parameters and CVD in ESRD patients seem highly relevant particularly as CVD and 
depression remain prominent co-morbidities among HD patients. In addition, research has 
shown associations between depressive affect and malnutrition in ESRD patients (Koo et 
al., 2003), although the related causality remains unknown. There is evidence of the 
association between malnutrition, inflammation, and atherosclerosis (MIA) in ESRD 
patients (Honda et al., 2006; Wang et al., 2004); some have suggested that depression 
could be involved in MIA syndrome (Simic Ogrizovic et al., 2009), albeit with a great need 
for further investigation. 
 
Although detailed description of the behavioural and pathological mechanisms underlying 
depression and mortality is beyond the scope of this chapter, there is evidence linking 
depression and mortality among the ESRD population (Boulware et al., 2006; Drayer et al., 
2006; Einwohner, Bernardini, Fried, & Piraino, 2004; Hedayati et al., 2008; Kimmel et al., 
2000; Lopes et al., 2004; Lopes et al., 2002; Shulman, Price, & Spinelli, 1989), including 
those withdrawing from dialysis (Lopes et al., 2004; McDade-Montez, Christensen, 
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Cvengros, & Lawton, 2006). A summary of this literature is presented in table 2.2. It should 
be noted that while a depression-mortality association is well established, the association 
between depression and withdrawal may be confounded by the fact that depression 
symptoms are likely to increase the nearer to death. Depressive symptoms (BDI≥11) have 
also been found to predicted peritonitis in a study of 162 PD patients after controlling for 
age, diabetes, race and coronary artery disease (hazard ratio= 2.7, 95% CI 1.23 and 6.03). 
However whether this was due to diminished health care behaviour or impaired 
immunological function is not known (Troidle et al., 2003). Furthermore given the current 
evidence regarding suitable BDI cut-off scores in ESRD, a BDI ≥11 may be considered too 
low as these scores requirement adjust in this patient group (Grant et al., 2008).  
 
It is important to note, that while most outcome studies control for co-variates such as co-
morbidity and age, studies differ with regards to the measurement of depression (symptom 
severity vs. diagnostic) and analytic techniques (time varying models, vs. fixed baseline 
models). Indeed, some studies have reported null findings with regards to any association 
between depression and mortality in ESRD patients (Christensen, Wiebe, Smith, & Turner, 
1994; Devins et al., 1990). Kimmel et al (2000) investigated the association between 
depression and mortality in 295 HD patients using the BDI and CDI. In adjusted models 
baseline depression scores failed to predict mortality. However in time-varying models, 
both the BDI and CDI predicted mortality after controlling for a range of clinical parameters 
(table 2.2). Bowlware et al (2006) investigated the relationship between depressive 
symptoms, cardiovascular events and mortality. Time varying models demonstrated that 
symptoms of depression were associated with increased all cause mortality and 
cardiovascular events at a 2 year follow-up, whereas baseline measures did not. This 
association was attenuated, however, after a 6-month time lag was incorporated into the 
analysis. This suggests that deteriorating co-morbidity may at least partially explain the 
association between depression and mortality rather than depression worsening morbidity. 
Both Kimmel et al (2000) and Boulware et al (2006) employed depression screening tools to 
assess depressive symptoms. In the case of the latter study, depression was assessed using 
a non-conventional approach (subscale from the Medical Outcomes Study Short Form-36 
questionnaire).  
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Recently the association between a formal diagnosis of clinical depression and mortality 
has been established (Hedayati et al., 2008). Ninety eight HD patients were assessed using 
the SCID, which identified 26 as suffering from depressive disorder. Differences between 
the depressed (as diagnosed via the SCID) and non-depressed revealed a greater 
prevalence of co-morbidity in the depressed. In multivariate analysis after controlling for 
age, ethnicity, gender, time of dialysis and co-morbidity, a diagnosis of depression was 
significantly associated with mortality. Interestingly, self-report measures were not 
significant predictors of mortality in sub-analysis.  
 
In summary there is considerable evidence regarding the association between depression 
and mortality in ESRD patients. While further research is required to better understand this 
relationship, it is also important to establish the utility of treating depression upon patient 
outcome of which the current evidence is mixed (Detweiler-Bedell, Friedman, Leventhal, 
Miller, & Leventhal, 2008). 
2.8 Depression and Non-Adherence 
Depression may be associated with increased health care costs and mortality due to 
decreased treatment adherence in these patients (DiMatteo, Lepper, & Croghan, 2000). A 
meta-analysis of depression and medical treatment non-adherence suggests that 
depression increases the odds of non-adherence 3 fold (odds ratio 3.3, 95%CI 1.96 to 4.89, 
DiMatteo et al., 2000). Interestingly analysis of six ESRD studies were reported in this meta-
analysis, revealing a standardised odds ratio of 3.44 (95% CI 1.26-8.1, p=0.008) for non-
adherence in depressed patients. Critically however, this analysis did not weight the effect 
size for methodological strengths for each study reported. A recent review of the literature 
evaluated the association between depression and non-adherence more cautiously 
(Raynor, Wing, & Phelan, 2006). Indeed, while 37% of the studies reviewed (n=41), report a 
significant negative association, a similar number reported that depression was related to 
some aspects of non-adherent behaviour but not all. These findings highlight the 
complexity of adherence and show that predictors may only partially explain one aspect of 
what are often demanding and multifaceted treatment regimes. Furthermore measuring 
adherence in the ESRD is a particular issue due to several clinical confounders (Leggat et al., 
1998). Kimmel et al (1998) suggest investigating behavioural non-adherence relating to the 
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dialysis treatment (i.e. shortening dialysis time and skipping dialysis sessions). They 
demonstrated that depression symptoms were associated with behavioural non-
adherence, and that non-adherence predicted mortality. However in this particular analysis 
they failed to find any association between depression symptoms and mortality. 
 
Recently the influence of depressive symptoms upon medication adherence in both ESRD 
and kidney transplantation patients has been investigated (Cukor, Rosenthal, Jindal, Brown, 
& Kimmel, 2009). The results showed that depressive symptomatology added significantly 
to the explained variation of medication adherence in both ESRD and transplant patients. 
Given this, it may be hypothesised that treating depression in ESRD patients would improve 
patient adherence. Some evidence suggests that treating depression improves dietary 
adherence in non-insulin dependent diabetics (Goodnick, Kumar, Henry, Buki, & Goldberg, 
1997). However other studies report mixed findings in this regard (Lustman, Griffith, 
Freedland, Kissel, & Clouse, 1998), and several methodological concerns confound certain 
studies. Prospective cohort studies are therefore required to test this hypothesis in ESRD 
patients.  
2.9 Clinical associations of depression 
The aetiology of depression in ESRD is probably complex and multifaceted. As already 
discussed, depression is associated with elevated inflammatory cytokine levels, suggesting 
that inflammatory processes have a possible role in the aetiology of depression. This is 
postulated to occur as a result of cytokine stimulation of the hypothalamic-pituitary-
adrenal axis, affecting serotonin, its precursor tryptophan and noradrenergic systems that 
are implicated in the pathogenesis of depression (Barden, 2004; Wichers & Maes, 2002). 
However the causal relationship between depression and inflammation is indeed complex 
and not well delineated. Results from a recent longitudinal study conducted in a sample of 
healthy 50-70 year olds, suggests that depressive symptoms precedes changes in IL-6 
(Stewart, Rand, Muldoon, & Kamarck, 2009). It is clear that further investigations are 
required to increase our understanding of the depression-inflammation relationship, 
particular with reference to dialysis patients of whom inflammatory responses are 
common. 
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Among the ESRD literature, there is preliminary evidence that depression is associated with 
increased immune-activity (Simic Ogrizovic et al., 2009). However others have found no 
association between depressive symptoms and proinflammotory cytokines in ESRD patients 
(Dervisoglu, Kir, Kalender, Eraldemir, & Caglayan, 2008). For example, among patients on 
HD, PD and conservative management, Dervisoglu et al (2008) found no association 
between IL-6 and TNF-α cytokine levels and depression (defined as a BDI≥17). Similarly the 
BDI failed to correlate with these indices (Dervisoglu et al., 2008). While depression and 
inflammation may serve as adaptive evolutionary mechanisms in response to illness, their 
relationships in ESRD may be complicated as chronic inflammatory states are common is 
this population. Whether such states are related to depression is not yet understood.  
 
Previously it was reported that uraemia itself may, possibly via an effect on the synthesis 
and metabolism of certain neurotransmitters, cause depression and suggested a possible 
genetic predisposition within the ESRD population (Israel, 1986; Smogorzewski, Ni, & 
Massry, 1995). Daily dialysis has been shown improve the quality of life in observational 
studies (Vos et al., 2006); a reduction in uraemic symptoms may improve depressive 
symptomatology (Heidenheim, Muirhead, Moist, & Lindsay, 2003; Kooistra, Vos, Koomans, 
& Vos, 1998). We await with interest the full results from the FREEDOM study, in which 
clinical and psychosocial parameters are included in the comparison of haemodialysis 
patients on daily HD with a matched group on thrice-weekly HD (Jaber et al., 2009). 
 
Analysis of the DOPPS cohort found that white race, age, female sex and greater dialysis 
vintage was associated with depression (Lopes et al., 2002). In addition depression has 
been associated with co-morbidities in ESRD including coronary heart disease and diabetes 
(Hedayati et al., 2006; Hedayati et al., 2005; Lopes et al., 2002), although there are 
inconsistencies in the literature. However the actual correspondence between reported 
symptoms and physical states can be inaccurate (Pennebaker, 1982), suggesting that the 
interpretation of illness and its severity, rather than co-morbidity per se, is a greater 
determinate of affect (Sacks et al., 1990). Indeed, evidence in other patient groups has 
generally failed to find direct relationships between disease severity (morbidity) and the 
extent of depression (Peck, Smith, Ward, & Milano, 1989). 
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Others have investigated possible dialysis-specific associations with affect. For example, the 
use of polysulfone dialysers in relation to depression was the focus of a recent investigation 
(Hsu, Chen, & Wu, 2009). The rationale was that polysulfone dialysers reduce inflammation 
during dialysis (Walker, Sutherland, & De Jong, 2004). The authors compared HD patients 
using polysulfone dialysers with cellulose derivative dialysers, with regards to depression 
symptoms using the Hospital Anxiety Depression Scale (HADS). A HADS depression score of 
>8 was used to define significant depressive symptoms. The results demonstrated that 
polysulfone dialysers reduced the odds of depression in multivariate analysis. However, the 
depressed and non-depressed groups did not differ in their inflammatory or malnutrition 
markers, making the basis for this finding uncertain. These results are probably confounded 
by the small sample and significant selection bias with regards to which patients used 
polysulfone dialysers. Larger controlled studies, looking at the biocompatibility of dialysers 
in relation to depressive symptoms, would nevertheless be of interest. 
 
Restless leg syndrome (RLS) is more prevalent in ESRD than in the general population, and 
is associated with insomnia, mortality and depression (Montplaisir et al., 1997; Sevim et al., 
2004; Takaki et al., 2003; Unruh et al., 2004).  In a large cohort of transplant and dialysis 
patients, RLS was predictive of significant depressive symptoms (CES-D >18) after 
controlling for several covariates including albumin and the number of co-morbidities 
(Szentkiralyi et al., 2009). Interestingly this association was independent of insomnia, 
suggesting that a lack of sleep did not mediate the relationship between RLS and 
depression (Szentkiralyi et al., 2009). When the dialysis patients were analysed separately, 
an even stronger association was observed. Pain, fatigue and helplessness are some of the 
potential mediating factors put forward to explain the association between depression and 
RLS (Kushida et al., 2007; Ulfberg, Nystrom, Carter, & Edling, 2001). However, causality 
cannot be inferred here, as it is also possible that depressive behaviours (e.g. lack of 
exercise,) may lead to RLS (Aukerman et al., 2006).  
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Table 2.2: The association between depression and outcome in ESRD patients 
Study n Assessment Model Outcome Adjusted Relative Risk  (95% CI)
 
(Boulware et al., 2006) 917 MHI-5 (≤52)  Baseline  All deaths 1.24 (0.81 to 1.89) 
   CVD deaths 0.72 (0.30 to 1.73) 
  Time Dependent All deaths 2.22 (1.36 to 3.60) 
   CVD deaths 3.27 (1.57 to 6.81) 
  Six to month lag All deaths 1.32 (0.77 to 2.25)  
   CVD deaths 0.89 (0.28 to 2.83) 
(Kimmel et al., 2000) 295 BDI  Time varying  All deaths 1.32 (1.13 to1.55) 
  CDI   1.23 (1.05 to 1.43) 
(Einwohner et al., 2004) 66 Zung SDS Baseline  All deaths 1.05 (1.01 to 1.08)
a 
(Lopes et al., 2002) 5256 Physician Diagnosis Baseline  All deaths 1.23 (1.08 to1.40) 
    1st Hospitalisation 1.11 (1.01 to 1.22) 
  “down in the dumps”  All deaths 1.48 (1.29 to1.70) 
    1st Hospitalisation 1.15 (1.04 to 1.27) 
  “down hearted and 
blue” 
 All deaths 1.35 (1.18 to1.55) 
    1st Hospitalisation 1.11 (1.01 to 1.22) 
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a
Adjusted Hazard Ratio 
b
no CI described. Zung SDS: Zung Self-report Depression Scale. BDI: Beck Depression Inventory. CDI: Cognitive Depression Index. PRIME-MD: Primary 
Care Evaluation of Mental Disorders Mood Module. CES-D: Center for Epidemiologic Studies Depression Scale. MHI-5: 5 item subscale from the Medical Outcomes Study 
Short Form-36. “down in the dumps” and “down hearted and blue”: items from the Kidney Disease and Quality of Life Short Form. 
#
80 HD and 21 PD patients
Study n Assessment Model Outcome Adjusted Relative Risk  (95% CI)
 
(Lopes et al., 2004) 6987 CES-D ≥10 Baseline  All deaths 1.42 (1.29 to1.57) 
    1st Hospitalisation 1.12 (1.03 to 1.22) 
    Withdrawal 1.55 (1.29 to1.85) 
  Physician Diagnosis  All deaths 1.26 (1.10 to 1.43) 
    1st Hospitalisation 0.97 (0.86 to 1.09) 
    Withdrawal 1.42 (1.11 to 1.80) 
(Hedayati et al., 2008) 98 SCID Baseline  Death/hospitalisation 2.07 (1.10 to 3.90) 
  BDI    1.01 (0.96 to 1.05) 
  CDI    0.99 (0.94 to 1.05) 
  CES-D   1.01 (0.98 to 1.04) 
  BDI ≥14   0.86 (0.45 to 1.64) 
  CES-D ≥18   1.06 (0.58 to 1.96) 
(Drayer et al., 2006) 62 PRIME-MD Baseline  All deaths 4.1 (1.2 to 13.8)
a 
(McDade-Montez et al., 2006) 240 CDI Baseline  Withdrawal 1.06
a
 p<0.05
b 
(Riezebos, Nauta, Honig, Dekker, & Siegert, 2010) 101
# 
HADS-D ≥7 Baseline  Mortality 11.7 (1.6 to 82)
a 
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2.10 Associated psychological features of depression in ESRD 
A number of studies have focused upon the psychological factors associated with 
depression in ESRD, with particular reference to internal locus of control (Baydogan & Dag, 
2008; Christensen, Turner, Smith, Holman, & Gregory, 1991). Earlier work from the Lister 
hospital observed a negative association between internal health locus of control and 
depression symptoms (Chilcot, Farrington, Wellsted, & Da Silva-Gane, 2008). Other work 
has shown the importance of perceptions of control and feelings of helplessness in the 
onset and maintenance of depression in ESRD patients, for example feelings of 
uncontrollability and perceptions of illness intrusiveness (Christensen & Ehlers, 2002; 
Devins, Binik, Hollomby, Barre, & Guttmann, 1981; Devins et al., 1983). The concept of loss 
received attention in a recent study among 151 ESRD patients (Chan, Brooks, Erlich, Chow, 
& Suranyi, 2009). Perceptions of loss were the strongest predictors of depression, which in 
turn predicted quality of life. Likewise, loss may be closely associated with perceptions of 
helplessness and uncontrollability. 
 
It has been suggested that perceptions of control and mastery are significant factors 
involved with cognitive adaptation to illness (Taylor, 1983). One study reports that a high 
illness identity (a self-concept congruent with a stereotypical kidney patient) correlated 
with illness intrusiveness and emotional distress (Devins, Beanlands, Mandin, & Paul, 1997).  
The authors propose that in individuals whose self concept is “tied” to that of illness, 
perceive less non-illness rewards and experiences thus predisposing them to depression.  
 
More recent work has focused upon underlying illness schema in predicting depressive 
symptoms among ESRD patients (Guzman & Nicassio, 2003). Self-schema refers to cognitive 
generalizations that impact upon the selection and processing of self relevant information 
(Markus, 1977). Having a negative illness schema would lead to biased processing with 
regards to negative health related information, that would typically lead to negative 
appraisals and perceptions. Guzman et al (2003) found in 109 ESRD patients that negative 
illness schemas were associated with higher BDI and CDI scores, whereas positive illness 
schemas were associated with reduced depression scores. Although this study suffers with 
some methodological concerns, including its cross sectional design, negative cognitions 
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(and underlying schemas) may be important determinants of depression in ESRD patients. 
Attempts to reconfigure such negative beliefs by psychological intervention seem highly 
relevant. In support of this line of research some work in ESRD has shown the importance 
of illness appraisals upon mood independent of disease severity (Sacks et al., 1990), while 
other studies have revealed associations between illness representations and quality of life 
among ESRD patients (Covic, Seica, Gusbeth-Tatomir, Gavrilovici, & Goldsmith, 2004; Griva, 
Jayasena, Davenport, Harrison, & Newman, 2009; Timmers et al., 2008). The association 
between illness perception and depression receives further attention in the following 
chapter.  
2.11 Treatment options for depression in ESRD 
Among patients with ESRD there are several treatment options available, all of which 
should be accompanied by supportive, educational and problem-solving strategies 
(MacHale, 2002). A systematic review of antidepressants in patients with a physical illness 
provides evidence for the effectiveness of drug treatment compared to no-treatment or 
placebos (Gill & Hatcher, 1999). The authors reported that 4.2 patients need to be treated 
to produce one recovery (95% CI: 3.2 - 6.4) although this is somewhat crude as it does 
ignore improvements in affect.   
 
Data from the DOPPS cohort revealed that among ESRD patients with a physician diagnosis 
of depression, only 34.9% were on antidepressants (Lopes et al., 2004), although the rate in 
Japan is reported to be only 1.2% (Fukuhara et al., 2006). Although this does not include 
the number of patients receiving psychotherapy, it appears that many patients are not 
receiving adequate treatment for their depressive disorders. It is thought that even fewer 
patients are receiving antidepressant medication at the start of dialysis therapy, a time 
when the onset of depression may be more frequent (Watnick et al., 2003). As previously 
stated, depression or adjustment disorders may manifest during this time period, thus 
suitable recognition and treatment would appear to be important. 
 
In ESRD the prescription of antidepressants requires some caution as there is potential for 
drug-drug interactions. The general guidance for anti-depressant prescription in this setting 
is to start at a lower dose and increase gradually (Kennedy, Craven, & Rodin, 1989; 
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MacHale, 2002). Generally older tricyclic medications have an adverse cardiac profile, thus 
merit caution in ESRD patients. Selective serotonin reuptake inhibitors (SSRIs) have more 
favourable side effect profiles, although they may increase some uraemic symptoms. 
Several small investigations have demonstrated the effectiveness of SSRI’s in dialysis 
patients (Blumenfield et al., 1997; Levy et al., 1996). As a part of an 8 week trial, Levy et al 
(1996) gave both depressed renal and depressed non-renal patients, 20mg/d of fluoxetine. 
In both patient groups, depressive symptoms were reduced significantly in 5 of the 6 
patients. The authors reported no adverse effects in the renal group (Levy et al., 1996). The 
results also indicated that there were no pharmacokinetic difference between HD and non-
renal patients, as both groups had similar plasma concentrations of fluoxetine (and 
norfluoxetine). Similarly fluoxetine (20mg daily), in a double blind placebo controlled study 
of HD patients, was effective in alleviating depression symptoms with no significant side 
effects (Blumenfield et al., 1997). Citalpram is thought to be safe considering its similarly 
with fluoxetine (Cohen, Tessier, Germain, & Levy, 2004). It is suggested however that 
fluoxetine should be avoided in diabetics due to its potential to change serum glucose 
levels. Furthermore duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor, 
is not recommended for use in patients with ESRD (Preskorn, 2004).  
 
A wider issue concerns the fact that some patients refuse treatment, while other are non-
adherent to antidepressants medication (Wuerth et al., 2001). One recent study suggests 
that patients may be unaware of depressive or anxiety symptoms, or feel that they do not 
require attention (Johnson & Dwyer, 2008). Understanding the possible barriers raised by 
these issues is of importance if patients are to receive suitable treatment for depression.  
 
The possible side effects and drug -drug interactions presented by psychotropic 
intervention highlight the need to establish and implement effective psychological 
interventions in patients with ESRD. Used solely or in parallel with drug treatment, 
psychological therapy has been used widely across a range of chronic illnesses. Of these, 
cognitive behavioural therapy (CBT) has been shown to be effective (Cukor, 2007; Cukor & 
Friedman, 2005; Lustman et al., 1998; White, 2001). A recent trial of group CBT was found 
to be an effective treatment for depression in HD patients (Duarte, Miyazaki, Blay, & Sesso, 
2009). Forty-one patients underwent a 12 week group CBT intervention, in comparison to 
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44 control patients whom received standard care.  At both 3 and 9 months follow up, the 
intervention group scored significantly lower on the BDI, and on items of the Mini 
International Neuropsychiatric Interview (M.I.N.I). This study, despite a few limitations, 
highlights the promise of CBT as a treatment option for dialysis patients. Further, a recent 
randomized, controlled, pilot investigation used CBT as an intervention to improve sleep 
quality in peritoneal dialysis patients and found it to be effective. Although several 
confounding factors may have influenced the results, this evidence adds to the potential 
benefit of CBT in improving quality of life among ESRD patients. Despite these advances 
there is a great need for further studies investigating the treatment options available for 
depressed ESRD patients.  
The empirical works presented here investigate the association between depression and 
illness representations in ESRD. As reviewed in the following chapter, maladaptive illness 
cognitions are associated with various health related outcomes, including depression and 
reduced quality of life. Therefore a prerequisite to further interventional research in ESRD 
is to understand the nature and content of patient’s illness cognitions in relation to affect.  
2.12 Concluding Remarks 
This chapter provided a review of depression in ESRD. The issues encountered when 
assessing mood in individuals with a chronic illness were discussed, but will be considered 
further in chapter 4. These issues are highly relevant in ESRD, due to the nature of renal 
failure and its symptoms. Although there is no consensus as to how to assess depression in 
this setting, evidence suggests that 20-30% of patients experience significant depressive 
symptoms. While the evidence in the ESRD population is complex, it is sufficient to link 
depression with adverse outcomes. Given this, it is alarming that depression is under 
recognised and under treated. It is therefore necessary to identify antecedent factors that 
are amenable to intervention. Indeed, there is a vast need to establish viable treatments 
for ESRD patient. CBT may be an important therapeutic method although further trials of 
psychotropic and psychotherapeutic interventions are required. 
 
The psychological and clinical parameters associated with depression are becoming 
evident, although a vast amount of research is still required if we are to understand the 
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pathogenesis of depression in ESRD. The aim of this thesis is to increase this level of 
understanding, by applying the self-regulatory illness representation model to the 
understanding of depression in ESRD. The following chapter outlines this model, described 
its development, and presents empirical data for the utility of the self-regulatory model of 
illness representations in the context of physical illness.  
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Chapter 3 
Self-Regulation in heath and Illness: The Common Sense Model of 
Illness Representations 
 
- “Health is not valued till sickness comes” 
Thomas Fuller (1608-1661) 
3.1 Introduction 
The aetiology of depression is conceptualised as a diathesis-stress model in cognitive 
theory (Beck, 1967). Therefore like other co-morbidities in ESRD, individuals have 
psychological risk factors (diathesis) which become activated by environmental or internal 
stressors. The onset of illness may be an important stressor that activates the depressive 
vulnerability, defined as depressive schema in cognitive theory (Beck, 1967). The 
interpretation and self-regulation of the illness event (i.e. the potential stressor) is 
potentially critical, as according to the principles of cognitive theory, the matching of the 
input stimulus with underlying depressive schema leads to depression. With this context 
the interpretation of illness may be important determinants of affect. It has been proposed 
that the interpretation and adaption to illness is best defined in terms of self-regulatory 
processes, with particular emphasis on the Common-Sense Model (CSM) of Illness 
representations. Although the entirety of the CSM model is not examined in this thesis, the 
present chapter aims to set the landscape and rationale behind studying illness 
representations in ESRD. The content of this chapter is organised as follows: 1) a concise 
overview of self-regulation and the historical development of CSM, 2) a description of the 
fundamental tenets of the CSM, 3) a review of empirical support for the CSM and of the 
model’s utility as applied psychological and clinical outcomes in chronic physical illnesses, 
and 4) a review of research into illness representations in ESRD. The reviews have drawn on 
searches of the Pubmed, Psycinfo, and the Web of Knowledge databases.  
Self-regulation is inherent to being human; it is the ability to set goals and adapt one’s 
behaviour in order to attain them (Scheier & Carver, 2003). This involves exerting control 
over internals states and responses (Baumeister, Heatherton, & Tice, 1994). In other words, 
humans strive to attain standards or goals by altering their thoughts, desires, emotions and 
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behaviours (Carver & Scheier, 1998). Moreover, it has been suggested that any system 
capable of problem solving has the potential to self-regulate (Powers, 1973). A generic 
conceptualisation is seen in cybernetic control theory (Miller, Galanter, & Pribram, 1960), 
which is governed by the TOTE framework (test, operate, test, and exit). According to TOTE, 
a self-regulatory system first tests an input against a standard (reference value). It then 
operates a procedure to reduce or in some instances increase the discrepancy between the 
input and reference value. The system then undergoes a further test against the reference 
value. This process is repeated until concordance is achieved between the input and 
reference value, at which point the process is ended (exit). The basic feedback architecture 
of TOTE underpins general models of self-regulation (Carver & Scheier, 1981), in which 
goals serve as reference values from which one’s current state (input function) is evaluated. 
Discrepancy between the goal standard and the input function, leads to the 
implementation of strategies to achieve the goals, which are then appraised as to their 
success at moving closer to the goal state (Carver & Scheier, 1981).  
While an in-depth account of self-regulation as applied to human behaviour is beyond the 
scope of this chapter, the description provided above represent key features of a self-
regulatory process, which also apply to the understanding of human behaviour and 
adaption. The discussion presented in this chapter will be constrained to self-regulation 
pertaining to health and illness, to which the work of Howard Leventhal and colleagues has 
been seminal. The Common Sense Model (CSM) specifically addresses self-regulatory 
processes encountered during the prevention, adaption and maintenance of behaviours 
relating to the disease (Leventhal et al., 1980; Leventhal et al., 1984). The CSM departs 
from social-cognitive models of health behaviour including the Theory of Planned 
Behaviour (Ajzen, 1991) and the Health Belief Model (Rosenstock, 1974). Although all infer 
that perceptions (or attitudes) from a part of the basis for motivated behaviour, the CSM 
describes these representations as both concrete experiential and abstract schematic 
components (Leventhal, Diefenbach, & Leventhal, 1992; Leventhal, Leventhal, & Contrada, 
1998). Moreover, the CSM defines at least five illness perceptions that coalesce to form an 
illness representation which operates within an individual’s pre-existing cognitive schema 
of illness.   
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The CSM posit that individuals are active problem solvers motivated to resolve the threat of 
illness (Leventhal et al., 2003). The targets (goals) that are being strived towards, refer to 
the somatic experiences, emotions, and competencies that evoke from the “physical and 
psychological self” (Leventhal et al., 2003). The strategies or procedures undertaken for 
regulation (i.e. health behaviours, emotional regulation) are the result of the interpretation 
of the health threat (i.e. the illness representation), and the emotional reaction to the 
threat. Therefore unlike general models of self-regulation (Carver & Scheier, 1981), the 
CSM not only defines the self regulatory process, but also provides content as to what is 
being regulated (Leventhal et al., 2003). This content refers to illness representations, or 
cognitions, that define the problem and set procedures for dealing with the illness threat.  
The work to be presented in this thesis argues that illness representations predict 
depression in ESRD, and both depression and illness representations are associated with 
adverse outcomes. However it should be noted that illness representations are more than 
just perceptions of illness. They sit within a specified content driven model of self-
regulation pertaining to health and illness (CSM). Therefore, the terms illness 
representations and illness perception are used interchangeably throughout this thesis 
depending upon the context in which they are described. Illness representations refer to 
the mental models of illness individuals hold, whereas the term illness perception is used to 
refer to single cognitions pertaining to a facet of the disease, for example how long will it 
last, or can it be controlled? An elaboration of the CSM and its development is provided in 
the following section. 
3.2. Historical Development of the CSM: the parallel response model 
The CSM is an extension of the parallel response model which arose from studies 
investigating fear communication (Leventhal, 1970). Early work on fear communication was 
influenced by the Fear-Drive Model (Dollard & Miller, 1950), which stated that fear was a 
motivation state, and that behaviours or procedures that reduced fear would be reinforced 
or learnt via Pavlovian and Instrumental conditioning. Leventhal and colleagues undertook 
a series of experiments designed to test the assumptions of the Fear-Drive Model. These 
experiments evaluated the compliance to recommended health behaviour following the 
communication of either high or low fear messages. In multi-factorial designs, fear 
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messages were combined with other factors including action planning. The hypothesis 
according to the fear-drive model was that high fear would produce the uptake of 
recommended health behaviour if paired with a procedure that reduced the motivational 
fear state. Data from numerous experiments (Dabbs & Leventhal, 1966; Leventhal, Singer, 
& Jones, 1965; Leventhal & Watts, 1966) found that high-fear messages were more 
effective in producing attitudinal change towards a behaviour (i.e. taking a tetanus shot 
and smoking cessation), compared to low-fear messages, although the effect was time 
limited generally disappearing between 24 -48 hours (Leventhal, 1970; Leventhal & Niles, 
1965). Moreover, two consistent findings discredited the models assumptions; 1) high fear 
messages were no more influential at producing actual health care behaviour as compared 
to low fear messages, and 2) either high or low fear messages paired with procedures for 
action (i.e. action plan) elicited overt health care behaviours (Leventhal, 1970). To illustrate, 
student participants were more likely to attend a clinic to receive tetanus if a fear message 
was presented to the participants accompanied by a plan of action, which in this instance 
was to examine their daily schedule and plan a time when they would be near to the 
university clinic (Leventhal et al., 1965). Although there was no apparent interaction 
between fear state (high vs. low) and the presence of action plans upon overt behaviour, it 
was clear that fear was a required state as action plans alone failed to elicit behaviour 
(Leventhal, 1970; Leventhal & Niles, 1965). Put another way, explicit plans regarding a 
health behaviour including when, how, and where to do it, was a poor predictor of actual 
behaviour in the absence of fear. These results led to the development of the parallel 
response model (Leventhal, 1970). This model posits two parallel responses to illness 
threats; an emotional state (fear control) which leads to the development and 
implementation of procedures to control the fear, as well as a cognitive representation of 
the threat and a need for corresponding procedures to control the threat (danger control, 
see figure 3.1).  Therefore following an illness threat, parallel emotional and cognitive 
systems serve as the interpretive stage of the self-regulatory process, guiding the selection 
and implementation of coping procedures, which are then appraised as to their efficacy. 
The appraisal represents the feedback process in which the outcome of the coping 
procedure is compared with the goal standards. Discrepancy between the input and goal 
standards (i.e. in TOTE) leads to continued self-regulation. 
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Figure 3.1: Graphical representation of the Parallel Response Model (Leventhal et al 1970, 1980, 
1984).  
3.3. A description of the CSM 
3.3.1 The bi-level nature of illness representations 
While it was clear from studies into fear communication that fear per se was not the 
essential motivation for the uptake of health care behaviour, the question remained; was 
there anything inherent to the threat message and its interpretation that influenced how 
individuals react and cope to the threat? A series of experiments were undertaken to 
address this question which involved studying patients about to undergo noxious medical 
procedures (Johnson, 1975; Johnson & Leventhal, 1974). For example during an endoscopy, 
the somatic sensations perceived during the procedure can elicit avoidance reactions if 
they are interpreted as signs of danger. Johnson and Leventhal (1974) conducted a study 
which varied two factors before an endoscopy examination, 1) sensory information and 2) 
specific coping instructions. Patients who were prepared with concrete information about 
the somatic sensations associated with endoscopy, where the sensations were identified as 
non-threatening, and action plans described for dealing with these sensations (breathing 
technique), gagged less during the procedure as compared to control patients who received 
standard care. Patients who monitored these somatic sensations could reduce or even 
eliminate fear because they were guided by a perceptual representation of the experience, 
which directed problem focused coping procedures in order to effectively self-regulate. 
This data suggests that the motivation effects behind a given heath behaviour is driven by 
efforts to control danger (cognitive representations) and fear (emotion), which are 
influenced by patient’s concrete perceptual experience and their interpretation. Moreover, 
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this data suggested that health threats were bi-level, represented as abstract linguistic 
(semantic) codes, and as concrete perceptual experiences. Further research revealed that 
this bi-level feature not only pertained to the experience of emotion, but also to the 
identity of the illness. For example in a study of patients undergoing treatment for 
hypertension, 90% reported they could tell when their blood pressure was up due to 
perceived symptoms like flushed faces and headaches (Meyer, Leventhal, & Gutmann, 
1985). Moreover, hypertensive patients were more adherent to medication if they believed 
that their medication controlled their symptoms (Meyer et al., 1985). However, 80% of the 
same sample reported, “people cannot tell when their blood pressure is up.” This data 
suggests that hypertensive patients held a bi-level representation of their condition; one 
that was based upon their concrete experience (i.e. my flushed face indicates a rise in my 
blood pressure), and the other based upon abstract semantic knowledge (that 
hypertension is asymptomatic). Others have produced complementary data showing that 
symptoms and illness labels are cardinal to illness representations in conditions such a 
cancer (Nerenz, Leventhal, & Love, 1982) and even in common illnesses such as colds (Lau 
& Hartman, 1983). Taken together it appears that illness representation are complex multi-
level concepts that can influence the interpretation, reporting and behaviours surround 
illness.  
3.3.2 Interactions between abstract and concrete illness representations: The 
Symmetry Rule 
Hypertension studies and studies of fear communication had found that illness 
representations were bi-level for both their emotional and cognitive components. 
Moreover there appeared to be a linkage between the concrete perceptual and abstract 
semantic representations. Indeed it was apparent that there was pressure or a heuristic to 
connect the concrete and abstract levels of representation (Meyer et al., 1985). This 
pressure termed symmetry rule, refers to the need to find an illness label (illness identity) 
given the experience of symptoms, and the need to identify symptoms once given a label. 
This notion compares with the theory of cognitive labelling of emotion, which posits that 
physiological arousal promotes a search for a label based upon the cognitions available to 
the individual (Schachter & Singer, 1962). The perception of arousal or change in internal 
states rather than actual change, has also been shown to be sufficient to start the cognitive 
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labelling process (Ross, Rodin, & Zimbardo, 1969). That is, the experience of arousal starts 
the search for an attribution of label to explain the arousal state.  
The influence of these two levels of representation (abstract and concrete) upon fear was 
the focus of subsequent research. Easterling and Leventhal (1989) report that women who 
perceived themselves as vulnerable to breast cancer, reported increase worry (fear) with 
an increase in perceived physical symptoms, despite the fact that the symptoms reported 
were not cancer specific. Therefore the interaction of physical symptoms (concrete 
representation) and an illness identity (vulnerability- abstract representation) lead to 
increased fear about potential cancer risk. Indeed, it was apparent that both symptoms and 
vulnerability were required to generate fear as either alone failed to increase worry 
(Easterling & Leventhal, 1989). This data suggest that the linkage of abstract and concrete 
representations provided a coherent representation, which in this instance increased 
illness-related worry with regards to cancer risk.  
Studies of hypertension provided further support for the symmetry rule. Meyer et al (1985) 
found that patients new to treatment were likely to report that their condition was 
symptomatic the longer they were in treatment. An illness label drove the selective search 
for “common-sense” symptoms based upon underlying illness schema. This data was 
confirmed in laboratory conditions. Students who were provided false-feed back as to their 
blood pressure reading (e.g. high blood pressure) reported experiencing a greater number 
of symptoms such as headaches and flushed faces (Baumann, Cameron, Zimmerman, & 
Leventhal, 1989). Furthermore, this data supports the work of Pennebaker (1982) and 
Pennebaker and Skelton (1981) which demonstrated that cognitive schema influence the 
selection and reporting of somatic sensations. In one study, participants were told that the 
effects of an ultrasonic noise (bogus) upon task performance was being investigated 
(Pennebaker, 1982; Pennebaker & Skelton, 1981). The participants were led to believe that 
the ultrasonic noise may lead to either increases or decreases in skin temperature. A 
control group were told that skin temperature would be monitored but received no 
information regarding ultrasonic noise effects. After the schema manipulation, a thermister 
was attached to participant’s fingers to collect objective reading of skin temperature. After 
two minutes of baseline recording, the ultrasonic noise was played. Participants then 
reported how much they were attending to temperature change and also provided 
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estimates of actual temperature. The data supported the hypothesis that the reporting of 
somatic sensations (finger temperature) would verify their expectations about the effects 
of the ultrasonic noise. Patients in the increase condition reported attending more to 
increases in skin temperature and less to sensations of decreasing temperature. The 
opposite was true for in decrease condition. Despite no actually differences in skin 
temperature across the groups, participants in the increase condition reported their fingers 
becoming warmer after exposure to the noise, whereas participants in the decrease 
condition reported their fingers getting colder. Moreover actual fluctuation in skin 
temperature was interpreted in accordance with participant’s manipulated schema. A 
positive correlation was found between objective skin temperature fluctuation and self-
reported skin temperature for participants in the increase condition, whereas in the 
decrease condition a negative correlation was evident. This suggests that pre-existing 
cognitive schema influenced the selection and reporting of somatic sensations. 
Furthermore, a perceived change in temperature was interpreted in different ways in 
accordance with underlying cognitive schema (Pennebaker, 1982; Pennebaker & Skelton, 
1981).  
3.3.3 Content of Illness Representations 
As described above, the construction of illness representations relies upon the perception 
and interpretation of both semantic and concrete processes. The substance of illness 
representations and their bi-level nature sets the CSM apart from other models of health 
behaviour such as the theory of planned behaviour and the health belief model. Indeed, it 
is the representation of illness that serves as the self-regulatory target that defines goals, 
and provides the reference values for regulation (Brownlee, Leventhal, & Leventhal, 2000). 
The content of illness representations has received the majority of empirical enquiry, and is 
the focus of the work to be reported in this thesis. 
Early in the development of the CSM, symptoms were identified as a core domain. In order 
to further understand the attributes of illness representations several approaches were 
undertaken in patient and student samples, including open ended interviews (Lau, Bernard, 
& Hartman, 1989; Lau & Hartman, 1983), multidimensional scaling and factor analysis 
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(Bishop & Converse, 1986, 1991). Results from these investigations reveal that illness 
representations consisted of five illness perceptions:  
1) Illness identity – Symptoms and labels of disease and the subsequent joining of 
these. 
2) Time-line – Perceived length of the illness, either short-term (acute), chronic, or 
cyclical. 
3) Consequences – Reflects perceived illness severity and the associated social, 
physical and psychological consequences of the illness. 
4) Causes – Patients beliefs about what caused the illness (e.g. germ or virus or one’s 
own behaviour. 
5) Controllability – Perceptions of whether the illness can be controlled or cured.  
While the nature and relative importance of illness representations may be disease specific 
(Heijmans & de Ridder, 1998) several reviews of illness representations, notably the meta-
analysis conducted by Hagger and Orbell (2003) confirm the five factor structure of illness 
representations (Kaptein et al., 2003; Scharloo & Kaptein, 1997b; Skelton & Croyle, 1991). 
Illness perceptions share logical inter-relationships (Hagger & Orbell., 2003), thus instead of 
operating as single cognitions, they coalesce to form an illness representation. The 
development of the Illness Perception Questionnaire (Weinman, Petrie, Moss-Morris, & 
Horne, 1996), and the Revised Illness Perception Questionnaire (Moss-Morris et al., 2002) 
has allowed researchers to assess illness perceptions using standardised methods (see 
general methods). Moreover, the development of these questionnaires has provided 
further evidence for the content of illness representations (Moss-Morris et al., 2002; 
Weinman et al., 1996). 
The content of illness representations and subsequent self-regulatory processes are not 
isolated from personal, social and culture factors. Prior illness experience will provide 
procedural and episodic memories which would act as heuristics following a similar illness 
episode. Individual differences regarding symptom perception is another factor that may 
influence the development and depth of a person’s illness representation (c.f Pennebaker, 
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1982). Social and cultural practices have a considerable influence upon the nature of illness 
representations and the respective action plans employed to overcome health threats. It is 
clear that cultural factors influence abstract perceptual knowledge regarding illnesses, but 
also how symptoms are attended to and reported (Brownlee et al., 2000). For example in 
the Chinese culture psychological symptoms are often down played due to a stigmatisation 
of psychological distress (Kleinman, 1980), thus conditions such as depression and anxiety 
are often under recognised or misdiagnosed as a physical condition. In addition the social 
environment is a critical source of information when faced with a health threat. Individuals 
often approach friends and family first when faced with an illness threat. Social comparison 
is also a critical part of the cognitive adaption to illness (Taylor, 1983), and is likely to 
influence personal illness representations.  
3.3.4 Illness Representations guide action and procedures: IF-THEN rules 
The CSM posits that illness representations guide action and procedures to regulate health 
threats (Leventhal et al., 1998; Leventhal et al., 1980). However the treatment of “coping” 
in the CSM deviates from factor analytic approaches such as the stress coping model 
(Lazarus & Folkman, 1984). Such approaches attempt to generalise how people cope with 
emotions yet ignore the specific content of the threat and how procedures (action plans) 
are selected in response to deal with them (Leventhal et al., 2003; Leventhal et al., 1992). In 
the CSM, coping procedures refer to the “cognitive and behavioural actions we take (or do 
not take) to enhance health and to prevent, treat (i.e. cure or control), and rehabilitate 
from illness” (Leventhal et al 1998, pp 772).  
Following the onset of a headache there are numerous “problem based” actions individuals 
employ including, taking analgesics or applying a cold cloth to the forehead. The 
representation of the headache, including its cause (i.e. stress or excessive alcohol intake), 
and expected or actual time-line (week long or a few hours) will shape the specific 
procedures undertaken to control it. Procedures are goal-relevant and related to outcome 
expectations (will doing X control Y? Bandura 1977). In addition, procedures have organised 
representations regarding their identity, time-line for action, cause, controllability and 
consequences. For example during a perceived stress-headache, one may decide to take an 
analgesic which is expected to alleviate the pain within 30 minutes (Brownlee et al., 2000). 
52 
 
If after this period the headache remains the representation maybe updated to reflect a 
more serious underlying health condition (consequences, timeline, and causes), thus 
requiring medical attention. Moreover, the use of medications also depends of specific 
cognitions surrounding them (Horne, 1997; Horne & Weinman, 1999, 2002). Perceptions 
regarding the concerns and necessity of medication have been shown to predict adherence 
(Horne & Weinman, 1999). If our headache sufferer is averse to taking a drug (i.e. due to 
side effects) they may instead take rest or take herbal remedies. Therefore specific health 
care behaviours are dependent upon the coherence between the illness representation and 
the procedures selected to deal with the threat. This is described as “IF-THEN” rules 
(Anderson, 1983; Brownlee et al., 2000; Leventhal et al., 2003). IF refers to the 
interpretation of the illness threat (targets for self-regulation); Then refers to the 
procedure and actions undertaken to tackle the threat.  
IF-THEN rules are the moderators and mediators in the CSM. Several heuristics have been 
suggested that provide detailed elaboration of the IF-THEN process. These heuristics aid the 
individual in the evaluation of illness indicators to determine “am I ill?” and “what should I 
do?” The first of these rules, the symmetry rule, has been described above. The prevalence 
rule simply refers to the perception that an illness is more severe the less common it is 
perceived to be (Kahneman & Tversky, 1973). For example, in one experimental study 
participants who believed they were the only person in a group to test positively for a 
fictitious antigen that was indicative of increased cancer risk, were more likely to report the 
disease as severe as compared to a group of individuals that were told they were all 
positive “carriers” (Croyle & Jemmott, 1991). The stress-illness rule refers to attribution of 
symptoms (illness) to stress. Accordingly individuals under condition of acute stress are like 
to attribute ambiguous somatic symptoms as products of their stress and avoid care 
seeking behaviour (Cameron, Leventhal, & Leventhal, 1995). The duration rule simply refers 
to the positive association between perceived severity of illness and symptoms duration. 
Indeed, the length of symptoms exposure predicts health seeking behaviour (Mora, 
Robitaille, Leventhal, Swigar, & Leventhal, 2002). The age-illness rule reflects a tendency 
with age to misattribute somatic symptoms as processes inherent with ageing, resulting in 
delays in seeking health-care (Croyle & Jemmott, 1991; Leventhal et al., 2003).  
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While it is likely that more heuristics exist, these rules appear to be important in the initial 
interpretation of an illness threat. Quite how these rules operate within the context of 
chronic illnesses, such as ESRD, remains to be elaborated.  
3.3.5 Illness Schema 
Illness schema exists within a cognitive framework, which guides the selection of illness 
related information. As initially conceived in the CSM individuals hold schemata for acute, 
chronic and cyclical conditions. Leventhal et al (1980) describe how coping procedures are 
encoded within illness schema. Indeed this is implicit in IF-THEN rules described previously. 
However few studies have explicitly examined the schematic nature of illness 
representations. Henderson, Orbell & Hagger (2009) addressed this need by conducting a 
series of experiments investigating illness schema and coping procedures associated with 
the common cold. In a 2 (prime vs. control) X 2 (past users of lozengers vs. nonusers) 
design, participant latencies for correct responses on a grammatical decision task (a 
common cold remedy) were measured. Participants who were experimentally primed for 
illness words relating to the common cold, and who were also past users of a specific 
coping procedure (e.g. lozeneger takers) showed an attentional bias for a common cold 
remedy reflected in longer response times. There was no significant main effect of the 
prime, or whether the participant was a past user of such remedies, or not. These results 
suggest that the past successful use of a coping procedure becomes encoded within the 
illness schema (Henderson, Orbell, & Hagger, 2009). The future activation of the illness 
schema may automatically activate the encoded coping procedures (within episodic and 
working memory). Moreover this reinforces the main tenets of the CSM: that is, illness 
representations set the goals for self-regulation and are not static trait like attitudes but 
instead dynamic perceptions amenable to change.   
3.4. Representations of Physical Illness 
Much of the theoretical and development strides in the CSM have been achieved by 
assessing individual reactions to new health threats, and the behaviours people adopt as a 
part of the self-regulation of health and illness. The CSM has also received considerable 
attention among chronic illnesses, particularly the nature and content of illness 
representations and how these relate to clinical and psychological outcomes.  A synthesis 
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of this literature can be found in the following sources (Hagger & Orbell, 2003; Kaptein et 
al., 2003; Skelton & Croyle, 1991). In summary, a wealth of research has shown that illness 
representations predict health-related outcomes. For example, perceptions of increased 
time-line and illness consequences predict illness related disability and slower return to 
work following a myocardial infarction (Petrie, Weinman, Sharpe, & Buckley, 1996), and 
perceptions of control predict attendance at cardiac rehabilitation clinics (Cooper, Lloyd, 
Weinman, & Jackson, 1999). There is convincing evidence that illness representations 
predict functional status and quality of life over time (Bijsterbosch et al., 2009; Graves, 
Scott, Lempp, & Weinman, 2009; Kaptein et al., 2010; Scharloo et al., 2000), and also 
psychological outcomes (Sheldrick, Tarrier, Berry, & Kincey, 2006). Furthermore illness 
perceptions are associated with a range of adherence and care-seeking behaviours 
(Hampson, Glasgow, & Toobert, 1990; Jessop & Rutter, 2003; Lawson, Bundy, Lyne, & 
Harvey, 2004; Scharloo et al., 1998; Scharloo et al., 1999; Whitmarsh, Koutantji, & Sidell, 
2003). There is comparatively less data examining the change in perceptions over the 
course of a disease (Fischer et al., 2010), although a few studies have shown that timeline 
and illness coherence perceptions increase over time, and emotion and perceived control 
perceptions decrease over time (Bijsterbosch et al., 2009; Lawson, Bundy, & Harvey, 2008). 
Furthermore changes in perceptions over time have been shown to predict functional 
outcomes in osteoarthritis (Kaptein et al., 2010) suggesting there may be some dynamic 
relationship between illness perceptions and outcomes among patients with chronic 
physical disease.  
The dynamics of illness perceptions over time is discussed in more detail later on (chapter 
8). Instead a narrative review to follow will focus on studies that have assessed illness 
representations and depression employing both cross-sectional and longitudinal designs. In 
addition literature specific to ESRD is overviewed. I will finish this review section by 
describing intervention studies that have attempted to alter maladaptive illness 
representations in order to improve health-related outcomes.  
3.4.1 Illness Representations and depression 
Negative perceptions of illness have largely been associated with health-related 
behaviours, functional disability, and psychological wellbeing (QoL). Fewer studies have 
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specifically investigated illness perceptions and depression using conventional assessments 
specific to depressive symptoms (i.e. the BDI). Several studies have examined the cross-
sectional association between depression and illness representations. A study of 
Rheumatoid Arthritis (RA) patients revealed that depression correlated positively with 
consequence perceptions, and negatively with control/cure perceptions, findings which 
were upheld after controlling for disease severity (Murphy, Dickens, Creed, & Bernstein, 
1999). The relationship between illness perception, depression and gender was the focus of 
one study in CVD patients (Grace, Krepostman et al., 2005). Males had significantly weaker 
perceptions of time-line and cyclical perceptions, and stronger perceptions of personal and 
treatment control compared to females. In males, depression symptoms were predicted by 
time-line perceptions, consequences and treatment control. The only illness perception 
associated with depression symptoms in females was stronger time-line beliefs. However, 
given that depression scores did not vary with gender it is important not to over stress the 
impact of gender upon illness perceptions from this data.  
Jopson & Moss-Morris (2003) examined the impact of illness representations in adjusting to 
Multiple Sclerosis (MS). Illness perceptions as assessed by the IPQ-R were significantly 
related to adjustment in a sample of 180 MS patients. Although illness severity predicted 
the most variance in physical disability, illness representations were strongly associated 
with fatigue, anxiety and depression. After adjusting for clinical and demographic variables, 
a lower perception of personal control, greater perceived consequences and perceptions of 
psychological causes predicted HADS- depression scores (Jopson & Moss-Morris, 2003).  
While there is convincing evidence that illness representations and depression are 
associated across a spectrum of physical diseases, the cross-sectional nature of these 
studies prevents the temporal relationship between depression and illness perceptions 
from being inferred. Negative illness perceptions may be the consequence of negative 
illness schema activated in depressed individuals, or may serve as a cognitive vulnerability 
for depression in patients with physical illness (Beck, 1967).  
One of the first longitudinal investigations assessed the relationship between illness 
representations and psychological adjustment in patients with RA and MS (Schiaffino, 
Shawaryn, & Blum, 1998). Depression was assessed using the Center for Epidemiologic 
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Studies Depression Scale and illness representations by the Implicit Models of Illness 
Questionnaire (IMIQ). In both patient groups illness representations were not associated 
with concurrent depression but did predict a change in depressive symptoms over time 
(Schiaffino et al., 1998). In RA patients both curability and personal responsibility 
perceptions predicted later depression, whereas a stronger perception that symptoms 
varied from day to day was predictive of depression in the MS sample. Moreover, there was 
an interaction between disease status and consequences perceptions for predicting 
depression in patients with RA suggesting that dynamic relationship between disease status 
and illness representations. Illness representations have also been found to predict 
depression following a surgical intervention for osteoarthritis (Orbell, Johnston, Rowley, 
Espley, & Davey, 1998). Higher preoperative control perceptions predicted depression at 3 
months post surgery. Causal attributions and outcome expectations predicted depression 9 
months post surgery (Orbell et al., 1998). Interestingly, social and demographic factors 
were not associated with depression suggesting the illness representations had an 
independent effect upon mood.  
More recent data reports that new-onset depression is associated with illness perceptions 
assessed days after a MI (Dickens et al., 2008). After considering covariates including 
measures of cardiac disease severity (Killip Class), chronicity and control perceptions 
predicted new-onset depression (Dickens et al., 2008). A recent investigation reports that 
illness perceptions before cardiac surgery predict depression and disability 3 months later 
(Juergens, Seekatz, Moosdorf, Petrie, & Rief, 2010). Similarly, stronger time-line 
perceptions in patients with head and neck cancer have been shown to predict depression 
6-8 months post-treatment (Llewellyn, McGurk, & Weinman, 2007). A study in patients 
with atrial fibrillation utilised growth modelling, which is a more robust method for 
handling longitudinal data (Lane, Langman, Lip, & Nouwen, 2009). The results revealed that 
baseline illness perceptions did not contribute to the growth trajectory of depression 
symptoms. However it should be noted that depression symptoms were remarkably low 
and stable in this patient group (Lane et al., 2009).  
Despite the longitudinal designs of the above studies, most only used a single baseline 
measurement of illness perceptions for predicting future outcomes. Critically this does not 
tell us how the illness representation changed over time in relation to outcome measures 
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such as depression. Multiple measures of illness perception are therefore required in order 
to evaluate the potentially dynamic relationship with depression over time.  
3.4.2 Illness Representations in ESRD 
A summary of studies that have examined illness representations (as pertains to the CSM) 
in relation to psychological, social or clinical outcomes in ESRD are shown in table 3.1. Eight 
studies were identified after searching Pubmed, Psycinfo, and the Web of Knowledge 
databases, using the search term “illness representations” and “ESRD”. An additional term 
“illness perceptions” was entered in subsequent searches.  
Five of the identified studies addressed the relationship between illness representations 
and Quality of Life (QoL), all of which report an association between illness representations 
and QoL in ESRD, although these studies differed in their methodological approach. All but 
one (Fowler & Baas, 2006) employed the SF-36 to measure health related QoL. In the 
largest most controlled study reviewed Griva et al (2009) report that treatment and illness 
cognitions are associated with QoL. After controlling for demographic and dialysis related 
factors, both perceptions of treatment disruptiveness and illness consequences were 
associated with the mental functioning component of the SF-36. Timmers et al (2008) 
reported that illness identity, consequences, personal control, and emotional 
representations, were associated with the physical component score of the SF-36, 
explaining an additional 30% of the variance above and beyond clinical and demographic 
variables. Mental QoL functioning was predicted by emotional representations and illness 
coherence, which uniquely explained 42% of the variance (Timmers et al., 2008). However 
the cross-sectional nature of these studies prevents the temporal relationship between QoL 
and illness representation from being inferred. Only one study has explored illness 
representations and QoL over time in dialysis patients. Covic et al (2006) followed HD 
patients over two years and reported that emotional representations reduced over time, 
whereas illness coherence and perceptions of treatment control increase. Moreover 
baseline illness representations predicted improvements in QoL. Higher personal control 
and illness coherence, and lower emotion representations at time one predicted improved 
physical QoL scores at time 2. Lower baseline consequence scores were associated with 
improvements in mental QoL functioning. Despite the relatively small sample size, only two 
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time points, and a lack of consideration of extra-renal co-morbidity, these results suggest 
that illness representations are dynamic and are associated with changes in QoL in HD 
patients.  
The utility of understanding illness representations in ESRD extends beyond QoL. Treatment 
and illness perceptions have been associated with measures of non-adherence in dialysis 
patients (Butler et al., 2004; O'Connor, Jardine, & Millar, 2008). O’Connor et al (2008) found 
that emotional representations and time-line perceptions explained an additional 16% of 
the variance in serum phosphate2, after controlling for demographic and clinical factors. A 
recent study examined whether illness representation predicted mortality in a sample of 
dialysis patients followed up for mean of 3.5 years (van Dijk et al., 2009). In adjusted 
survival analysis lower treatment control perceptions were significantly associated with 
increased mortality risk, although depression was not assessed and hence not controlled 
for in the analysis which may be a potential confound. Nevertheless it is suggested that 
lower treatment perceptions may influence self-care and non-adherence behaviours, which 
in turn may impact upon survival.  
These studies all examined the full content domains of illness representations according to 
the CSM. However by casting the net a little wider and looking at similar concepts, there is 
further evidence that perceptions pertaining to illness are associated with QoL, adherence 
and depression in ESRD. For example as reviewed in chapter 2, perceptions of control and 
illness intrusiveness are associated with depression in ESRD. Similarly greater internal 
health locus of control and lower emotion-focused coping correlates with QoL in PD 
patients (Pucheu, Consoli, D'Auzac, Francais, & Issad, 2004). Further, perceptions of self-
efficacy and health locus of control have been associated with non-adherence behaviour in 
ESRD (Karamanidou, Clatworthy, Weinman, & Horne, 2008; Schneider, 1992; Zrinyi et al., 
2003). 
                                                          
2 Serum phosphate can be used as a clinical proxy measure of non-adherence to phosphate-
binding medications. Higher levels of serum phosphate suggest non-adherence to the 
medication. 
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In summary, there is a relative lack of research that has examined the associations between 
illness representations (CSM) and outcomes in ESRD. The current empirical landscape, 
albeit limited, has shown that illness representations are associated with QoL, mortality, 
and non-adherence in ESRD. While it is clear than more research is required to confirm 
these findings, no studies have examined the impact of illness representations upon 
depression in ESRD. As reviewed in the previous chapter depression is a common yet 
complex psychopathology in dialysis patients. How illness representations impact upon 
depression in ESRD is unknown and is the focus of the subsequent works to be reported in 
this thesis. It is known that that depression is treatable, although certain challenges arise 
when treating depression among chronic physical illnesses. Furthermore, illness 
representations are amenable to psychological intervention and improve health related 
outcomes, which are briefly reviewed in the following section.  
3.4.3 Changing illness perceptions: Interventions 
The CSM provides a theoretical platform from which adaption to, and management of 
physical illnesses can be evaluated. However there have been few studies that have utilised 
the CSM in order to influence this process and to potentially improve health-related 
outcomes (McAndrew et al., 2008). Previous studies in myocardial infarction patients 
revealed that illness perceptions predicted functional disability, the time it took to return to 
work (Petrie et al., 1996), and attendance at cardiac rehabilitation (Cooper et al., 1999). A 
landmark study investigated whether altering maladaptive illness perception soon after an 
MI led to improvements in health-related outcomes (Petrie et al., 2002). An in-hospital 
intervention was developed and administered at a point soon after MI. The intervention 
involved three sessions with a psychologist, and was individualised for each patient 
following their response on the IPQ. The sessions involved explaining the physiology of MI 
using concrete images, exploring personal illness perceptions, dispelling misconceptions, 
exploring self-care behaviours and developing an action plan to reducing future risk. 
Patients were randomised to receive either the intervention or standard nurse lead 
education. The results revealed that the intervention significantly altered illness 
perceptions pertaining to time-line and control-cure perceptions as measured by the IPQ 
three months post MI. As compared to the control group, intervention patients returned to 
work significantly sooner and reported fewer angina symptoms (Petrie et al., 2002). 
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Table 3.1: A review of studies that have examined Illness Representations in End-Stage Renal Disease. 
Study Objectives Methods Results Conclusions 
(van Dijk et al., 2009) Explored whether illness 
perceptions of ESRD are related 
to mortality. 
182 dialysis patients assessed 
by IPQ-R 
 
Survival analysis: Adjusted Cox 
proportional hazards models 
61 deaths.  
Weaker perceptions of treatment control 
associated with increased mortality risk 
(Adjusted OR=0.65 95% CI 0.46-0.92). 
Patient’s personal illness beliefs 
are predictive of mortality in 
ESRD patients. 
     
(Griva et al., 2009) Explored whether treatment 
and illness beliefs differed 
between dialysis and transplant 
patients, and to examine which 
beliefs are associated with QoL 
Cross-sectional. 145 dialysis and 
117 kidney transplant patients. 
 
Questionnaires: IPQ, IEQ, TEQ 
and a QoL measure the SF-36  
Transplant patients had better QoL as compared 
to dialysis patients. Dialysis patients had higher 
illness identity, time-line and lower perceptions 
of control 
 
In regression analysis treatment and illness 
beliefs accounted for 22.9-67.6% of the variance 
in QoL (SF-36). 
Illness beliefs differ between 
dialysis and transplant patients.  
 
Illness cognitions predict health 
related QoL in ESRD.  
     
(O'Connor et al., 2008) Explored whether the CSM 
predicted non-adherence. 
Cross-sectional assessment of 
IPQ-R and brief COPE (n=73)- 3 
week follow-up (clinical data). 
 
Adherence measures: 
Phosphate (PO4), Weight gain 
(IDWG) and Diet (Potassium, K) 
In multiple regression analysis emotional 
representations predicted dietary adherence (K), 
and both emotion and timeline perceptions 
predicted drug adherence (PO4).  
 
 
 
Despite small effect, illness 
perceptions predicted facets of 
non-adherence in ESRD above 
and beyond clinical and 
demographic factors.  
     
(Timmers et al., 2008) Examined the relationship 
between illness representations 
and QoL. 
Cross-sectional. 91 HD and 42 
PD patients completed the  
IPQ-R and the SF-36. 
HD patients held weaker perceptions of control 
and coherence as compared to PD. 
 
17-51% o of QoL variance explained by illness 
representations. 
Illness representations differ 
across ESRD treatment 
modalities, and are associated 
with QoL. 
     
(Fowler & Baas, 2006) Assessed the relationship 
between illness representations 
and QoL. 
Cross-sectional. 42 HD patients 
completed IPQ-R and a QoL 
measure (IWB). 
 
Consequences and emotion correlated 
negatively with QoL.    
Illness perceptions have a 
moderate univariate association 
with QoL. 
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Study Objectives Methods Results Conclusions 
(Covic, Seica, Mardare, & 
Gusbeth-Tatomir, 2006) 
Explored the longitudinal 
relationship between QoL and 
illness representations. 
81 HD patients followed up 
over a two-year period. 
 
Assessed on the IPQ-R and SF-
36. 
Multivariate regression revealed that baseline 
control, emotion, and coherence perceptions 
predicted a change in the physical component 
SF-36 score, after controlling for baseline QoL.  
 
Baseline consequence perception scores 
predicted a change in mental component scores. 
Illness representations are 
associated with a change in QoL 
in HD patients.  
 
 
     
(Covic et al., 2004) Examined the relationship 
between illness representations 
and QoL in HD patients, with 
dialysis vintage. 
Cross-sectional. 82 HD patients 
completed the IPQ-R and the 
SF-36. 
Emotional representations correlated negatively 
with treatment duration.  
 
Greater time-line perceptions and lower emotion 
predicted SF-36 physical component score. 
Greater personal control and lower emotion 
predicted SF-36 mental component score. 
Illness perceptions are 
associated with QoL, although 
the regression analysis did not 
control for demographic and 
clinical factors.  
     
(Butler et al., 2004) Examined the relationship 
between depression, treatment 
and illness perceptions with 
adherence to anti-rejection 
medication.  
58 transplant patients. 6 week 
electronic monitoring of drug 
taking (>20% of days missed = 
non-adherent. 
 
Measures: IPQ, BMQ and CIS-R 
In logistic regression analysis, live donor 
transplantation, and low necessity beliefs 
regarding the medication predicted non-
adherence. 
This small study suggests that 
treatment perceptions predict 
non-adherence. No specific 
illness perception predicted 
non-adherence. 
IPQ-R: Revised Illness Perception Questionnaire.  IPQ: Illness Perception Questionnaire. QoL: Quality of Life. IEQ: Illness effects questionnaire. TEQ: Treatment effects 
questionnaire. SF-36: Short Form Health Survey. IDWG: Interdialytic Weight Gain. COPE: Coping Orientation to Problems Experienced questionnaire. IWB: Index of Well-
Being. HD: Haemodialysis. PD: Peritoneal Dialysis BMQ: Beliefs about Medicines Questionnaire. CIS-R: Revised Clinical Interview Schedule.
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A recent study extended the scope of this early intervention study in MI patients by 
broadening the definition of MI based upon the cardiac enzyme troponin T (Broadbent, 
Ellis, Thomas, Gamble, & Petrie, 2009). One hundred and three MI patients were 
randomised to receive an illness perception intervention or standard care. The intervention 
successful changed causal attributions of MI and increased patients understanding of the 
condition (illness coherence). As with the earlier study (Petrie et al., 2002) the intervention 
group returned to work faster, reported more use of exercise, and lower anxiety about 
returning to work (Broadbent et al., 2009). The authors suggest that the intervention 
altered different illness representations than those identified in the Petrie et al (2002) 
study due to the broader sample of MI patients studied based upon troponin T levels. 
Nevertheless both sets of data show that targeting maladaptive illness perceptions can 
improve health related outcomes following an MI.  
A pilot of a psycho-educational intervention in dialysis patients, designed to improve 
understanding of the need for phosphate control revealed promising results (Karamanidou, 
Weinman, & Horne, 2008). As compared to controls, patients who received the 
intervention reported improved knowledge regarding their phosphate binders and greater 
outcome efficacy throughout the study follow-up. Although the study was not powered to 
detect improvements in phosphate control, the findings suggest that psychological 
interventions can improve patient perceptions towards a defined behaviour in this setting.  
3.5 Concluding Remarks 
Illness representations are activated following an illness threat and are maintained 
throughout the illness experience. They provide a mental interpretation of the illness, and 
guide the selection and adoption of health behaviours as a part of a dynamic self-regulatory 
model (CSM). In this chapter the main tenets of the CSM have been described and the 
specific content of illness perceptions defined. After an examination of the current 
literature several points can be inferred: 
1) Illness representations are associated with a range of health-related outcomes including, 
adherence, functional status and QoL. 
2) Illness representations, particularly consequences, timeline and control are associated 
with depression across several disease states.  
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3) Preliminary studies in ESRD suggest the utility of Illness representations in explaining 
adherence, QoL and mortality albeit with a greater need for investigation.  
4) Illness representations are amenable to psychological intervention and improved health 
outcomes.  
The main issue across the literature is lack of longitudinal measures of illness 
representations in order to establish variation over time. Indeed the regulation of illness 
representations is cardinal to the CSM, yet is not a feature in most empirical studies 
(Fischer et al., 2010; Kaptein et al., 2010).  In the studies reported in the following chapters 
the relationship between illness representations and depression is explored in both cross-
sectional and longitudinal samples of dialysis patients. In addition the relationship between 
illness representations and depression with outcomes (adherence and mortality) is also 
evaluated. I will argue that illness representations are essential components related to 
depression and health-related outcomes in individuals with ESRD. 
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Chapter 4 
General Methods 
 
4.1 Introduction 
Methodological features that pertain to all the subsequent empirical work to follow are 
described in the present chapter. The first section provides a rationale for the study designs 
and considers the patient population investigated. The questionnaires common to each of 
the empirical chapters are then described. Specifically, these are the Beck Depression 
Inventory-II (BDI) and the Revised Illness Perception Questionnaire (IPQ-R). The assessment 
of co-morbidity, functional performance and the collection of clinical data are also 
considered. The final section regards the statistical methods employed in parts of the 
analysis that follow, with an emphasis on structural equation modelling (SEM) techniques. 
An overview of SEM and relevant techniques is presented, as an in-depth discussion of the 
technique is beyond the scope of this chapter. In addition to SEM, other statistical 
approaches that feature are described. 
4.2 Design Rationale 
The empirical studies presented in this thesis emerge from two large multi-center studies 
of illness representations and depression symptoms in dialysis patients. The majority of the 
literature surrounding illness representations are largely limited to cross-sectional studies. 
While such studies allow the association between depression and illness perceptions to be 
determined, they cannot infer temporal relationships between the constructs. In addition, 
there is a paucity of longitudinal data considering the course of depression in ESRD and its 
predictors, and studies that have tended to use panel designs have often only two time 
points (i.e. baseline and one follow-up).  
In order to address these needs and to examine the potentially dynamic relationship 
between illness representations and depression, a multi-centred three-wave panel design 
study was conducted. In addition to the longitudinal sample, a large cross sectional study 
was undertaken. The rationale and description of these designs follows below. 
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4.2.1 Cross-sectional study 
A large cross sectional study was undertaken to assess depressive symptomatology and 
illness representations among established haemodialysis patients. Not only does this 
exploration provide data on the prevalence of significant depression symptoms in this 
population, but also serves as a comparator to the longitudinal data. Further it allows the 
association between illness perceptions and depression in other illness groups to be 
explored in this patient setting, and promotes comparisons across patient populations. That 
is, is depression related specifically to facets of illness or rather due to the psychological 
interpretation and regulation of the disease as posited in the CSM. 
In addition the cross-sectional investigation provided a significant amount of BDI data, 
which could be combined with a selection of data from the longitudinal study in order to 
conducted relevant analyses to examine the BDI’s underlying factor structure using 
Confirmatory Factor Analysis (CFA). This is important given the current lack of data 
concerning the factorial structure of the BDI in ESRD and the broader issues of assessing 
depression in the context of physical disease.  
4.2.2 Longitudinal Study 
A longitudinal study design was employed in order to evaluate the change in depression 
symptoms over the first year of dialysis, and to identify relevant illness perceptions that are 
associated with such change. The benefits of following individuals up not only allows 
changes over time and predictors of change to be identified, it also allows individual 
variability through the employment of more advanced statistical methods (Latent Growth 
Modeling) to be evaluated.  
Initiating dialysis patients were assessed within the first three months of treatment, and 
again at six and twelve months later (figure 4.1). Screening dialysis patients for depression 
3-6 months after dialysis initiation and again at a year has been recommended by several 
authors (Hedayati et al., 2006; Hedayati & Finkelstein, 2009). The three-wave panel design 
employed in the longitudinal study conforms to this recommendation, and allows the 
course of depression and it’s antecedents to be identified over the first year of dialysis. 
Furthermore three time points also allows a closer examination of the trajectory of change 
66 
 
over time. A description of the study follow-up with regards to patient recruitment and 
attrition is described in methods section of chapter 8. 
 
 
 
 
 
 
 
Figure 4.1: Pictorial representation of the three-wave panel design. 
4.3 Patients  
All of the patients recruited in the work to follow had ESRD treated with dialysis. The 
majority of dialysis patients were recruited from the renal service of the East and North 
Hertfordshire NHS trust (Lister Hospital and two satellite units based in St Albans and 
Luton-Dunstable Hospitals). In addition patients were recruited from the renal service of 
Addenbrooke’s Hospital, and the Royal Free Hospital (including the satellite unit at St John 
and Elizabeth’s Hospital). All patients were recruited providing they satisfied the following 
criteria; i) no known significant visual or physical impairment that would prevent the 
completion of the questionnaires, ii) fluency in verbal and written English language3, (iii) 
not hospitalised at the time of assessment and iv) no cognitive impairment, as indicated by 
an age adjusted score of <22 on the Mini Mental State Examination (Folstein, Folstein, & 
McHugh, 1975). Inclusion criteria that pertain to particular studies are presented in the 
relevant chapters accompanied by consent rates. NHS ethics and local Research and 
Development approval was sought for each study. All patients provided informed consent 
and were given a minimum of 24 hours to consider participation. Copies of the ethics 
approval letters are shown in the appendix.  
                                                          
3
 The BDI is not easily translatable and the construct of depression in non-western cultures remains largely 
undefined. For these reasons the studies were restricted to English speaking patients.  
Dialysis 
Initiation 
 
Assessment 1 (t1)  
 Assessment 2 (t2)                   Assessment 3 (t3) 
 3 months                             6 months^                                12 months^ 
^after t1 
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All but one of the investigations that follow exclusively studied patients receiving in-
hospital HD. It was decided to focus on this treatment group for the following reasons; 1) 
HD is the most common form of renal replacement therapy, 2) there is limited published 
data to suggest that depression would vary across HD and PD modalities, and 3) increased 
accessibility to the HD patient population.  
4.4 Haemodialysis 
There were some differences between the haemodialysis programmes in the 3 participating 
centres:  
4.4.1 Lister Renal Unit 
Patients were treated exclusively using high flux membranes, predominantly polysulphone. 
Approximately forty percent of patients were treated by on-line haemodiafiltration (HDF). 
Bicarbonate was used exclusively as the buffer. Water quality was regularly monitored to 
ensure tight bacteriological standards (<0.1 cfl/mL and <0.03 EU/ml). Dialysis was 
prescribed and monitored according to a target two-pool total Kt/V of 1.2 (dialysis plus 
residual renal function) per dialysis session for thrice weekly dialysis. Adequacy monitoring 
was carried out monthly and included estimates of residual renal function (as kidney urea 
clearance – KRU).  
4.4.2 Addenbrooke’s Renal Unit 
Patients were treated exclusively using high flux membranes. Bicarbonate was used as the  
buffer. Water quality was regularly monitored to ensure tight bacteriological standards. 
Dialysis was adequacy was monitored every three months with a target single-pool Kt/V of 
1.2.  
4.4.3 Royal Free Center for Nephrology, UCL 
Patients were treated exclusively using high flux polysulphone membranes. 
Approximately six percent of patients were treated by on-line haemodiafiltration (HDF). 
Bicarbonate was used exclusively as the buffer. Ultrapure water, which is free of 
chloramines, is used as standard. Dialysis was prescribed and monitored according to a 
target minimum single pool on-line Kt/V of 1.4 per dialysis session for thrice weekly dialysis. 
Adequacy monitoring was carried out monthly and included estimates of residual renal 
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function (KRU). Patients with significant residual renal function often have once a week or 
twice a week dialysis (<0.1% of patients with a weekly KRU of >1.0 receives 3x week HD). 
4.5 Questionnaire methods 
4.5.1 The Assessment of Illness Representations 
The conceptualisation of illness representation evolved from fear communication studies, 
adopting predominantly qualitative research methods. Since Leventhal’s early work, a 
plethora of studies have been conducted investigating illness perceptions utilising both 
qualitative and quantitative approaches (Hagger & Orbell, 2003; Scharloo & Kaptein, 
1997a). Leventhal’s seminal work focused on in-depth semi-structured interviews, of which 
the emphasis was on the concrete aspects of the illness experience (Leventhal et al., 1980). 
However while of value, interviews are time consuming thus not suited to particular study 
designs or indeed hypothesis-driven research. As noted elsewhere there is no psychometric 
evidence regarding eliciting illness representations via interviews (Weinman et al., 1996). A 
novel approach still in its infancy concerns pictorial representations of disease (e.g. 
drawings of hearts following a myocardial infarction), which have been shown to be 
associated with health-related outcomes (Broadbent, Ellis, Gamble, & Petrie, 2006; 
Broadbent, Petrie, Ellis, Ying, & Gamble, 2004). Although this method requires further 
evaluation, is this clear that such an approach may have utility in groups of patients where 
language barriers prohibit conventional assessment.   
Several questionnaires have been employed to assess illness representations (Hagger & 
Orbell, 2003) although the vast majority of these were not specifically designed for the 
purposes of measuring the five cognitive representations of illness (identity, timeline, 
control/cue, consequences and causes), and were not validated across illness groups. The 
need to develop a theoretically derived validated method of assessing illness 
representations was realised by John Weinmen and colleagues (Weinman et al., 1996). The 
Illness Perception Questionnaire (IPQ) was the first attempt to systematically assess the 
core cognitive facets of illness representations, as developed across several illness groups 
(Weinman et al., 1996). The questionnaire consists of five dimensions each assessing a 
component of illness representations on a likert type scale. Although the IPQ prompted the 
rapid expansion of research into the self-regulation of health and illness, it was clear that 
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there were a few psychometric issues with the IPQ. Additionally the IPQ did not consider 
emotional representations, which is a significant feature of the CSM regarding an 
individual’s emotional reaction to illness threats. These issues were addressed in the 
development of the Revised Illness Perception Questionnaire (IPQ-R) (Moss-Morris et al., 
2002), which is employed in the empirical studies that follow.  
4.5.2 The Revised Illness Perception Questionnaire (IPQ-R) 
The IPQ-R (Moss-Morris et al., 2002) was derived from eight illness groups (n=711) using 
factor analysis. The revised questionnaire has a number of improvements with regards to 
its treatment of illness identity, timeline, control/cure perceptions and causal attributions. 
Illness identity consists of 14 common illness symptoms, in which the patient has to rate 
whether they have first experienced the symptoms (yes/no), and then if so do they 
attribute the symptoms to their illness (i.e. their kidney problem). The sum of the 
attributed symptoms forms the IPQ-R identity subscale (scoring 0-14). This structure avoids 
potential somatisation of symptoms possible in the original IPQ, as symptoms were rated 
on an intensity scale, which may reflect symptom perception rather than the concept of 
illness identity (Moss-Morris et al., 2002). Furthermore the IPQ-R distinguishes cyclical 
time-line perceptions from acute/chronic time-line perceptions, thus contains two 
respective subscales to reflect this. The addition of an emotional subscale in the IPQ-R 
allowed the consideration of individual’s emotional response to illness. These items were 
derived from previous data (Cameron, Leventhal, & Leventhal, 1993). Causal items were 
extended from 10 (IPQ) to 18 (IPQ-R), although the authors recommend conducting 
exploratory factor analysis in order to establish underlying causal factors. An illness 
coherence subscale was added to assess patients overall understanding of their condition. 
Further, factor analysis of the original IPQ items suggested that the control/cue dimension 
loaded onto two separate factors 1) treatment control and 2) personal control. These 
factors were developed and incorporated into the IPQ-R. Moss-Morris et al (2002) 
conducted a principle component analysis (PCA with varimax rotation) on 50 items 
pertaining to the time-line, control, consequences, illness coherence and, emotion 
representation scales. After the removal of multi-loading items, and non significant 
loadings, 38 items produced a total of seven factors, accounting for 64% of the variance 
(Consequences, Emotional, Timeline, Cyclical timeline, Illness coherence, Personal Control 
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and Treatment Control). All of these illness perception factors are measured on a five point 
likert scale (strongly disagree- strongly agree); Consequences (e.g. “my kidney problem has 
major consequences on my life”), Emotional representations (e.g. “I get depressed when I 
think about my kidney problem”), Timeline (e.g. “my kidney problem will last for a long 
time”), Cyclical timeline (e.g. “my symptoms come and go in cycles”), Illness coherence (e.g. 
“my kidney problem is a mystery to me”), Personal Control (e.g. “I have the power to 
influence my kidney problem”) and Treatment Control (e.g. “my treatment can control my 
kidney problem”). High scores on the timeline and consequences dimensions reflect 
strongly held beliefs about the chronicity and negative consequences of the condition and 
the cyclical dimensions reflect strongly held beliefs that the condition is cyclical in nature. 
High scores on the personal control, treatment control and coherence sub-scales reflect 
strong perceptions of illness controllability and a greater personal understanding of the 
condition. The IPQ-R as used in the studies to follow can be found in the appendix. 
Although the IPQ-R was developed and tested in a rigorous manner by Moss-Morris et al 
(2002) a more robust method to evaluate the questionnaires constructs and discriminant 
validity is CFA. Hagger & Orbell (2005) conducted a CFA of the IPQ-R in patient undergoing 
cervical screening and report that the factor model could be reproduced adequately from 
their sample data. After removing two items responsible for model misspecification, good 
model fit was demonstrated. Furthermore, the inter-correlations between the latent 
variables supported those found in previous studies and their discriminant validity (Hagger 
& Orbell, 2005).  
4.5.3 Scoring the IPQ-R 
The IPQ-R was scored according to the instructions available on the Illness perception 
website (http://www.uib.no/ipq/). Illness identity was calculated by summing the positive 
(yes) response to the experience of symptoms attributed to ESRD. Responses on the illness 
perception subscales were scored accordingly (strongly disagree =1, disagree =2, neither 
agree nor disagree = 3, agree = 4, strongly agree = 5). Items IP1, IP4, IP8, IP15, IP17, IP18, 
IP19, IP23, IP24, IP25, IP26, IP27, IP36 required reverse scoring (1=5, 2=4, 4=2 and 5=1). The 
illness perception subscales were calculated by summing the following items:  
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Timeline (acute/chronic): sum items IP1 - IP5 + IP18 
Consequences:  sum items IP6 - IP11 
Personal control: sum items IP12 - 1P17 
Treatment control items: sum items IP19 – IP23 
Illness coherence items: sum items IP24 – IP28 
Timeline cyclical: sum items IP29 – IP32 
Emotional representations: sum items IP33 – IP38 
 
In all the analysis to follow in sections of this thesis, the IPQ-R subscales were computed 
using the SPSS syntax described below: 
 
RECODE ip1 ip4 ip8 ip15 ip17 ip18 ip19 ip23 ip24 ip25 ip26 ip27 ip36 (1=5) (2=4) (4=2) 
(5=1).  
COMPUTE timeline = 6*MEAN.4(ip1,ip2,ip3,ip4,ip5,ip18).  
COMPUTE timecycl = 4*MEAN.3(ip29,ip30,ip31,ip32) .  
COMPUTE conseque = 6*MEAN.4(ip6,ip7,ip8,ip9,ip10,ip11).  
COMPUTE perscon = 6*MEAN.4(ip12,ip13,ip14,ip15,ip16,ip17) . 
COMPUTE treatcon = 5*MEAN.4(ip19,ip20,ip21,ip22,ip23).  
COMPUTE illcoher = 5*MEAN.4(ip24,ip25,ip26,ip27,ip28).  
COMPUTE emotrepr = 6*MEAN.4(ip33,ip34,ip35,ip36,ip37,ip38). 
EXECUTE. 
 
On subscales with 6 items Moss-Morris et al (2002) allowed for a maximum of 2 missing 
items (as evident by the .4 syntax command). For the remainder, 1 missing item per 
subscale was allowed (as evident by “.” number of items-1 syntax command). 
4.5.4 The assessment of Depression  
As described in chapter two assessing depression among physical illnesses is problematic 
largely due to the potential overlap between depression symptoms and those of somatic 
illness. Currently there is no accord as to how to best deal with somatic items in both 
diagnostic and screening methods. Furthermore screening tools lack diagnostic capabilities, 
instead providing an assessment of symptomatology in terms of frequency and severity. 
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However self-report methods have the advantage of practicality, allowing a large 
population to be assessed. On the negative side self-report methods like the BDI contain a 
number of somatic items that inflate estimates of depression prevalence when using 
conventional cut-off scores. Diagnostic schemes generally produce less false positive cases 
but are not best suited for research activities or for the regular clinical evaluation of a large 
population. It is important to be cognizant of the distinction between diagnoses and 
severity, as both assessments have different underlying assumptions yet both are often 
attributed the same term, “depression”. The term depression as applied to the results of 
subsequent chapters refers to a symptom severity and not a diagnosis.  
In the empirical studies to follow, depression symptoms were assessed by a self-report 
severity measure, namely the BDI-II (Beck, Steer, & Brown, 1996). The BDI is a widely 
administered self-report questionnaire designed to assess the severity of depressive 
symptoms including cognitive, affective, and behavioural components. The BDI-II consists 
of 21 items, which are each rated upon a 4 point ordinal scale (0-3) indicating the frequency 
or severity of a particular depressive symptom (scores range from 0-63). The scores are 
summed to given a total depression score of which higher scores represent the reporting of 
more and severe symptoms. According to Beck et al (1996) a cut-off score of 13 indicates 
minimal depression, 14-19 mild depression, 20-28 moderate depression and ≥29 severe 
depression. 
The BDI-II is a revision of the original BDI-1A in order to correspond with the diagnostic 
criteria of the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) 
criteria for Major Depressive Disorder. The BDI-II included four new items not present in 
the BDI-1A: Agitation, Worthlessness, Loss of Energy and Concentration Difficulty. Four 
items on the BDI-1A: Weight Loss, Body Image, Work Difficulty and Somatic Preoccupation, 
were not included in the BDI-II. In addition the BDI-II asks patients to answer the questions 
regarding how they have been feeling over the “past two weeks, including today”, 
reflecting the time-frame for symptoms described in the DSM-IV. The BDI-II has been found 
to have good reliability (α=0.91) in outpatients samples with various psychiatric disorders 
(Beck, Steer, Ball, & Ranieri, 1996). Comparison of the BDI-II with the BDI-1A reveals similar 
correlates with regards to sex, ethnicity, diagnosis of mood disorder and anxiety, however 
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it was found that the BDI-II total scores were approximately two points greater than the 
total scores of the BDI-1A (Beck, Steer, Ball et al., 1996).  
The BDI-II was chosen for use in the studies to be presented because it conforms to current 
diagnostic criteria for MDD (DSM-IV), and because its properties in general and clinical 
samples have been well examined (Beck, Steer, & Brown, 1996; Steer, Ball, Ranieri, & Beck, 
1999). Furthermore, the original BDI has also been used with the ESRD setting and more 
recent work has shown the original compares well with diagnostic standards, if cut-off 
scores are adjusted upwards (Grant et al., 2008). In one of the first empirical studies to test 
the BDI in ESRD patients Craven et al (1988) evaluated the measure against DSM-III criteria 
for depression in 99 patients. Craven et al (1988) found that a BDI ≥15 produce optimal 
sensitivity (0.92) and negative predictive value (0.99). The authors note that increasing the 
cut-off above ≥15 decreased sensitivity and did not produce a meaningful increase in 
positive predictive value. 
More recent data confirms that the cut-off on the BDI needs to be adjusted upwards for 
use in ESRD patients, presumably due to increased somatic experiences encountered in this 
population. For example, a BDI cut-off ≥16 was shown to compare well with diagnostic 
standards, revealing a 91% sensitivity and 86% specificity for depression as assessed by the 
SCID in ESRD patients (Watnick et al., 2005). In addition, Watnick et al (2005) revealed 
utility for the shorter Patient Health Questionnaire (Spitzer, Kroenke, & Williams, 1999), 
where a cut-off score of ≥10 was associated with 92% specificity and sensitivity. 
The BDI and CES-D measures were compared against the SCID in a larger study of 98 HD 
patients (Hedayati et al., 2006). The authors report that a CES-D score >18 gave 69% 
sensitivity and 83% specificity for depression. A BDI cut-off of 14 yielded 62% sensitivity and 
81% specificity. A recent study in UK dialysis patients compared the BDI against the ICD-10 
diagnostic criteria for MDD (Grant et al., 2008). Analysis of 57 dialysis patients BDI scores 
against the diagnostic criteria found that a BDI ≥15 produces 78% specificity and 100% 
sensitivity, whereas a BDI ≥20 produces 92% specificity and 71.4% sensitivity.  
 
These studies have all utilised the BDI and compared them against diagnostic standards. 
Interestingly these studies have utilised the original BDI and not the BDI-II. Given that the 
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BDI-II leads to slightly higher mean total scores as compared to the BDI, it could be 
assumed that a cut-off score based upon the BDI-II in ESRD would be marginally higher that 
the 14-15 cut-off scores reported in studies that has used the BDI. However it should be 
noted that some confusion has been reported within the wider literature regarding the 
correct citation of versions of the BDI (Scalera & Shear, 2002). For example, in one ESRD 
study the authors failed to cite the version of the BDI used, instead citing apparent 
“validation” studies (Watnick et al., 2003). The failure to adequately describe the 
questionnaire version inhibits the reliable comparison of scores between studies (and 
estimated prevalence based upon cut-off scores which differ between versions) and may 
misinform as to which version to use in subsequent studies. In all the empirical works that 
follow the term BDI refers to the BDI-II.  
4.6 The assessment of Extra Renal Comorbidity  
Extra renal co-morbidities are common among individuals with ESRD and are associated 
with adverse clinical outcomes (Collins, Hanson, Umen, Kjellstrand, & Keshaviah, 1990). 
Accordingly some adjustment for this case-mix is desired particularly when evaluating 
prognostic models or conducting empirical analysis of the kind to be presented. Currently 
numerous co-morbidity scoring systems have been developed which differ in their 
approach and complexity. Methods that adopt a continuous measurement approach 
include the Charlson Index (Charlson, Pompei, Ales, & MacKenzie, 1987) and the ESRD-
Severity Index (Craven, Littlefield, Rodin, & Murray, 1991). Stratification into risk groups is 
also popular (Chandna, Schulz, Lawrence, Greenwood, & Farrington, 1999; Davies, Phillips, 
Naish, & Russell, 2002; Khan et al., 1993; Wright, 1991). Currently there is no consensus as 
to which methods is preferred, while others suggest that the separate assessment of 
individual co-morbidities provides a better case mix adjustment (Van Manen et al., 2003).   
 
Of the current semi-quantitative approaches the Davies method is the simplest. The 
rationale behind this approach was to define a simple index of co-morbidity that could 
define a group of patients at high risk of adverse clinical outcomes (Davies et al., 2002). 
Accordingly one point for each of the following conditions is assigned: ischemic heart 
disease (defined as prior myocardial infarction, angina, or ischemic changes on ECG), left 
ventricular dysfunction (defined as clinical evidence of pulmonary oedema not due to 
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errors in fluid balance, or history of congestive heart failure), peripheral vascular disease 
(includes distal aortic, lower extremity, and cerebrovascular disease), malignancy, diabetes, 
collagen vascular disease, and other significant pathology. The grade of co-morbidity is then 
derived from this total score; low (score=0), medium (score of 1-2) and high (score of 3 or 
more). The Davies method has been shown to compare well with the Charlson index, and 
predicts hospitalisation and death in ESRD patients (Fried, Bernardini, & Piraino, 2003), 
although its initial use and validation is restricted to the PD population.  
 
The work to follow utilised the method described by Chandna et al (1999), a semi-
quantitative approach not that dissimilar to the methods proposed by Davies et al (2002) 
and Wright (1991). This method was adopted in the work to follow for the following 
reasons; 1) data has shown that the present method has increased prognostic power 
compared to other semi-quantitative approaches (Chandna et al., 1999), 2) it incorporates 
severity into the coding and, 3) the clinicians responsible for the coding were involved in 
the development of the approach thus had valuable insight and familiarity with the 
concept. Patients were scored on the number and severity of the following conditions: 
Cardiac Disease, Peripheral Vascular Disease, Liver disease, Central Nervous System 
disorders, and Respiratory disease. Cardiac disease was rated according to the New York 
Heart Associations functional classification. The other disease groups were scored in a 
similar manner: 0= none, 1= minimal, 2= mild, 3= moderate and 4= advanced. Cancer was 
also graded (1-4) according to its activity and nature (medium term survival). Cirrhosis was 
scored as a 4. Scores were summed to form a combined co-morbidity score. To note, 
diabetes was not considered in the scoring system, rather treated as a separate condition. 
Patients were then stratified according to their score, following a similar classification to 
Wright (1991) and Davies et al (2002). A score of ≥3 was graded as “high” if the total score 
was derived from at least one illness group (i.e. at least moderate disease in one system). 
Medium risk was defined by a score of 2-3 (where a score of 3 was not derived from one 
system group). A score of 0-1 was defined as low risk.  
4.7 Functional Status  
The assessment of Functional Status is a useful complement to clinical and demographic 
information as a method of quantifying disease impact. The Karnofsky Performance Scale 
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(KPS) was developed in the cancer setting and is a widely used method of assessing 
functional status (Karnofsky, Abelmann, Craver, & Burchenal, 1948). The KPS consists of an 
11 item ordinal scale (see table 4.3). A score of 100 represents normal functioning and, zero 
is death. In research the KPS is also treated by its functional classes with various 
categorisations employed (Joly et al., 2003; Zubrod et al., 1960), for example ≥70 to signify 
independent functioning. It is common for researchers to use both the ordinal scale and 
categorical function groups, and there is no consensus as to which method is preferable. 
Rather preference for either method should be judged according to the distribution of the 
data collected. Furthermore little work has been conducted within ESRD patients to 
examine the reliability of KPS. Early data suggests that the KPS has poor inter-rater 
reliability in HD patients (Hutchinson et al., 1979), however data from the oncology setting 
suggests a far higher inter-rater reliability (Schag, Heinrich, & Ganz, 1984).  
The KPS has been extensively applied to the ESRD population (Edgell et al., 1996). Despite 
the lack of investigations pertaining to the psychometric properties of the KPS in ESRD, 
there is evidence that KPS scores predict adverse outcomes in ESRD. Several studies have 
shown that functional status as measured by the KPS predicts mortality in ESRD (Chandna 
et al., 1999; Ifudu, Paul, Homel, & Friedman, 1998; McClellan, Anson, Birkeli, & Tuttle, 
1991) and acute renal failure (Perez Valdivieso, Bes-Rastrollo, Monedero, De Irala, & Lavilla, 
2007). For example in a sample of incident dialysis patients McClellan et al (1991) reported 
that the KPS score was a significant independent predictor of mortality after controlling for 
several covariates including Quality of Life, age and co-morbidity.  
4.8 Cognitive Function 
Although in the work to follow cognitive function was not evaluated in relation to the 
psychology factors, it was necessary to screen for cognitive impairment using a screening 
method.  The Mini Mental State Examination (MMSE, Folstein et al., 1975) was employed 
to ensure that the patients had adequate capacity to complete the questionnaire methods. 
The MMSE consists of 30 items evaluating various dimensions of cognitive ability including 
orientation, memory and arithmetic. A score of ≥25 from a possible 30 indicates “intact” 
functioning, although adjustments can be made for age. In the work that follows cognitive 
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impairment was indicated by an age adjusted score of <22 on the MMSE (Folstein et al., 
1975).  
Table 4.1: KPS classification 
Score Description General Category 
100 Normal functioning N
o
rm
al 
A
ctivity 
90 Normal Activity minor signs of disease 
80 Activity with some effort minor signs of disease 
70 Care for self but unable to carry on with normal activity  Dep
en
d
en
t 
A
ctivity 
60 Requires some assistance, but cares for self 
50 Requires considerable assistance and frequent care 
40 Disabled. Requires considerable care N
ee
d
s sign
ifican
t 
assistan
ce
- 
P
ro
gressive  
d
eterio
ratio
n
 
30 Severely Disabled, hospitalisation indicated 
20 Very sick, Hospitalised, active support needed  
10 Moribund 
0 Dead 
 
4.9 Clinical Data 
The following clinical data was collected for each of the studies presented in this thesis; 
Blood haemoglobin levels (Hb g/dL), dialysis adequacy (Kt/Vurea), serum albumin (g/dL) and 
serum C-Reactive-Protein (CRP mg/l). Dialysis vintage was computed (in days) for each 
patient from the time of dialysis initiation to the day of the study assessment. Primary renal 
diagnosis was coded in accordance with the data from the UK Renal Registry; Uncertain 
aetiology, Glomerulonephritis, Pyelonephritis, Diabetes, Polycystic Kidney, Hypertension, 
Renal Vascular Disease, Other. In addition smoking status was collected by self-report. 
To determine whether patients had a documented history of depression, the problem lists 
from clinical letters and the electronic clinical data-bases were inspected. A positive 
depressive history was defined as having documented in the medical history either; 
“Depression,” “Major Depressive Disorder (MDD)” or “Manic Depression (Bi-Polar).” 
Transplant status was determined via self-report. Patients were asked if they were 
currently on the transplant waiting list (yes, no or don’t know). It was felt that the patient’s 
perception and knowledge regarding their transplant status would be more closely related 
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to their mood and illness perceptions, rather than their actual status. Other clinical 
methods pertaining to particular chapters are described in the relevant sections.  
4.10 Demographic Information 
Age, gender, ethnicity, marital-status and work-status were collected by a 14 item patient 
question (see appendix). Due to the small numbers of eligible patients from ethnic 
populations represented in the work that follows, patients were grouped as white vs. non-
white. All categorical variables were dummy coded (i.e. male= 0 vs. female =1, white =0 vs. 
non-white) in the analyses that follow.  
4.11 Statistical Software  
All univariate and multivariate (excluding SEM) analysis was evaluated in SPSS v.17. All SEM 
and related analysis was evaluated in Mplus version 5.21 (Muthén & Muthén, 2007). 
4.12 Statistical Analysis 
The statistical analysis presented as a part of this thesis employed an array of statistical 
methods suited to the hypothesis under investigation and the suitability of the techniques 
given statistical assumptions and the consideration of sample size. Where relevant the 
statistical analyses that pertain to particular studies are described in the chapters that 
follow. The following section briefly describes some common features that apply to the 
majority of the data to be reported, and then focus more specifically on SEM and Latent 
Growth Models.  
Univariate comparisons between groups were evaluated using t-tests, Mann-Whitney U 
test depending on the distribution, or in cases where three of more groups were compared 
Analysis of Variance (ANOVA). Differences between groups with respect to the distribution 
of categorical variables were examined using the Chi-squared test. In several chapters the 
illness perceptions of “depressed” and “non-depressed” patients were compared (chapter 
7 & 8). Given that there were several illness perceptions to be compared between the 
depressed and non-depressed patients there was the potential for type I errors. A more 
appropriate analysis is Multivariate analysis of Variance (MANOVA). MANOVA allows the 
combination of several dependent variables - DVs (i.e. illness perceptions) into one analysis 
thus controlling type one error. In MANOVA a combined overall effect between the 
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categorical independent variable-IV (i.e. depressed vs. non-depressed) and the DVs (illness 
perceptions) is calculated. Furthermore differences between the groups with regards to 
individual DVs (illness perceptions- i.e. coherence) are evaluated. MANOVA also features in 
chapter 9 because comparisons of illness perceptions between “adherent” and “non-
adherent” patients were sought.  
Two of the chapters reported here employed logistic regression to predict a binary 
outcome, specifically depression (chapter 7) and adherence (chapter 9). Logistic regression 
differs from conventional linear regression in that the underlying function refers to 
probabilities (odds). Further, the assumption surrounding the normal distribution of IVs is 
less stringent. For this method variables were entered in a hierarchical manner in order to 
examine the improvement in the regression models after adding particular variables. In the 
first two steps demographic and clinical variables were evaluated as predictors of the 
outcome variable. In a final step illness perceptions were entered in order to evaluate their 
association with the outcomes variables after controlling for the demographic and clinical 
factors. A significant change in the chi-square (∆chi-square) between two models is 
interpreted as an improvement in the model fit. Nagelkerke R2 was evaluated as a measure 
of explained variance in the dependent variables. In logistic regression the interpretation of 
the regression estimates are as odds ratios. That is, a 1 point increase (or decrease) in the 
IV increases (or decreases) the odds of the outcome variable (e.g. depression). 
4.12.1 Structure Equation Modeling 
The following sections on Structural Equation Modeling (SEM) attempt to provide a brief 
overview of the techniques employed at later points in this thesis. Specific details of the 
models tested including their specification are described in the relevant empirical chapters. 
SEM is family of related statistical techniques that allows relationships between one or 
more independent (IV, exogenous) and dependent variables (DV, endogenous) to be 
evaluated. In SEM either the IV or DV can be measured directly (i.e. an absolute score) or as 
latent variable (a variable that is not directly measured but is assumed to be related to 
directly observable variables). A latent variable typically refers to some hypothetical 
construct that is not directly observable, examples of which could be personality, cognitive 
ability and depression. SEMs are often depicted graphically. Table 4.2 displays the common 
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symbols employed in SEM diagrams. An example SEM path model is shown in figure 4.2. 
The model shows three IVs and two DVs. The three IVs are specified to be intercorrelated 
as indicated by the double headed arrows between them. The single headed arrows 
between the IVs and DVs are stating a direct association between the two variables that is, 
the IV is predicting the DV. Statistical estimates of the direct effects are estimated in the 
modeling procedure which are interpreted as regression coefficients (either standarised or 
unstandardised). Inspection of figure 4.2 shows that DV1 is actually both an IV and DV, as 
not only do IVs 1-3 predict DV1, DV1 has a direct path form it to DV2. Specifying a model in 
this way allows tests for mediation, otherwise known as indirect effects.  
Table 4.2: Symbols commonly used in SEM 
Symbol Description 
 Observed variable- a variable directly observable by the 
researcher. 
 Latent  variable- a variable that is unobserved (factor) 
 Direct effect between two variables i.e.  
X           Y : X is a predictor of Y 
 
Correlation or covariance-  two variables assumed to co-
vary but no hypothesis about the direction is stated – 
“unanalysed association”  
E Residual Error- unexplained variance 
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IV1 
IV2 
IV3 
DV1 
DV2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: An example of a SEM  
 
In the model of figure 4.2 IVs 1-3 are set to predict DV1 and DV2. Furthermore, indirect 
effects of IVs 1-3 on DV2 through (as mediated by) DV1 is also specified in the model. Of 
course instead of observed variables latent variables could be included in the model.  
There are a number of advantages to employing SEM techniques over conventional 
regression analysis. Firstly in SEM multiple DVs can be assessed in the models, and latent 
variables can be included in the specified model. Moreover SEM allows a cleaner statistical 
model as it estimates the residual variance (the error) and accounts for this “error” in the 
modelling. For these reasons SEM was utilised in chapter 8 particularly as there were 
multiple DVs to model (illness perceptions) and meditational effects (indirect relationships) 
to evaluate. Moreover illness perceptions could be treated as latent variables and their 
relationship with depression modelled after accounting for measurement error. 
4.12.2 Model Estimation and Fit 
Model estimation techniques determine the model parameters (as in regression analysis). 
Maximum likelihood (ML) is the most common estimation method and allows all 
parameters to be simultaneous estimated. The mathematical operations of ML estimation 
are far beyond the scope of this chapter. In brief, ML estimation assumes the estimates to 
be population values, which are the values that maximise the likelihood that the data 
(observed covariances) were drawn from this population.  
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Another estimation technique is Weighted Least-Squares with Mean and Variance 
Adjustment (WLSMV) estimation. WLSMV was employed in the SEM models that follow 
(excluding the latent growth models) because it is an appropriate technique when the data 
is skewed, categorical or ordinal. The WLSMV estimation unlike Maximum Likelihood (ML) 
procedures makes no assumptions about the distribution of the data (Muthén & Muthén, 
2007) and models polychoric correlations. WLSMV estimation has been shown to produce 
accurate model statistics across models that vary in sample size, complexity and normality 
(Flora & Curran, 2004).  
The essential question in SEM is whether the observed covariance matrix from the sample 
data fits, or is similar to, the estimated covariance matrix (i.e. the proposed model). In 
other words does the model derived data fit with the actual sample data. Typically this can 
be evaluated using a chi-square goodness of fit test, which derives the deviation between 
the estimated covariance matrix with the observed covariance matrix. A non-significant chi-
square is desired suggesting that the reproduced and observed covariance matrixes do not 
differ significantly hence the data fits the proposed model structure. However the chi-
square statistic is very sensitive to sample size (Ullman, 2006), and it is quite often the case 
that the chi-square is significant. For these reasons fit indices are utilised in conjunction 
with the chi-square test to inform the relative fitness of a model. The comparative fit index 
(CFI) is an incremental fit index that compares the proposed model with the null model, 
and uses an approach based on the noncentral chi-square distribution (Bentler, 1990). A CFI 
≥0.95 indicates good fit (Hu & Bentler, 1999). The Tucker Lewis Index (TLI) was also 
employed , which has the a similar interpretation to the CFI but also considers the number 
of parameters (Tucker & Lewis, 1973). A final index, The Root Mean Square Error of 
Approximation (RMSEA) considers model complexity. A RMSEA <0.05 is considered to 
demonstrate reasonable fit, while a value of >0.1 suggests poor fit (Browne & Cudeck, 
1993). All three indices were considered in the models that follow. 
4.12.3 Confirmatory Factor analysis (CFA) 
CFAs are known as measurement models in that they describe how observed variables 
(indicators) measure underlying concepts (latent factor). CFA is employed to test how well 
the latent factors explain observed variables (i.e. how well the model fits the data). CFA 
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differs from exploratory factor analysis because in CFA the researcher has an idea of the 
proposed measurement structure and seeks to confirm the structure using SEM based 
techniques. Consider the measurement model in figure 4.3, which specifies a two factor 
measurement model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: An example of a CFA measurement model. 
 
The latent variables (F1 & F2) are hypothesized to predict 3 observed items each (thus the 
latent variables are in fact IVs). As an example, the latent variables here could be cognitive 
(F1) and somatic (F2) items on a questionnaire, with the observed items representing the 
scores for each particular question. Typically the latent variables are set to be correlated 
(unanalyzed association). Each item also has corresponding error terms (E) that represents 
the variance in the item that is not explained by the latent variable. Model fit is determined 
by the methods described above. As with other SEM there is an opportunity to modify the 
model according to modification indices computed by modeling software such as Mplus. 
Model Modification uses modification indices to examine whether freeing parameters (an 
effect between two variables) that are constrained to zero improves the model fit. 
Furthermore, they can identify which parameters should be added to the model to improve 
the model fit (Ullman, 2006), including the correlation of residual errors. Modification 
indices estimate the amount by which the chi-square fit statistic will decline (i.e. improve) 
when the modification is made. Modification can however be a dangerous procedure, as it 
essentially turns the confirmatory technique into an exploratory one. It should be borne in 
Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 
 E  E  E  E  E  E 
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mind that the CFA is theory dependent so modification was only attempted if the proposed 
changes appeared theoretically valid. CFA of the BDI is presented in chapter 6 in order to 
evaluate the underlying structure of the questionnaire as applied to dialysis patients. In 
addition a CFA of illness perceptions as measured by the IPQ-R was evaluated in chapter 8.  
4.12.4 Latent Growth Models 
Latent growth models (LGM) are kinds of SEM for the analysis of longitudinal data and 
allow the trajectory of a measure (i.e. depression) to be assessed over time. Unlike 
alternative methods, LGMs account for residual variance for an observed item. 
Furthermore LGMs are particularly suited for longitudinal studies were patient attrition is 
expected as each individual trajectory is considered with all the available data. For these 
reasons LGMs were utilised in the longitudinal study presented in chapter 8, allowing the 
trajectory of depression over time to be evaluated.  
In order conduct LGM several requirements are necessary; 1) minimum of three time 
points, 2) dependent variables have the same units over time and measure the same 
construct, 3) data are time structured in that all are collected at the same intervals. 
Depicted in figure 4.4 is a LGM. As with all LGMs the dependent variables at each time 
point (V1-V3) are specified to be predicted by two latent constructs representing the 
intercept (starting value) and a slope (change over time). The intercept is analogous to the 
intercept on a regression equation (i.e. start value). All the loadings on this factor to each of 
the observed DVs are fixed to one. Since all three values are fixed at the same value, this is 
the constant level of depression, if there were no growth. The loadings on the slope are 
fixed at intervals of 0, 0.5 and 1 which represent the times of the measurement (i.e. at 
baseline, half a year and 1 year). In this example the rate of change is specified as linear 
because the time slopes are increasing by the same amount at every interval. Finally the 
intercept and slope are said to co-vary, that is the estimate of this covariance indicates 
whether the initial level is related to change over time. Unspecified growth models allow 
one or more (in larger models) of the slope estimates to be freely estimated by the 
statistical software. Such models are often employed when the function of the change over 
time is not known (non-linear). In addition LGMs can also be included as a part of SEMs. For 
example, factors that are thought to predict the slope or intercept can be entered by 
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regressing the latent variables (slope and intercept) onto the hypothesised predictors 
(illness perceptions). This kind of modelling features in chapter 8 where illness perceptions 
are specified to predict the slope (i.e. change) of depression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: An example of a latent growth model. 
 
4.13 General Comments 
A description of the general methodologies employed in the works throughout this thesis 
has been described, including the measurement of depression and illness representations 
and the assessment of co-morbidity. Moreover an overview of the study designs and 
statistical methods have been presented. 
The following chapter presents a pilot study that examined the application of the methods. 
Specifically, the validity and reliability of assessing depression and illness perceptions while 
on-dialysis is evaluated. 
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Chapter 5 
Screening for depression and assessing illness perceptions: An 
evaluation of on-dialysis assessment 4 
5.1 Introduction 
This chapter serves to evaluate the application of the questionnaire methods (BDI and IPQ-
R) which are employed throughout this thesis. The intention was to establish whether the 
BDI and IPQ-R questionnaires could be completed while patients were actively on HD. On-
dialysis assessment has some particular advantages for research and clinical based 
activities, particularly as the vast majority of patients reported in this programme of 
empirical work were receiving in-hospital HD. Indeed, on-dialysis assessment attempts to 
standardise the condition in which patients are assessed, while also being highly practical. 
From a clinical perspective assessing depression symptoms while patients dialyse may 
provide a platform for regular assessment in this setting. The work of James W. Pennebaker 
(1982) on the “Psychology of Physical Symptoms” is also relevant in this chapter as the 
context of dialysis may lead to a variety of sensory and perceptual experience which could 
influence self-reported symptoms. This chapter serves to evaluate the application of the 
methods, and not to explicitly test theories relating to symptom perception. However 
pragmatically, the work here allowed comment on these theories as an additional interest. 
A pilot study is presented, in which on-dialysis assessment of depression symptoms (BDI) 
and illness perceptions (IPQ-R) were compared with the same measures completed off-
dialysis. In addition to evaluating the context of assessment, the accuracy of the BDI as 
compared to diagnostic criteria for MDD was also assessed.  
5.1.1 Screening for depression in HD patients 
As discussed previously, the numerous methods employed to assess depression or 
depressive symptoms contribute to the variation in reported prevalence estimates. Further, 
there remains substantial debate regarding the most effective way to assess and define 
                                                          
4
 To note, parts of this chapter have been published in; Chilcot, J., Wellsted, D., Farrington, K (2008). 
Screening for depression while patients dialyse: an evaluation. Nephrology Dialysis & Transplantation, 
23(8):2653-9 
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depression among illness states, with reference to both screening and diagnostic methods. 
Owing to the lack of clear direction in this debate I have decided to focus predominantly on 
the application of a depression screening tool (BDI) in this chapter. The logic here was to 
establish a procedure which could fulfil the needs of subsequent works which investigated 
depression symptoms and illness representations in longitudinal and cross-sectional 
samples of ESRD patients. 
Despite several published studies revealing the relative accuracy of the BDI as a screening 
tool among ESRD patients, the screening procedure has received sparse attention. In 
comparison with diagnostic interviews it is recognised that depression screening offers a 
practical solution that allows a large clinical population to be assessed. In an early review of 
the topic it was indicated that self-report depression tools may aid the detection and 
treatment of depression in medical settings (Meakin, 1992). However, the effectiveness of 
depression screening in clinical practice is questionable (Gilbody, House, & Sheldon, 2001a; 
Gilbody, Sheldon, & House, 2008). It is worth reiterating though that most of this data has 
been generated from primary care settings therefore the utility of depression screening 
among individuals with chronic illness is unknown. Screening techniques are unlikely to be 
of value unless they are routinely used and demonstrate an effect upon treatment 
prescription (Gilbody et al., 2001a). However screening is advocated if the costs are 
reasonable and the subsequent treatment options defined and available (Valenstein, Vijan, 
Zeber, Boehm, & Buttar, 2001). The scope of this chapter allows us to explore the 
procedure of regular depression assessment in ESRD patients in order to promote both a 
research and a clinical method.  
It seems reasonable to regularly assess mood in ESRD patients given that depression is 
prevalent and associated with adverse outcomes. It is suggested here that that on-dialysis 
screening is one possible technique that would satisfy this need. Drayer et al (2006) 
reported assessing depression while HD patients were dialysing, in an attempt to minimize 
the impact of fluctuating uraemic symptoms on mood and cognition that would inevitably 
be present in patients during the interdialytic period (Drayer et al., 2006; Kurella, Chertow, 
Luan, & Yaffe, 2004). However, few studies have explicitly employed on-dialysis assessment 
and little is known about the legitimacy of such a procedure. The uncertainty here is 
whether the context of actively dialysing influences depression screening? The purpose of 
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the work reported is to evaluate the reliability of on-dialysis assessment. Specifically we 
investigated the level of agreement (LoA) between BDI scores obtained on-dialysis with 
scores obtained off-dialysis. Level of agreement (Bland & Altman, 1986) is appropriate in 
this context as we anticipated some intra-individual variation in symptom reports over a 
period of time. We were particularly interested in understanding if on-dialysis assessment 
had a substantial influence on somatic BDI scoring.  
The focus of this pilot work was extended in order to examine the accuracy of the BDI in 
relation to a diagnostic standard for MDD. This was deemed to be of importance because at 
the time of this study all related data originated from the United States, thus no 
comparable UK data was available. Examining the accuracy of the BDI allowed us to 
determine a BDI cut-off score relevant to our sample of haemodialysis patients. 
5.1.2 Does the context of dialysing influence self reported illness perceptions? 
The second question addressed in this chapter concerns the viability of on-dialysis IPQ-R 
assessment. The primary aim here was to define the level of agreement between subscale 
scores on the IPQ-R, completed on- and off-dialysis. 
Previous research has shown that the interpretation of symptoms is dependent upon a 
range of factors including mood, cognition and environmental factors. The seminal work of 
James Pennebaker revealed that individual perceptions of symptoms often correlate poorly 
with physiological states (Pennebaker, 1982; Pennebaker & Watson, 1988). Indeed, 
perceptual experiences can be influenced by cognitive schemata which influence the 
selective search, and inference of symptoms and sensations (Pennebaker, 1982; Skelton & 
Croyle, 1991). Pennebaker (1982) demonstrated the importance of attention on symptom 
perception. It was proposed that because attention is finite, internal sensory and external 
stimuli compete for attention. According to Pennebaker (1982) “the probability of noticing 
internal cues can be expressed as a function of the ratio of the quantity or salience of 
potential internal information to external information” (p.21). Therefore if the environment 
is of sufficient interest to the individual, attention will be directed towards the particular 
external stimuli resulting in the decreased selection of encoded internal sensations. 
Similarly if the environment is boring or tedious, internal sensory processes are likely to be 
selected after encoding (i.e. active in working memory) as attention would be directed 
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inwards.  For example in a novel study, Pennebaker (1982) found a significant negative 
correlation between reported interest in an environmental stimulus (video) and the 
attention paid to internal states, as measured by the number of coughs recorded during the 
video viewing. Pennebaker argued that the lack of environmental interest directed 
attention inwards so that every tickle in the throat and chest was more salient to the 
individual. While the validity of this approach is questionable Pennebaker and colleagues 
demonstrated similar effects across various paradigms, including the perception of heart 
palpitations. Other reports have demonstrated support for the competition of cues 
principle regarding the perception of fatigue (Fillingim & Fine, 1986), and have shown that 
the manipulation of self-focused attention increases symptom reports (Pennebaker, 1982; 
Schmidt, Wolfs-Takens, Oosterlaan, & van den Hout, 1994).  
The importance of symptom perception is highly relevant in this context since symptoms 
form an integral part of an individual’s illness representation. As described earlier the bi-
level nature of illness representations (abstract vs. concrete levels) can activate cognitive 
and emotional representations of disease (Leventhal et al., 1980). The context of dialysis 
does induce physiological changes resulting in a variety of physical sensations. In addition 
given that routine dialysis treatment is somewhat tedious, sensory perceptions may be 
influenced according to the competition of cues principle (Pennebaker, 1982). Put another 
way, the environmental context of dialysis could impact symptom perception due to an 
internal attentional focus, which may then alter reported illness perceptions.  In order to 
observe whether illness perceptions differed across assessment conditions, we compared 
IPQ-R perceptions reported on-dialysis with off-dialysis assessments. To further evaluate 
the impact of contextual factors upon self-reported physical symptoms, we also analysed 
the number of endorsed physical symptoms patients reported having since their kidney 
problem (taken from the IPQ-R identity scale), regardless of whether they attributed the 
symptom to ESRD.  
While focus of attention can influence symptom reports, there is also evidence that 
negative affect and self-focused attention are associated (Duval & Wicklund, 1972; 
Pyszczynski & Greenberg, 1987; Salovey, 1992). Indeed it is thought that negative affect 
draws attention to somatic symptoms (Stegen, Van Diest, Van de Woestijne, & Van den 
Bergh, 2001). For example experimentally induced negative mood has been shown to 
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heighten self-focus and influence perceptions of perceived health and symptoms reports 
(Croyle & Uretsky, 1987). Of further empirical interest is the potential “joint-impact” 
between mood and self-focused attention upon reported symptoms (Gendolla, Abele, 
Andrei, Spurk, & Richter, 2005). The potential interaction between depression and 
assessment condition (on- vs. off-dialysis) upon the number of self-report symptoms was 
explored in sub-analysis. 
In summary, the main aims of the pilot work here were as follows: 
Primary aims: 
1) To test whether depression symptoms and illness perceptions varied across the 
assessment conditions (on- vs. off-dialysis). 
Secondary aims: 
2) To examine the accuracy of the BDI against a diagnostic standard for MDD. 
3) To test whether there was any interaction between the assessment condition (on- 
vs. off-dialysis) and depression (depressed yes vs. no) upon reported illness 
perceptions. 
5.2.1 Methods 
5.2.2 Participants 
HD patients from the renal service of the East and North Hertfordshire NHS Trust were 
approached, excluding patients with known dementia or a history of major psychiatric 
disorders other than depression. Adult ESRD patients who had been receiving HD for >3 
months were recruited. All patients were receiving high-flux haemodialysis or on-line 
haemodiafiltration three times weekly. None of the patients required hospitalisation 
between assessments. 
Forty-three adult HD patients agreed to participate, corresponding to a 78% consent rate. 
Two patients dropped out of the study prior to follow-up, and one patient was excluded 
due to a significant counselling intervention being provided between assessments.  
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5.2.3 Materials 
The BDI, IPQ-R and MMSE have been described previously. To note, the IPQ-R causal 
perceptions were not included in the analysis in this particular study. As an addition, the 
number of endorsed physical symptoms from the initial part of the illness identity scale 
(IPQ-R) was summed, regardless of whether the patient believed the symptom was due to 
ESRD. This symptom inventory allowed the comparison of the number of reported physical 
symptoms across conditions. A 15 item non-somatic subscale of the BDI (cognitive 
depression index – CDI), was computed according to the work of others (Sacks et al., 1990). 
The rationale of the CDI according to Sacks et al (1990) is to remove the potential 
problematic somatic questions leaving a cognitive subscale. As discussed previously this 
specific approach has not been subject to factor analysis in the ESRD population. This issue 
is addressed further in the following chapter which evaluates the factor structure of the 
BDI-II. However at this point there was insufficient data to conduct a factor analysis in order 
to understand the particular structure of the BDI (i.e. cognitive and somatic). Rather given 
its use within the renal literature, and because comparing cognitive and somatic symptoms 
separately is desired here, the CDI subscale was used in the form described elsewhere 
(Sacks et al., 1990).  
Depression was assessed using the Mini International Neuropsychiatry Interview (M.I.N.I) 
The M.I.N.I is a structured diagnostic interview for both DSM-IV and ICD-10 psychiatric 
disorders (Lecrubier et al., 1997; Sheehan et al., 1997). The M.I.N.I depression module 
consists of two diagnostic filter questions, concerning depressed mood and loss of interest 
during the past two weeks. If either of these symptoms is confirmed, seven additional 
symptoms are evaluated. These are; 1) loss of appetite, 2) sleeping difficulties, 3) 
restlessness, or slow movement or speech, 4) a lack of energy 5) feelings of worthlessness 
or guilt, 6) concentration difficulties, and 7) consideration of suicide or self-harming. The 
presence of five or more symptoms indicated MDD. The M.I.N.I has demonstrated high 
reliability and validity against the Structured Clinical Interview for Depression (SCID) and 
the Composite International diagnostic Interview (CIDI) for MDD, data from which is 
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summarised in table 5.1 (Lecrubier et al., 1997; Sheehan et al., 1997). Sheehan et al (1997) 
report high inter-rater (kappa=1)5 and re-test reliability (kappa=0.87) for the M.I.N.I. 
Table 5.1: Validity of the M.I.N.I against the SCID and CIDI. 
   M.I.N.I 
Comparator Study N Kappa Sensitivity Specificity PPV NPV 
SCID Sheehan et al  (1997) 370 0.84 0.96 0.88 0.97 0.93 
CIDI Lecrubier et al (1997) 343 0.73 0.94 0.79 0.56 0.99 
N: sample size. PPV: Positive Predictive Value. NPV: Negative Predictive Value 
5.2.4 Demographic and Clinical data 
Demographic characteristics as described in the general methods, accompanied by routine 
clinical parameters (haemoglobin, albumin and Kt/V) were collected. In addition, whether 
patients were on anti-hypertensive medication was recorded from medical notes.  Co-
morbidity was defined using the methods described in chapter 4 (Chandna et al., 1999).  
5.2.5 Design and Procedure 
The study employed a within-subjects design, with the order of assessments 
counterbalanced to control for order effects. Assessment order was randomised 
determined by a random number sequence, with the order allocated on the basis of the 
next available order as the patients were recruited. Patients were asked to complete the 
BDI, IPQ-R and demographic questionnaires during a stable dialysis session, commencing 30 
minutes after initiation.  
The off-dialysis assessments were completed either before or after a treatment session 
according to patient preference. For the off-dialysis assessment patients were invited to 
the renal unit to complete the same questionnaires (BDI and IPQ-R), with the addition of 
the interview component involving the M.I.N.I and MMSE. The on- and off-dialysis 
assessments took place on average 10.7 (±4.2) days apart.  
                                                          
5
 A kappa=1 suggests perfect concordance between raters, thus caution should be noted here as one would 
expect some discrepancy in a sample of 370.  
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5.2.6 Analysis 
The primary aim was to determine the extent to which the situation in which patients were 
assessed (on dialysis or not) influenced their response.  The default assumption was that 
the situation would have no discernable influence on the patients’ responses. A high level 
of agreement (LoA) was therefore expected between the two BDI assessment scores and 
the two sets of illness perception data (on- vs. off-dialysis). Level of agreement was 
assessed by the method described by Bland and Altman (1986). A high level of agreement 
would indicate that the location of the assessment did not influence the patient’s 
responses to the assessment tool. Furthermore give that up to this point there is no data 
concerning the internal reliability of the IPQ-R dimensions in dialysis patients, Cronbach’s α 
were calculated for IPQ-R scores on- and off-dialysis.  
 
Receiver Operating Characteristic (ROC) analysis was used to determine suitable cut-offs for 
the BDI and CDI, measured against the diagnostic scheme. Chi-Square tests were employed 
to test associations between the diagnostic scheme, and defined BDI and CDI cut-offs.  
 
Interactions between depression (assessed by the M.I.N.I) and the assessment condition 
upon reported illness perceptions were evaluated in mixed model ANOVAs, with one 
between subjects variable (depressed yes and no) and one within subjects variable 
(assessed on- and off-dialysis). Main effects of depression and the assessment condition 
upon illness perceptions were evaluated accompanied by their interaction (i.e. 
depression*assessment). 
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5.3 Results Part I: The assessment of depression on-dialysis 
The following results section is structured in two parts; (1) compares on- and off-dialysis 
BDI assessments, and evaluates the accuracy of the BDI against the M.I.N.I and, (2) 
compares the IPQ-R responses assessed on- and off-dialysis. In addition the interaction 
between depression and the assessment condition upon reported illness perceptions was 
evaluated.  
5.3.1 Patient characteristics 
Patient characteristics and clinical data are displayed in table 5.2.  Of the forty patients 
assessed, 22.5% (n=9) met the criteria for MDD based upon the M.I.N.I. Comparisons were 
sought between the depressed and non-depressed with regards to demographic and 
clinical factors. As observed in table 5.2 there were no significant demographic or clinical 
differences between the groups, although haemoglobin did near significance.  
5.3.2 On- vs. off-dialysis BDI assessment  
Table 5.3 displays the mean BDI and CDI scores on- and off-dialysis, for the whole sample 
and for subsets defined by the presence of depression based upon the diagnostic 
assessment. For depressed patients, the mean BDI and CDI scores did not differ significantly 
across the assessment conditions. However the non-depressed scored significantly higher 
on the somatic component of the BDI while on-dialysis, evident by significantly higher BDI 
scores but similar CDI scores. Across all patients this effect was maintained (Cohen’s effect 
size, d =0.41). LoA plots for the BDI and CDI are displayed in figure 5.1. The mean difference 
between the BDI scores on- and off-dialysis was 1.8 (4.29) indicating a non-significant bias 
for higher scores on dialysis, and the 95% confidence range of agreement was -6.8 to +10.4. 
Similarly the mean difference between CDI scores was 0.95 (3.26) biased to on dialysis 
with a confidence range of -5.6 to +7.5 (non-significant). Both LoA plots depict satisfactory 
levels of agreement across the two conditions. 
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Table 5.2: Demographic and clinical data: comparing depressed and non-depressed patients. 
  N=40 Depressed 
(n=9) 
Non-Depressed 
(n=31) 
Sig 
Demographics     
Gender % (n)     
 Male  60 (24) 44.4 (4) 64.5 (20) 0.242a 
 Female 40 (16) 55.6 (5) 35.5 (11)  
Age (Years) 
 
   
 Median (IQR) 55.0 (22.25) 46.0 (38.0) 59.0 (22.0) 0.463b 
Ethnicity %(n) 
 
   
 White 87.5 (35) 88.9 (8) 87.1 (27) 0.689a 
 Non-white 12.5 (5) 11.1 (1) 12.9 (4)  
Work % (n) 
 
   
 Yes 50 (20) 44.5 (4) 51.6 (16) 0.809a 
 No 17.5 (7) 22.2 (2) 16.1 (5)  
 Retired 32.5 (13) 33.3 (3) 32.3 (10)  
Marital Status % 
 
   
 Married/Living with partner 72.5 (29) 88.9 (8) 67.7 (21) 0.195a 
 Divorced/Separated 15 (6) 11.1 (1) 16.1 (5)  
 Widowed 2.5 (1) 0 (0) 3.3 (1)  
 Single  10 (4) 0 (0) 12.9 (4)  
Dialysis Vintage (months) 
 
   
 Median (IQR) 33.0 (51.0) 31.0 (63.5) 33.0 (52.0) 0.973b 
Clinical Variables (mean ±SD) 
 
   
 Haemoglobin (g/dl) 11.7 (±1.3) 10.6 (±1.9) 12.0 (±0.9) 0.065c 
 Albumin (g/l) 37.7 (±3.6) 36.5 (±3.7) 38.0 (±3.6) 0.296c 
 Dialysis Adequacy (Kt/V)  1.3 (±0.2) 1.3 (±0.2) 1.3 (±0.2) 0.231c 
 Active on Transplant List  % 60 (24) 33.3 (3) 41.9 (13) 0.647a 
 Hypertensive medication % 70 (28) 77.8 (7) 67.7 (21) 0.568a 
Extra-Renal Co-Morbidity %     
 None-Low 40 (16) 44.4 (4) 38.7 (12) 0.549a 
 Medium 40 (16) 44.4 (4) 38.7 (12)  
 High 20 (8) 11.2 (1) 22.6 (7)  
a 
Fisher’s Exact test 
b
Mann-Whitney U  
c 
T-test IQR= inter-quartile range. 
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                 A                                      B 
 
 
 
 
 
Figure 5.1: The level of agreement between the BDI (A) and CDI (B) assessments made on and off dialysis.  Shown are the mean bias (middle line) and the 
limits of agreement (mean ±2SD), between which the vast majority of points lie.
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5.3.3 Accuracy of the BDI and CDI 
In order to assess the accuracy of the BDI in our sample of patients, off-dialysis scores were 
compared with the M.I.N.I. ROC analysis (see figure 5.2) showed high predictive accuracy 
for the BDI (area under the curve 0.961, p=0.001) versus the M.I.N.I. Optimal cut-off values 
were determined by the location in which the number of accumulating false positive values 
exceeded the number of false-negatives. The optimal cut-off detected for the BDI was ≥16. 
Employing this cut-off revealed an 88.8% positive predictive value, and an 87.0% negative 
predictive value, with 88.9% sensitivity (95% CI 75.1 to 95.5) and 87.1% specificity (95% CI 
72.9 to 94.4). Chi-square analysis revealed significant associations between the M.I.N.I 
(depressed/non-depressed) and BDI classification  16 (Fisher’s exact test p=0.001, table 
5.4). The mean BDI score for patients who did not meet the M.I.N.I criteria for depression 
but had a BDI ≥16 (discrepant cases) was 17.7 (range =3), compared to 25.7 (range=20) for 
those meeting both the M.I.N.I and BDI criteria. This difference was significant t(10)=2.4, 
p=0.03. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: ROC curve for the sensitivity and specificity of the BDI. 
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Table 5.3: Mean BDI and CDI scores for patients assessed on and off dialysis, defined by those who 
meet the diagnostic criteria for MDD using the M.I.N.I. 
   Mean Scores  
  Measure Dialysis Not Dialysis Significance~ 
      
D
ep
re
ss
ed
 (
M
.I
.N
.I
) Yes 
n=9 
BDI 25.6 (7.0) 24.3 (7.4) ns 
CDI 16.2 (6.6) 15.0 (5.9) ns 
Somatic 9.4 (2.1) 9.3 (2.5) ns 
     
No 
n=31 
BDI 9.3 (6.2) 7.3 (5.7) 0.007 
CDI 4.9 (4.2) 4.0 (3.9) ns 
Somatic 4.4 (2.5) 3.3 (2.1) 0.01 
      
Total n=40 
BDI 12.9 (9.3) 11.1 (9.4) 0.011 
CDI 7.4 (6.7) 6.5 (6.4) ns 
Somatic 5.5 (3.2) 4.7 (3.4) 0.013 
Mean and Standard Deviation ~T-test 
The analysis was replicated using the off-dialysis CDI assessment. ROC analysis revealed 
high predictive accuracy for the CDI (area under curve 0.941, p=0.001). The optimal cut-off 
detected for the CDI was ≥10. Employing a CDI≥10 led to 77.8% sensitivity (95% CI 62.3 to 
88.1) and 80.6% specificity (95% CI 65.4 to 90.1) with 77.7% positive predictive value, 80.6% 
negative predictive value. These findings suggest that the CDI, excluding somatic enquiry, 
has reduced sensitivity and specificity compared to the BDI. Further, as compared to the 
M.I.N.I, using a BDI≥16 yielded 4 false positives and 1 false negative; whereas a CDI ≥10 had 
6 false positives and 2 false negatives (table 5.4). 
Table 5.4: False-Positive and False Negatives cases for the BDI and CDI against the diagnostic 
standard (M.I.N.I). 
 
M.I.N.I Depressed 
  Yes No Total   Yes No Total 
BDI 16 
Yes 8 4 12  
CDI 10 
7 6 13 
No 1 27 28  2 25 27 
Total 9 31 40  9 31 40 
All numbers represent n cases 
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5.3.4 BDI and CDI cut-off classification on- and off-dialysis 
When assessed on-dialysis 32.5% of patients had a BDI score ≥16 compared to 30.0% 
assessed off-dialysis. The CDI assessment was consistent across the conditions with 32.5% 
of patients scoring ≥10 in both conditions. Fisher’s exact test confirmed that there was a 
significant association between the number of patients who satisfied the BDI cut-offs (≥16) 
on- and off-dialysis (p=0.001, table 5.5). 
Table 5.5: Comparison of patients classified as having significant depressive symptoms on and off-
dialysis.   
 
  Off-Dialysis   Off-Dialysis 
BDI ≥16  Yes No CDI ≥10  Yes No 
On- Dialysis 
Yes 11 2 
On-Dialysis 
Yes 11 2 
No 1 26 No 2 25 
All numbers represent n cases 
5.3.5 Timing of the off-dialysis BDI and M.I.N.I assessment 
The off-dialysis BDI and M.I.N.I assessments were timed according to patient convenience. 
Twenty-three patients conducted their off-dialysis assessment before a treatment session, 
and seventeen after. In order to determine if the timing of the off-dialysis assessment 
influenced the findings, patients who were assessed pre- and post-dialysis were compared. 
The number of patients who satisfied the M.I.N.I criterion when assessed before dialysis 
was 4, compared to 5 when assessed after dialysis. This difference was non-significant 
(Fisher’s exact test p=0.456).  
The median off-dialysis BDI score, when completed before dialysis was 8.0 (inter-quartile 
range=10.0) compared to 5.0 (inter-quartile range= 17.0) after dialysis. This difference was 
non-significant (Mann-Whitney U = 192, p=0.94) suggesting that the timing of the off-
dialysis assessment had no influence upon the BDI scores. As no differences were apparent, 
it is suggested that the above findings were not influenced by the timing of off-dialysis 
assessments (pre/post dialysis).  
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5.4 Conclusion I (Depression Assessment on- vs. off-dialysis) 
The purpose of this section of the chapter was to ascertain the legitimacy of on-dialysis 
depression screening using the BDI. To summarise, on-dialysis screening appears viable, 
comparing suitably with off-dialysis assessment. From a practical stance on-dialysis 
depression screening is highly convenient for both research and clinical needs. Indeed, 
given the under recognition of depression in ESRD evident from the literature, screening for 
depression while patients dialyse may promote increased monitoring and recognition. In 
addition on-dialysis as compared to off-dialysis assessments yielded two more properties, 
(1) a small bias for increased on-dialysis scoring suggests that the BDI will capture more 
cases of depression and although increasing false positives will reduce false negatives, and 
2) clinical interviews cannot be conducted on-dialysis, limiting the identification of 
depression. Taken together, this suggests a regimen of on-dialysis screening supplemented 
with diagnostic interviews for those patients identified as being at risk.  
 
There was good agreement between on- and off-dialysis BDI assessments, as determined 
by LoA plots. Importantly these findings were not influenced by the timing of the off-
dialysis assessment. On-dialysis assessment revealed significantly higher BDI somatic 
scoring, compared with the off-dialysis scores. While statistically significant, the practical 
implications of such a difference are relatively small. Critically the BDI and CDI scores did 
not reliably differ across the assessment conditions for patients who met the M.I.N.I criteria 
for MDD. Evidently the assessment condition did not influence the screening response for 
depressed individuals. The non-depressed scored consistently on the CDI but differed on 
the BDI, scoring reliably higher while dialysing. The heightened BDI scores reflected 
increased somatic scoring while dialysing. This effect was maintained across all patients. 
This could reflect the natural variation of symptoms (and perceived symptoms) over the 
assessment period or biased somatic scoring while on-dialysis. Given these findings it is 
suggested that on-dialysis assessment increases somatic not cognitive scoring rather than 
the suggestion that on-dialysis assessment may control the impact of fluctuating uraemic 
symptoms upon mood and cognition (Drayer et al., 2006; Kurella et al., 2004). Of course 
what may be meant here is that while on patients may be experiencing similar symptoms 
rather than fluctuating sensations possibly experienced over the interdialytic period.  
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Further, a BDI≥16 demonstrated good diagnostic accuracy for MDD as compared with a 
short clinical interview, supporting previous findings (Watnick et al., 2005) albeit it with the 
original BDI. In addition the BDI (≥16) inclusive of all somatic enquiries, had increased 
sensitivity and specificity over the CDI (≥10 which excludes somatic enquiry), favouring an 
inclusive approach to depression screening. Furthermore, the BDI (≥16) had fewer false 
positive and false negatives cases than the CDI (≥10). An inclusive approach has also been 
recommended by Drayer et al (2006) who found that depressed dialysis patients report 
more somatic symptoms than the non-depressed, and that physical symptoms relate more 
closely to depression than medical co-morbidity (Drayer et al., 2005). To note, the 
increased sensitivity and specificity of the BDI over the CDI may be the result of the 
diagnostic approach, which included somatic enquiry.  
  
Two diagnostic approaches for depression in physical illnesses have been suggested 
previously; the research approach with adopts an exclusive criteria, and a clinical approach 
which employs an inclusive criteria (Cohen-Cole et al., 1993). The diagnostic criteria 
employed in this study (M.I.N.I) adopted an inclusive approach to assessment. This was 
done in-order to increase the sensitivity of our diagnostic assessment with which the BDI 
was compared. Following the administration of the M.I.N.I, 22.5% met the criteria for MDD. 
Estimated prevalence based upon a BDI≥16 ranged between 30 and 32.5%. These reports 
conform to the literature, as it is widely known that screen tools inflate estimates of 
depression among the medically ill. It is important to consider therefore, that estimates 
based upon symptom reports are at best indicators of potential depression. However they 
do meet their purpose in being able to assess the severity of depressive symptomatology, 
and remain a useful research tool. Indeed the data presented here, along with previous 
works (see chapter 4) suggest the utility of the BDI as a screening tool in HD patients. 
 
This investigation was not without limitations.  As noted previously the “CDI” has not been 
derived via factor analysis, thus its validity is questionable. In comparison the BDI has been 
subject to extensive psychometric evaluation, although not specifically in a renal 
population.  This issue is addressed in the following chapter. Further, it is acknowledged 
that the consideration of other psychiatric co-morbidities, by means of a research 
interview, would have strengthened the data presented here. Lastly, due to the limited 
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sample size of our study we cannot exclude the possibility that the observed effects are due 
to confounding factors that cannot be fully evaluated due to limited power (i.e. differences 
between the depressed and non-depressed).  
 
In response to increasing evidence highlighting the negative impact of depression upon the 
dialysis population, regular depression screening may be justified. Screening patients while 
actively dialysing may facilitate regular evaluation, increase identification of the condition, 
and allow monitoring of the effects of treatment interventions. For these reasons, 
bolstered by its appealing practicality, on-dialysis assessment was employed throughout 
the work presented in this thesis.  
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5.5 Results Part II: The assessment of illness perceptions on-dialysis 
5.5.1 On- vs. off-dialysis illness perception assessment. Comparing dimension 
means 
Table 5.6 shows the means for each of the illness perception dimensions, as assessed on 
and off-dialysis. In addition the internal reliability of each sub-scale on and off-dialysis is 
presented (α). Examining the dimension means reveals that patients reported greater 
perceptions of treatment control when assessed off-dialysis as compared to on-dialysis. 
Furthermore, emotion representations were greater when assessed on-dialysis, compared 
to off-dialysis reports. With the exception of treatment-control perceptions, all IPQ-R 
subscale dimensions had good internal reliability both on- and off-dialysis. Treatment 
control perceptions could only demonstrate modest internal reliability. LoA plots for each 
of the IPQ-R dimensions are displayed in figure 5.3 with the accompanying statistics 
displayed in table 5.7. While all plots display suitable agreement, emotional 
representations show a bias for on-dialysis assessment with a mean difference of 1.12 (95% 
CI 0.07 and 2.19). Treatment control perceptions were lower when assessed off-dialysis, 
biased towards off-dialysis assessment (mean difference= -1.05, 95% CI -0.14 and -1.95). 
5.5.2 The timing of the off-dialysis IPQ-R assessment 
In order to determine if the timing of the off-dialysis assessment influenced self-reported 
illness perceptions, comparisons were sought between those who were assessed pre- and 
post-dialysis. Mean scores on the IPQ-R dimensions did not differ significantly between 
patients assessed pre- and post dialysis. 
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Table 5.6: Comparison of the IPQ-R dimensions on- and off-dialysis. 
Dimension 
Mean 
on-dialysis SD 
Mean 
off-dialysis SD 
Significance 
(paired t-test) 
On-Dialysis 
Cronbach's Alpha 
Off-dialysis 
Cronbachs's Alpha 
Identity 5.42 3.55 5.75 3.52 t(39)=0.80 0.823 0.813 
Timeline 25.61 4.50 25.76 4.50 t(39)=0.13 0.843 0.831 
Cyclical 9.87 3.23 10.07 3.18 t(39)=0.97 0.758 0.843 
Consequences 21.65 4.18 21.65 4.02 t(39)=0.05 0.61 0.661 
Personal Control 18.07 4.39 18.37 5.20 t(39)=0.24 0.732 0.789 
Treatment Control 14.63 3.04 15.68 2.75 t(39)=2.5* 0.405 0.438 
Illness Coherence 19.81 4.64 19.73 4.46 t(39)=0.44 0.929 0.889 
Emotion 17.12 5.43 16.0 5.26 t(39)=2.4* 0.866 0.854 
*p<0.05 SD=Standard Deviation 
Table 5.7: Level of agreement analysis for each of the IPQ-R dimensions, based upon the method described by Bland-Altman (1986). 
 
BIAS CI BIAS 
 
CI (UL) 
 
CI (LL) 
 
Dimension 
Mean difference (SE) lower upper Mean +2SD (UL) lower upper Mean -2SD (LL) lower upper 
Identity -0.325 (0.4) -1.14 0.49 4.8 3.38 6.21 -5.45 -6.86 -4.03 
Timeline -0.150 (0.5) -1.24 0.94 6.71 4.81 8.61 -7.01 -8.91 -5.11 
Cyclical -0.205 (0.5) -1.24 0.88 6.56 4.69 8.43 -6.96 -8.83 -5.09 
Consequences 0.005 (0.5) -1.0 1.0 6.41 4.63 8.18 -6.4 -8.17 -4.62 
Personal Control -0.300 (0.6) -1.57 0.97 7.7 5.49 9.91 -8.3 -10.51 -6.09 
Treatment Control -1.050 (0.4) -1.95 -0.14 4.63 3.06 6.2 -6.73 -8.3 -5.16 
Illness Coherence 0.078 (0.5) -0.89 1.0 6.14 4.46 7.81 -5.99 -7.66 -4.31 
Emotion 1.120 (0.5) 0.07 2.19 7.73 5.9 9.55 -5.48 -7.3 -3.65 
SE: Standard Error CI: Confidence Interval UL: Upper Limit LL: Lower Limit 
 
105 
 
Figure 5.3: LoA plots for each of the IPQ-R dimensions (mean bias, and mean ±2SD). 
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Figure 5.3: LoA plots for each of the IPQ-R dimensions (mean bias, and mean ±2SD) continued... 
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Figure 5.3: LoA plots for each of the IPQ-R dimensions (mean bias, and mean ±2SD) continued... 
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5.5.3 The interaction of depression and assessment condition upon illness 
perceptions 
The interaction of depression (as assessed by the M.I.N.I) and assessment condition (on- vs. 
off-dialysis) upon illness perceptions was explored using mixed model ANOVAs. 
Unsurprisingly there was a main effect of depression upon emotional perceptions (table 
5.8), that is depressed patients reported more emotional distress than the non-depressed 
patients. Furthermore emotion scores were greater when assessed on-dialysis as compared 
to off-dialysis. In addition there was a main effect of the assessment condition upon 
reported treatment control perceptions. Patients tended to report greater perceptions of 
treatment-control when not on dialysis. There were no significant interactions between 
assessment condition and depression.  
Table 5.8. Mixed ANOVA for depression and assessment condition effects on IPQ-R scores. 
IPQ-R Dimension 
Main effect of 
Assessment condition 
Main effect of 
depression 
Assessment X Depression 
Interaction 
Identity F(1,38) =0.347 F(1,38) =3.01 F(1,38) =0.18 
Timeline F(1,38) =0.515 F(1,38) =0.495 F(1,38) =3.01 
Cyclical F(1,38) =0.214 F(1,38) =0.013 F(1,38) =0.075 
Consequences F(1,38) =0.634 F(1,38) =2.72 F(1,38) =2.05 
Personal Control F(1,38) =1.35 F(1,38) =0.02 F(1,38) =2.0 
Treatment Control F(1,38) =5.87* F(1,38) =0.917 F(1,38) =0.756 
Illness Coherence F(1,38) =0.277 F(1,38) =0.634 F(1,38) =1.29 
Emotion F(1,38) =4.49* F(1,38) =13.6** F(1,38) =0.409 
*p<0.05 **p<0.01 F Statistics shown 
 
5.5.4 The effect of depression upon symptom reports 
The IPQ-R illness identity dimension concerns the reporting of physical symptoms that are 
attributed to ESRD. In addition, the number of endorsed physical symptoms regardless of 
their perceived aetiology was explored. The average number of reported symptoms was 7.4 
(±3.6) when assessed on-dialysis, which did not differ significantly from symptoms reports 
made off-dialysis (7.6 ±3.4, t(39)=0.46, p=0.651). The mean number of symptoms reported 
in the off-dialysis condition assessed before treatment was 8.3 (±3.0), compared to 6.6 
(±4.1) when assessed after dialysis. This difference was not significant (t(25.19)=1.4, 
p=0.168), although the effect size was moderate (d=0.58).  
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A mixed ANOVA model was performed to examine the following effects on reported 
somatic symptoms, 1) main effect of depression 2) main effect of assessment condition 
(on- vs. off-dialysis) and, 3) interactional effect (depression X assessment). There was a 
significant between-subject effect of depression upon reported symptoms scores 
(F(1,38)=7.6, p=0.009), with depressed patients scoring higher on the symptom scale than 
the non-depressed patients (table 5.9). There was no effect of the assessment condition 
upon reported symptoms (F(1,38)=0.32, p=0.57), however an interaction (depression X 
assessment condition) tending towards significance was observed (F(1,38)=3.04, p=0.08). 
The depressed patients reported more physical symptoms when on-dialysis and 
comparative less when off-dialysis (table 5.9). 
Table 5.9: Mean symptom scores across assessment conditions and depression groups.  
 
 
 
 
Data shown are Mean and Standard Error 
5.6 Conclusion II (Illness Perceptions on- vs. Off-dialysis) 
The second part of this investigation was to ascertain the level of agreement between 
illness representations reported on-dialysis with off-dialysis reports. The results confirm the 
preceding finding in that on-dialysis IPQ-R assessment is viable. The trend for increased 
emotional representations while on-dialysis is similar to the findings for depression. 
Treatment control perceptions were also significantly different between the assessment 
conditions, with a bias for higher scores while off-dialysis. A point of caution is worthy here, 
as the treatment control subscale had low internal reliability (α). The potential issue here 
relates to the multiple facets of treatment associated with ESRD. Presumably, when 
patients are assessed on-dialysis “treatment” is being interpreted as “dialysis” because it is 
most salient to them at this time. One possible explanation for lower treatment control 
scores while on-dialysis may be that it is a relatively passive procedure, with most relying 
on the nursing team to set-up and administer the dialysis treatment. However differences 
Symptom score Depressed Non-Depressed 
On-dialysis 10.4 (1.1) 6.5 (0.59) 
Off-dialysis 9.6 (1.1) 7.0 (0.58) 
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in personal control may have also been expected if this was solely the reason. At this point 
given the pilot nature of this work it is important not to accentuate this observation.  
Although the aim was to evaluate the procedure of on-dialysis IPQ-R assessment, this work 
did provide an opportunity to comment on the psychology of symptom reporting. Given the 
afforded opportunity, I was guided by the work of Pennebaker (1982). According to 
Pennebaker self-focus to internal somatic activity is greater when the external environment 
lacks interest. It was assumed that dialysis is a tedious exercise, thus individuals may show 
a bias when reporting physical symptoms under such conditions. Although this study did 
not set out to explicitly test this hypothesis, there was no suggestive evidence for this 
theory. To note, the study here was an observational cohort, whereas previous studies 
have tended to be experimental investigations with student populations. Furthermore the 
underlying assumption that being on-dialysis increases self-focus was not tested directly. 
These factors combined with a relatively small sample size may have contributed to the null 
findings reported here. 
Although no evidence was found for increased somatic symptom reporting while on-
dialysis, it was found that depressed patients reported more somatic symptoms (as 
assessed by reported symptoms of the illness identity scale- regardless of believed cause) 
than non-depressed patients. These findings support past studies showing that individuals 
with high negative affectivity have a bias towards somatic activity (Stegen et al., 2001). 
More recent evidence has shown that depression is associated with inflated symptoms 
reports, more so than negative affectivity and neuroticism (Howren, Suls, & Martin, 2009). 
Of further interest is the marginal interaction was between depression and assessment 
condition (on- vs. off-dialysis) upon reported somatic symptoms. The depressed patients 
appear to report more symptoms while on-dialysis as compared to off-dialysis, with the 
non-depressed showing no discernable difference. It is possible that for the depressed 
patients, the context of dialysis increased self-focused attention and thus their symptoms 
reports. These results lend some support for the “joint impact hypothesis” (Gendolla et al., 
2005), which posits that both negative affect and self-focus enhance the reporting of 
physical symptoms. The data presented here suggest that the joint impact of self-focus (i.e. 
on-dialysis) and depression exacerbated symptom reports but was not necessary as 
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depression alone increased reporting of somatic symptoms. The evidence presented here 
supports the notion that depressed patients are more likely to report physical symptoms. 
The experience of physical symptoms could be inflated by the cognitive products of 
depression, for example overgeneralisation and magnification (Beck, 1967), or due to 
increased self-focus (Duval & Wicklund, 1972; Pyszczynski & Greenberg, 1987). 
Alternatively the reporting of increased physical symptoms may be due to greater 
underlying morbidity, which may increase depressive vulnerability.  
Finally, there was a marginal interaction between depression and assessment condition 
with regards to time-line perceptions. It is possible that the increased somatic reporting of 
the depressed patients while on-dialysis has a subtle effect upon time-line cognitions. 
However again, due to the small sample size it is important not to accentuate this 
observation.  
To conclude, while this section provides some interesting evidence regarding theories on 
the psychology of physical symptoms, the primary aim was to evaluate the procedure of 
on-dialysis IPQ-R assessment. By and large these data suggest that on-dialysis assessment 
would yield comparable data to assessments made off dialysis. Accordingly, on-dialysis IPQ-
R and BDI assessments were employed in later studies presented in this thesis. Importantly, 
this method allowed HD patients to be assessed in a standardised manner.  
5.7 General Remarks 
This chapter presented a pilot study investigating the viability of on-dialysis BDI and IPQ-R 
assessments. Both questionnaires yield good agreement with their respective off-dialysis 
assessments. While the main focus here was on the procedure, the following chapter 
extends the inspection of the methods by evaluating the factor structure of the BDI among 
a large cross-sectional sample of haemodialysis patients.  
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Chapter 6 
A Confirmatory Factor Analysis of the BDI-II in ESRD patients 
 
6.1 Introduction 
As discussed at some length in the preceding chapters, the assessment of depression is 
challenging when applied to the context of physical illness due to potentially overlapping 
somatic symptoms. The data presented in chapter five demonstrated that the BDI-II 
compares well with diagnostic standards for MDD providing the cut-off score is adjusted 
accordingly (≥16). The present chapter extends this work by examining the factor structure 
of the BDI-II, that is, do particular groups of questions measure particular underlying 
constructs of depression? The rationale was to establish whether the BDI-II measured 
distinct somatic and cognitive components of depression in ESRD patients.  
The BDI in various forms has been used to assess depressive symptomatology in ESRD 
patients. Several authors have considered a 15 item non-somatic BDI-I total named the CDI, 
for use in ESRD patients (Kimmel, Weihs, & Peterson, 1993; Sacks et al., 1990). It was 
claimed that the CDI provided a better assessment of depression symptoms due to the 
removal of somatic items which would be confounded with the somatic symptoms of ESRD 
(Kimmel et al., 1993). Indeed this method was tentatively applied albeit it to the BDI-II in 
chapter 5 as measure of “cognitive depression”. However the conception of the CDI was 
not via factor analysis, thus the measurement structure of the BDI, or indeed BDI-II is not 
defined within this patient group. Beck adopted a similar notion with regards to the 
measurement of depression among physical illnesses, suggesting that somatic items may 
inflate estimates of depression. Accordingly Beck and co-workers developed the BDI-fast 
screen which is essentially the BDI-II minus somatic performance related questions (Beck, 
Steer, & Brown, 2000). However the authors stress that the BDI fast screen is not a 
substitute for BDI-II in medical inpatients (Beck et al., 2000). Furthermore, there is still 
contention regarding whether somatic items should be excluded from depression 
assessments among physical illnesses (Aikens et al., 1999). Considering the BDI-II’s 
underlying structure in dialysis patients using Confirmatory Factor Analysis (CFA see general 
methods), will enable a “cleaner” measurement of depression to be established and tested 
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in subsequent chapters of this thesis. CFA achieves this cleaner measurement model 
because the technique enables estimates of variance relating to error (measurement error) 
to be removed, and can separate the variance between defined latent variables such as 
cognitive and somatic factors.  
6.1.1 Studies of the factor structure of the BDI-II 
The BDI-II was developed in accordance with symptoms from the DSM-IV (Beck, Steer, & 
Brown, 1996), and was intended as a global measure of the depression construct, although 
its specific structure has been of empirical interest (Beck, Steer, & Brown, 1996). However, 
due to the somatic items included in the BDI-II concerns have be raised with respect to its 
performance in the context of physical illness (Leentjens, Verhey, Luijckx, & Troost, 2000). 
Understanding the underlying structure of the BDI-II is important because sub-dimensions 
may be associated with different correlates (Mackinger & Svaldi, 2004). Furthermore 
particular factors may be more relevant and sensitive for detecting change in longitudinal 
analysis  (Vanheule, Desmet, Groenvynck, Rosseel, & Fontaine, 2008), and it may be 
desirable to be able to differentiate predictive factors related to aspects of the depression 
construct (for example somatic vs. cognitive latent variables).  
The structure of the BDI-II has received considerable empirical interest, although the results 
from numerous factor analyses have not been entirely consistent. Most studies report a 
two factor solution, representing cognitive and somatic latent variables that are well 
correlated. A two factor solution was evident in the initial study conducted by Beck et al 
(1996). Exploratory Factor Analysis (EFA) of the BDI-II administered to psychiatric patients 
(n=500) revealed oblique somatic-affective (SA) and cognitive (C) dimensions (Beck, Steer, 
& Brown, 1996). The SA and C factors consisted of 12 and 9 items respectively. The SA-C 
measurement model has received support from studies in general (Kojima et al., 2002), 
medical outpatient (Grothe et al., 2005) and psychiatric samples (Steer et al., 1999). Beck et 
al (1996) however failed to replicate the SA-C model in a student sample, but instead 
reported an alternative model consisting of a 16 item cognitive-affective (CA) dimension 
and a 5 item somatic (S) dimension. Several studies have also observed the CA-S structure 
in student samples (Steer & Clark, 1997; Wiebe & Penley, 2005). Two additional studies 
have confirmed the CA-S model, only however when some residual variances (error terms) 
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were allowed to correlate in the CFA model6 (Storch, Roberti, & Roth, 2004; Whisman, 
Perez, & Ramel, 2000).  
Alternative models have been developed since several studies have failed to replicate the 
factor models proposed by Beck et al. Several alternative two factor models have been 
proposed (Arnau, Meagher, Norris, & Bramson, 2001; Dozois, Dobson, & Ahnberg, 1998; 
Steer et al., 1999; Viljoen, Iverson, Griffiths, & Woodward, 2003) while others report a 
three factor solutions with the inclusion of an “affective” factor (Beck, Steer, Brown, & van 
der Does, 2002; Buckley, Parker, & Heggie, 2001; Osman et al., 1997).  
Arnau et al (2001) examined the BDI-II in a sample of medical patients and proposed a two 
factor solution comprising of a 12 item somatic-affective factor and an 8 item cognitive 
factor. Penley et al (2003) examined the factor model proposed by Arnau et al (2001) in 122 
ESRD patients. This is the only published studied that has examined the factor structure of 
the BDI-II in this patient group. The results suggested that the data had a relatively poor fit 
to the Arnau et al factor model (CFI=0.75, RMSEA=0.1), although the authors claimed that 
the model was “adequate7” (Penley et al., 2003). The failure to undertake model 
modification and consider alternative factor models as evident within the literature, are 
considerable limitations. Given this, the factor structure of the BDI-II has yet to be defined 
in ESRD.  
More recently a three factor model consisting of a general depression factor (G) that loads 
onto all 21 BDI-II items, and two smaller orthogonal cognitive (C, 8 items) and somatic 
factors (S, 5 items) has been proposed (Ward, 2006). The Ward (2006) model also includes 
two minor two items factors called Anhedonia (An) and Self Criticism (SC) that were present 
in the Beck et al (1996) clinical sample analysis. The G-S-C model of Ward was tested in a 
sample of myocardial infarction patients (Thombs, Ziegelstein, Beck, & Pilote, 2008). In 
their analysis the G-S-C model provided better fit to the data than CA-S and SA-C two factor 
models, although the fit as examined by the CFI and RMSEA was marginal (0.92 and 0.07 
                                                          
6
 The authors allowed 3 pairs of meaningful item measurement errors to correlate suggesting that these 
residuals co-varied and that the items themselves were highly correlated. 
7
 As noted later in the methods both fit indexes indicated in the Penley et al study suggest poor fit based upon 
recommended guidelines, thus the model appears not to represent a robust factor structure in ESRD patients. 
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respectively). Simplifying the G-S-C by removing the Anhedonia and Self Criticism factors 
did not decrease the model fit (Thombs et al., 2008). This modified G-S-C model was 
recommended by Thombs et al (2008) as a novel approach to understanding the factor 
structure of the BDI-II in MI patients. 
A comparative study of several BDI-II factor structures suggested that three-factor models 
including the G-S-C, provide better fit in both clinical and non-clinical samples as compared 
with two factor models (Vanheule et al., 2008). However none of the overall fit indices 
were particularly satisfactory. In an attempt to improve some of the models fit indexes, 
Vanheule et al (2008) used an item deletion algorithm to test whether removing some 
items led to more robust measurement models. Vanheule et al demonstrated that the 
model fit of the SA-C model (Beck et al., 1996) improved after the removal of 5 items 
(CFI=0.961 RMSEA=0.045). Similarly the three factor model of Buckley et al (2001) was 
improved after the deletion of 6 items (clinical patients CFI=0.960 RMSEA=0.047).  
Given the various models proposed within the literature, the sole aim of the investigation 
presented here was to compare the relative fit of several two and three factor BDI-II 
models reviewed above, with data from dialysis patients using CFA. The objective was to 
identify the best fitting factorial structure for the BDI-II in ESRD patients.  
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6.2 Methods 
6.2.1 Patients 
BDI-II data from dialysis patients recruited from two multi-centered studies (one cross-
sectional [n=215] and one longitudinal [n=160]) which are presented in the following 
empirical chapters (7 & 8 respectively), were pooled in order to maximise the sample size 
for CFA (total n=375). Data from the longitudinal study consisted of the baseline BDI-II 
assessment, as at this time point a greater number of patients were in the study. Details of 
the respective inclusion criteria, procedures, and study designs are described in the 
chapters that follow, in addition to the clinical and demographic characteristics pertaining 
to the two study samples (chapters 7&8). 
6.2.2 Data Analysis 
CFAs were evaluated in MPlus version 5.21 (Muthén & Muthén, 2007) using Weighted 
Least-Squares with Mean and Variance Adjustment (WLSMV) estimation. WLSMV was 
employed as the responses on the BDI-II items were skewed. Furthermore it is more 
appropriate to treat the ordinal BDI-II item scales as categorical variables. The WLSMV 
estimation unlike Maximum Likelihood (ML) procedures makes no assumptions about the 
distribution of the data (Muthén & Muthén, 2007) and models polychoric correlations. 
WLSMV estimation has been shown to produce accurate model statistics across models 
that vary in sample size, complexity and normality (Flora & Curran, 2004).  
Missing data was minimal in the dataset. Overall 46 values were missing (0.6% of the total 
information)8. In order to retain all of the data for the CFAs, missing values were imputed 
with the item median. The median was used because imputing the mean was not possible 
as non-integer values cannot be analysed when using WLSMV estimation. Although not 
reported here, all the results shown in this chapter were replicated in a data-set that had 
the list-wise removal of missing data (n=356).  
Eleven models were evaluated via CFA, 7 of which were two factor models and 4 of which 
were three factor models. A summary of the factors and items of these models are 
                                                          
8
 Total number of observations = 375 (patients) * 21 (items) =7875. Total missing cases, n =46. Percentage of 
missing data = 46/7875 *(100) =0.6. 
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presented in table 6.1. The structures of these various models were evaluated using chi-
square goodness of fit test, which derives the deviation between the reproduced 
covariance matrix with the observed covariance matrix. A non-significant chi-square is 
desired suggesting that the reproduced and observed covariance matrixes do not differ 
significantly hence the data fits the proposed model structure. However as described in the 
general methods the chi-square statistic is sensitive to sample size (Ullman, 2006) thus 
several fit indices were also evaluated. The comparative fit index (CFI) is an incremental fit 
index that compares the proposed model with the null model, and uses an approach based 
on the noncentral chi-square distribution (Bentler, 1990). A CFI ≥0.95 indicates good fit (Hu 
& Bentler, 1999). The Tucker Lewis Index (TLI) was also employed , which has the a similar 
interpretation to the CFI but also considers the number of parameters (Tucker & Lewis, 
1973). A final index, The Root Mean Square Error of Approximation (RMSEA) considers 
model complexity. A RMSEA <0.05 is considered to demonstrate reasonable fit, while a 
value of >0.1 suggests poor fit (Browne & Cudeck, 1993). 
The best fitting models based upon these criteria where subject to model modification, in 
order to see whether the fit could be further improved (see general methods). 
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Table 6.1: Summary of the factors and items proposed by previous authors for the BDI-II. 
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A Beck et al (1996) Clinical SA    +      + + + +  + + + + + + + 
  C + + +  + + + + +     +        
B Beck et al (1996) Non-clinical CA + + + + + + + + + + + + + +   +    + 
  S               + +  + + +  
C Dozois et al (1998) CA + + +  + + + + +    + +        
  SV    +      + + +   + + + + + + + 
D Steer et al (1999) C  + +  + + + + +     +        
  NC +   +      + + + +  + + + + + + + 
E Arnau et al (2001) SA +   +    +   + + +  + + + + + + + 
  C  + +  + + +  + +    +        
F Viljoen et al (2003) SA +   +       + + +  + + +  + + + 
  C  + +  + + + + + +    +    +   + 
G Beck et al (2002) C   +  + + + +     + +        
  S         + +     + + + + + + + 
  A + +  +     +   +          
H Buckley et al (2001) C + + +  + + + + +     +        
  A    +      +  + +         
  S           +    + + + + + + + 
I Vanheule et al (2008) -Beck C + + +   + +  +     +        
  SA    +      + + +   + +  + +  + 
J Vanheule et al (2008) -Buckley  C  + +   +  + +     +        
  A    +      +  +          
  S                + + + + + + 
K Ward et al (2006) G-S-C G + + + + + + + + + + + + + + + + + + + + + 
  S               + +  + + +  
  C  + +  + + + + +    +         
+ Indicates items loaded onto the factor. SA= Somatic Affective. C= Cognitive. CA=Cognitive Affective. S= Somatic. SV =Somatic Vegetative. NC =Noncognitive. S =Somatic. G = General  
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6.3 Results 
The average age of the pooled sample was 59.1 (±15.7) years. Of the 375 patients, 66.9% 
were male and the majority were white (89.3%). The median dialysis vintage was 323 (IQR 
1397) days. The majority of patients were receiving HD treatment (92.5%) with the 
reminding on PD. A BDI≥16 was evident in 28% of the sample indicating significant 
depressive symptomatology. Descriptive characteristics of the BDI-II items are displayed in 
table 6.2. The mean BDI-II score for the pooled sample was 12.1 (±8.4). The mean BDI-II 
score from the baseline collection of the longitudinal study was 12.1 (8.7), which did not 
differ significantly from the mean observed in the cross-sectional sample (12.2 ±8.2, 
t(373)=0.15, p=0.988). The distributions of the BDI-II scores for each of the study samples 
are shown in figure 6.1. Examination figure 6.1 shows that the data had a similar 
distribution across the two sample data sets in that both display a slight positive skew. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1: Distributions of the BDI-II total scores across the two study data sets. 
 
Model fit statistics for each of the two, and three factor BD-II models tested are presented 
in table 6.3. The two factor models (models A-F) had moderate levels of fit, accompanied 
by the two of the three factor models (models G & H). The shortened SA-C model of Beck et 
al (1996) and the shortened 3 factor model of Buckley et al (2001), as devised by Vahnheule 
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et al (2008, models I&J respectively, table 6.3), showed improved fit as compared to models 
A-H, evident by CFI’s in the order of 0.95 and RMSEA’s near 0.05.  
Table 6.2: Item characteristics of the BDI-II: measures of central tendency, variation, and 
distribution. 
Item Mean S.E S.D Median IQR Skewness Kurtosis 
BDI1 0.30 0.03 0.54 0 1 2.05 5.25 
BDI2 0.62 0.04 0.76 0 1 1.27 1.52 
BDI3 0.34 0.04 0.71 0 0 2.01 3.11 
BDI4 0.68 0.04 0.75 0 1 1.15 1.49 
BDI5 0.29 0.03 0.57 0 0 1.96 3.55 
BDI6 0.26 0.04 0.75 0 0 2.95 7.60 
BDI7 0.41 0.03 0.66 0 1 1.59 2.24 
BDI8 0.37 0.03 0.64 0 1 1.99 4.40 
BDI9 0.14 0.02 0.39 0 0 3.10 11.52 
BDI10 0.37 0.04 0.72 0 1 2.23 4.76 
BDI11 0.45 0.03 0.62 0 1 1.36 2.20 
BDI12 0.42 0.04 0.75 0 1 2.03 3.87 
BDI13 0.34 0.03 0.63 0 1 2.05 4.60 
BDI14 0.37 0.03 0.63 0 1 1.51 1.32 
BDI15 1.22 0.03 0.64 0 1 0.35 0.36 
BDI16 1.23 0.05 0.89 0 1 0.48 -0.41 
BDI17 0.44 0.03 0.62 0 1 1.28 1.43 
BDI18 0.82 0.04 0.79 1 1 0.72 0.02 
BDI19 0.57 0.04 0.68 0 1 0.89 -0.00 
BDI20 1.11 0.04 0.75 1 0 0.60 0.44 
BDI21 1.33 0.06 1.16 1 3 0.29 -1.38 
BDITOTAL 12.1 0.43 8.40 11 10 1.08 1.229 
S.E = Standard Error S.D = Standard Deviation IQR= Inter-quartile range 
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Table 6.3: Summary of CFA results for various BDI-II models. 
Model~ Chi-Square df P value CFI TLI RMSEA 
A Beck et al (1996) Clinical 266.2 76 <0.001 0.913 0.964 0.082 
B Beck et al (1996) Non-clinical 261.3 77 <0.001 0.916 0.965 0.080 
C Dozois et al (1998) 271.0 76 <0.001 0.911 0.963 0.083 
D Steer et al (1999) 288.9 76 <0.001 0.903 0.959 0.086 
E Arnau et al (2001) 284.7 76 <0.001 0.905 0.960 0.086 
F Viljoen et al (2003) 284.7 76 <0.001 0.905 0.960 0.086 
G Beck et al (2002) 271.6 76 <0.001 0.910 0.962 0.084 
H Buckley et al (2001) 237.8 75 <0.001 0.926 0.968 0.076 
I Vanheule et al (2008) Short Beck 140.1 57 <0.001 0.950 0.977 0.062 
J Vanheule et al (2008) Short Buckley  112.8 52 <0.001 0.952 0.977 0.056 
K Ward et al (2006) G-S-C 185.3 75 <0.001 0.950 0.979 0.063 
L Ward et al (2006) G-S-C Modified 143.6 75 <0.001 0.969 0.987 0.049 
M Ward et al (2006) Simplified  144.5 75 <0.001 0.968 0.987 0.050 
~Estimation: WLSMV. CFI = Comparative Fit Index. TLI= Tucker Lewis Index. RMSEA= Root Mean Square Error 
of Approximation. 
 
The G-S-C model of Ward (2006, model K in table 6.3) demonstrated comparable good fit to 
the models of Vanheule et al. To note, in the G-S-C model the minor factor of Anhedonia 
and Self-Criticism have equality constraints9 placed on their factors loadings in order for the 
model to be identified. Given that models of Vanheule et al were already modified via a 
deletion algorithm, Ward’s G-S-C was selected for model modification in the present 
analysis. An examination of the modification indexes suggested that item 1 (sadness) would 
improve the model fit if loaded onto the cognitive latent variable (Modification index= 
16.67). Furthermore loading item 21 (sex) onto the somatic latent variable suggested a 
modification index of 31.13. Since these changes appeared to be theoretically viable the G-
S-C model was modified with these changes and reanalysed. The modified model (model L) 
showed improved fit over the standard G-S-C model (CFI= 0.969, RMSEA = 0.049). The 
standardised factor loadings, r2 and residual variances for this modified G-S-C model are 
displayed in table 6.4. All the factor loadings (model L) were significant except both of the 
                                                          
9
 Equality constraints were placed as only two items were specified to load onto a factor, thus the model 
could not be identified. Constraining the variances to be equal allows the model to be identified. 
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items on the SC factor, which were self-dislike and self-criticism. Factor loadings on the G 
factor were all reasonably high, with 14 of the 21 items having standardised loadings in 
excess of 0.60.  
The G-S-C model was then simplified by excluding the minor factors self-criticism and 
anhedonia, which has been shown by others not to affect the overall model fit (Thombs et 
al., 2008). Indeed, in the present analysis, removing these two factors from the modified G-
S-C model did not affect the model fit (model M, table 6.3 CFI=0.968 RMSEA=0.05). This 
final G-S-C model is depicted in figure 6.2. Each of the G-S-C factors had good internal 
reliability (G α=0.89, S α=0.66 and, C α=0.84).  
Correlations were sought between the G-S-C latent factors and the total BDI-II scores. The 
general depression factor (G) correlated highly with total BDI-II scores (r=0.9, p<0.001), 
explaining 81% of the variance. Correlations between the S and C factors with the total BDI-
II scores were r=0.254 (p<0.001), and r=0.18 (p<0.001) respectively. Taken together, all 
three factors (G-S-C) explained 91% of the total variance in BDI-II total scores.  
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Table 6.4: Standardised factor solution from the CFA of the modified G-S-C model. 
  Factor   
Number Item description G S C SC An R2 Residual Variance 
BDI1 Sadness 0.707  0.317   0.600 0.400 
BDI2 Pessimism 0.652  0.228   0.477 0.523 
BDI3 Past Failure 0.628  0.589   0.742 0.258 
BDI4 Pleasure 0.723    0.296 0.611 0.389 
BDI5 Guilt 0.616  0.388   0.530 0.470 
BDI6 Punishment 0.497  0.470   0.469 0.531 
BDI7 Self-Dislike 0.780  0.326 0.143a  0.735 0.265 
BDI8 Self-Criticism 0.670  0.290 0.143a  0.554 0.446 
BDI9 Suicide 0.659  0.296   0.522 0.478 
BDI10 Crying 0.691     0.477 0.523 
BDI11 Agitation 0.751     0.564 0.478 
BDI12 Interest 0.753    0.296 0.655 0.345 
BDI13 Indecisiveness 0.763     0.583 0.417 
BDI14 Worthlessness 0.741  0.374   0.690 0.310 
BDI15 Loss of Energy 0.530 0.671    0.731 0.269 
BDI16 Sleep 0.419 0.311    0.272 0.728 
BDI17 Irritability 0.745     0.555 0.445 
BDI18 Appetite 0.448 0.138~    0.219 0.781 
BDI19 Concentration 0.685 0.127~    0.485 0.515 
BDI20 Fatigue 0.497 0.619    0.631 0.369 
BDI21 Sex 0.275 0.374    0.215 0.785 
         
         
G= General Factor. S= Somatic Factor. C=Cognitive Factor. SC= Self Criticism Factor. An=Anhedonia Factor. 
Unless otherwise indicated all p<0.01. ~p<0.05 
a
p>0.05
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Figure 6.2: Modified G-S-C model for the BDI-II  
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6.4 Discussion  
This chapter is the second in succession to give specific attention to the measurement of 
depression symptoms in ESRD patients. The attention afforded in the present chapter was 
to examine the underlying structure of the BDI-II by means of confirmatory factor analysis. 
The importance of this undertaking extended beyond conceptual interest; rather it allowed 
a robust latent measurement model to be defined that could then be modelled in future 
large scale investigations, and allowed the validity of the measure to be evaluated in this 
patient group.  
In order to achieve this aim several CFAs evaluated the relative fit of specified two, and 
three factor structures for the BDI-II in a sample of dialysis patients in the data collected for 
this thesis. The main findings support data from previous publications suggesting that an 
alternative three factor model containing a general depression factor and two orthogonal 
somatic and cognitive factors have better fit than two factor models (Thombs et al., 2008; 
Ward, 2006). Furthermore, modification of the G-S-C by loading sadness onto the cognitive 
factor and sex onto the somatic factor, improved the G-S-C model fit further. The nature of 
the factor loadings were similar to those reported by Thomb et al (2008) who confirmed 
the G-S-C structure in a sample of myocardial infarction patients. As with Thomb et al, the 
data here provided little support for the inclusion of the Anhedonia and Self-Criticism 
factors. Their removal did not impact upon the models overall fit.  
The modified G-S-C presented here provides an alternative description of the measurement 
structure of the BDI-II, although the findings here may be specific to the ESRD population. 
As reviewed by others (Thombs et al., 2008; Ward, 2006) the G-S-C model has several 
conceptual and empirical advantages over common two factor approaches. The cognitive 
and somatic latent factors in two factor models are highly correlated thus multicollinearity 
remains an issue when regressing both factors in a chosen analysis. Furthermore, several 
items fail to fit onto either cognitive or somatic factors thus the distinction between these 
two latent factors is not robust (Thombs et al., 2008). Moreover, Steer et al (1999) reports 
that two factor models are not stable because dimensions tend to shift in different 
samples. The G-S-C model is advantageous as its structure appears relatively stable (Ward, 
2006). The notion of a general depression factor conforms with the proposed rational of 
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the BDI-II as global measure of depression severity (Beck, Steer, & Brown, 1996). Moreover 
the G-S-C model allows the variance from the orthogonal cognitive and somatic latent 
variables to be separated from the general depression factor. The cognitive and somatic 
distinction in the G-S-C model allows a “cleaner” measure of the underlying latent 
constructs that are not confounded by an underlying depression factor, as may be the case 
in two factor models (i.e. SA-C and CA-S). Although the G factor contributes most to the 
explained variance, the cognitive and somatic constructs explain a small yet unique amount 
of addition variance. It is therefore possible to model and test specific questions that 
pertain to the cognitive and somatic latent variables after separating the common variance 
associated with general depressive symptoms. However a caveat here is that because the 
bi-factor G-S-C model separates the variance between the three factors, in order to regress 
the latent variables upon potential independent variables (predictors) would require a very 
large sample size.  
The G factor correlated highly with the total BDI-II score. Taken together the three factors 
of the G-S-C explained over 90% of the variance in the total BDI-II scores. This suggests that 
using a total BDI-II score in various analyses in ESRD patients would produce similar findings 
to those of a measurement model containing a general depression factor. Given that SEM 
may not be appropriate in some instances, and for most studies issues of power may 
prevent the use of the bi-factor model, a total BDI-II score appears to be a good indicator of 
global depressive symptoms. For these reasons a total BDI score will be utilised in the 
empirical studies that follow.  
Finally, these results shown here have significant implications for the “CDI”, which has been 
used in several ESRD studies to assess apparent “cognitive” depression (Sacks et al., 1990). 
Although the CDI was derived from the BDI-I, whereas the BDI-II was used here, it is clear 
that two factor models of depression (cognitive vs. somatic) do not represent the most 
robust model for depression in ESRD. Further, as suggested elsewhere removing somatic 
symptoms may also reduce the BDI-II’s content validity (Penley, Wiebe, & Nwosu, 2003). It 
is proposed that the modified G-S-C model presented here provides a better understanding 
and measurement model for the BDI-II as applied to ESRD patients.  
127 
 
The strengths of this analysis include the consideration and evaluation of several models in 
a reasonably large sample of dialysis patients.  However the small number of PD patients in 
the analysis was a limitation. This prohibited comparison of the BDI-II’s structure between 
HD and PD patients using multi-group CFA analysis. While the G-S-C appears relatively 
robust, it would be of interest to examine any potential differences between treatment 
modalities in future investigations. Further the “construct” of depression in this setting was 
only considered in English speaking patients. Cultural representations and constructs of 
depression may differ from measurement models identified in English speaking patients. 
Developing reliable measures of depression among the multi-ethnic dialysis population is 
required if clinicians and researchers alike are to fully appreciate the extent of depression 
in ESRD and identify the associated antecedents. This however is likely to be a considerable 
undertaking. 
6.5 General Remarks  
The BDI-II provides a good measure of global depressive symptoms in ESRD patients 
supporting its validity in this setting. The modified G-S-C model is a novel approach to 
understanding the underlying latent constructs of depression in ESRD as measured by the 
BDI-II, which can be modelled in subsequent analyses. Given the potential issues 
surrounding depression assessment in chronic illnesses, the G-S-C model may provide a 
useful measurement approach in other diseases (see Thombs et al., 2008). This is 
potentially useful as comparisons between disease groups with regards to antecedents and 
time-course could be sought.  
Up to this point considerable attention has been devoted to the assessment and 
measurement of depression in ESRD. Not only has this empirical work assessed the validity 
of the measure and identified a latent measurement model for the BDI-II in ESRD patients, 
it has also established a practical procedure in which the BDI-II can be administered. 
The next chapter directs attention to the thesis argued in this body of work; providing 
evidence for the association between illness perceptions and depression in a multi-centred 
cross-sectional study of established HD patients.  
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Chapter 7 
The Association between Depression and Illness Representations in 
Haemodialysis Patients: A Cross-sectional Study 
 
7.1 Introduction 
The aetiology of depression can be considered to involve biological, psychological and 
social vulnerabilities, which are by no means independent antecedents. These 
vulnerabilities are amplified in the context of chronic physical disease, and across a variety 
of physical illnesses depression is known to be more common than in general populations 
(Creed & Dickens, 2007). Given this, it is important to identity factors that distinguish the 
depressed from the non-depressed within the context of chronic physical disease. 
The focus of the present chapter is to understand whether illness perceptions pertaining to 
the CSM are associated with depression in established haemodialysis patients. As described 
in chapter 3, illness representations are important contributors to psychological adjustment 
including depression. Furthermore examining illness perceptions in relation to depression is 
of interest since both are associated with adverse outcomes among patients with physical 
illnesses, and indeed in ESRD. lllness representations set the targets for self-regulation in 
order to control and resolve health threats. Maladaptive perceptions could therefore 
influence the selection of maladaptive coping procedures and behaviours that increase an 
individual’s vulnerability for depression. For example there is evidence that stress and 
coping are associated with depression and psychological distress in dialysis patients (Welch 
& Austin, 2001), which supports the wider literature (Goldstein, Holland, Soteriou, & 
Mellers, 2005; Lazarus & Folkman, 1984). Furthermore, illness perceptions have been 
shown to predict self-efficacy (Lau-Walker, 2004), and self-efficacy has been associated 
with depression among patients with physical illness (Tedman, Thornton, & Baker, 1995; 
Tsay & Chao, 2002). However the importance of coping and concepts of control such as 
self-efficacy, as mediators between illness perceptions and outcomes have received limited 
empirical support (Edgar & Skinner, 2003; Evans & Norman, 2009; Heijmans, 1999; Moss-
Morris, Petrie, & Weinman, 1996). Goldstein et al (2005) reported that coping mediated the 
association between illness identity and depression in patients with epilepsy, although the 
small sample size and cross-sectional design are limitations. In addition behavioural 
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disengagement and restraint coping mediated the relationship between illness perceptions 
(cure/control and consequences) and depression in a sample of patients suffering from 
irritable bowel syndrome (Rutter & Rutter, 2002), although in a follow-up investigation 
there was no evidence of mediation over time (Rutter & Rutter, 2007). 
The contention surrounding coping as a mediator between illness representation and 
outcome may have its roots in the conceptualisation of the CSM, and how it views coping. 
The treatment of “coping” in the CSM deviates from factor analytic approaches such as the 
stress coping model (Lazarus & Folkman, 1984) which are arguably over simplistic 
categorisations. Indeed using such approaches, coupled with cross-sectional designs, make 
it hard to tease apart coping from illness perceptions. For example does the perception that 
a disease is acute reflect avoidant coping or a genuine belief about the disease’s expected 
time-line? As articulated recently, depression in physical illnesses may be the product of 
effective coping procedures undertaken to deal with disease management (Detweiler-
Bedell et al., 2008). It is argued that the under-regulation of mood may result from illness 
representations that define the strategies and behaviours that are adaptive for disease 
management, yet to the disadvantage of emotion regulation (Baumeister & Heatherton, 
1996; Detweiler-Bedell et al., 2008). 
Negative cognitions are cardinal features of the cognitive theory of depression (Beck, 1967) 
thus according to principles of cognitive theory, it may be speculated that negative illness 
perceptions may increase the vulnerability for depression via the activation of depressive 
schema. Alternatively, the relationship between illness perceptions and depression may 
also reflect underlying morbidity. Indeed others have reported an interaction between 
illness severity and illness perceptions as a predictor of depression (Schiaffino et al., 1998). 
However this study was conducted in RA patients where symptomatic cyclical fare ups may 
lead to temporal changes in illness perceptions. A longitudinal study looking at changes in 
health related QoL in Coronary Heart Disease patients, found that illness perceptions 
mediated the association between disease severity and wellbeing (Aalto et al., 2006). This 
suggests a dynamic relationship between disease status and illness representations. In 
addition it is well established that illness perceptions predict functional status in several 
diseases including MI and RA patients (Bijsterbosch et al., 2009; Petrie et al., 2002; Petrie et 
al., 1996). The association between functional status (in terms of disability) and depression 
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is also known (Buchi et al., 1998; Egede, 2007; McFarlane & Brooks, 1988). However, the 
relationship between co-morbidity and depression is less understood. In dialysis patients 
some data reports a significant association between extra renal co-morbidity and 
depression (Brown et al., 2010; Hedayati et al., 2008; Lopes et al., 2002; Simic Ogrizovic et 
al., 2009), although other studies have found no relationship (Drayer et al., 2006; Kimmel, 
Peterson et al., 1998). 
There is evidence that the relationship between depression and physical disease is 
bidirectional. Depression has been found to influence the progression of disease; and also 
depression can result from the onset of disease (Creed & Dickens, 2007; Steptoe, 2007). 
Prospective studies in RA suggest that medical intervention alone does little to predict or 
improve mood. Rather, it is the perceptions around the illness that are more influential 
upon subsequent mood and indeed health-related outcomes, rather than objective 
measures of disease or co-morbidity (Jopson & Moss-Morris, 2003; Petrie et al., 1996; Sacks 
et al., 1990; Sharpe, Sensky, & Allard, 2001). Despite good evidence that illness 
representations predict depression among other illness groups (Dickens et al., 2008; Jopson 
& Moss-Morris, 2003; Scharloo et al., 1999) no study has addressed the relationship in 
ESRD.  
As reviewed in chapter 3, illness perceptions are associated with QoL in dialysis patients. 
Timmers et al (2008) reported that illness identity, consequences, personal control, and 
emotional representations, were associated with the physical component score of the SF-
36, explaining an additional 30% of the variance above and beyond clinical and 
demographic variables. Griva et al (2009) reported that treatment and illness perceptions 
are associated with QoL. After controlling for demographic and dialysis related factors, both 
perceptions of treatment disruptiveness and illness consequences were associated with the 
mental functioning component of the SF-36. This data suggests that a major influence of 
QoL in ESRD relates to the interpretation and regulation of illness. Given the association 
between quality of life and illness perception reported in dialysis patients it was envisaged 
that depression and illness perceptions would share a close relationship. 
Depression is a well established psychopathology in ESRD, yet illness-related psychological 
and clinical factors are not well understood in terms of their relationship with affect. The 
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CSM provides a theoretical platform to explain how patients understand and adapt as a 
part of continuous self-regulatory efforts, and may therefore aid in the explanation of 
depression among HD patients. The present study examined depression symptoms in a well 
establish multi-centred sample of haemodialysis patients using the BDI-II. In order to 
provide an estimate of depression a BDI≥16 was employed to define potential cases. The 
nature of illness perceptions in relation to affect was explored. In light of the findings from 
past studies investigating the association between illness perceptions and depression, the 
following hypotheses were constructed: 
1) Clinical factors will be largely unrelated to depression. 
2) Consequences and control perceptions would be associated with depression. 
3) Illness perceptions will be strong predictors of depression, and provide a significant 
improvement in explained variance, above and beyond clinical and demographic 
factors. 
7.2 Methods 
7.2.1 Patients 
Patients established on an in-hospital haemodialysis programme from three UK NHS renal 
centers (Lister n=155, Royal Free n=15, and Addenbrooke’s n=55) were recruited into the 
study (n=215). Patients were eligible for inclusion if the following criteria was met; i) no 
known significant visual or physical impairment that would prevent the completion of the 
questionnaires, ii) fluency in verbal and written English language, (iii) not hospitalised at the 
time of assessment, iv) had been receiving haemodialysis for >6 months and v) no cognitive 
impairment, as indicated by an age adjusted score of <22 on the Mini Mental State 
Examination (Folstein et al., 1975). 
7.2.2 Materials 
Demographic questionnaire: Information on age, gender, ethnicity, marital-status, and 
work-status were collected by means of a patient questionnaire. Transplant status was 
determined via self-report. Patients were asked if they were currently on the transplant 
waiting list (yes, no or don’t know).  
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The Revised Illness Perception Questionnaire (IPQ-R): As described in chapter 4. The sample 
size permitted Principle Component Analysis on the 18 causal items of the IPQ-R as 
recommended by (Moss-Morris et al., 2002). Initially all the causal items were entered into 
the analysis. Item 2 (hereditary cause) was removed due an insufficient Measure of 
Sampling Adequacy (MSA <0.5) revealed in the anti-image matrix. Item 7 (pollution) was 
also removed as it loaded onto more than one factor. Analysis of the remaining 16 items 
with direct Oblimin rotation revealed a three factor solution (see table 7.1). All extracted 
factors had Eigen-values >1.1. The first factor consisted of 7 items and demonstrated good 
internal reliability (α=0.87). These items pertained to attributions surrounding stress, 
emotion, and behaviour, thus was labelled psychological causes. The second factor labelled 
risk factors contained 6 items which largely oriented around general risk factors for illness, 
including smoking and ageing. This second factor also demonstrated adequate reliability 
(α=0.80). A final factor labelled external causes consisted of 3 items and had relative low 
internal consistency (α=0.52). 
Depression Symptoms: Depression symptoms were assessed via the Beck Depression 
Inventory (BDI-II) as described in Chapter 4. A BDI≥16 was employed to define patients with 
probable depression (see chapter 5).  The BDI was treated as a categorical outcome (i.e. 
BDI≥16) because the aim here was to examine illness perceptions that were associated 
with a group of patients who are likely to being suffering from depression as suggested by 
an adjusted BDI cut-off score.  
7.2.3 Clinical Data 
Functional Status and Comorbidity: Karnofsky Performance Score was employed to assess 
functional status (see chapter 4). Comorbidity was assessed using a semi-quantitative 
technique (Chandna et al., 1999), scored by consultant nephrologist who assigned a 
severity score for each patient (1= no co-morbidity, 2= mild moderate co-morbidity, 3= 
severe co-morbidity. This method has been described previously in the general methods 
(see chapter 4).  
Clinical parameters: Standard haematological and biochemical parameters are collected as 
a part of the routine care of patients within the service. These included Haemoglobin, 
Albumin, CRP and dialysis Kt/V (see methods).  
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Table 7.1: Principle Component analysis of the IPQ-R causal items: Structure Matrix of factors and 
their loadings. 
 Structure Matrixa 
  Factor 
  1 2 3 
Factor 1. Psychological Causes (α=0.87)    
 Emotion State  .815 .427 .284 
 Own Behaviour  .766 .435 .151 
 Family Problems .762 .278 .151 
 Overwork .737 .459 .290 
 Stress or Worry .727 .239 .280 
 Mental Attitude .699 .481 .288 
 Diet or Eating Habits .691 .526 .239 
Factor 2. Risk factors (α=0.80)    
 Smoking  .371 .813 .051 
 Alcohol .433 .787 .145 
 My Personality .575 .776 .259 
 Accident or Injury .375 .765 .256 
 Altered Immunity .180 .578 .488 
 Ageing .360 .558 .175 
Factor 3. External Causes (α=0.516)    
 Germ .275 .301 .764 
 Chance or Bad Luck .164 .144 .695 
 Poor Past Medical Care .285 .110 .598 
a
Extraction Method: Principal Component Analysis.  Rotation Method: Oblimin with Kaiser Normalization. 
 
7.2.4 Design and Procedure:  
The study employed a cross-sectional design. Patients were approached while receiving 
dialysis and given relevant information as to the study requirements. After providing 
informed consent, patients completed the questionnaire methods while undergoing a 
stable HD session (see chapter 5).  
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7.3 Results 
Two hundred and seventy-five HD patients were approached, of which 215 consented and 
completed the questionnaire assessments (consent rate =78.2%). There was no significant 
gender difference between responders and non-responders (X2[1,275]=0.57, p=0.45). 
However there was a significant difference between responders and non-responders with 
regards to renal centre, with a higher consent rate evident at the Lister (consent rate= 
83.8%, Addenbrooke’s = 68.2%, and the Royal Free =66.2%, X2[2,275]=10.4, p=0.005). 
Demographic and clinical data for the sample is shown in table 7.2 (n=215). The majority of 
the sample were male (66.5%) and white (88.4%). The average age of the sample was 60.5 
(SD=15.5) years. The median dialysis vintage was 1315 days (IQR=1679). Of the 215 patients 
94 reported being on the transplant waiting list, 105 not, and 16 did not know. High co-
morbidity was prevalent in 61 (28.4%) of patients. The mean BDI score was 12.2 (±8.2). 
Sixty-four patients had a BDI ≥16 indicating potential depressive cases (29.8%).  
Univariate comparisons between the depressed (BDI ≥16) and non-depressed (BDI<16) 
were undertaken with regards to clinical and demographic variables (table 7.2). Three 
variables differed between the depressed and non-depressed patients. Depressed patients 
were significantly younger than the non-depressed, and had significantly lower 
haemoglobin. Functional status as measured by the KPS was significantly lower in the 
depressed patients as compared to the non-depressed patients, indicating worse physical 
functioning in the former (table 7.2). None of the other parameters described in table 7.2 
were associated with depression including gender, renal centre, marital status, transplant 
status, co-morbidity, CRP and albumin.  
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Table: 7.2: Clinical and Demographic differences between depressed and non-depressed HD 
patients. 
Unless stated otherwise values are means and SDs. ~Median and Inter-quartile Range U= Mann Whitney  
 
7.3.1 Description of Illness Perceptions  
Mean IPQ-R scores are displayed in table 7.3. Overall HD patients held strong perceptions 
of the chronicity of the disease, and perceived it to have adverse consequences. Personal 
control perceptions appear to be stronger than treatment control perceptions. However, 
both treatment control and external causes had relatively low internal reliability (α). Illness 
perceptions showed logical inter-correlations as presented in the correlation matrix of table 
7.4. For example time-line perceptions correlated positively with consequence perceptions, 
coherence and emotion, and negatively with treatment and personal control. Depression 
  Total Depressed Non-Depressed  
  N=215 BDI ≥16 (n=64) BDI <16 (n=151) Sig 
Demographic     
Gender n (%)     
 Male  143 (66.5) 42 (65.6) 101 (66.9) X
2
(1,215)=0.3, p=0.85
 
 Female 72 (33.5) 22 (34.6) 50 (33.1) 
 
Age (mean SD) 60.5 (15.5) 57.0 (15.9) 61.9 (15.1) t(213)=2.1,p=0.034 
Ethnicity n (%)     
 White 190 (88.4) 58 (90.6) 132 (87.4) X
2
(1,215)=0.45, p=0.50 
 Non-white 25 (11.6) 6 (9.4) 19 (12.6)  
Marital status n (%)     
 Married/living with partner 143 (66.5) 39 (60.9) 104 (68.9) X
2
(3,215)=2.9, p=0.41 
 Divorced/separated 18 (8.4) 8 (12.5) 10 (6.6)  
 Widowed 23 (10.7) 6 (9.4) 17 (11.3)  
 Single 31 (14.4) 11 (17.2) 20 (13.2)  
Transplant List  n (%)     
 Yes 94 (43.7) 29 (45.3) 65 (43.0) X
2
(2,215)=4.0, p=0.14 
 No 105 (48.8) 27 (42.2) 78 (51.7)  
 Don’t know 16 (7.4) 8 (12.5) 8 (5.3)  
KPS~ 80 (20) 70 (18.6) 80 (20) U=3500, P=0.001 
Renal Centre  n (%)      
 Lister 155 (72.1) 50 (78.1) 105 (69.5) Fisher’s Exact Test p=0.44 
 Addenbrooke’s 45 (20.9) 10 (15.6) 35 (23.2)  
 Royal Free 15 (7.0) 4 (6.3) 11 (7.3)  
Clinical Data     
Dialysis Vintage (days)~ 1315 (1679) 1390.5 (2341.3) 1226 (1481) U=4303, p=0.21
 
Co-morbidity Group  n (%)     
 Low 76 (35.3) 22 (34.4) 54 (35.8) X
2
(2,215)=0.38, p=0.83 
 Moderate 78 (36.3) 22 (34.4) 56 (37.1)  
 Severe 61 (28.4) 20 (31.3) 41 (27.2)  
Diabetic  n (%) 36 (16.7) 11 (17.2) 25 (16.6) X
2
(1,215)=0.01, p=0.91 
Cancer  n (%) 19 (8.8) 4 (6.3) 15 (9.9) X
2
(1,215)=0.76, p=0.38 
Kt/V 1.3 (0.3) 1.3 (0.3) 1.3 (0.3) t(213)=0.19,p=0.85 
Haemoglobin (g/dL) 11.4 (1.3) 11.1 (1.2) 11.6 (1.4) t(213)=2.0,p=0.043
 
Albumin (g/dL) 36.6 (4.1) 36.4 (4.4) 36.7 (4.0) t(123)=0.43,p=0.671 
C-Reactive Protein (mg/l)~ 5.0 (8.0) 5.0 (12.6) 5.0 (7.6) U=4364, p=0.25 
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scores correlated with all the IPQ-R dimensions and negatively with functional status as 
measured by the KPS (table 7.4). KPS scores correlated negatively with personal control and 
the BDI. Inspection of the coefficients suggests that the relationship between the illness 
perceptions were small-moderate in effect-size.  
7.3.2 Comparing illness perceptions between the depressed and non-depressed 
patients  
Comparison of illness perceptions between depressed and non-depressed patients were 
sought via MANOVA (table 7.3). MANOVA with all the IPQ-R dimensions as dependent 
variables revealed a significant overall effect (F*11, 203+=9.1, p=0.001 η2=0.329). Depressed 
patients had a stronger illness identity and perception of time-line (chronicity), cyclical 
time-line, and negative consequences as compared to the non-depressed. Unsurprisingly 
depressed patients scored significantly higher on the emotion IPQ-R subscale than the non-
depressed patients. Depressed patients reported lower illness coherence and treatment 
control. Personal control perceptions were lower in the depressed as compared to the non-
depressed, a difference that was tending towards significance (p=0.06). With regards to 
causal perceptions, depressed patients scored significantly higher on the psychological and 
external factors subscales (table 7.3).  
7.3.3 Comparing illness perceptions between co-morbidity groups 
A MANOVA was evaluated in-order to compare illness perceptions between co-morbidity 
groups. MANOVA with all the IPQ-R dimensions as dependent variables revealed a non- 
significant overall effect (F[22, 406]=9.1, p=0.335 η2=0.057). The only illness perception that 
differed significantly across the co-morbidity groups was illness coherence (F(1,212) =4.4, 
p=0.014 η2=0.04). Post-hoc comparisons revealed that patients in the high co-morbidity 
group had significantly lower illness coherence scores (mean =17.3 S.E=0.53) as compared 
to those with medium co-morbidity (mean =19.2 S.E=0.47, p=0.01) and none-low co-
morbidity (mean =19.3 S.E=0.48, p=0.008). This suggests a lower level of illness 
understanding for patients with severe co-morbidity.  
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Table 7.3: MANOVA comparisons of the illness perceptions (IQ-R) between depressed and non-depressed patients.  
 
   Mean (SD) MANOVA  
IPQ-R Subscale α Possible Range Overall Depressed 
(n=64) 
Non-Depressed 
(n=151) 
F η2 
Illness Identity 0.83 0-14 5.3 (3.2) 6.5 (3.0) 4.8 (3.2) 13.9** 0.061 
Timeline 0.83 6-30 25.4 (4.8) 26.6 (4.1) 24.9 (5.0) 5.3* 0.024 
Cyclical 0.80 4-20 10.3 (3.5) 11.8 (3.4) 9.7 (3.4) 17.0** 0.074 
Consequences 0.70 6-30 22.0 (4.4) 24.0 (3.6) 21.1 (4.4) 21.7** 0.093 
Personal Control 0.78 5-25 18.1 (4.8) 17.1 (4.7) 18.5 (4.9) 3.8¥ 0.018 
Treatment Control 0.44 6-30 15.1 (3.2) 13.9 (3.3) 15.6 (3.1) 12.0** 0.053 
Illness Coherence 0.87 5-25 18.9 (4.3) 17.5 (5.1) 19.2 (3.8) 7.8** 0.036 
Emotion 0.86 6-30 16.2 (5.3) 20.4 (4.8) 14.4 (4.4) 79.2** 0.271 
Psychological Causes 0.87 7-35 13.5 (5.2) 15.0 (6.0) 12.8 (4.6) 8.7** 0.039 
Risk Factor Causes 0.80 6-30 11.0 (4.0) 11.7 (4.3) 10.7 (3.9) 2.5 0.012 
External Causes 0.52 3-15 7.5 (2.6) 8.2 (2.8) 7.2 (2.5) 7.0** 0.032 
**p<0.01 *p<0.05  ¥p=0.06 η2=Partial effect size α =Cronbach’s Alpha 
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Table 7.4: Correlation Matrix between the IPQ-R illness perceptions, BDI and, KPS scores. 
 
  1 2 3 4 5 6 7 8 9 10 11 12 
1 BDI             
2 Illness Identity .334**            
3 Timeline .193** .025           
4 Cyclical .309** .340** -.047          
5 Consequences .376** .457** .422** .209**         
6 Personal Control -.176** .023 -.213** .169* -.112        
7 Treatment Control -.286** -.080 -.293** .053 -.157* .431**       
8 Illness Coherence -.193** .051 .137* -.199** -.006 .065 -.090      
9 Emotion .642** .354** .135* .428** .408** -.049 -.157* -.194**     
10 Psychological Causes .231** -.018 -.035 .193** -.014 .065 .009 -.242** .250**    
11 Risk Causes .153* -.114 -.070 .086 -.071 -.042 -.060 -.292** .117 .614**   
12 External Causes .246** .118 .048 .105 .055 .124 -.026 -.093 .231** .358** .330**  
13 KPS -.263** .045 -.091 -.081 -.041 .152* .074 .118 -.012 -.045 -.069 -.002 
**p<0.01 *p<0.05 
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7.3.4 Logistic Regression: Predicting depression (BDI≥16) 
Logistic regression was undertaken to identify predictors of depression (DV= BDI≥16). 
Demographic, clinical and psychological variables were entered into the model in a 
hierarchical fashion (see table 7.5). In step 1 age, gender and KPS were entered. This 
baseline model was significant (Chi-Square =20 df=3 p=0.001) which accounted for 12.6% of 
the variance estimation in depression. Functional status (β=-0.045, p=0.001) and age (β=-
0.036, p=0.001) were both significant predictors of depression in this initial model. In step 2 
Hb, Albumin and Kt/V were entered. Adding these clinical variables did not improve the 
model significantly (∆Chi-Square =3.7 df=3 p=0.3), adding only 2% to the explained variance 
over model 1.  
 
In the final step the regression model improved significantly by adding all the IPQ-R items 
(except emotion, ∆Chi-Square =53.4 df=10 p=0.01), adding a further 28% to the explained 
variance in depression. Emotion was not added in the model due to its highly significant 
relationship with depression. In this final model age (β=-0.037, p=0.014), KPS (β=-0.048, 
p=0.002), Hb (β=-0.31, p=0.042), treatment control (β=-0.149, p=0.03), consequences 
(β=0.134, p=0.02) and illness coherence (β=-0.119, p=0.014) were all significant predictors 
of depression. Both cyclical time-line (β=0.115, p=0.059) and psychological causes (β=0.093, 
p=0.07) were marginal predictors of depression. In terms of odds a one point increase in 
consequences increased the odds of depression by 14% (table 7.5). A one point increase in 
treatment control was associated with a 14% reduction in odds for depression. 
Furthermore, a one point increase in illness coherence was associated with an 11% 
decrease in the odds for depression.  These results remained unchanged after including co-
morbidity and CRP in the model. Both of these variables were not associated with 
depression in any stage of the model building. The analysis was repeated with treatment 
control and external causes removed as both had relatively low internal consistency (α). 
After doing so the results were very similar to those reported in table 7.5. The only 
difference was that personal control became a significant predictor of depression (β=-
0.089, p=0.027) after removing treatment control. A one-point increase in personal control 
lead to an 8% decrease in the risk for depression (OR= 0.92 95% CI 0.85 – 0.99).  
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Table 7.5: Hierarchical Logistic Regression Models. Demographic, clinical and psychological predictors of depression (BDI ≥16). 
 
 Step 1 (model 1) Step 2 (model 2) Step 3 (model 3) 
IVs Wald OR 95% CI Wald OR 95% CI Wald OR 95% CI 
Age 10.7** 0.96 0.94-0.99 10.7** 0.96 0.94-0.99 6.05** 0.96 0.94-0.99 
Male 0.37 1.23 0.63-2.41 0.42 1.25 0.63-2.50 0.76 1.43 0.64-3.17 
KPS 14.4** 0.96 0.93-0.98 13.6** 0.96 0.93-0.98 9.93** 0.95 0.93-0.98 
Hb    3.31^ 0.80 0.62-1.02 4.15* 0.74 0.55-0.99 
Albumin    0.64 1.03 0.95-1.12 1.34 1.06 0.96-1.16 
Kt/V    0.39 1.46 0.44-4.79 0.01 0.94 0.24-3.66 
Illness Identity       0.54 1.05 0.92-1.20 
Timeline       0.73 1.04 0.95-1.15 
Cyclical       3.58
¥
 1.12 0.99-1.26 
Consequences       5.41* 1.14 1.02-1.27 
Personal Control       1.43 0.95 0.87-1.04 
Treatment Control       4.67* 0.86 0.75-0.99 
Illness Coherence       6.04** 0.89 0.81-0.98 
Psychological Causes       3.26^ 1.10 0.99-1.21 
Risk Causes       0.45 0.96 0.84-1.09 
External Causes       0.90 1.08 0.92-1.30 
          
 Chi-Square =20 df=3 p=0.001 
Nagelkerke R
2 
= 0.126 
Overall % Correct = 70.7 
∆Chi-Square =3.7 df=3 p=0.3  
Model Chi-Square =23.7 df=6 p=0.001 
Nagelkerke R
2 
= 0.148 
Overall % Correct = 72.1 
∆Chi-Square =53.4 df=10 p=0.01 
Model Chi-Square =77.1 df=16 p=0.001 
Nagelkerke R
2 
= 0.428 
Overall % Correct = 82.3 
**p<0.01 *p<0.05 ^p=0.07 
¥ 
p=0.06  DV= Depressed (yes/no) OR= Odds Ratio
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7.4 Discussion 
In this study depression and illness representations were examined in a relatively large 
cross-sectional sample of established HD patients. The data here provides the first line of 
evidence in support of the thesis that illness representations pertaining to the CSM are 
associated with depression among dialysis patients. Depression was found here to be 
prevalent in approximately 30% of HD patients, which confirms past data (Chilcot, Wellsted, 
Da Silva-Gane, & Farrington, 2008; Drayer et al., 2006; Hedayati et al., 2006; Kimmel, 2002). 
Of course it should be borne in mind that the method of defining cases based of depression 
upon an adjusted BDI cut-off score is not a diagnosis of MDD. Rather this data suggests that 
a significant proportion of established HD patients have significant depressive symptoms.  
Depressed patients had worst physical functioning as assessed by self-report than non-
depressed patients, which is in accordance with data from other physical illnesses (Buchi et 
al., 1998; Egede, 2007; McFarlane & Brooks, 1988). Although causality cannot be inferred, 
depression may lead to worse disability or influence the reporting of disability. Alternatively 
poorer functional status may result in decreased mood. There was also a negative 
relationship between age and depression which supports previous findings in dialysis 
patients (Drayer et al., 2006; Koo et al., 2003; Lopes et al., 2002). It is speculated that 
younger patients may be more vulnerable to depression due to greater life disruption with 
regards to work and social roles. Depression was unrelated to dialysis vintage which is in 
accordance with past data (Hedayati et al., 2008; Kimmel & Peterson, 2005; Kimmel, 
Peterson et al., 1998). Others report significant associations between depression and CRP 
(Simic Ogrizovic et al., 2009), and between depression and albumin (Koo et al., 2003) 
although the data here did not support either. In addition, several studies in dialysis patients 
report an association between depression and co-morbidity (Hedayati et al., 2008; Lopes et 
al., 2002; Simic Ogrizovic et al., 2009), although findings are mixed (Drayer et al., 2006; 
Kimmel, Peterson et al., 1998) and the association was not supported here. Different 
methods of assessing both depression and extra-renal co-morbidity may underlie such 
contradictory findings presented within the literature. Nevertheless, the data shown here 
supports the first hypothesis that clinical factors add little to account for depression in 
established HD patients.  
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With regards to the second and third hypotheses; that control and consequences 
perceptions would be associated with depression and, in multivariate analysis illness 
perceptions would be the strongest predictors of affect, both were supported. Depressed 
patients had a more maladaptive illness representation of ESRD compared to the non-
depressed reflected by a stronger illness identity, perception that ESRD is unpredictable, has 
adverse consequences, and is uncontrollable. Furthermore depressed patients reported 
greater disease-related worry, and less illness coherence (illness understanding). In logistic 
regression illness perceptions significantly added to the prediction of depression above and 
beyond clinical and demographic factors, explaining an additional 28% of the variance. 
Specifically, consequence, coherence, and treatment control all were independent 
predictors of depression. Concerns regarding the relatively low internal consistency of 
treatment control and risk factor causes lead to the regression being repeated with these 
items removed. As described earlier (chapter 5) treatment control is a complex term in ESRD 
due to the multifaceted treatment regimes, which may explain the relatively low internal 
consistency. After the removal of treatment control and causal risk factors, the findings 
remained largely unchanged except that personal control predicted depression. Taken 
together the findings demonstrate that perceiving greater disease-related consequences, 
and lower illness-related control and understanding (coherence) is associated with 
depression in HD patients. These findings also support past studies in dialysis patients that 
have examined illness perceptions in relation to QoL (Covic et al., 2004; Covic et al., 2006; 
Fowler & Baas, 2006; Griva et al., 2009; Timmers et al., 2008).  
The findings described here have shown that illness perceptions are strong predictors of 
depression in HD patients, more so that clinical factors. Indeed these results are similar to 
data gathered in other illness groups (Jopson & Moss-Morris, 2003; Sharpe et al., 2001) and 
early data in dialysis patients (Sacks et al., 1990). Taken together it appears that the 
interpretation of illness is more strongly associated with mood rather than disease severity. 
Moreover illness perceptions appear to be largely unrelated to extra renal co-morbidity in 
HD patients. Illness coherence was the only perception related to co-morbidity, with lower 
coherence associated with increased co-morbidity. This suggests that illness understanding 
is reduced when individuals have several other diseases. This may be the result of more 
somatic symptoms and treatment requirements in highly co-morbid patients.  
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The thesis that illness perceptions are associated with depression is supported further by 
data from several disease groups (Dickens et al., 2008; Jopson & Moss-Morris, 2003; 
Murphy et al., 1999; Orbell et al., 1998; Schiaffino et al., 1998). For example, a study of 
Rheumatoid Arthritis (RA) patients revealed that depression correlated positively with 
consequence perceptions, and negatively with control/cure perceptions, which were upheld 
after controlling for disease severity (Murphy et al., 1999). Furthermore in MS patients 
Jopson et al (2003) revealed that lower perception of personal control, greater perceived 
consequences and perceptions of psychological causes predicted HADS-depression scores. 
The data shown here in ESRD patients provides similar findings to these past studies 
suggesting that control and consequence illness perceptions are associated with depression. 
In addition, causal attributions have been shown to predict depression in the context of 
physical illness (Orbell et al., 1998; Jopson et al., 2003). Indeed, psychological causes were 
marginal predictors of depression in the analysis reported here suggesting that causal 
attributions may be important cognitions related to psychological outcomes (Roesch & 
Weiner, 2001; Taylor, 1983).  Contrary to other empirical data illness identity (Scharloo et 
al., 1999) and timeline (Dickens et al., 2008) did not predict depression in the present 
analysis. Presumably given the chronic nature of ESRD and the reliance on 3x weekly 
dialysis, chronicity and identity perceptions were well defined in this sample of established 
HD patients.  
Although this is the first study to show that illness perception are associated with 
depression in dialysis patients several study limitations should be considered. While the 
data here suggests that depression is characterised by different illness perceptions it is 
premature to infer causality given the cross-sectional design. There was also a bias in the 
recruitment of patients across the three centres, with Addenbrooke’s and the Royal Free 
having lower consent rates compared to the Lister. This may be because of the nature and 
exposure Lister patients have had to this and related research areas. Importantly depression 
was not associated with the location of the renal service.  
Furthermore exploration of the psychological mediators underlying the established illness 
perception-depression relationship was not undertaken (i.e. measures of coping). Although 
a full evaluation of the CSM was not sought in the works of this thesis, it is unlikely that 
current factor analytic approaches to coping will prove overly helpful in explaining the 
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relationship identified in this chapter. Another limitation was a lack of information regarding 
previous ESRD related treatments (e.g. dialysis modalities and the number of years since 
ESRD diagnosis). Illness representations are conceptualised to be dynamic perceptions that 
operate within illness schema. These schema are likely to be complex and updated as a 
result of previous dialysis history, transplantation and years with CKD. Further studies 
should consider factors relating to past dialysis and CKD histories.  
7.5 Concluding remarks 
In a cross-section sample of HD patients the thesis that illness representations would predict 
depression was supported. The findings underline the importance of understanding the 
nature and content of illness perceptions in relation to psychosocial outcomes, particularly 
as psychological interventions aimed at improving maladaptive illness perceptions improve 
outcomes (Broadbent et al., 2009; Petrie et al., 2002). Significantly these findings highlight 
that it is not the disease per se that decreases mood, rather it is the interpretation and 
regulation of the disease that appears to be more salient.  
The following chapter extends this work by examining the longitudinal relationship between 
depression and illness perceptions in an incident cohort of dialysis patients over the first 
year of dialysis therapy.  
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Chapter 8 
A Longitudinal Evaluation of Depression and Illness Representations 
in incident dialysis patients 
 
 
8.1 Introduction 
The cross-sectional study presented in the previous chapter supports the thesis that illness 
perceptions and depression are associated in established haemodialysis patients. Moreover 
it appears that clinical variables including co-morbidity explain little variation in depression. 
Rather it is an individual’s representation and regulation of the disease that is associated 
with depressive symptoms. The present chapter builds upon this cross-sectional work by 
examining the relationship between illness representations and depression over the first 
year of dialysis in a sample of incident dialysis patients. Studying incident dialysis patients 
has several advantages in this regard; 
1) It is presumed that the first year of treatment represents a period of adaption, thus a 
platform from which to study the self-regulation of illness through illness 
representations. That is, illness representations are expected to alter over time 
according to continued self-regulation.  
2) Patients start dialysis via different “paths”; some after receiving dialysis education 
and work-up (i.e. a progressive deterioration in renal function- termed planned 
starters), and others who start suddenly (for example acute presenters - termed 
unplanned starters). It is assumed that there will be different interpretations (i.e. 
representations) of illness during this period depending on how individuals start 
their therapy (unplanned vs. planned start).  
As suggested by the evidence presented in chapter 7 and from elsewhere within the 
literature, depression and illness representations are closely associated. It is therefore 
hypothesised that starting dialysis via a particular route (e.g. an unplanned start) would 
involve different illness representations that may serve as vulnerabilities for depression. 
Therefore the study of incident patients allows a dynamic model between illness 
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representations and depression to be assessed over time using variations of Structural 
Equation Modelling (SEM). The overarching aim of this chapter is to describe illness 
representations in incident dialysis patients and their relationship with the trajectory of 
depression symptoms over the first year of therapy.  
8.8.1 Depression in ESRD: initiation and time course 
As reviewed in chapter 2 depression is a common issue among ESRD patients, with many 
studies examining the point prevalence of the disorder, using either diagnostic approaches 
or screening tools. While cross-sectional studies are useful in this regard and allow 
associations with psychological and clinical factors to be established, they suffer in that they 
cannot make temporal associations nor can they assess the variability of depression (i.e. 
change) and the associated antecedents. There is little data describing the extent of 
depressive symptoms and impairments in health related quality of life soon after dialysis 
initiation (Korevaar et al., 2000; Merkus et al., 1997). Nevertheless some US data suggests a 
relatively high level of depression symptoms following the initiation of dialysis therapy, with 
44% scoring ≥15 on the BDI (Watnick et al., 2003). A larger study of incident patients report 
a similar prevalence, with 45% screening positive for depression on a three item measure 
derived from the diagnostic interview schedule (Walters et al., 2002). Walters et al (2002) 
report that depressed patients had lower health related quality of life compared with the 
non-depressed, yet the two groups did not differ significantly on demographic or clinical 
variables including co-morbidity. Given this, one intriguing question is whether there is 
anything inherent in the manner in which individuals start dialysis that increases the 
vulnerability to depression. In a small study Miura et al (1999) assessed depression 
symptoms before and after dialysis initiation comparing those with a planned start, to those 
who started unplanned. The results indicated that both before and after dialysis 
introduction, patients with an unplanned start had greater depression symptoms as 
assessed by the Zung self-rating depression scale, compared to those with a planned start. 
This study albeit very small and largely uncontrolled, suggests that unplanned dialysis 
initiation is associated with more depressive symptoms as compared to planned initiation.    
Others have assessed the timing of dialysis initiation (when to put a patient onto dialysis) 
according to opinion based guidelines (KDOQI) in relation to health related QoL (Korevaar et 
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al., 2002). Patients were defined as timely dialysis starters or untimely dialysis starters 
based upon the level of urea clearance (Kt/Vurea) and normalised protein catabolic rate 
(nPCR), which is a measure of protein nutritional adequacy based on urea kinetic modelling. 
Patients who had a timely start to dialysis according to the guidelines had greater perceived 
health related QoL at baseline compared to untimely starters on several components of the 
SF-36. However over a 12 month follow-up differences between the two groups 
disappeared suggesting the timing of dialysis initiation upon QoL is transient and only 
observed during the first few months of dialysis therapy. Interestingly timely and untimely 
starters did not differ significantly at baseline, or over time on mental health scores of the 
SF-36. This evidence supports the argument presented earlier that clinical factors are not 
strong associates of psychological distress among dialysis patients.  
As for longitudinal data describing the course of depression over time, there remain few 
examples in the ESRD population. A longitudinal study of HD patients reports a 29% 
prevalence rate for depressive disorder using the SCID at baseline assessment (Cukor et al., 
2008). Interestingly, 43% of patients diagnosed with depressive disorder at baseline still 
satisfied the criteria 16 months later. A persistent depressive course was associated with 
reduced perceived health status and quality of life and a depressive history (Cukor et al., 
2008).  Although of interest, this study fails to evaluate the variability of change over time 
and only employed a two-wave design. A larger study of incident patients reports that the 
mental health component scores of the SF-36 improved significantly over the first year of 
dialysis therapy (Korevaar et al., 2002). Although depression symptoms were not directly 
evaluated (i.e. via the BDI or HADS), the merits of this study include an appropriate design 
(i.e. several time points) and use of multi-level modelling. Evidently there is a paucity of 
longitudinal data, and the trajectory of depression over the dialysis career remains 
undefined.  
8.8.2 Illness Perceptions over time and their association with depression 
As reviewed in chapter 3 there is good evidence that illness perceptions predict an array of 
outcomes in functional status, quality of life and depression. Indeed, a key tenet of self-
regulation is that individuals consistently monitor and adapt behaviours in order to obtain 
particular goals. According to the CSM illness perceptions provide the interpretation of the 
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illness threat and inform coping procedures (via “IF-THEN rules) in an attempt to control the 
threat (Leventhal et al., 2003; Leventhal et al., 1992). Given the dynamic nature of the CSM, 
illness perceptions may be expected to change over time as individuals self-regulate. 
Remarkably however, few data are available that describe the change in illness perceptions 
over time. Longitudinal data from chronic illness groups including cardiac diseases (Sheldrick 
et al., 2006), diabetes (Lawson et al., 2008) and osteoarthritis  (Bijsterbosch et al., 2009; 
Kaptein et al., 2010) suggest that timeline and illness coherence perceptions increase with 
time, whereas controllability perceptions and emotional representations decrease over 
time. It has also been demonstrated that changes in illness perceptions predict clinical 
(Bijsterbosch et al., 2009; Kaptein et al., 2010) and psychological outcomes (Sheldrick et al., 
2006). However others report relative stability in illness perceptions over time in patients 
with lower back pain (Foster et al., 2008) and irritability bowl syndrome (Rutter & Rutter, 
2007), although the later study of Rutter and Rutter was most probably underpowered.  
Illness perceptions as predictors of later depression have been reported in some studies, yet 
there are vast differences in designs and statistical approaches to the analysis. As previously 
described (chapter 3) Schiaffino et al (1998) reported that illness perceptions predict the 
change in depression over time in RA and MS patients. In RA patients both curability and 
personal responsibility perceptions predicted later depression, whereas a stronger 
perception that symptoms varied from day to day was predictive of depression in the MS 
sample. Similarly, control perceptions predicted post-operative depression in patients who 
received a surgical intervention for osteoarthritis (Orbell et al., 1998). Dickens et al (2008) 
provides additional evidence revealing that time-line and control perceptions predict new-
onset depression following a MI. While most data is supportive of illness perceptions 
predicting depression at a later point in time, few have utilised more advanced statistical 
approaches like growth or multilevel models. Lane et al (2009) found no support that illness 
perceptions predicted the trajectory of depression in patients with atrial fibrillation using 
growth modelling. In ESRD only one study has examined illness perceptions over time 
together with changes in health related quality of life (Covic et al., 2006). Covic et al (2006) 
followed HD patients over two years and reported that emotional representations reduced 
over time, whereas illness coherence and perceptions of treatment control increased. 
Moreover baseline illness representations predicted improvements in QoL. Higher personal 
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control and illness coherence, and lower emotion representations at time one predicted 
improved physical QoL scores at time 2. Lower baseline consequence scores were 
associated with improvements in mental QoL functioning. Despite the relatively small 
sample size, only two time points, and a lack of consideration of extra-renal co-morbidity, 
these results suggest that illness representations are dynamic and are associated with 
changes in QoL in HD patients.  
While data corroborate the utility of the CSM by showing that illness perception are 
associated with depression in other illness groups, and may be associated with the change 
in depression over time, no study has explored their longitudinal associations in ESRD. 
Therefore this study set out to examine the following hypothesis and defend the thesis that 
illness perceptions and depression share a longitudinal relationship. 
Baseline Hypotheses:  
1) Patients with an unplanned path to dialysis have different illness perceptions and 
more depressive symptoms compared to planned patients. 
2)  Illness perceptions predict depression. Path to dialysis has an indirect effect upon 
depression mediated by illness perceptions. Clinical and demographic factors are 
largely unrelated to depression. 
Longitudinal Hypotheses: 
3) Depression symptoms decrease over time. 
4) Patients self-regulate, evidenced by a change in illness perceptions over time, 
although given the nature of ESRD changes may be relatively small.  
5) Illness perceptions predict the change in depression over time. 
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8.2 Methods 
8.3.1 Patients 
An incident cohort of dialysis patients from three UK renal centres were approached and 
recruited during the period of May 2007- May 2009. All patients were recruited within 3 
months of dialysis initiation. Patients were approached providing they met the following 
criteria; i) started in-centre HD or PD within last 3 months, ii) no previous dialysis history, iii) 
no known significant visual or physical impairment that would prevent the completion of 
the questionnaires, iv) fluency in verbal and written English language, (v) not hospitalised at 
the time of assessment and vi) no cognitive impairment as indicated by an age adjusted 
score of <22 on the Mini Mental State Examination (Folstein et al., 1975).  
8.3.2 Materials 
Demographic questionnaire: Information on age, gender, ethnicity, marital-status, and 
work-status were collected by means of a patient questionnaire. Transplant status was 
determined via self-report. Patients were asked if they were currently on the transplant 
waiting list (yes, no or don’t know). Smoking status was ascertained via self-report.   
The Revised Illness Perception Questionnaire (IPQ-R): As described in chapter 4. The sample 
size permitted Principle Component Analysis on the 18 causal items of the IPQ-R as 
recommended by (Moss-Morris et al., 2002). The three causal items identified in the 
previous chapters were employed here.  
Depression Symptoms: Depression symptoms were assessed via the Beck Depression 
Inventory (BDI-II) as described in Chapter 4. A BDI≥16 was employed to define patients with 
probable depression (see chapter 5). The BDI was treated as a categorical outcome (i.e. 
BDI≥16) to evaluate differences between depressed and non-depressed patients. Given that 
the aim was to examine the change in depression symptoms over time, the BDI was also 
treated as a continuous variable in the Structure Equation Modelling that follows (i.e. a BDI 
total score). As described in chapter 6 the total BDI scores provides a good overall measure 
of depressive affect encompassing general, cognitive and somatic symptoms.  
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8.3.3 Clinical Data 
Functional Status and Comorbidity: Karnofsky Performance Score was employed to assess 
functional status (see chapter 4). Comorbidity was assessed using a semi-quantitative 
technique (Chandna et al., 1999), scored by consultant nephrologist who assigned a severity 
score for each patient (1= no co-morbidity, 2= mild moderate co-morbidity, 3= severe co-
morbidity. A similar method described by Davies et al was also employed. Both methods 
have been described previously in the general methods (see chapter 4).  
Clinical parameters: Routine haematological and biochemical parameters collected as a part 
of the routine care of patients within the service were recorded. These included 
Haemoglobin, Albumin, CRP and sessional dialysis Kt/V. In addition primary ESRD diagnosis 
was recorded from medical notes. Estimated GFR was calculated from serum creatinine 
concentrations at the time of dialysis initiation, using the modified MDRD equation below 
(Levey et al., 1999).  
eGFR (ml/min/1.73m2) = 186 X [Serum Creatinine] -1.154 X [Age] -0.203 X [0.742 if female] X 
[1.21 if black].  
Depressive History: Depressive history was recorded, where depressive disorders were listed 
in the medical problem lists in patients’ medical record. Anti-depressant use at the time of 
assessment was also recorded. 
Path to dialysis: Planned starters were defined as those with known Stage V CKD who saw a 
nephrologist at least once within 90 days pre-initiation. Unplanned starters were those who 
had no contact with a nephrologist within 90 days pre-dialysis, including some who may 
have been seen before this 90 day period. This definition is defined and implemented in the 
UK renal registry. 
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8.3.4 Design and Procedure 
A three-wave panel design was employed in this study. Patients were recruited at a point 
soon after dialysis initiation (within three months of initiation, t1) and assessed 6 (t2) and 12 
months (t3) thereafter.  
Eligible HD patients were approached while on-dialysis, whereas eligible PD patients were 
approached via phone or whilst in clinic. HD patients completed the measures while on 
dialysis (chapter 5), while PD patients completed the measures during a routine clinic 
appoint or were sent the questionnaires in the post. Clinical data as described above were 
collected from electronic medical records.  
8.3.5 Statistical Methods  
The results presented in the following section are separated into two parts. Part one 
describes the baseline data and addresses the first two hypotheses (1-2) described in the 
introduction. The second part concerned the longitudinal data thus addressed the 
longitudinal hypotheses (3-5) as described above.  
In order to examine the baseline hypotheses SEM was employed to examine the cross-
sectional association between path to dialysis, illness perceptions and depression. Before 
examining the structural relations between these variables a measurement model for the 
IPQ-R was defined, the data from which is presented in the results. The SEM was defined 
based upon the assumption that path to dialysis would influence patients illness 
perceptions. Further, illness perceptions were hypothesised to be associated with 
depression in accordance with the data presented in the preceding chapter.  
Model fit was assessed via examination of the chi-square statistic and fit indices, specifically 
the CFI, TLI and RMSEA (see general methods). To reiterate, a CFI=0.95, TLI=0.95 and 
RMSEA=0.05 each suggest adequate fit to the data. Model trimming was attempted by 
removing non-significant regression paths from the SEM with the model then re-evaluated. 
The DIFFTEST10 in Mplus was used to test whether the original and the trimmed (i.e. nested 
model) differed significantly. A non-significant chi-square between the two models 
                                                          
10
 The difference in chi-square between two nested models when the estimator is WLSMV cannot be 
determined by the convention chi-square difference test. In Mplus the DIFFTEST can be used in such cases 
(mean-adjusted robust chi-square test). 
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demonstrates that the two models (original vs. nested) do not differ significantly with 
regards to their relative fit.  
In the second part of the analysis the trajectories (i.e. mean change and the variance of the 
change) for depression and illness perceptions were assessed using Latent Growth Models 
(LGM). For each model the loads of the intercept factor (i.e. baseline starting value) were 
constrained to 1. The loadings on the slope (i.e. the change factor) were set at 0 at the 
baseline (t1), 0.5 at the 6 month follow-up (t2) and 1 at the 12 month follow-up (t3). Loading 
the slopes in this manner implies a linear change over time.  
In addition to the linear latent growth model, an unspecified latent growth model for 
depression was also evaluated since the function of the trajectory was not known. In this 
unspecified model two of the slopes were fixed to be 0 (t1) and 0.5 (t2), with the final slope 
loading (t3) freed to be estimated in the model. Therefore the co-efficient of the final slope 
is statistically estimated from the data.  
Finally, predictors of the trajectory (linear change) of depression over one year were sought 
in latent growth models, where the intercept and slopes were regressed upon independent 
variables (illness perceptions). Initially the predictability of each illness perception (subscale 
scores) upon the trajectory of depression were evaluated in separate growth models in 
order to retain power. Perceptions that predicted the trajectory of depression were then 
entered into a combined model controlling for the effects of each of the selected perception 
variables.  
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8.3 Results Part I: Analysis of Baseline Data 
8.3.1 Patient characteristics 
Two hundred and twenty one initiating dialysis patients who were eligible for study were 
approached. One hundred and sixty patients gave consent and completed the base-line 
measures (consent rate =72.4%). The median dialysis vintage at baseline was 30.5 days (min 
1- max 100, IQR =35.8). Participants (n=160) and non-participants (n=61) did not differ 
significantly with regards to their age (t[219]=0.19,p=0.233], sex (X2[1,221]=1.62, p=0.20), 
treatment modality (X2[1,221]=0.99, p=0.32), or renal service. (X2[2,221]=4.4, p=0.11). A 
summary of patient attrition over the study period is presented in figure 8.1. Of the 160 
patients recruited at baseline, 133 were still on dialysis at the 6 month assessment, with 106 
dialysing at 12 months. Patients who remained on dialysis (completers n=106) were 
compared with patients would did not complete the study (non-completers n=27, excluding 
patients who died or were transplanted). There was no association between the renal 
service and non-completion (X2[2,221]=1.5, p=0.48), nor was there any gender difference 
between completers and non-completers (X2[1,221] =0.05, p=0.83). In addition completers 
and non-completers did not differ significantly with regards to age (t[219]=0.19,p=0.233]. 
However non-completers did have significantly higher baseline BDI scores (mean =15.9 
±10.8) as compared to completers (mean =10.4 ±7.2, t[32.2]=2.5, p=0.02). Furthermore 
there was a significant association between non-completion and treatment modality with all 
PD patients11 completing (n=24, 100%), versus 82 (72.2%) of HD patients (X2[1,221] =7.5, 
p=0.006).  
A summary of clinical and demographic characteristics at baseline (n=160) is presented in 
table 8.1. The mean age of the sample was 54.7 (±16.0). The majority of patients were male 
(67.5%), white (90.6%) and on HD (82.5%). Unplanned dialysis initiation occurred in 45 
patients (28.1%). A positive depressive history was noted in 24 patients (15%). At baseline 
forty-one patients (25.6%) scored ≥16 on the BDI suggesting possible depression.  
 
 
                                                          
11
 Excluding deaths and transplantation  
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Figure  8.1: Summary of patient accrual and follow-up. 
8.3.2 Differences between depressed and non-depressed patients at baseline 
Baseline differences between the depressed and non-depressed patients with regards to 
clinical and demographic factors are displayed in table 8.1. Depressed patients were 
significantly younger than the non-depressed and had better physical functioning.  
12 Month Follow-up (n=106) 
Eligible Patients Approached (n=221) 
Patients Recruited (baseline n=160) 
Non-consent (n=61) 
 
6 Month Follow-up (n=133) 
Withdrawn (n=3) 
Recovered Renal Function (n=2) 
Transplanted (n=3) 
RIP (n=11) 
Lost to Follow-up (n=8) 
 
 
 
 
Withdrawn (n=4) 
Recovered Renal Function (n=4) 
Transplanted (n=10) 
RIP (n=17) 
Lost to Follow-up (n=19) 
*Cumulative 
 
 
 
 
 
156 
 
Table 8.1: Demographic and clinical data at baseline: Comparisons between the depressed (BDI≥16) 
and non-depressed (BDI<16) patients. 
  Overall  n=160 Depressed n=41 Non-depressed n=119  Sig. 
Age (mean SD) 57.4 (16.0) 53.2 (14.3) 58.8 (16.3) t(158)=1.95, p=0.05 
Gender (male n, %) 108 (67.5%) 25 (61%) 83 (69.7%) X
2
(1,160)=1.07, p=0.301 
Ethnicity (white n, %) 145 (90.6%) 35 (85.4%) 110 (92.4%) Fisher’s Exact Test, p=0.215 
Marital Status (n, %)     
 Married/Living with Partner 106 (66.3%) 27 (65.9%) 79 (66.4%) X
2
(1,160)=0.04, p=0.95 
 Single/Widowed 54 (33.7%) 14 (34.1%) 40 (33.6%)  
Path to dialysis (n, %)     
 Planned 115 (71.9%) 22 (53.7%) 93 (78.2%) X
2
(1,160)=9.05, p=0.003 
 Unplanned 45 (28.1%) 19 (46.3%) 26 (21.8%)  
Dialysis Vintage (days) 38.6 (26.7) 41.0 (28.4) 37.8 (26.2) t(158)=0.68, p=0.498 
KPS<70 (dependent n, %) 24 (15%) 15 (36.6%) 9 (7.6%) X
2
(1,160)=20.2, p<0.001 
Diagnosis (n, %)     
 
Uncertain aetiology 
29 (18.1%) 7 (17%) 22 (18.5%) Fisher’s Exact Test, p=0.757 
 
Glomerulonephritis 
21 (13.1%) 6 (14.6%) 15 (12.6%)  
 
Pyelonephritis 
6 (3.8%) 2 (4.9%) 4 (3.4%)  
 
Diabetes 
27 (16.9%) 6 (14.6%) 21 (17.6%)  
 
Polycystic kidney 
19 (11.9%) 2 (4.9%) 17 (14.3%)  
 
Hypertension 
14 (8.7%) 4 (9.8%) 10 (8.4%)  
 
Renal vascular disease 
8 (5%) 2 (4.9) 6 (5%)  
 
Other 
36 (22.5%) 12 (29.3%) 24 (20.2%)  
Treatment (HD n, %) 132 (82.5%) 34 (82.9%) 98 (82.4%) X
2
(1,160)=0.07, p=0.934 
Smoker (n, %) 57 (35.6%) 14 (34.1%) 43 (36.1%) X
2
(1,160)=0.053, p=0.819 
Mod-High-comorbidity (n, %) 58 (36.3%) 16 (39%) 42 (35.3%) X
2
(1,160)=0.184, p=0.668 
Diabetic (n, %) 39 (24.4%) 10 (24.4%) 29 (24.4%) X
2
(1,160)=0.01, p=0.998 
Positive depressive history (n, %) 24 (15%) 10 (24.4%) 14 (11.8%) X
2
(1,160)=3.81, p=0.05 
Hb (g/dL mean SD) 10.3 (1.9) 10.5 (1.8) 10.3 (1.9) t(158)=0.79, p=0.431 
Albumin (g/l mean SD) 35.6 (5.4) 34.6 (6.2) 36.0 (5.1) t(158)=1.43, p=0.153 
CRP (mg/l)
a 
7.0 (14.0) 8.0 (14.3) 6.0 (14.0) U=2341, p=0.698 
eGFR (ml/min)
b 
8.9 (3.3) 8.8 (3.8) 8.9 (3.1) t(158)=0.152, p=0.879 
aMedian and inter-quartile range beGFR  according to the MDRD equation U= Mann Whitney U. 
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Depressed patients were also more likely to have a positive history of depression (OR= 2.4, 
95% CI 1.0-5.9, p<0.05) as compared to the non-depressed patients. In addition depressed 
patients were significantly more likely to have an unplanned start to dialysis (OR=3.1, 95% CI 
1.5-6.6, p<0.05) as compared to the non-depressed. As found previously in chapter 7, 
depression was not associated significantly with the remaining variables displayed in table 
8.1 including, treatment modality, gender, renal diagnosis, albumin, CRP, eGFR and co-
morbidity.  
The mean BDI scores across the co-morbidity groups (low [n=66], medium [n=36], and high 
[n=58] were 12.2 (±8.4), 11.4 (±10.9) and 12.7 (±7.4) respectively. ANOVA revealed the BDI 
scores did not vary significantly across the co-morbidity groups (F[2,159]=0.27, p=0.78). 
These null findings were confirmed after coding co-morbidity according to the Davies et al 
(2002) method (F[2,159]=2.5, p=0.10).  
Comparisons of illness perceptions between depressed and non-depressed patients were 
sought via MANOVA (table 8.2). MANOVA with all the IPQ-R dimensions as dependent 
variables revealed a significant overall effect (F[11, 148]=7.1, p=0.001 η2=0.347). Depressed 
patients had a stronger illness identity and cyclical time-line perceptions, greater perceived 
negative consequences, and lower illness coherence as compared to the non-depressed. 
Unsurprisingly depressed patients scored significantly higher on the emotion IPQ-R subscale 
than the non-depressed patients. With regards to causal perceptions, depressed patients 
scored significantly higher on the psychological subscale compared to the non-depressed. 
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Table 8.2: Comparison of illness perceptions between depressed and non-depressed patients. 
**p<0.01 *p<0.05 η
2
= Partial effect size. Values shown are means and standard deviations.  
8.3.3 Correlates of depression scores at baseline 
Correlations between the BDI with demographic, clinical and illness perception data were 
sought. The BDI correlated significantly with age (r=-0.299, p=0.04) and functional 
performance (Spearman’s rho =-0.435, p=0.001). The BDI failed to correlate with albumin 
(r=-0.092, p=0.248), Haemoglobin (r=-0.04, p=0.645), CRP (Spearman’s rho =0.06, p=0.445), 
dialysis vintage (r=0.05, p=0.573) and eGFR (r=0.08, p=0.328). The BDI correlated 
significantly with several IPQ-R dimensions: identity (r=0.375, p=0.001), cyclical-timeline 
(r=0.291, p=0.001), consequences (r=0.411, p=0.001), coherence (r=-0.267, p=0.001), 
emotion (r=0.673, p=0.0001), psychological causes (r=0.195, p=0.014) and external causes 
(r=0.174, p=0.028).  
  Mean (SD) MANOVA  
IPQ-R Subscale  Overall Depressed  
(n=41) 
Non-Depressed  
(n=119) 
F η2 
Illness Identity  4.6 (2.8) 5.6 (3.1) 4.3 (2.7) 7.6* 0.046 
Timeline  24.3 (4.2) 23.8 (4.6) 24.5 (4.0) 0.7 0.004 
Cyclical  10.4 (3.4) 11.3 (3.7) 10.1 (3.2) 4.2* 0.026 
Consequences  21.8 (4.0) 24.1 (3.5) 21.0 (3.9) 20.8** 0.116 
Personal Control  20.3 (4.4) 20.1 (4.8) 20.3 (4.3) 0.01 0.00 
Treatment Control  16.7 (3.2) 16.2 (3.3) 16.9 (3.2) 1.5 0.01 
Illness Coherence  17.4 (4.6) 15.6 (4.7) 18.0 (4.4) 8.9** 0.053 
Emotion  17.3 (5.3) 22.3 (4.9) 15.6 (4.3) 68.6** 0.303 
Psychological  Causes  14.2 (5.1) 15.8 (5.9) 13.6 (4.8) 5.7* 0.035 
Risk Factor Causes  11.4 (4.0) 11.7 (4.6) 11.3 (3.8) 0.4 0.002 
External Causes  7.1 (2.1) 7.5 (2.2) 7.0 (2.1) 1.6 0.01 
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8.3.4 Differences between unplanned and planned patients at baseline. 
Unplanned and planned starters did not differ at baseline with regards to the following 
variables: age, gender, renal centre, co-morbidity, eGFR, depressive history and dialysis 
vintage (data not presented). However unplanned patients had significantly lower albumin 
(mean=33.7 ±5.9) as compared to planned patients (mean =36.4 ±5.0, t[158]=2.8, p=0.005). 
In addition haemoglobin was significantly lower in the unplanned group (mean =9.4 ±2.0) as 
compared to planned group (mean 10.7 ±1.7, t[158]=4.0, p=0.0001).  
As noted above unplanned entry was associated with a greater portion of BDI scores ≥16 as 
compared to planned entry. In addition mean BDI scores in unplanned starters were 
significantly higher than planned starters (15.6 ±8.5 vs. 10.9±8.4, t[158]=3.17, p=0.002). 
Comparison of the groups with regards to their illness perceptions at baseline was evaluated 
in MANOVA (see table 8.4 for means and 95% CIs). MANOVA revealed a significant overall 
effect between the groups (F*11,148+=3.1, p=0.001 η2=0.190). Specifically unplanned 
starters had significantly lower time-line perceptions (F*1,158+=5.8, p=0.017 η2=0.035), 
greater perceptions of cyclicality (F[1,158+=11.1, p=0.001 η2=0.065), greater perceptions of 
adverse consequences (F*1,158+=4.4, p=0.038 η2=0.027), a greater emotional response 
(F*1,158+=7.8, p=0.006 η2=0.047) and lower illness coherence (F[1,158]=14.1, p=0.001 
η2=0.082), as compared to the planned starts. With regards to the causal items, unplanned 
starters had stronger perceptions of external (F*1,158+=6.1, p=0.014 η2=0.038) and 
psychological causes (F*1,158+=7.8, p=0.006 η2=0.047).  
8.3.5 Difference between treatment modality at baseline 
HD and PD patients had comparable mean BDI scores at baseline (12.2 ±8.8 vs. 12.3 ±8.1 
respectively t[158]=0.63, p=0.95). MANOVA revealed a non-significant overall effect 
between the treatment groups with regards to illness perceptions (F[11,148]=1.8, p=0.056 
η2=0.119). Only two individual perceptions appeared to differ between the groups. As 
compared to HD patients, PD patients had greater illness identity (5.8±2.4 vs. 4.4±2.9 
F[11,148]=5.7, p=0.018 η2=0.035) and greater illness coherence (20.1±4.0 vs. 16.9±4.5 
F[11,148]=12.5, p=0.001 η2=0.073).  
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8.3.6 Structural Equation Model: Defining a measurement model for illness 
perceptions (IPQ-R) 
 
A measurement model for six illness perceptions (illness identity, cyclical timeline, illness 
coherence, perceived consequences, psychological causes and external causes) was 
evaluated in Confirmatory Factor Analysis. These perceptions were selected for inclusion in 
the measurement due to their cross-sectional relationship with depression as determined in 
univariate analysis. Baseline emotion scores were not included in the measurement model 
due to a high correlation with baseline depression scores. Since emotion would not be 
included in the structural models that follow, it was decided to evaluate the measurement 
model without these items. Missing data on the IPQ-R and BDI was small and replaced with 
median scores of the item. Since the subscales on the IPQ-R are treated on an ordinal scale, 
and illness identity comprised of summing the number of symptoms attributed to ESRD, 
WLSMV estimation was employed which is used when data is either categorical or ordinal. 
Three items in the illness identity were not included in the model because very few patients 
reported these symptoms (sore throat, sore eyes, and wheeziness).   
The model parameterisation is depicted in table 8.3 accompanied by the standardised 
model estimates, variance explained and residual variance (error). Model fit as evaluated by 
chi-Square suggested poor fit (X2=142.7 df=70, p<0.001), however as described in the 
general methods and chapter 6 the chi-square statistic is sensitive to sample size (Ullman, 
2006) thus several fit indices were evaluated. The fit indices suggested that the 
measurement model had adequate fit (CFI= 0.96, TLI= 0.96, RMSEA=0.08). This IPQ-R 
measurements model was therefore utilised in a structural model evaluated below.   
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Table 8.3: A confirmatory factor analysis of selected illness perceptions (IPQ-R). 
       
Item Description of item  Factor Loading
~ 
R
2 
Residual 
Variance 
ID1 Pain  IDENTITY 0.674 0.455 0.545 
ID2 Sore Throat  IDENTITY 0.800 0.640 0.360 
ID4 Breathlessness  IDENTITY 0.444 0.198 0.802 
ID5 Weight Loss  IDENTITY 0.357 0.127 0.873 
ID6 Fatigue  IDENTITY 0.663 0.440 0.560 
ID7 Stiff Joints  IDENTITY 0.448 0.200 0.800 
ID10 Headaches  IDENTITY 0.475 0.226 0.774 
ID11 Upset Stomach  IDENTITY 0.666 0.444 0.556 
ID12 Sleep Difficulties  IDENTITY 0.558 0.312 0.688 
ID13 Dizziness  IDENTITY 0.586 0.343 0.657 
ID14 Loss of Strength  IDENTITY 0.674 0.454 0.546 
IP6 My kidney problem is serious  CONSEQUENCES 0.773 0.597 0.403 
IP7 Major Consequences on life  CONSEQUENCES 0.829 0.687 0.313 
IP8 Does not have much effect  CONSEQUENCES 0.539 0.290 0.710 
IP9 Affects the way others see me  CONSEQUENCES 0.567 0.322 0.678 
IP10 Financial consequences  CONSEQUENCES 0.576 0.332 0.668 
IP11 Difficulties for those who are close  CONSEQUENCES 0.553 0.306 0.694 
IP24 Symptoms are puzzling  COHERENCE 0.891 0.794 0.206 
IP25 Kidney problem is a mystery  COHERENCE 0.923 0.852 0.148 
IP26 Don’t understand my kidney problem  COHERENCE 0.909 0.826 0.174 
IP27 Kidney problem doesn’t make sense  COHERENCE 0.881 0.776 0.224 
IP28 I have a clear picture/understanding of my condition  COHERENCE 0.542 0.294 0.706 
IP29 Symptoms change day to day  CYCLICAL TIME 0.860 0.740 0.260 
IP30 Symptoms come and go in cycles  CYCLICAL TIME 0.792 0.627 0.373 
IP31 Kidney problem if unpredictable  CYCLICAL TIME 0.770 0.592 0.408 
IP32 Cycles where kidney problem gets better/worse  CYCLICAL TIME 0.834 0.695 0.305 
C1 Stress or worry  PSYCHOLOGICAL CAUSES 0.724 0.524 0.476 
C4 Diet  PSYCHOLOGICAL CAUSES 0.559 0.313 0.687 
C8 Own Behaviour  PSYCHOLOGICAL CAUSES 0.692 0.479 0.521 
C9 Mental Attitude  PSYCHOLOGICAL CAUSES 0.915 0.838 0.162 
C10 Family Problems  PSYCHOLOGICAL CAUSES 0.868 0.754 0.246 
C11 Overwork  PSYCHOLOGICAL CAUSES 0.703 0.494 0.506 
C12 Emotional State  PSYCHOLOGICAL CAUSES 0.901 0.811 0.189 
C13 Ageing  EXTERNAL CAUSES 0.545 0.297 0.703 
C14 Alcohol  EXTERNAL CAUSES 0.819 0.671 0.329 
C15 Smoking  EXTERNAL CAUSES 0.786 0.618 0.382 
C16 Accident or injury  EXTERNAL CAUSES 0.742 0.551 0.449 
C17 Personality  EXTERNAL CAUSES 0.898 0.806 0.194 
C18 Altered Immunity  EXTERNAL CAUSES 0.756 0.571 0.429 
       
~Standardised loading. Items shown are the questions from the IPQ-R. “ID” refers to illness identity items, “IP” 
to man body of items (consequences, Coherence, Cyclical time-line) and “C” to causal items. 
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8.3.7 Structural Equation Model of the Baseline data: the relationship between path 
to dialysis, illness perceptions and depression 
 
In an initial SEM path to dialysis was specified to predict several illness perceptions which in 
turn were specified to predict depression (total BDI score, see figure 8.2). A direct path 
between path to dialysis and depression was also specified. Age, physical function (KPS) and 
co-morbidity were all entered in the model as interrelated variables, and were all specified 
to have direct effects upon depression. Physical function was regressed on path to dialysis, 
and an indirect effect between path to dialysis and depression through physical function. 
This model yielded good fit as determined by several fit indices (CFI=0.952, TLI=0.958, 
RMSEA=0.079), although the chi-square was significant (X2= 157.1 df=79, p<0.001). Path to 
dialysis predicted illness coherence, cyclical timeline perceptions, and marginally predicted 
perceived consequences. Specifically unplanned path to dialysis predicted less illness 
coherence, greater perceptions of cyclical symptoms, and stronger perceptions of 
psychological causes. Path to dialysis did not have a significant direct effect on depression in 
the SEM. 
In addition, path to dialysis predicted physical performance score (KPS). Lower illness 
coherence, greater perceived consequences and higher cyclical timeline predicted 
depression scores. Shown in figure 8.2 are the standardized model estimates. A one 
standard deviation increase in illness coherence was associated with a -0.23 standard 
deviation change in depression. A point standard deviation increase in consequence and 
cyclical timeline perceptions, increases the BDI by 0.36 and 0.21 standard deviations 
respectively.  
Age and KPS had a negative relationship with depression; however co-morbidity was 
unrelated to depression. Age, KPS and co-morbidity were all inter-correlated (figure 8.2). 
Age was negatively related with KPS and positively associated with co-morbidity. As 
expected KPS was negatively correlated with co-morbidity. Age and co-morbidity both 
correlated negatively with illness identity.  
Indirect effects between path to dialysis and depression, through physical performance and 
the illness perceptions were tested.  The overall indirect effect between path to dialysis and 
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depression was significant (standardized estimate=0.30, p<0.001). Specifically there were 
indirect effects between path to dialysis and depression through illness coherence 
(standardized estimate=0.06, p=0.013), and through cyclical perceptions (standardized 
estimate=0.06, p=0.034). This suggests, albeit from cross-sectional analysis, that illness 
perception mediate the association between path to dialysis and depression.  
Furthermore there was an indirect effect of path to dialysis on depression through KPS 
(standardized estimate=0.106, p<0.001).  
Model trimming was attempted by removing the non-significant paths from the model 
depicted in figure 8.2. This trimmed model is shown in figure 8.3. A DIFFTEST between the 
original and the trimmed (i.e. nested model) suggest that the two models did not differ 
significantly (p=0.07). The trimmed model showed good fit as determined by the fit indices 
(CFI=0.951, TLI=0.958, RMSEA=0.079). The indirect effects between path to dialysis and 
depression stated above were maintained in this model. In addition an indirect effect 
through consequences was tending towards significance (p=0.07). 
Alternative SEM models were tested, which included the following variables; treatment 
control, personal control, timeline and emotion, haemoglobin, albumin and gender. None of 
these variables were associated with depression, and the model fit did not improve 
significantly beyond the models described in figures 8.2 and 8.3. 
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-0.394** 
Figure 8.2: SEM between path to dialysis, illness perceptions and depression at baseline (note correlations between the latent variables and error terms have been emitted in 
this figure but did feature in the modelling).  
*p<0.05 **p<0.01 ^p=0.06 
Shown are standardised estimates 
“IDEN”= identity, “CON”= consequences, 
“COH”=coherence, “CYC”= cyclical time-line      
“PSYC”= psychological cause, “EXTC”= external cause. 
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Figure 8.3: Trimmed SEM between path to dialysis, illness perceptions and depression at baseline (note correlations between the latent variables  and error terms have been 
emitted in this figure but did feature in the modelling). 
*p<0.05 **p<0.01 ^p=0.06 
Shown are standardised estimates 
“IDEN”= identity, “CON”= consequences, 
“COH”=coherence, “CYC”= cyclical time-line. 
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8.4  Results Part II: Analysis of Longitudinal Data 
8.4.1 Change in depression symptoms and illness perceptions over time using 
Linear Latent Growth Models  
The observed means with 95% confidence intervals, for BDI and illness perception scores at 
baseline (n=160), 6 month follow-up (n=133) and 12 month follow-up (n=106) are displayed 
in table 8.4. In order to establish the trajectory of depression and each illness perception of 
the IPQ-R, a series of Latent Growth Models were evaluated using Mplus. As described in 
the methods, each model assumed linear growth.  
 
A summary of the LGMs are presented in table 8.5 including the mean and variance of both 
the intercept and slope. There was significant variation in BDI scores at baseline, suggesting 
inter-individual variability. The mean change for depression was -0.43 over the one year 
follow-up which was non-significant, suggesting that depression symptoms were relative 
stable over this period (table 8.5). Furthermore there was no signification variation in the 
change over time. All of the illness perceptions showed significant variance at the intercept 
(i.e. at the baseline). Only two illness perceptions changed significantly over time. Illness 
identity reduced by -0.59 units (p<0.05) over the follow-up suggesting that illness identity 
was reducing with time. Furthermore there was a significant amount of variance in the 
change over time, suggesting that there were individual differences in the change. Illness 
coherence had an increasing trajectory over time (1 point increase over 1 year) suggesting 
that illness understanding was improving with time. However there was not a significant 
amount of variance in the change of coherence over time (table 8.5), suggesting the 
variability of the slopes for individuals did not differ. Personal control did not differ 
significant over time with regards to mean change, yet there was significant variation in the 
scores over time, suggesting that the variance was increasing (i.e. individual scores 
becoming more divergent over time).  
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Table 8.4:  Means and 95% confidence interval for depression scores and illness perceptions at the baseline, 6 month and 12 month follow-up. 
 
 Overall Planned Unplanned 
Variable Baseline 6 month 12 month Baseline 6 month 12 month Baseline 6 month 12 month 
n 160 133 106 115 98 80 45 35 26 
BDI 12.2 (10.9–13.6) 10.6 (9.3–11.9) 10.6 (9.0–12.3) 10.9 (9.4-12.6) 9.5 (8.0-11.0) 9.5 (7.9-11.2) 15.6 (13.1-18.1) 13.7 (11.2 -16.2) 14.2 (10.7-17.7) 
Illness Identity 4.6 (4.2-5.0) 4.4 (3.8-4.9) 3.9 (3.4-4.5) 4.4 (3.9-4.9) 3.9 (3.3-4.4) 3.7 (3.0-4.3) 5.1 (4.3-5.9) 5.7 (4.6-6.8) 4.8 (3.7-5.8) 
Timeline 24.3 (23.7-25.0) 24.5 (23.8-25.2) 25.1 (24.2-25.9) 24.8 (24.1 –25.5) 24.8 (24.0-25.6) 25.4 (24.4-26.3) 23.1 (21.7-24.4) 23.5 (22.0-24.9) 24.2 (22.4-25.9) 
Cyclical 10.4 (9.9 -10.9) 10.4 (9.8-11.0) 10.2 (9.5-10.9) 9.9 (9.3-10.5) 9.8 (9.2-10.5) 9.7 (9.0-10.4) 11.8 (10.8-12.8) 11.9 (10.7-13.0) 11.6 (9.9-13.3) 
Consequences 21.8 (21.6-22.4) 21.6 (20.8-22.3) 22.0 (21.2-22.8) 21.4 (20.6-22.1) 20.8 (20.0-21.6) 21.5 (20.6-22.4) 22.8 (21.8-23.9) 23.6 (22.5-24.8) 23.4 (21.9-24.9) 
Personal Control 20.3 (19.6-21.0) 19.9 (19.1-20.7) 19.7 (18.9-20.5) 20.4 (19.6-21.1) 19.7 (18.8-20.6) 19.7 (18.8-20.7) 20.1 (18.6-21.6) 20.5 (18.8-22.3) 19.4 (18.1-20.8) 
Treatment Control 16.7 (16.2-17.2) 16.1 (15.6-16.7) 16.3 (15.7-16.9) 16.5 (15.9-17.1) 16.2 (15.6-16.8) 16.3 (15.7-17.0) 17.3 (16.3-18.3) 16.0 (14.9-17.1) 16.3 (15.1-17.5) 
Illness Coherence 17.4 (16.7–18.1) 18.3 (17.5-19.0) 18.6 (17.7-19.5) 18.2 (17.5-19.0) 18.8 (17.9-19.6) 19.3 (18.4-20.2) 15.3 (13.9-16.7) 16.9 (15.4-18.4) 16.6 (14.6-18.5) 
Emotion 17.3 (16.4–18.1) 16.5 (15.7-17.4) 16.4 (15.4-17.5) 16.6 (15.6-17.5) 15.5 (14.6-16.4) 15.6 (14.5-16.7) 19.1 (17.5-20.7) 19.4 (17.8-21.1) 19.0 (16.8-21.3) 
Psychological  Causes 14.2 (13.4–15.0) 14.1 (13.4-14.9) 13.8 (12.9-14.8) 13.5 (12.6-14.4) 13.5 (12.6-14.4) 13.6 (12.4-14.7) 16.0 (14.5-17.5) 16.0 (14.8-17.1) 14.7 (13.0-16.5) 
Risk Factor Causes 11.4 (10.7–12.0) 11.7 (11.0-12.4) 11.5 (10.8-12.3) 11.1 (10.4-11.9) 11.4 (10.6-12.2) 11.4 (10.6-12.3) 12.0 (10.9-13.2) 12.6 (11.5-13.7) 11.8 (13.6) 
External Causes 7.1 (6.8–7.4) 7.2 (6.8-7.6) 7.1 (6.6-7.6) 6.8 (6.5-7.2) 6.9 (6.5-7.4) 7.0 (6.4-7.5) 7.8 (7.2-8.4) 8.0 (7.3-8.6) 7.6 (6.5-8.7) 
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Table 8.5: Summary of a series of linear Latent Growth Models for depression scores and illness perceptions over a one year follow-up. 
 Parameter
a
    
 Mean of 
Intercept 
Variance of 
Intercept 
Mean of change Variance of 
change 
Covariance 
between level 
and change Fit 
Variable Coeff. (SE) Coeff. (SE) Coeff. (SE) Coeff. (SE) Coeff. (SE) Model X
2
 (df) CFI RMSEA 
BDI 11.6 (0.7) ** 44.6 (8.8)** -0.43 (0.7) 15.4 (18.4) -1.4 (10.1) 6.5 (1) 0.971 0.187 
Identity 4.6 (0.2)** 6.4 (1.3)** -0.59 (0.7)* 5.1 (2.4)* -2.7 (1.4) 0.0 (1) 1.0 0.0 
Timeline 24.3 (0.3)** 11.5 (3.0)** 0.47 (0.4) 6.9 (6.2) -3.1 (3.9) 0.8 (1) 1.0 0.0 
Consequences 21.7 (0.3)** 11.3 (2.5)** 0.28 (0.3) 3.8 (4.5) -2.4 (2.7) 1.9 (1) 0.992 0.07 
Personal Control 20.3 (0.3)** 17.9 (3.2)** -0.58 (0.4) 16.8 (5.3)** -10.4 (3.5)** 0.0 (1) 1.0 0.0 
Treatment control 16.6 (0.2)** 5.7 (1.6)** -0.5 (0.3) 2.8 (3.2) -1.7 (1.8) 3.1 (1) 0.97 0.115 
Cyclical timeline 10.4 (0.3)** 5.4 (1.8)** 0.03 (0.3) -0.3 (3.9) 1.5 (2.2) 0.2 (1) 1.0 0.0 
Coherence 17.5 (0.3)** 10.2 (2.9)** 1.0 (0.3)** -7.7 (6.1) 3.9 (3.5) 0.8 (1) 1.0 0.0 
Emotion 17.1 (0.4)** 15.0 (3.7)** -0.4 (0.4) -5.9 (7.6) 5.6 (4.2) 1.3 (1) 0.998 0.045 
Psychology Causes 14.2 (0.4)** 12.4 (3.3)** -0.4 (0.4) -6.5 (6.9) 3.4 (3.9) 0.02 (1) 1.0 0.0 
External Causes 7.1 (0.2)** 2.7 (0.7)** 0.2 (0.2) 2.3 (1.6) -0.3 (0.9) 0.3 (1) 1.0 0.0 
a
unstandardised estimates *p<0.05 **p<0.01 
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8.4.2 Unspecified latent growth model for depression 
As described above, depression did not change significantly over the year follow-up as 
evaluated by a linear latent growth model. However examination of the observed means as 
shown in figure 8.4 suggests that there is an initial decline in depression symptoms from 
baseline to 6 month follow-up which then stabilises from 6 months to 12 months.  
 
Figure 8.4: Observed and estimated means for the BDI at baseline, 6 and 12 month follow-up. 
 
Furthermore, examination of individual curves taken at random (n=10) suggests a pattern 
of declining BDI scores from baseline- 6 month follow-up (figure 8.5). Further, inspection of 
figure 8.5 suggests that there may well be different clusters of trajectories (those who stay 
constant, those who decline over time and those improve over time). However to test this 
in “latent class” analysis would require a very large sample size thus was not attempted 
here. Nevertheless, it appears that any potential change in depression scores may be non-
linear. Conventionally this could be tested by entering a quadratic term into the growth 
model; however for the model to be identified there needs to be a minimum of 4 time 
points. Given this, an unspecified latent growth model for depression was examined where 
the final time slope was freed to be estimated (see methods). This essentially allows the 
growth to be estimated, rather than stipulating that the growth is linear. An unspecified 
latent growth model as depicted in figure 8.6 was examined in Mplus. The model was 
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saturated (i.e. just identified) as there were no degrees of freedom following model 
estimation. As expected from a saturated model the model provided excellent fit according 
to the fit indices (CFI=1, TLI=1 and RMSEA=0.0). As shown in figure 8.6 the mean at the 
intercept was 12.2 (SE=0.7).  
 
Figure 8.5: A random selection of 10 individual growth curves for BDI scores over time. 
 
Further, there was significant variation at the intercept. The mean change as estimated by 
the model was -2.8 (p=0.013) suggesting that depression scores decreased over time. There 
was no significant variation in the change over time (p=0.521). Furthermore the intercept 
and slope did not share a significant amount of co-variation (p=0.99). This suggests that 
depression may be declining over time during the first year of dialysis (probably the first 6 
months), although the change appears to be non-linear. However it should be noted that 
there are not enough time points to evaluate the function of the change over time and that 
there is not a significant amount of variance in the change over time. Taken together there 
appears to be a trend for declining depression scores over the first 6 months of dialysis. 
 
 
 
 
171 
 
BDI TOTAL
1
BDI TOTAL
2
BDI TOTAL
3
1 1
1
0.5
0
*0.5
0
***
Intercept Slope
I mean = 12.3**
I var = 44.0**
S mean = -2.8 *
S var = 51.6
-0.3
*p<0.05
**p<0.01
*** Parameter freed to be estimated  
 
Figure 8.6: An unspecified latent growth model for depression scores over a 1 year follow-up. 
 
8.4.3 Predictors of  the change in depression 
Predictors of the change in depression were evaluated by regressing the intercept and 
slope from the linear growth model described above onto the following independent 
variables, age, kps, path to dialysis, co-morbidity, and the illness perceptions. In other 
words do particular independent variables predict the intercept (i.e. the initial starting 
values at baseline) and the change in depression scores over a year follow-up? The linear 
growth model, and not the unspecified latent growth model, for depression was chosen 
here because the interpretation of non-linear change with only three time points is difficult, 
particularly when regressing upon an independent variable. Initially each independent 
predictor was entered separately into a latent growth model in order to retain power. 
Table 8.6 displays a summary of the slope and intercepts which were regressed upon the 
independent variable. Several independents variables predicted the intercept (i.e. the 
baseline BDI score) which have been described in detail in the SEM reported above.  
With regards to potential factors that predict the change (slope) in depression neither age, 
kps, co-morbidity or path to dialysis were associated with the trajectory of depression over 
time (table 8.6). In addition the effect of baseline Haemoglobin, Albumin and treatment 
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modality on the change in depression scores was tested in subsequent models, and 
revealed non-significant findings.  
Several of the baseline IPQ-R perceptions predicted the trajectory of depression, namely 
time-line perceptions, illness coherence, external causes and emotion (table 8.6). A one 
point increase in timeline perception at baseline was associated with a 0.63 unit increase in 
BDI scores over time. A one point increase in illness coherence at baseline is expected to 
predict a 0.33 increase in BDI score over-time. External causes also predicted the trajectory 
of depression, with a one point baseline increase being associated with a -0.602 unit 
decrease in BDI scores over time. As expected, emotion representations predicted the 
change in depression over time, with a one point increase at baseline being associated with 
a -0.38 decrease in BDI scores. These four illness perceptions were entered into a 
multivariate latent growth model where the depression intercept and slope was regressed 
upon them. This model is shown in figure 8.7 and had good fit to that according to the fit 
indices (CFI=0.978, TLI=0.935, RMSEA=0.091). After controlling for coherence and external 
cause perceptions, both timeline and emotion predicted the trajectory of depression in this 
multivariate model (figure 8.7). A one point increase in timeline perception at baseline was 
associated with a 0.56 unit increase in BDI scores over time. Emotion representations 
predicted the change in depression over time, with a one point increase at baseline being 
associated with a -0.27 decrease in BDI scores. 
Adding other variables to the model described in figure 8.7 including, age, path to dialysis, 
KPS did not improve the model fit significantly, nor did any of the variables predict the 
trajectory of depression.  
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Table 8.6: Predictors of the intercept and slope in a linear latent growth model of depression. 
 LINEAR GROWTH MODEL FOR DEPRESSION 
 Estimate on intercept
a 
Estimate on slope
a 
FIT 
Variable Coeff. (SE) Coeff. (SE) CFI RMSEA 
Age -0.111** 0.027 0.972 0.133 
Gender 2.55 -0.73 0.976 0.122 
KPS -0.237** 0.056 0.968 0.148 
Path 4.75** -1.196 0.978 0.118 
Comorbidity 0.747 0.034 0.960 0.156 
Identity 1.03** -0.018 0.963 0.160 
Timeline -0.176 0.626** 0.979 0.115 
Consequences 0.837** -0.03 0.976 0.131 
Personal Control -0.149 -0.104 0.965 0.147 
Treatment control -0.270 -0.277 0.973 0.130 
Cyclical timeline 0.680** -0.320 0.971 0.136 
Coherence -0.570** 0.322* 0.972 0.137 
Emotion 1.047** -0.388** 0.977 0.144 
Psychology Causes 0.313* -0.191 0.976 0.121 
External Causes 0.805** -0.602* 0.976 0.122 
a
Unstandarised p<0.05**p<0.01 
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Figure 8.7: Illness perceptions predicting the intercept and slope of depression over a year follow-
up (note correlations between the observed independent variables and errors for the dependent 
variables are emitted from the figure).  
8.5 Discussion  
The study presented here is the first to examine the trajectory of depression over the first 
year of dialysis in relation to illness perceptions. Corroborating with data from the 
preceding chapter, the present analysis supports the thesis that illness perceptions and 
depression are related. Moreover the data here has shown that illness perceptions predict 
the trajectory in depression over time. The discussion will focus on three key aspects of the 
findings, 1) the baseline associations between path to dialysis, illness perception and 
depression, 2) the change in depression and illness perceptions over time, and 3) illness 
perceptions predicting the trajectory of depression over time. 
The data provides support for the first hypothesis tested here, that unplanned patients 
hold different illness perceptions at baseline as compared to planned patients. Indeed the 
findings here are novel and demonstrate that unplanned patients had lower time-line 
perceptions, greater perceptions of disease variability (cyclical-timeline), adverse 
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consequences and emotional response, and lower illness coherence as compared with 
patients who had planned starts. With regards to the causal items, unplanned starters had 
stronger perceptions of external and psychological causes compared to planned patients. 
Furthermore a similar pattern of differences with regards to illness perceptions were 
observed between the depressed and non-depressed patients at baseline supporting the 
differences observed in the cross-sectional study of chapter 7. In addition, univariate 
analysis revealed that unplanned patients scored significantly higher on the BDI, as 
compared to planned patients thus supporting the data of Miura et al (1999).  
In SEM path to dialysis predicted several illness perceptions. Furthermore illness 
perceptions predicted depression symptoms. In line with the cross-sectional data 
presented in chapter 7 greater cyclical perceptions and perceived consequences and lower 
illness coherence predicted depression scores. Again the finding that illness perceptions are 
associated with depression symptoms supports previously published data reviewed in 
chapter 3 (Jopson & Moss-Morris, 2003; Juergens et al., 2010; Murphy et al., 1999). This is 
of interest as in chapter 7 depression was treated as a categorical dependent variable, 
whereas in the current analysis depression was treated as a continuous dependent 
variable, yet similar findings were uncovered using both approaches. Moreover as found in 
chapter 7, clinical variables including co-morbidity did little to explain the variation in 
depression scores, rather it was the interpretation of the condition that contributed to its 
explanation (e.g. Sacks et al., 1990).  
Interestingly there was no direct association between path to dialysis and depression after 
controlling for illness perceptions, yet there was evidence of an indirect effect (i.e. 
mediation) between path to dialysis and depression through perceptions. This data 
suggests that starting dialysis in an unplanned manner led to a different interpretation of 
the illness threat, which in turn increased the vulnerability for depression. It is important to 
note however, that this association is derived from the baseline data (hence cross-sectional 
associations) thus caution is merited in its interpretation as it is possible that path to 
dialysis increased depression symptoms which in turn impacted upon illness perception via 
negative depressive schema.  
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Consistent with findings from elsewhere in literature concerning depression in physical 
illnesses, in the present study, age and physical performance were negatively associated 
with depression scores (Drayer et al., 2006; Egede, 2007; Lopes et al., 2002). Younger age 
and worse physical performance were predictive of depression in the SEM after controlling 
for co-morbidity and illness perceptions. Treatment modality was unrelated to depression 
in the analysis reported here, although there is mixed evidence regarding differences 
between dialysis modalities and depression (Brown et al., 2010; Martin, Tweed, & Metcalfe, 
2004; Zimmermann, Poli de Figueiredo, & Fonseca, 2001). These findings may relate to lack 
of power as differences between dialysis modalities were not the focus of this study.  
With regards to examining changes over time, there are few data in ESRD describing the 
course of depression. Furthermore, there are relatively few studies that have examined the 
dynamics of illness perceptions among chronic physical conditions (Fischer et al., 2010). 
Using LGMs, the data here suggests that depression was relatively stable over time, thus 
there was no reliable evidence for the hypothesis that depression declines over the first 
year of treatment. A caveat is that with only three time points the function of change is 
hard to define. There was some suggestion in the unspecified LGM that depression scores 
were in fact decreasing over time suggesting a potentially non-linear decline. Further 
examining individual trajectories (e.g. figure 8.5) suggest that some patients may be stable, 
whilst some improve and others worsen over time. Unfortunately the sample size inhibited 
the undertaking of latent class growth analysis which is an appropriate technique to 
examine clusters of trajectories over time, and their predictors. While there appeared to be 
a significant amount of variation in the BDI scores at the baseline data, the variance in the 
change over time was non-significant, which again suggests relative stability in the inter-
individual change over time (i.e. variability of the slope). To note, the variance of the slope 
was large suggesting that some variability was occurring between patients yet it is possible 
that the limited follow-up period and sample size influenced the significance test here.  
Others suggest that depression may be stable in dialysis patients (Cukor et al., 2008), while 
data in incident patients suggest that there may be improvements in mental health 
functioning during the first year of dialysis therapy (Korevaar et al., 2002). Moreover 
studies that have compared CKD and ESRD patients suggest that the level of depression is 
comparable between populations (Abdel-Kader, Unruh, & Weisbord, 2009; Hedayati et al., 
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2009). Although anecdotal this may suggest that depression is prevalent in CKD and 
remains so through to dialysis (ESRD).  
With regards to the trajectories of illness perceptions over time, past data among chronic 
illness groups suggest that timeline and coherence perceptions increase over time, while 
control perceptions and emotional reaction decrease (Bijsterbosch et al., 2009; Lawson et 
al., 2008; Sheldrick et al., 2006). Covic et al (2006) report that over a two year follow-up of 
dialysis patients, emotional reactions decreased while coherence and treatment control 
perceptions improved. The data here revealed a similar trajectory for illness coherence, 
that is over the one year follow-up, patients’ understanding significantly increased. In 
addition, illness identity decreased significantly suggesting that individuals tended to 
identify their ESRD with fewer somatic symptoms over time. Contrary to previous published 
data there was no evidence here of increasing timeline perceptions over time, nor 
decreasing control perceptions and emotional reactions. It is possible that timeline and 
control perception did not change because the study focused on incident dialysis patients, 
whereas Covic et al assessed established patients over a longer period.  
Establishing the predictors of change in depression was sought by regressing the slope of 
LGMs upon independent variables. Firstly no baseline demographic or clinical variables 
including path to dialysis predicted the change in depression over time. This is particularly 
interesting as it suggests albeit tentatively that the differences between planned and 
unplanned patients depression scores at baseline is maintained over the first year of 
therapy. Of course more advanced modeling is required in order to test this assumption, 
however the sample size and follow-up period presented here prohibited such analysis. 
Nevertheless the data from the LGMs revealed that path to dialysis does not predict change 
over time.  
 
The final hypothesis stated in this chapter was that illness perceptions would predict the 
trajectory of depression over time. In growth models where each illness perception was 
entered separately, several baseline perceptions predicted the change in depression over 
time. Examination of the predictors in multivariate model revealed that baseline timeline 
perceptions and emotion reactions predicted the change in depression overtime. Higher 
chronicity perceptions at baseline predicted an increase in depression, while a greater 
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emotional reaction at baseline predicted a decline in depression. With regards to timeline 
perceptions, Dickens et al (2008) demonstrated that such perceptions predicted later 
depression in MI patients. Greater baseline emotion predicting a decrease in depression 
over time may suggest that patients are self-regulating their initial distress at baseline and 
focusing efforts to improve mood. This may explain why emotion correlates negatively with 
BDI change over time. Increasing control perceptions did not feature as predictors of 
depression change. Others report that control perceptions predict later levels of 
depression, which conforms to psychological theories with regard to hopelessness as 
antecedents for depression (Abramson, Alloy, & Metalsky, 1989). The stability of control 
perceptions over time may be the result of unpowered LGMs, or because during a relatively 
short term follow-up such perception are unlikely to vary, particularly as most patients 
were receiving in-hospital HD. What was of interest is that the variability in personal 
control scores did vary over time, suggesting that there was more divergence as time went 
by, which may be detrimental to psychological outcomes at points later on in the dialysis 
career.  
 
Taken together this data shows that depression and illness perception share a strong cross-
sectional association and that unplanned dialysis initiation is associated with maladaptive 
illness perceptions which may predispose an individual to depression. Furthermore the 
majority of illness perceptions appear somewhat stable during the first year of therapy 
presumably as little ongoing education and support is given to patients, although the 
variances of the change were large suggesting some between patient variance in 
trajectories. Path to dialysis failed to predict a change in depression, and although not 
reported in the results, failed to predict change in any of the illness perceptions variables. 
Rather, the data here suggests that initial illness perceptions can predict the trajectory of 
depression over this period, although the amount of change overtime at a group level is 
small, and individual trajectories do vary. Preliminary evidence here suggests that patients 
may well be self-regulating mood over a year or so of therapy, yet there clearly is a 
requirement to target maladaptive illness perceptions via psychological intervention soon 
after patients start dialysis. In this regard tacking the maladaptive perceptions of unplanned 
dialysis starters seems particularly vital.   
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While the data here has provided evidence in support of the thesis, it is worthy to consider 
the study limitations. It is clear that in order to further define the trajectory of depression 
larger studies with longer follow-up are required. Extending the study would also allow dual 
growths to be examined, where the change (slope) of a perception could be specified to 
predict the change (slope) of depression. This would further add to the data here and allow 
extended hypothesis to be evaluated. Furthermore, it is clear than depression is a 
multifaceted psychopathology and that several factors not considered here may help 
further explain variation in the depression among individual with ESRD, including social 
support, deprivation and marital satisfaction. A further limitation relates to the absence of 
time since diagnosis data. While data on depressive history was collected from the medical 
notes, it is probable that this method is somewhat crude as unplanned patients may not 
have such a detailed history document at the beginning of dialysis. Given this significant 
limitation data on depression history was not included in the modelling yet it is 
acknowledge that a history of depression is a known predictor of depression in renal 
patients (Cukor et al., 2008).  
8.5 General comments 
As evident in the last two chapters illness perceptions share a close relationship with 
depression. Coherence, cyclical timeline and perceived consequences appear to be 
particularly important perceptions in this regard. Moreover the data here shows that 
timeline perceptions and emotional reactions predict the trajectory of depression over the 
first year of treatment, although by-and-large both depression and illness perceptions 
appear relatively stable over this period.  
 
The following chapter develops the argument that illness representations posited by the 
CSM have utility beyond the explanation of depression in ESRD. Specifically chapter 9 
investigates whether there is an association between illness perceptions and fluid non-
adherence in a sample of haemodialysis patients. Non-adherent behaviour is of particular 
interest as it is associated with adverse clinical outcomes in dialysis patients, thus 
attempting to understand apparent self-regulatory failure is important.  
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Chapter 9 
An Illness Representation approach to the understanding of Fluid 
Non-adherence 12  
9. 1 Introduction 
The preceding empirical chapters inform the cardinal features of this thesis, describing the 
associations between depression and illness representations. The aims of this section are to 
extend the scope of the work presented thus far with respect to its clinical application.  In 
the chapters to follow two clinical areas are addressed; 1) the utility of the Common Sense 
Model of illness representations for explaining specific ESRD health behaviour, and 2) the 
impact of depression and illness perceptions upon survival among incident dialysis patients.  
First the CSM and adherence is considered in the present chapter. As delineated in chapter 
3, the utility of exploring illness representations in relation to health-related outcomes, 
including health behaviour, functional outcome and psychological adaption, has received 
support from several sources. Unlike other models of health behaviour (e.g. health belief 
model) the CSM posits a dynamic process in which health related decisions (or coping 
procedures) are taken in response to a health threat. Further, in the context of adherence, 
a treatment or behavioural requirement (e.g. fluid restriction) is viewed as a potential facet 
of coping, whereby its uptake is dependent upon the interpretation of the current illness 
threat. More recently Robert Horne has developed the necessity-concerns framework, 
which addresses the cognitions surrounding medication adherence (Horne, 1997; Horne & 
Weinman, 1999). While the necessity-concerns framework is a useful extension to the CSM, 
it has not been operationalised to other protective health behaviours (e.g. fluid restriction).  
For a given health behaviour the CSM stresses the importance of coherence between the 
illness representation and coping procedure. Accordingly, the process of self-regulation is 
operationalised through “IF-THEN” rules (Leventhal et al., 1998, see chapter 3). 
                                                          
12
To note, a paper based on this chapter has been published in Chilcot, J., Wellsted, D., Farrington, K (2010). 
Illness perceptions are associated with fluid non-adherence among haemodialysis patients. Journal of 
Psychosomatic Research, 68 (2), 203-212. 
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9.1.1 Adherence on dialysis 
Dialysis is a time consuming and stressful activity. The complications of ESRD require 
numerous additional treatments including multiple drugs to facilitate management of 
blood pressure, anaemia, abnormalities of mineral metabolism, and other problems related 
to extra-renal co-morbidities. A potential stressor is the need to restrict dietary intake of 
phosphates and potassium rich foods, and reduce salt and fluid intake. Adherence to ESRD 
can therefore be categorised into the following facets; 1) medication, 2) dietary and fluid, 
and 3) dialysis prescription (Lamping & Campbell, 1990). Indeed, the adaption and 
maintenance to these requirements are crucial in the disease management. 
Fluid non-adherence is one particular concern that is regularly observed in clinical practice. 
It is associated with adverse clinical outcomes including left ventricular hypertrophy, 
cardiac failure and premature death (Leggat et al., 1998). Fluid intake is driven by thirst 
which is strongly related to the body's sodium balance. Estimates of fluid non-adherence 
are varied and largely dependent upon methodology and definition. Typically, fluid intake is 
evaluated by inter-dialytic weight gain (IDWG). IDWG refers to the amount of fluid gained 
between two dialysis treatment sessions, and is estimated by subtracting the post-dialysis 
weight from the pre-dialysis weight of the following treatment session. Although IDWG 
serves as a suitable physiological proxy of fluid adherence (Manley & Sweeney, 1986), the 
heterogeneity of definitions used has had a major impact upon reported estimates of non-
adherence. Critically IDWG alone is insufficient to define non-adherence, as it is influenced 
by residual renal function (the amount of intrinsic renal function the patient has remaining) 
(Manley & Sweeney, 1986), and dry weight (the patients “ideal weight” when free of excess 
fluid) (Chazot et al., 1999; Sensky, Leger, & Gilmour, 1996). The failure to consider these 
parameters when assessing fluid non-adherence based upon IDWG may lead to inaccurate 
prevalence rates and misidentified antecedent factors. The present empirical work 
addressed both of these issues. 
9.1.2 Predictors of non-adherence in ESRD 
Several factors have been associated with non-adherence among dialysis patients including 
age, gender, and psychological factors such as health beliefs (Cummings, Becker, Kirscht, & 
Levin, 1982; Kutner, Zhang, McClellan, & Cole, 2002), social support (Kara, Caglar, & Kilic, 
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2007; O'Brien, 1990), personality factors (Christensen & Smith, 1995), locus of control and 
self-efficacy (Brady, Tucker, Alfino, Tarrant, & Finlayson, 1997; Kutner et al., 2002; Sensky et 
al., 1996), and depression (Cukor et al., 2009). Evidence tends to support the increased 
predictive utility of cognitive factors over emotional states (Schneider, Friend, Whitaker, & 
Wadhwa, 1991). However it is likely that these factors have complex interactions and vary 
with different behavioural demands (Sensky et al., 1996). The application of social-cognitive 
models of health behaviour in ESRD patients has received surprisingly little attention, yet 
promises utility given empirical work in other health domains. Currently only one study has 
demonstrated the predictive utility of the CSM model in explaining self-care behaviour in 
HD patients, although when applied specifically to fluid intake behaviour, illness 
representations (both cognitive and emotional) failed to explain the variation in IDWG 
(O'Connor et al., 2008).  
9.1.3 The present Study 
This study investigated whether there were significant differences between fluid-adherent 
and non-adherent patient’s illness representations, as measured by the IPQ-R. In addition, 
whether illness representations predicted fluid non-adherence was tested. The definition of 
fluid non-adherence involved computing IDWG as a percentage of patient’s dry weight, 
thus reducing potential confound. Although investigating the variation of IDWG in relation 
to hypothesised predictive factors is of value, it was felt that exploring the psychology of a 
clinically relevant patient group, who would be at greater risk of developing fluid-related 
complications, would be more clinically useful. In order to achieve this goal, patients in the 
upper-quartile of the percentage weight gain distribution were defined as non-adherence 
and subsequently compared to the remaining patient sample.  
Given these methodological considerations, it was hypothesized that, 1) in univariate 
analysis, there would be significant differences between illness perceptions of adherent 
versus non-adherent patients, and 2) illness perceptions would be associated with fluid 
adherence after controlling for clinical and demographic factors including residual renal 
function, thus supporting the utility of the CSM in this context. 
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9.2 Methods 
9.2.1 Patients 
A sample of adult HD patients from the renal service of the East and North Hertfordshire 
NHS Trust were approached for inclusion, provided they satisfied the  criteria described in 
chapter 4 (general methods). All patients were required to be receiving HD 3 times per 
week. 
9.2.2 Materials 
Demographic questionnaire: Age, gender, ethnicity, marital-status, and work-status were 
collected by means of a questionnaire (see general methods chapter 4).  
The Revised Illness Perception Questionnaire (IPQ-R): As described in chapter 4. To note, 
The sample size prevented factor analysis on the 18 original IPQ-R causal items. The mean 
scores on each individual causal item were compared between the adherence groups. 
Depression Symptoms: Depression symptoms were assessed via the Beck Depression 
Inventory (BDI-II) as described in Chapter 4. 
Functional Status and Comorbidity: Karnofsky Performance Score was employed to assess 
functional status. Comorbidity was assessed using a semi-quantitative technique, scored by 
consultant nephrologist who assigned a severity score for each patient (1= no co-morbidity, 
2= mild moderate co-morbidity, 3= severe co-morbidity, as described in (Chandna et al., 
1999, see chapter 4).   
Clinical parameters: Standard haematological and biochemical parameters are collected as 
a part of the routine care of patients within the service. These include blood levels of 
haemoglobin, albumin, and urea. Dialysis adequacy (Kt/V), dry weight (kg), and residual 
renal function (measured by urea clearance (KRU, ml/min)) were also assessed. KRU is 
measured routinely in this dialysis centre, and included in urea kinetic modelling, as 
recommended in the national kidney foundation guidelines for HD adequacy (KDOQI, 
2006). KRU was derived from a 48 hour interdialytic urine collection, and mean interdialytic 
urea concentration13 (McKane, Chandna, Tattersall, Greenwood, & Farrington, 2002). Dry 
                                                          
13
 the mean of the pre- and post-dialytic serum urea concentrations 
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weight (or “ideal weight”) is the principle target for fluid removal in dialysis, and refers to 
the normal fluid weight of the patient (euvolemic), without oedema or excess interstitial 
fluid. IDWG was computed by subtracting the post-dialysis weight from the pre-dialysis 
weight of the following treatment session (kg). All clinical parameters were averaged over a 
three month period prior to the administration of the IPQ-R. This included the clinical 
parameters obtained during the month of the IPQ-R assessment. KRU was measured every 
month, IDWG every dialysis session (3 times per week), with all other clinical parameters 
collected at least monthly as part of routine practice. Clinical variables were averaged due 
to the potential error in single clinical parameter estimates. 
Measuring fluid intake and defining adherence: The definition of adherence was based 
upon IDWG and dry weight (Leggat et al., 1998). IDWG is insufficient to estimate 
adherence; a larger person is expected to gain more weight in the interdialytic period.  
However IDWG is a good indicator of fluid intake as long as KRU and dry weight are taken 
into account. IDWG was therefore computed as a percentage of the patient’s dry weight 
(i.e. percentage weight gain). In-order to define a group of patients that represent a clinical 
concern given inadequate fluid control, patients in the upper quartile of the % weight gain 
distribution (non-adherent) were compared to those in the lower three quartiles 
(adherent). The upper quartile (i.e. non-adherent patients) had IDWGs ≥3.21% of dry 
weight. In other words, over the interdialytic period the non-adherent patients were 
defined as those who had increased their body weight by at least 3.21% of their clinically 
ideal weight. The mean % weight increase in the non-adherent group was 4.0% (sd= 0.9), 
compared to 1.9% (sd=0.7) in the adherent group.  
9.2.3 Design and Procedure:  
A cross-sectional design was used in this investigation. Patients who satisfied the inclusion 
criteria were identified by a nephrologist. Patients completed the questionnaire measures 
(BDI and IPQ-R) during a stable haemodialysis session, during the second half hour of 
treatment (see chapter 5). KRU and IDWG data were verified by a consultant nephrologist.  
 
 
185 
 
9.3 Results 
One hundred and eighteen patients were approached in which one hundred patients 
provided consent (17 refused, 1 excluded after the administration of the MMSE). One 
patient was excluded as they had been receiving dialysis only twice a week during the past 
3 months. Data on 99 patients is presented, of which the demographic and clinical 
characteristics are shown in table 9.1. The mean IDWG was 1.77 kg (sd =0.85). Patients 
weight increased on average by 2.46% (sd =1.2) over the interdialytic period.   
Demographic and clinical characteristics between fluid adherent and non-adherent patients 
are presented in table 9.1. There was a significant association between gender and fluid 
adherence. Females had greater odds of non-adherence (unadjusted OR=0.34 95% CI 0.13 
and 0.87). Non-adherent patients were significantly younger, had higher Kt/V, greater 
serum urea, lower KRU and more years on dialysis (dialysis vintage) as compared with the 
adherent patients (table 9.1). There was no significant association between ESRD diagnosis 
and adherence (Fisher’s exact test, p=0.10).  
9.3.1 Illness Representations  
Mean scores for each of the IPQ-R dimensions for adherent and non-adherent patients are 
displayed in table 9.2. On average, patients held strong perceptions of the chronicity and 
negative consequences of ESRD and moderately strong perceptions of personal and 
treatment control. Univariate comparisons between adherent and non-adherent patients 
revealed that time-line perceptions were significantly lower in the non-adherent patients, 
suggesting that they held weaker perceptions of the chronicity of ESRD (t[30.6]=2.6, 
p=0.014). Consequences perceptions were higher in the adherent patients as compared to 
the non-adherent (figure 9.1). Although this different was not significant, a medium 
univariate effect size was evident (d=0.37).  
A MANOVA was also evaluated comparing the illness perceptions between adherent and 
non-adherent groups (see table 9.2). MANOVA with all the IPQ-R dimensions as dependent 
variables revealed a marginal non-significant overall effect (F*8,90+=1.9, p=0.057 η2=0.115). 
As with the univariate analysis time-line was the only perception to differ between the 
groups in the MANOVA (F*1, 97+=10.5, p=0.002 η2=0.098).  
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The most frequently endorsed IPQ-R causal item was chance/bad luck attributes (44.4%), 
followed by hereditary beliefs (30.3%) and poor past medical care (20.2%). Examination of 
the individual IPQ-R causal item means, revealed no significant differences between the 
adherence groups.  
9.3.2 Clinical and demographic correlates: Age, urea, KRU and dialysis vintage all 
correlated significantly with % weight gain (table 9.3). As expected, % weight gain 
correlated significantly with Kt/V and treatment time.  
9.3.3 Psychological Correlates: % weight gain correlated significantly with illness 
identity, time-line and cyclical time-line perceptions (table 9.4). Personal control and 
treatment control perceptions failed to correlate with % weight gain. Illness identity 
correlated with the BDI, perceived consequences, cyclical perceptions and emotion. Time-
line correlated with the BDI, consequences, personal control, treatment control and 
emotion scales. Cyclical perceptions correlated with perceived consequences. The only 
individual causal items to correlate significantly with % weight gain were germ/virus 
attributes, and emotional attributes. 
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Table 9.1: Demographic and clinical data: comparing fluid adherent and non-adherent patients. 
  Total  
(n=99) 
Adherent  
(n=25) 
Non-adherent  
(n=74) 
Statistic 
Female % (n) 33.3 (33) 27 (7) 52 (38) 0.028a 
Male  % (n) 66.7 (66) 73 (18) 48 (36)  
Age (Mean SD) 58.6 (15.6) 61.1 (14.7) 51.3 (16.1) t(97)=2.78, p=0.006 
Ethnicity (%)     
 White 88.9 (88) 90.5 (23) 84 (62) 0.462a 
 Non-White 11.1 (11) 9.5 (2) 16 (12)  
Marital status (%)     
 Married/living with partner 67.7 (67) 70.3 (18) 60 (44) X2 (2,99)=1.12, p=0.571 
 Divorced/separated/single 24.2 (24) 23 (6) 28 (21)  
 Widowed 8.1 (8) 6.8 (1) 12 (9)  
KPS  (Median and IQR) 80 (20) 80 (20) 80 (20) U=911, p=0.907 
Clinical Data     
Diabetic (%) 15.2 (15) 13.5 (3) 20 (15) 0.520a 
Smoker (%) 11.1 (11) 9.5 (2) 20 (15) 0.139a 
Co-morbidity (%)     
 Nil 38.4 (38) 32.4 (8) 56 (41) X2 (2,99)=4.5, p=0.104 
 Moderate 41.4 (41) 44.6 (11) 32 (24)  
 Severe 20.2 (20) 23 (6) 12 (9)  
Mean (SD)     
 Treatment time (Td minutes) 191.8 (45.5) 188.8 (48.6) 200.9 (33.7) t(97)=1.15, p=0.252 
 Kt/V 1.3 (0.2) 1.2 (0.2) 1.3 (0.2) t(97)=3.1, p=0.003 
 Haemoglobin (g/dL) 11.7 (1.4) 11.7 (1.2) 11.6 (1.9) t(97)=0.42, p=0.672 
 Albumin (g/dL) 37.9 (3.8) 38 (4.0) 37.8 (3.2) t(97)=0.23, p=0.814 
 Urea (mmol/L) 22.6 (5.5) 21.9 (4.9) 24.7 (6.6) t(97)=2.3, p=0.02 
 Dry Weight (Kg) 73.2 (17.9) 74.8 (18) 68.4 (17.2) t(97)=1.56, p=0.12 
Median (IQR)     
 KRU (ml/min/1.73m2 BSA) 0.4 (1.6) 1.0 (2.0) 0.1 (0.3) U=502, p=0.001 
 Dialysis Vintage (years) 2.6 (4.2) 2.1 (3.2) 3.9 (4.4) U=596, p=0.001 
*p<0.05  **p<0.01. IQR: inter-quartile range, SD: standard deviation, aFisher’s Exact Test, t: 
Student’s t-test, U: Mann-Whitney U, X2: Pearson Chi-square, MMSE: Mini Mental State 
Examination, KPS: Karnofsky Performance Score, IDWG: Interdialytic weight gain, KRU: Residual 
Renal Function. 
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Table 9.2: Mean illness perception scores, comparing the adherent and non-adherent patients using MANOVA. 
 
   Sample Adherent Non-adherent    
 α Possible Range Mean SD Mean SD Mean SD F η2 Univariate effect size (d) 
Identity 0.84 0-14 5.3 3.1 5.1 3.1 5.9 3.1 1.3 0.014 0.26 
Time-line 0.84 6-30 25.9 4.4 26.7 3.6 23.5 5.7 10.5** 0.098 0.66 
Cyclical time-line 0.83 4-20 9.7 3.4 9.6 3.2 10.0 3.9 2.6 0.026 0.10 
Consequence 0.69 6-30 21.8 4.2 22.2 4.0 20.6 4.6 1.4 0.014 0.37 
Treatment Control 0.44 5-25 14.9 3.1 14.8 3.0 15.2 3.6 0.3 0.003 0.20 
Personal Control 0.73 6-30 18.5 4.4 18.2 4.3 19.4 4.5 0.8 0.008 0.27 
Illness Coherence 0.87 5-25 19.0 4.2 18.8 4.4 19.7 3.8 0.2 0.002 0.21 
Emotion 0.86 6-30 16.5 5.4 16.4 5.0 16.6 6.5 0.02 0.000 0.03 
α: Cronbach’s Alpha. F= MANOVA F statistic. η
2
=Partial effect size. **p<0.01
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Figure 9.1: Means and 95% confidence intervals for the IPQ-R time-line and consequence scores, 
comparing adherent and non-adherent patients.  
Table 9.3: Demographic and clinical correlates of % weigh gain. 
 Correlation 1 2 3 4 5 6 7 8 9 
1 % weight gain 1.00         
2 Age -.339 1.00        
 p .000         
3 Kt/V .336 -.350 1.000       
 p .000 .000        
4 Urea .372 -.151 .026 1.00      
 p .000 .068 .400       
5 Albumin .069 -.108 .081 .339 1.00     
 p .247 .145 .213 .000      
6 Hb -.094 .045 .134 .141 .203 1.00    
 p .178 .329 .092 .083 .022     
7 Treatment time .317 -.128 -.202 .112 .097 -.153 1.00   
 p .001 .103 .022 .134 .169 .066    
8 KRU
a 
-.547 .049 -.030 -.073 .139 .075 -.557 1.00  
 p .000 .315 .384 .237 .084 .232 .000   
9 Dialysis Vintage
a 
.410 .000 .173 -.077 .044 .085 .158 -.438 1.00 
 p .000 .498 .044 .224 .334 .200 .059 .000  
10 KPS
a 
.054 -.333 .023 .357 .258 .212 -.014 .091 -.018 
 p .299 .000 .411 .000 .005 .017 .444 .186 .428 
a 
Spearman’s Rho. Bold indicates significance (p<0.05).  
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Table 9.4: Psychological correlates with % weight gain. 
 Pearson’s r 1 2 3 4 5 6 7 8 9 10 11 
1 % weight gain 1.00           
2 BDI .111 1.00          
 P .138           
3 Identity .262 .380 1.00         
 p .004 .000          
4 Timeline -.197 .243 .108 1.00        
 p .025 .008 .143         
5 Consequences .003 .325 .453 .450 1.00       
 p .489 .001 .000 .000        
6 Personal Control .039 -.128 .024 -.190 -.117 1.00      
 p .349 .104 .405 .030 .125       
7 Treatment Control -.019 -.300 -.038 -.279 -.061 .356 1.00     
 p .425 .001 .355 .003 .276 .000      
8 Coherence .101 -.172 -.011 .080 -.081 .040 -.046 1.00    
 p .160 .044 .456 .216 .214 .348 .327     
9 Cyclical .167 .158 .316 .088 .321 .160 .091 -.119 1.00   
 p .049 .060 .001 .193 .001 .056 .185 .120    
10 Emotion .099 .679 .521 .222 .416 -.109 -.218 -.052 .253 1.00  
 p .164 .000 .000 .014 .000 .140 .015 .305 .006   
11 Causes Germ .229 .136 .175 -.036 .002 .011 .156 -.134 .219 .198 1.00 
 p .022 .179 .083 .723 .981 .914 .122 .185 .029 .049  
12 Causes Emotion .233 .240 .010 -.111 .024 .010 .009 .026 .285 .244 .167 
 p .020 .017 .923 .272 .813 .920 .931 .801 .004 .015 .098 
Bold indicates significance (p<0.05). 
 
9.3.4 Logistic Regression:  
In order to test the hypothesis that illness representations would predict a clinically 
relevant group of non-adherent patients, logistic regression was undertaken. Age, gender, 
KRU, dialysis vintage and urea were all entered into an initial model as control variables. 
Given that the distribution of KRU was skewed, and in-keeping with previous studies from 
the renal service at Lister Hospital, we defined patients as having some (≥1 ml/min), or 
minimal (<1 ml/min) KRU (Vilar, Wellsted, Chandna, Greenwood, & Farrington, 2009). Kt/V 
was not entered in the models as it was deemed not to be a predictor of fluid-non-
adherence, rather a consequence of increased weight gain (i.e. longer dialysis sessions, td). 
This first model was significant as compared to a constant only model (Chi-square=29.8 
df=5, p=0.0001, Nagelkerke R2 =0.385, table 9.5). Gender, urea and KRU were all 
significantly associated with non-adherence. In a second model, BDI scores, illness identity, 
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time-line, consequence, personal control, cyclical perceptions and two causal items (germ 
and emotions) were entered. Treatment control was excluded due to inadequate internal 
reliability (α=0.44), as was the IPQ-R emotion dimension as it correlated highly with the 
BDI. This second model was significant, and improved the model fit (∆Chi-square=20.4 df=8, 
p=0.009, Nagelkerke R2 =0.59). This model demonstrated that after controlling for several 
clinical factors including KRU, perceived consequences significantly predicted non-
adherence (table 9.5). Holding all variables constant, a 1 point increase in consequence 
perception scores, reduced the odds of non-adherence by approximately 25%. Gender was 
also a significant predictor of non-adherence, with females being 12 times more likely to be 
non-adherent, albeit with wide confidence limits.  
Table 9.5: Logistic Regression models predicting fluid non-adherence.  
 Step 1 (Model 1)   Step 2 (Model 2)  
   95% CI OR     95% CI OR  
 Wald OR Lower Upper Sig  Wald OR Lower Upper Sig 
Age 
2.68 .97 .93 1.00 .10  2.20 .966 .922 1.01 .138 
Female 5.22 3.95 1.21 12.88 .02  8.13 12.65 2.21 72.36 .004 
KRU<1  6.82 6.34 1.58 25.33 .009  5.89 9.59 1.54 59.49 .015 
Vintage 
2.11 1.06 .97 1.16 .14  6.08 1.19 1.03 1.37 .014 
Urea 
4.43 1.12 1.00 1.26 .035  5.75 1.19 1.03 1.38 .016 
BDI       .92 1.04 .953 1.15 .338 
Identity 
      .84 .881 .672 1.15 .359 
Time-line 
      1.66 .888 .742 1.06 .197 
Consequences       4.41 .786 .628 .984 .036 
Personal Control 
      1.15 1.09 .927 1.29 .283 
Cyclical 
      .065 .969 .759 1.23 .799 
Causal Germs       .072 1.09 .580 2.05 .788 
Causal Emotion 
      .859 1.55 .611 3.96 .354 
Step  1. Model Chi-square=29.8 df=5, p=0.0001. Nagelkerke R
2
 =0.385. Overall predicted correct 83.8% 
Step 2. Model Chi-square=50.3 df=13, p=0.0001. ∆Chi-square=20.4 df=8, p=0.009 Nagelkerke R
2
 =0.59. Overall predicted 
correct 86.9%. OR= Odds Ratio. DV= Adherence (yes/no). 
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9.4 Discussion  
The aim of this chapter was to establish the potential utility of the CSM in explaining fluid 
non-adherence. Put another way, do fluid non-adherent patients hold different illness 
representations as compared to fluid adherent patients? Given the potential issues 
described previously, efforts were taken to define a clinically relevant group of non-
adherent patients who would be at risk of fluid related complications. This included the 
consideration of dry weight and residual renal function. The results revealed that non-
adherent patients reported significantly lower time-line perceptions as compared to the 
adherent, suggesting that these patients held weaker perceptions of illness chronicity. Past 
reports have also identified the importance of time-line perceptions upon self-care 
behaviour (Bucks et al., 2009; Meyer et al., 1985). The importance of consequence 
perceptions upon patient fluid adherence was identified in multivariate analysis. Lower 
consequence perceptions increased the odds of non-adherence in this patient group. This 
finding supports past studies which have shown that consequence perceptions are related 
to health related outcomes (Hagger & Orbell, 2003; Horne & Weinman, 2002; Petrie et al., 
1996). For example, in a longitudinal assessment of rheumatoid arthritis patients, stronger 
consequence perceptions were associated with more outpatient clinic visits (Scharloo et al., 
1999).  
This evidence offered in this chapter supports the CSM in understanding health-related 
behaviour as applied to chronic illness states. However, as noted elsewhere (Stafford, Berk, 
& Jackson, 2009) consequence perceptions are similar to perceived severity perceptions 
outlined in the health belief model. Therefore the findings here may have also been 
replicated using alternative models of health behaviour. Critically however, the implication 
of measuring representations of disease and not attitudes regarding fluid restriction is 
important. To elucidate, the data described here may be explained in terms of self-
regulatory failure or misregulation (Carver & Scheier, 1981), which may have an impact 
upon fluid intake behaviour. According to the CSM, coping is embedded in “IF-THEN” rules 
(Leventhal et al., 1998). The “IF” is the interpretation of the illness; “THEN” refers to the 
procedures adopted in response to the defined threat. “IF” the ongoing disease threat is 
not perceived as serious (i.e. low perceived consequences) then the need to adopt strict 
health care behaviour (i.e. fluid control) may not be highly salient to the individual. The IF-
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THEN rules reflect a coherent self-regulatory system (Leventhal et al., 1998). Therefore it is 
speculated that non-adherent patients under-regulate this health behaviour based upon 
their definition and interpretation of their illness. However the role of coping in IF-THEN 
rules is unclear. While the CSM posits that coping produces should mediate the relationship 
between illness representations and health related outcomes, studies have failed to 
confirm this (Heijmans, 1999; Scharloo et al., 1998). Longitudinal studies examining illness 
representations and coping in ESRD patients seem highly relevant if we are to increase our 
understanding of the relationship between self-regulatory processes and outcome. 
This is only the second empirical investigation to explore the utility of illness 
representations in respect to non-adherence among ESRD patients. O’Connor et al (2008) 
demonstrated that time-line perceptions predicted dietary adherence among ESRD 
patients, but failed to find any association with fluid adherence. Theoretically perceptions 
of control (or self-efficacy) should be important determinants of outcome in ESRD patients 
(Christensen & Ehlers, 2002). Indeed a previous study has shown that self-efficacy was 
related to fluid adherence, as assessed by a self report questionnaire (Zrinyi et al., 2003). 
However in the present analysis there was no evidence that perceptions of control differed 
between the adherent and non-adherent groups. These null findings may reflect the lack of 
specificity in the IPQ-R questions with regards to particular treatment behaviours (i.e. fluid 
control). Indeed it is suggested that self-efficacy is a powerful predictor of behavioural 
change and goal attainment (Bandura, 1977). As suggested earlier, it is likely that questions 
about treatment control in the IPQ-R were interpreted as “dialysis treatment control,” as 
this is the most salient regime to the patient when on-dialysis (see Chapter 5). As in other 
social-cognitive models asking about specific behavioural self-efficacy may have value (e.g. 
Theory of Planned Behaviour). For example in the Theory of Planned Behaviour, self-
efficacy for a given behaviour has been shown to have a direct relationship with actual 
behaviour, and is independent of intention (Armitage & Conner, 2001).  
In keeping with the ideas posited in the CSM, Horne and colleague’s developed the 
necessity-concerns framework regarding beliefs about medicines, which has shown to be 
important determinants of medication adherence (Horne, 1997; Horne & Weinman, 1999). 
The scope of applying the necessity-concerns framework to specific health behaviours such 
as fluid control may also bear fruit. For example, asking patients about how necessary they 
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think fluid control is, and exploring perceptions regarding the consequences and concerns 
of restricting fluid intake may be a useful aid in understanding the psychology of specific 
health behaviours. The elaboration of such models may be of further value given that 
treatment regimes encountered in ESRD and other chronic conditions are complex and 
multifaceted, and are likely to involve different antecedent factors.  
The thesis of a recent review elegantly argued that self-regulatory efforts should integrate 
both affective and disease management elements (Detweiler-Bedell et al., 2008). To 
illustrate, although we suggest that lower consequence perceptions are associated with 
non-adherence, other empirical evidence suggests that consequence perceptions relate 
positively with psychological distress (Hagger & Orbell, 2003). Altering a particular cognition 
to improve health behaviour may have a negative impact upon psychological functioning, if 
the integration of affective and cognitive factors is not considered (Detweiler-Bedell et al., 
2008). For example, a recent investigation revealed that greater perceived consequence 
perceptions were associated with poorer well-being in HD patients (Timmers et al., 2008), 
and data presented in previous chapters in this thesis suggest that illness perceptions are 
associated with depression in this patient group.  
Of the demographic factors explored gender was a significant predictor of non-adherence. 
However the gender non-adherence association demonstrated in this study appears to 
oppose the direction found in past studies (Bame et al., 1993), as females were likely to be 
more non-adherent. We suspect that controlling for dry weight lead to these somewhat 
surprising findings; women tend to have a lower weight and a lower IDWG, and therefore 
would be underrepresented in non-adherence defined by IDWG compared to % weight gain 
(i.e. the amount of weight increased as a proportion of their ideal dry weight). Further, it 
appears that this finding was not confounded by KRU, as males and females have similar 
KRU. However, the confidence limits obtained were large, thus the effect of this finding 
should be taken with care.  
It is acknowledged that this investigation had some limitations, the most significant being 
the cross-sectional design, which prevents the identification of temporal relationships. Our 
assessment of illness perceptions were time limited, whereas the clinical parameters were 
averaged over a period of time, although it is unlikely that over this short period illness 
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perceptions would alter significantly. A further consideration concerns the patient’s 
knowledge of renal failure and subsequent treatment, which was not measured. This limits 
the distinctions we can make between intentional and non-intentional non-adherence 
(Horne, 1997). However it is interesting to note that the knowledge of kidney disease did 
not predict adherence in a previous study (O'Connor et al., 2008). However given the 
increasing age of dialysis patients with known cognitive impairments, forgetting and a lack 
of comprehension are likely to contribute to non-adherence. 
With regards to the IPQ-R, we used the original illness identity items and, due to our 
sample size could not use factor analysis on the causal items. Factor analysis is the 
preferred method of assessing the IPQ-R causal items, and promotes more meaningful 
results than exploring single items. Larger studies are needed to address these issues in 
order to confirm our findings. Further, our decision to define non-adherence, and compare 
groups, as opposed to assessing the variation in weight gain was pragmatic as we aimed to 
examine a clinically relevant group after considering dry weight. Additionally unlike past 
studies we did not exclude patients with urine volumes >500 ml/day. A number of patients 
still pass significant amounts urine, thus in order to improve the sample representativeness 
it was decided to control for residual renal function. 
Despite the study limitations our data suggests that illness representations are associated 
with fluid non-adherence and should be further investigated with the scope for suitable 
intervention. A premise to this investigation regards interventional research that has shown 
that the modification of illness perceptions by psychological intervention leads to 
improvements in health related outcomes (Hall, Weinman, & Marteau, 2004; Petrie et al., 
2002). Targeting maladaptive self-regulatory processes seem important if we are to 
improve adherence in ESRD patients (Christensen, Moran, Wiebe, Ehlers, & Lawton, 2002).  
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9.5 General remarks  
This chapter has explored the illness representations that relate to fluid non-adherence. To 
surmise, the CSM has predictive utility in this context. The potential to improve non-
adherence may be realised by targeting maladaptive illness cognitions. However, it is 
stressed that an integrative approach to disease management may be fundamental to such 
efforts as posited by Detweiler-Bedell et al (2008). The rationale is that a maladaptive 
cognition for treatment adherence may reflect an adaptive cognition for a positive 
psychological outcome (i.e. to repair mood see Detweiler-Bedell et al., 2008). 
The final chapter of this thesis extends the clinical application of the research conducted so 
far by examining the association between depression and illness perceptions with 
mortality. Specifically, data is presented that examines the short-term survival of the 
incident cohort (chapter 8) and evaluates whether psychological factors predict mortality.  
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Chapter 10 
Depression and illness perceptions as predictors of short-term 
survival in incident dialysis patients 
 
10.1 Introduction 
The final chapter in this clinical section addresses the relationship between depression, 
illness perception and mortality in incident ESRD patients. There is increasing evidence that 
depression is associated with adverse outcomes, including mortality among patients with 
physical disease. Particular attention has been devoted to the relationship between 
depression and cardiac disease and events (Steptoe, 2007). Indeed, it is well established 
that depression is associated with the development of cardiac diseases and events, 
recurrent events and death (Anda et al., 1993; Barefoot et al., 1996; Frasure-Smith, 
Lesperance, & Talajic, 1993; Lesperance, Frasure-Smith, Talajic, & Bourassa, 2002; Penninx 
et al., 1998; Rosengren et al., 2004). Furthermore depression is associated with mortality 
among other physical conditions including diabetes (Black & Markides, 1999) and stroke 
(Morris, Robinson, Andrzejewski, Samuels, & Price, 1993). 
In the UK the age adjusted survival rate for incident dialysis patients over the first year of 
therapy is 89% (Ansell et al., 2008). While several factors have been associated with short-
term survival in the UK incident dialysis population the effect of depression has not been 
assessed. 
As reviewed in chapter 2 (see table 2.2), there is good evidence that depression predicts 
mortality in dialysis patients, after considering an array of demographic and clinical 
covariates. However some studies have produced null findings, which may be attributable 
to the various assessments of depression used, the statistical methods employed, the 
populations studied (incident vs. established populations), sample size, and possibly reverse 
causality (Boulware et al., 2006). Both Kimmel et al (2000) and Boulware et al (2006) 
treated depression in a time-varying manner and found a positive association between 
depression and mortality, but failed to find an association between baseline depression and 
all-cause mortality. Furthermore, Boulware et al (2006) demonstrated that in adjusted 
time-varying models, depression was associated in a three-fold risk of CVD related death, 
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and a two-fold increase in all cause mortality. However the affect for both all-cause 
mortality and CVD death was attenuated after incorporating a six month time lag into the 
analysis, suggesting the potential role of reverse causality (i.e. medical morbidity causing 
depression, rather than depression leading to worsening morbidity). Large cross-sectional 
studies (e.g. data from DOPPS) report significant associations between base-line depression 
and mortality, albeit using relatively unconventional methods of depression assessment 
(Lopes et al., 2002). More recently others have used formal diagnostic approaches, and 
report a significant association between MDD and mortality, yet failed to replicate this 
association when using self-report questions to assess depressive symptoms (Hedayati et 
al., 2008). 
In a related area, authors have examined the relative association between Quality of Life 
(QoL, physical and mental functioning) and mortality in ESRD (DeOreo, 1997; Knight, 
Ofsthun, Teng, Lazarus, & Curhan, 2003; McClellan et al., 1991). A study of over 14,000 
ESRD patients revealed that both physical and mental functioning predicted survival over a 
year follow-up (Knight et al., 2003). Moreover, a decline in these QoL parameters was 
associated with increased mortality risk, after controlling for the baseline scores. A recent 
investigation examined the relationship between QoL, risk of ESRD, and mortality (Tsai et 
al., 2009) in patients with CKD. The combined end-point of either time to first dialysis or 
death was predicted by physical and psychological domains of the WHO-QoL questionnaire, 
after controlling for several co-variates (Tsai et al., 2009). Although CKD is a different 
population to ESRD, theses results suggest the poor QoL is a risk factor for adverse 
outcomes across the spectrum of chronic kidney disease.  
The mechanisms behind the depression-mortality association are likely to be complex (see 
chapter 2). The measurement or assessment of depression in ESRD is confused with 
somatic symptoms of illness, thus depression may be a marker of sub-threshold disease. 
Others have proposed that the association is explained by non-adherence to medical 
regimes (Carney, Freedland, Eisen, Rich, & Jaffe, 1995), and changes in hemostatic (Berk & 
Plein, 2000) and immune functioning (Kimmel et al., 1993; Lett et al., 2004), which are 
particularly implicated in the pathogenesis of Coronary Heart Disease and Cardiovascular 
Disease which remain significant co-morbidities in patients with ESRD (chapter 2). 
Furthermore maladaptive health behaviours associated with depression may also underlie 
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the association between depression and mortality including alcohol abuse and physical 
inactivity (Camacho, Roberts, Lazarus, Kaplan, & Cohen, 1991) and smoking (Lehto et al., 
2000).  
10.1.1: Illness perceptions and mortality 
The evidence presented earlier in this thesis supports the contention that illness 
perceptions predict depression in ESRD. Moreover among dialysis patients there is good 
empirical support for depression predicting mortality.  Therefore, it could be hypothesized 
that illness perceptions would predict mortality in ESRD, and that depression would 
potentially mediate the relationship. Indeed, preliminary evidence suggests that illness 
perceptions are associated with survival in dialysis patients (van Dijk et al., 2009). This study 
found that after controlling for demographic and clinical factors, weaker treatment control 
perceptions predicted mortality, although depression was not considered in the analysis 
(van Dijk et al., 2009). While the authors suggest that illness perceptions may impact 
survival by reducing the motivation for adaptive health care behaviours, there seems to be 
a strong rationale that depression may mediate the association between perception and 
mortality. Indeed this would fit the tenets of the CSM, as illness perceptions may lead to 
maladaptive coping procedures that may serve as cognitive and behavioural vulnerabilities 
for depression. Alternatively the misregulation or under-regulation of an illness threat may 
have detrimental effects upon health-related outcomes (Baumeister & Heatherton, 1996; 
Baumeister et al., 1994; Carver & Scheier, 1981; Detweiler-Bedell et al., 2008). The 
underlying assumption is that self-regulatory strength is a limited resource and can become 
depleted (Baumeister et al., 1994; Carver & Scheier, 1981). The implications of this resource 
view of self-regulation suggests that regulating an illness threat may lead to the successful 
adoption of positive health care behaviours, yet the under-regulation of emotion (i.e. 
vulnerability for depression). Similarly successfully regulating mood may lead to the under-
regulation of disease management (Detweiler-Bedell et al., 2008). For these reasons it 
seems pragmatic to explore both depression and illness perceptions in relation to mortality 
risk, in order to broaden the scope for understanding the processes underlying such 
relationships.    
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The data to be reported here assessed survival in incident dialysis patients who were 
followed up for an average of approximately 18 months. The aims of the investigation 
were: 
1) To determine whether depression predicts mortality in this cohort after controlling 
for co-variates associated with premature death in ESRD including age, 
inflammation (CRP), albumin and co-morbidity. 
2) To determine if illness perceptions predict mortality, and whether depression 
mediates this relationship.  
10.2 Methods 
10.2.1 Design and Patients: 
The survival of incident dialysis patients recruited in the longitudinal investigation (n=160, 
see chapter 8) was assessed over the study period (May 2007-December 2009). HD and PD 
patients were approach and recruited into the study at a point soon after dialysis initiation 
(median vintage 30.5 days, min 1 - max 100 days). Patients were eligible for inclusion if the 
following criteria was met; i) no known significant visual or physical impairment that would 
prevent the completion of the questionnaires, ii) fluency in verbal and written English 
language, (iii) not hospitalised at the time of assessment, iv) had been receiving HD or PD 
for ≤3 months, and v) no cognitive impairment as indicated by an age adjusted score of<22 
on the Mini Mental State Examination (Folstein et al., 1975). Baseline depression scores 
(BDI), illness perception scores (IPQ-R), demographic information, clinical data, and KPS 
scores collected as a part of the incident cohort (chapter 8) were used in the survival 
analysis.  
10.2.2 Co-morbidity and functional performance  
Co-morbidity was assessed using the criteria described in the general methods (chapter 4). 
For the purpose of this short-term survival analysis, patients were classified as having, 1) 
no-low co-morbidity or 2) moderate-high co-morbidity. Moderate-high co-morbidity was 
defined as having advanced disease in any one system, or the presence of cancer (see 
methods). Patients were also classified as independent (≥70) or dependent (<70) based 
upon their KPS (see chapter 4). 
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10.2.3 Clinical parameters  
In addition to demographic factors, baseline clinical data was recorded from electronic 
medical records including; primary ESRD diagnosis, smoking status, blood haemoglobin,  
serum albumin and C-reactive protein (CRP). CRP was skewed therefore it was treated 
using a laboratory clinical cut-off (>5 vs. ≤5). Estimated GFR was calculated from serum 
creatinine concentrations at the time of dialysis initiation, using the modified MDRD 
equation (Levey et al., 1999). Depressive history was recorded, where depressive disorders 
were listed in the medical problem lists in patients’ medical record. Anti-depressant use at 
the time of assessment was also recorded. As in chapter 8, path to dialysis was defined as 
either planned or unplanned.   
10.2.4 Outcome assessment 
All cause mortality was the outcome measure, which was ascertained by active surveillance 
through the renal clinics by the local consultant nephrologist, who verified the date of 
death. Patients were censored if they received a transplant, were lost to follow-up, 
recovered renal function, or were still alive at the end of follow-up. 
10.2.5 Survival Analysis 
Group comparisons (differences between depressed *BDI ≥16+ and non-depressed 
[BDI<16]) were assessed via parametric, and where appropriate, non-parametric inferential 
statistics including Independent t-tests, Mann-Whitney U tests, and Chi-Square analysis 
(Pearson’s and Fishers exact test where appropriate). This data is present earlier in this 
thesis (chapter 8). 
Kaplan Meier (KM) plots, with log-rank tests, were constructed to examine differences in 
survival (in days) between groups of patients. This was repeated across several variables to 
determine which variables may contribute to survival in a multivariate Cox model. Survival 
was described in terms of the cumulative proportion (Standard Error, S.E) of patients 
surviving 18 months (540 days) post dialysis initiation. It was not possible to estimate 
median survival due to the limited number of events.  
A series of Cox proportional hazards models evaluated the association between depression 
symptoms and survival in both unadjusted and adjusted models. Adjusted models 
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controlled for the following covariates; age, sex, albumin, haemoglobin, path to dialysis, 
moderate-high co-morbidity, CRP>5, and KPS<70. The co-variates were selected due to 
their univariate association with either survival or depression. Two sets of models were 
produced, one in which depression was treated as a continuous variable (total BDI scores), 
and the other where depression was treated as a categorical variable (employing a BDI≥16 
to define depressed patients, see chapter 5).  
A second series of Cox-models evaluated the association between illness perceptions and 
survival. Crude and adjusted models (controlling for the covariates described above) were 
evaluated. Depression-Adjusted models controlled for age, sex, albumin, haemoglobin, 
path to dialysis, moderate-high co-morbidity, CRP>5, KPS<70 and BDI scores. According to 
tests of mediation (Baron & Kenny, 1986), illness perceptions that predict mortality should 
become non-significant after controlling for depression, if depression mediates the 
relationship between illness perception and survival.  
10.3 Results 
One hundred and sixty initiating dialysis patients completed the BDI soon after dialysis 
initiation and were followed up for median of 511 days (min 47- max 1027 days), during 
which there was 27 deaths (16.9%). Over the study period 4 patients recovered renal 
function, 14 became lost to follow-up and 14 were transplanted. Two patients died within 
90 days of dialysis initiation, all survived at least 30 days. The cumulative survival at one 
year post dialysis initiation was 87.7% (S.E= 0.03), and at 18 months 85.9% (S.E=0.03). The 
mean age of the incident cohort was 57.4 (±16.0) years. The majority of patients were male 
(67.5%) and white (90.6%). Approximately one in four patients (25.6%) scored ≥16 on the 
BDI, and 15% had a documented history of depression in their medical records. Seventeen 
patients (10.6%) were on anti-depressants.  
Differences between depressed patients (BDI≥16) and non-depressed (BDI<16) patients, 
with regards to baseline demographic and clinical factors were presented earlier as apart 
the longitudinal study (see results in chapter 8). Depressed patients were significantly 
younger and were more likely to have an unplanned entry to dialysis as compared to the 
non-depressed. In addition depression was significantly associated with dependent physical 
functioning (KPS<70), and with a depressive history. There was no difference between the 
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co-morbidity groups (none-low vs. moderate-high) with regards to BDI scores (11.9 ±9.3 vs. 
12.3 ±7.7, t(158)=0.318, p=0.751). As shown in chapter 8, baseline BDI scores failed to 
correlate significantly with albumin, Hb, CRP, and dialysis vintage.  
10.3.1 Univariate Analysis: Kaplan Meier survival functions with log-rank tests 
There was a significant difference in survival between depressed (BDI ≥16) and non-
depressed (BDI<16) patients (p=0.013, figure 10.1). At 18 months the cumulative survival 
(CS) in depressed patients was 74.9% (SE=0.07) compared to 89.6% (SE=0.03) in the non-
depressed group. Functional status had a significant bearing upon survival (figure 10.2), 
with patients scoring KPS >70 surviving significantly longer (CS at 18 months= 90.6% 
SE=0.03) as compared to those with a KPS ≤70 (CS at 18 months= 58.5% SE=0.11, p<0.01). 
The cumulative survival at 18 months in patients with CRP>5 was 77.6% (SE=0.05) 
compared to 95.8% (SE=0.02) in those with CRP≤5 (figure 10.3), which was a significant 
difference (p=0.001). Survival functions defined by co-morbidity group are shown in figure 
10.4. Moderate-high co-morbidity was associated with reduced survival (CS at 18 months = 
76.1% SE=0.06) compared to none-low co-morbidity (CS at 18 months = 91.6% SE=0.03, 
p=0.001). Survival was not associated with any of the following factors, depressive history 
(p=0.474), diabetes (p=0.302), treatment modality (p=0.302), anti-depressant use (p=0.08), 
gender (p=0.486), and renal service (p=0.731). There was an effect of the path to dialysis 
upon survival tending towards significance, with unplanned starters having shorter survival 
(p=0.059, figure 10.5). The 18 month cumulative survival in unplanned patients was 77.0% 
(SE=0.07) compared to 89.3% (SE=0.03) in planned patients. 
10.3.2 Cox-survival models: Depression and mortality  
In unadjusted Cox-proportional hazard models, the BDI was significantly associated with 
mortality, with a one point increase in BDI increasing the hazard of death by 6% (table 
10.1). The BDI remained significant after controlling for age and sex, and in fully adjusted 
models which controlled for the variables described in the methods (see table 10.1). A one 
point BDI increase was associated with an 8% increase in the hazard for death. This equates 
to approximately twice the risk of death for a 1 standard deviation change in the BDI. The 
results were replicated after substituting the continuous BDI scores with a BDI ≥16 to 
categorise depressed patients (vs. non-depressed, BDI <16). In a fully adjusted model 
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patients with a BDI ≥16 had a 2.4 increase in the hazard for death as compared to patients 
with a BDI<16 (p=0.05, figure 10.6). 
Table 10.1: The association of depression symptoms with all cause mortality.  
 Type of analysis 
HR (95% Confidence Interval) 
Predictor Crude Age-Sex Adjusted Fully Adjusteda 
BDI 1.06 (1.03 - 1.10), p=0.001 1.08 (1.04 - 1.10), p<0.001 1.08 (1.03 - 1.13), p=0.002 
BDI ≥ 16b 2.58 (1.19 - 5.63), p=0.017 2.90 (1.31 - 6.32), p=0.009 2.40 (1.0 -  5.80), p=0.05 
aAdjusted for age, sex, albumin, haemoglobin, path to dialysis, moderate-high co-morbidity, CRP>5, 
KPS<70  
bWhere reference category (1.0) was non-depressed (i.e. BDI<16). 
 
10.3.3 Cox-survival models: Illness perceptions and mortality 
All of the illness perceptions were entered individually into crude Cox survival models to 
examine any associations with mortality. Only two illness perceptions showed a significant 
relationship with mortality, namely treatment control perceptions and illness coherence. In 
both crude and adjusted models, treatment control and illness coherence predicted 
survival (table 10.2). In depression-adjusted models (controlling for BDI scores) illness 
coherence was no longer a significant predictor of survival, whereas treatment control 
remained significant. This suggests that depression mediates the association between 
illness coherence and mortality. A one point increase in treatment control perceptions was 
associated with a 14% reduction in mortality risk. As with the previous Cox survival analysis 
(section 10.3.2) BDI score was also a significant predictor of mortality (HR=1.06 95% CI 1.01 
– 1.11, p=0.02). 
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Fig 10.1: Survival functions for depressed (BDI ≥16) vs.                                Fig 10.2: Survival functions for functional performance (KPS)                    Fig 10.3:  Survival functions for patients with a CRP ≤5 
non-depressed  (BDI<15) patients (p=0.013).                                              KPS>70 vs. KPS≤70 (p<0.001).                                                                            vs.CRP>5 (p=0.001).                                                                         
Fig 10.4: Survival functions for patients with none-low vs.                       Fig 10.5: Survival functions for patients with a planned vs. unplanned         Fig 10.6: Adjusted~ Survival functions comparing                  
moderate-high co-morbidity (p=0.001)                                                         start to dialysis (p=0.059)                                                                                       depressed vs. non-depressed patients (p=0.05) 
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Table 10.2: The association of illness perceptions with all cause mortality. 
 Type of analysis 
HR (95% Confidence Interval) 
Predictor Crude Adjusted Depression- Adjusted~ 
Treatment 
control 
0.86 (0.77 – 0.98), p=0.02 0.84 (0.72 – 0.97), p=0.02^ 0.86 (0.74 – 0.99), p=0.04 
Illness 
Coherence 
0.90 (0.84- 0.98), p=0.01 0.90 (0.80 – 0.99), p=0.03¥ 0.92 (0.83 – 1.03), p=0.14 
^Adjusted for age, sex, albumin, haemoglobin, path to dialysis, moderate-high co-morbidity, CRP>5, 
KPS<70 and Illness coherence. ¥ Adjusted for age, sex, albumin, haemoglobin, path to dialysis, 
moderate-high co-morbidity, CRP>5, KPS<70 and treatment control. ~Adjusted for all the factors 
just described and BDI scores. 
 
10.4 Discussion 
There is convincing published evidence that depression is associated with adverse clinical 
outcomes among patients with physical diseases. However while there is a similar 
consensus within the ESRD literature, some studies have provided null findings, and there is 
heterogeneity with regards to the size of the effect. Furthermore, studies have varied in 
their methodological approach, and there is no UK data. Given this, a meta-analysis of the 
association between depression and mortality in ESRD seems highly relevant.  
The data from this incident cohort reveals that the presence of depressive symptoms soon 
after dialysis initiation is associated with short-term survival. This finding supports data 
from previous research, which have utilised different statistical approaches and 
assessments of depression. As described earlier both Boulware et al (2006) and Kimmel et 
al (2000) failed to find an association between baseline depression and survival yet report 
an effect after depression was treated as a time-varying component. Lopes et al’s (2002) 
analysis of the DOPPS cohort found that two simple questions relating to mood (at 
baseline) predicted survival, although this was not an incident cohort. After using a 
conventional assessment of depressive symptoms, the data here demonstrates that 
baseline depression predicts short-term survival after adjusting for covariates including, 
albumin, path to dialysis and co-morbidity. These findings were not dependent upon how 
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the BDI scores were treated, either as a continuous variable or as an adjusted BDI cut-off 
score (BDI ≥16); both methods yielded a significant association between depression and 
mortality.  
Depression and co-morbidity share a close relationship, thus the finding that depression 
predicts mortality may be confounded by co-morbidity; or that even the assessment of 
depression is a surrogate marker for co-morbidity. Although the data here, and in past 
reports suggest that the effect of depression is independent of co-morbidity, the study by 
Boulware et al (2006) suggest that worsening co-morbidity leads to increased depression 
rather than vice versa. As reported earlier, there was no evidence of an association 
between co-morbidity and depression, however it should be noted that co-morbidity was 
treated as a categorical variable in order to define a group of at risk patients (Chandna et 
al., 1999). Depression may have also been related to sub-threshold disease or to diseases 
not deemed to be high risk. Other explanations underlying the depression-mortality 
relationship include non-adherence (Carney et al., 1995), poor lifestyle (Ziegelstein et al., 
2000), malnutrition (Koo et al., 2003), alterations to immune functioning (Kimmel et al., 
1993; Lett et al., 2004), and increased platelet activation (Berk & Plein, 2000). 
Hypoalbuminemia, a known risk factor for mortality in ESRD (Leavey, Strawderman, Jones, 
Port, & Held, 1998) has also been associated also with depression in ESRD (Koo et al., 
2003). No association between depression symptoms and albumin was found here, 
although it has been found that depression predicts decreasing serum albumin over time 
(Friend, Hatchett, Wadhwa, & Suh, 1997). Furthermore others report an association 
between depression and inflammation in ESRD patients (Simic Ogrizovic et al., 2009), 
although there is mixed evidence (Dervisoglu et al., 2008) highlighting the need for further 
empirical study. CRP was not associated with depression here, however it is likely that 
more specific markers like IL-6 and hsCRP are more appropriate. There is evidence of a 
association between malnutrition, inflammation, and atherosclerosis (MIA) in ESRD 
patients (Honda et al., 2006; Wang et al., 2004), and some preliminary evidence suggests 
that depression could be involved in MIA syndrome (Simic Ogrizovic et al., 2009), albeit 
with a great need for further investigation. Of further interest is residual renal function 
(Vilar et al., 2009) which has been show to predict survival in haemodialysis patients, and 
may be associated with depression (Chilcot, Wellsted, Vilar, & Farrington, 2009). A paper 
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describing the association between depression and residual renal function can be found in 
the appendix (Chilcot et al., 2009).  
As presented earlier (chapter 8) depression symptoms are greater in patients who have an 
unplanned start to dialysis. A Kaplan-Meirer plot with a log-rank test demonstrated a near 
significant association between an unplanned start to dialysis and mortality which confirms 
previous data (Chandna et al., 1999); although the relationship was non-significant in 
adjusted Cox model. The inclusion of depression, albumin and co-morbidity in the adjusted 
model may mediate the relationship between unplanned path and mortality, although 
further investigation is required to confirm this assumption.  
While the discussion to this point has focused upon the depression-mortality association, 
the secondary aim of this investigation was to determine if illness perceptions predicted 
mortality. One previous study found that lower treatment control perceptions predicted 
mortality in ESRD (van Dijk et al., 2009). The data reported here revealed that both lower 
treatment control perceptions and weaker illness coherence (illness understanding) 
predicted mortality after controlling for demographic and clinical variables. However unlike 
the van Dijk study, depression was controlled for in subsequent “depression-adjusted” 
models. After adjustment the relationship between illness coherence and mortality was 
attenuated, while the BDI total score remained associated with mortality. This suggests that 
the association between illness coherence and mortality is mediated by depression. 
Treatment control perceptions remained a significant predictor of mortality even after 
controlling for depression scores, suggesting that illness perceptions and depression can 
have independent effects upon survival. This notion is in accord with the tenets of the 
parallel response model described in chapter 3 (Leventhal, 1970). Lower treatment control 
perceptions may be associated with survival due to behavioural factors such as non-
adherence. In chapter 9 treatment control was not a significant predictor of fluid 
adherence, although as discussed previously non-adherence is multifaceted in ESRD. Lower 
treatment control may be associated with other maladaptive health behaviours in ESRD 
which may add to the explanation of this mortality-association.  
Following dialysis initiation, efforts are made to correct ESRD related problems including 
problems relating anaemia, and bone and mineral metabolism. The data presented here 
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indicates that the treatment of co-morbid depression and altering maladaptive illness 
perceptions may be helpful during this early period. As eluded to earlier in this thesis 
(chapter 2), there is there is mixed evidence that treating depression has a positive impact 
on survival and outcomes in physical illnesses (Detweiler-Bedell et al., 2008), even though 
treatment may have an important role in improving quality of life. The data shown here 
supports the thesis of Detweiler-Bedell et al (2008) who propose an integrated approach of 
depression and disease management in order to avoid self-regulatory failure and 
maladaptive outcomes (Baumeister & Heatherton, 1996; Baumeister et al., 1994). While it 
is clear that illness perception and depression share a dynamic relationship, the data shown 
here argues the case that mood and perceptions can have independent effects upon 
survival outcomes.  
The study here did have a few limitations which are worthy of discussion. Although we 
employed a conventional depression severity tool (and used an adjusted BDI cut-off for 
ESRD patients), recent evidence questioned the association between depression, as 
assessed by questionnaire methods, and mortality, instead reporting an effect only with a 
diagnostic scheme for MDD (Hedayati et al., 2008). Future studies should utilise diagnostic 
assessment for MDD in order to identify whether the mortality association is upheld. There 
was also some heterogeneity as to the time when patients were assessed post dialysis 
initiation. However the data shows that there was no relationship between dialysis vintage 
and depression symptoms, therefore it appears that the time since dialysis initiation during 
the 3 month recruitment window did not have an undue influence on the relationship 
between mood and mortality. A further limitation regards the assessment of depressive 
history. Relying on a documented history is likely to under represent depressive history, 
particularly as depression is often under recognised in this patient population (Wang & 
Watnick, 2004). However the impact of depressive history may not be all that important, as 
research into patients with a recent MI suggest that it is post and not pre-MI depression 
that is predictive of future cardiac events and death (Dickens et al., 2008; Grace, Abbey et 
al., 2005). With regards to the treatment of co-morbidity our approach differed from 
others. Given the relatively short follow-up it was important to define a group of patients 
who were at high risk over this period. While the findings did not change when using 
alternative methods including the Davies method (Davies et al., 2002), the current method 
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was preferred because it was a stronger predictor of mortality in the adjusted Cox 
proportional hazard models.  
10.5 General remarks  
Data has been presented in this chapter that demonstrates a significant risk of death for 
patients with depressive symptoms shortly after dialysis initiation. This is the first UK data 
that has examined the impact of depression upon survival and adds to the wider body of 
literature. Moreover illness perceptions are associated with mortality which supports one 
other study in ESRD. Increasing our understanding of the pathways between depression, 
illness perception, and mortality in ESRD may help better define and develop integrated 
interventions to attenuate the risk of depression and death, and thus improving the 
psychological and clinical sequel of dialysis patients. 
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Chapter 11 
General Discussion 
11.1 Overview 
The evidence presented in preceding chapters is offered to defend the thesis-  
Depression is a common psychopathology in patients with End-Stage Renal Disease that is 
associated with maladaptive illness representations. Moreover depression and illness 
representations predict adverse outcomes in End-Stage Renal Disease.  
In summary the investigations have established several novel findings: 
1) On-dialysis depression screening is a viable procedure for the assessment of 
depression. Furthermore a BDI score of ≥16 compares well with a diagnostic 
method for Major Depressive Disorder in ESRD patients. 
2) The factor structure of the BDI used with ESRD patients is best understood in terms 
of a bi-factor measurement model. 
3) Illness perceptions are strongly associated with depression in dialysis patients and 
predict the trajectory of depression over the first year of dialysis. 
4) Clinical variables are largely unrelated to depression in ESRD; rather it is the 
interpretation of the condition via illness representations that is more fundamental. 
5) Illness perceptions explain fluid non-adherence in ESRD patients. 
6)  Depression and illness perceptions predict short-term survival among incident 
dialysis patients.  
11.2 Consideration of methodology: Assessing depression in ESRD  
In order to achieve the aims of the empirical work presented, careful consideration of the 
methodology was required. Accordingly two studies were devoted to the evaluation of the 
methods (chapters 5 &6). This was particularly important for several reasons. Firstly it was 
important to establish a practical procedure for assessing patients. Since the majority of 
patients recruited in the studies would be receiving in-hospital haemodialysis it seemed 
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sensible for them to complete the BDI and IPQ-R while on-dialysis. Furthermore screening 
for depression while on-dialysis has potential implications for regular screening in routine 
practice, particularly since depression remains a common yet under recognised 
psychopathology (Wang & Watnick, 2004). Finally the issues of measuring depression 
among patients with chronic illnesses are well documented (Cavanaugh et al., 1983; Koenig 
et al., 1997), thus establishing the validity of the BDI in UK ESRD patients was of 
importance. 
The results from the pilot study of chapter 5 suggest that on-dialysis depression and IPQ-R 
assessments are viable and lead to similar responses made by the same individuals 
assessed off-dialysis. On-dialysis assessments were employed for all haemodialysis patients 
in the subsequent studies, therefore providing a standardised method of assessment.  
Interestingly, there was a slight bias for higher scores on the somatic items of the BDI when 
on-dialysis as compared to off-dialysis. If used regularly as a screening tool in clinical 
practice, on-dialysis screening would potentially produce more false positive screens for 
depression, yet would capture more patients and thus reduce false negative cases. With 
regards to defining a relevant BDI cut-off score for depression, scores were compared 
against a diagnostic interview conducted as part of the assessment. First and foremost it 
was clear, as others have reported, that BDI cut-offs require adjustment in ESRD patients 
(Grant et al., 2008; Watnick et al., 2005). The results here revealed that a BDI≥16 had 
optimal sensitivity and specificity for major depression. These findings support the results 
of Watnick et al (2005), although it remains important to distinguish the original BDI as 
used by Watnick et al and indeed others (Craven et al., 1988) with the BDI-II as used here.  
The factor structure of the BDI was the focus of chapter 6. Several proposed factors for the 
BDI are suggested in the literature, and were evaluated by confirmatory factor analysis 
from data pooled between longitudinal and cross-sectional investigations presented in this 
thesis. The best fitting model, as determined by absolute fit indices, was found to be a bi-
factor measurement model as suggested by Ward (2006). This analysis is the first to 
evaluate the underlying factor structure of the BDI in ESRD patients, and has substantial 
implications for how others have treated BDI data by using a cognitive subscale (CDI, 
Kimmel et al., 2000; Sacks et al., 1990). As previously articulated in chapters 2, 3 and 6, the 
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CDI was never derived via factor analysis. There was little evidence from the CFA conducted 
in chapter 6 that distinctive cognitive and somatic factors (e.g. two factor models) explain 
the underlying measurement structure of the BDI in this patient context. Rather, a general 
depression factor was supported accompanied by two orthogonal cognitive and somatic 
factors (Ward 2006). Taken together it is possible to separate the variance from a general 
depression factor in order to form cognitive and somatic factors although these individual 
factors contribute little unique variance to the measurement model above and beyond 
“general depression”. It is therefore appropriate to utilise the BDI (total score) as a global 
measure of depression as was done in the analysis of chapter 8. It is also possible to utilise 
the measurement model defined in chapter 6, particularly if researchers are interested in 
evaluating predictors that explain unique variance in the cognitive or somatic factors of the 
BDI.  
In summary, the first empirical section devoted a substantial amount of consideration to 
the methodology particularly the measurement of depression. In doing so the factor 
structure of the BDI for use with ESRD patients was best defined, a procedure of on-dialysis 
assessment evaluated, and an adjusted BDI cut-off identified for use within the UK renal 
population. 
11.3 Illness Representations and Depression in ESRD 
The second empirical section examined the cardinal feature of this thesis, namely the 
relationship between depression and illness representations. In both the cross-sectional 
and longitudinal studies, depression as estimated by a BDI cut-off score ≥16 was highly 
prevalent (29% and 26% respectively). These estimates are similar to those found 
elsewhere (Hedayati et al., 2008; Kimmel et al., 2000) and reaffirm that depression is the 
most common psychopathology in ESRD patients.  
The CSM of illness representations posits a dynamic self-regulatory system that attempts to 
resolve or manage illness threats (Leventhal et al., 1980; Leventhal et al., 1984). 
Accordingly, core features of the representation namely illness perceptions (identity, 
timeline, consequences, control and causes) accompanied by a parallel emotional response 
serve as the psychological interpretation of the illness state. Illness representations guide 
the selection, maintenance and adaption of coping procedures, employed to tackle the 
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illness threat. Furthermore the CSM posits that following coping efforts, appraisal of the 
outcomes is undertaken which inform new targets for regulation, or continued regulation, 
of the current state by updating the representation or coping procedures. However, it 
should be noted that the appraisal process defined in the CSM has received little empirical 
attention. Furthermore there is limited support that coping mediates the association 
between illness representations and outcomes (Heijmans & de Ridder, 1998; Scharloo et 
al., 1998). Nevertheless, as reviewed in chapter 3 it is clear that illness representations are 
associated with psychological and functional outcomes (Bijsterbosch et al., 2009; Hagger & 
Orbell, 2003; Juergens et al., 2010). Furthermore there is evidence that specific illness 
perceptions (in particular consequences and timeline) predict depression in both cross-
sectional and longitudinal studies. However, there are notable differences within the 
literature with regards to the assessment of depression, study designs and statistical 
methodologies. A meta-analysis on the topic would therefore be of considerable value.  
Chapter 7 is the first study to investigate the relationship between illness representations 
and depression in ESRD patients. Indeed the results demonstrated an association between 
depression and several illness perceptions. Furthermore, depressed individuals as defined 
by a BDI≥16 were characterised by different illness perceptions as compared to the non-
depressed. Perceptions of lower control, greater consequences and lower coherence 
predicted depression in established HD patients. These findings agree with the results in 
other illness groups (Jopson & Moss-Morris, 2003; Schiaffino et al., 1998), suggesting that it 
is the interpretation and regulation of illness that serve as vulnerabilities for depression 
among patients with chronic illnesses. Chronic illness and its interpretation through illness 
representations are likely to perpetuate negative cognitions that are associated with 
depression. Indeed individuals with chronic physical disease are likely to have lower self-
esteem and locus of control as compared to healthy controls (Bailis & Chipperfield, 2002; 
Leung & Bryant, 2000). Illness representations may increase the vulnerability for depression 
by activating negative depressive schema or by maladaptive self-regulation as posited in 
the CSM (Detweiler-Bedell et al., 2008). The under regulation of mood and subsequent 
failure to “repair mood” may occur as a direct consequence of the regulation of the disease 
state (Detweiler-Bedell et al., 2008). Put simply, focusing on the regulation of the disease 
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state may help attain disease related goals, but to the detriment of mood due to the failure 
to invest attention and self-regulatory effort to mood repair. 
The longitudinal study of chapter 8 corroborated the findings of chapter 7. At baseline 
illness perceptions were associated with depression. What is of specific interest is the novel 
finding that path to dialysis was associated with illness perceptions, and in structural 
equation modelling illness perceptions mediated the association between path to dialysis 
and depression. This suggests that individuals with an unplanned start to dialysis held a 
different interpretation of their illness, and presumably different targets for self-regulation. 
It is therefore likely that unplanned patients were attempting to regulate aspects of the 
disease management, particularly as they reported lower illness coherence and greater 
unpredictability. As articulated above, the attention unplanned patients may have devoted 
to self-regulation of the illness, may have lead to the under regulation of mood as 
evidenced by increased depression scores. Although somewhat speculative, such an 
explanation does conform to current perspectives in the regulation of health and illness, 
albeit with a need to further address the dynamics of regulation pertaining to chronic 
disease.  
Evaluating the data over time revealed relative stability in depression and illness 
perceptions. There was a tendency for the BDI to decline over the follow-up as determined 
in an unspecified latent growth model. Examination of individual BDI trajectories suggests 
however, that there may be some patients who remain stable over time, and others who 
improve or worsen over time. An appropriate method of identifying different clusters of 
trajectories is latent class growth analysis (Nagin & Odgers, 2010). However, this could not 
be undertaken here because of a relatively small follow-up and sample size. Taken 
together, there appears to be some change in mood over the first year of dialysis therapy, 
yet further empirical investigation is required in order to identify its function.  
Examination of the IPQ-R dimensions in latent growth models revealed that illness identity 
decreased over time, and illness coherence strengthened (i.e. improved). This implies that 
patient’s illness identity based upon symptoms attributed to ESRD is reducing, whilst their 
illness understanding is increasing over time. Others report larger differences in illness 
perceptions over time (Bijsterbosch et al., 2009; Fischer et al., 2010; Lawson et al., 2008) 
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however it is likely that the disease specific nature of the condition is largely responsible for 
these larger differences. For example, following an acute MI, illness perceptions may 
change over time as individuals move from the “illness state” into the “recovery state”. In 
chronic conditions like the ESRD the illness state remains constant, although in some 
conditions like RA, cyclical symptomatic events can occur that may potentially lead to 
altered perceptions. Indeed, Heijmans et al (1998) highlight differences between disease 
groups with regards to illness perceptions, yet few studies have followed suit. Such 
comparisons may provide good opportunities to test specific theories relating to the 
change in illness perceptions over time between patient populations.  
A central consideration in chapter 8 was establishing the predictors of the change in 
depression over the first year of dialysis using latent growth modelling. LGM is particularly 
suited to this kind of analysis, yet few researchers have attempted this method to examine 
the trajectory of depression in chronically ill populations. The findings suggested that 
baseline timeline and emotional reaction predicted a significant change in depression over 
time. Greater timeline perceptions at baseline predicted an increase in depression over 
time. Indeed this finding supports those from other studies suggesting that chronicity 
perceptions are particular cognitions associated with depression that may reflect feelings of 
hopelessness. Furthermore stronger timeline perceptions may have been associated with 
different regulatory goals, which as posited previously, may have led to insufficient mood 
regulation. An interesting additional observation was that greater emotional 
representations at baseline were associated with reduced depression symptoms over time. 
This may reflect some regression towards the mean phenomena, or alternatively suggest 
that greater baseline distress promoted attention to the regulation of mood resulting in 
improved depression scores over time (i.e. mood repair).  
In summary, the second empirical section has provided support for the cross-sectional 
association between depression and illness representations, and has also shown that illness 
representations are associated with the trajectory of depression among incident dialysis 
patients.  
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11.4 Illness Representations and health behaviour 
The final empirical section attended to clinical outcomes in dialysis patients. The first study 
in this section investigated the predictors of fluid non-adherence, taken to mean poor 
adherence to dietary salt and water restriction since fluid intake is driven by thirst which is 
closely linked to salt intake. Fluid restriction is just one facet of the ESRD treatment regime, 
in which non-adherence remains a significant concern. Failure to adequately control the 
intake of fluid can result in adverse clinical outcomes including hospitalisation and death, 
thus understanding the psychology of this behaviour is highly relevant. As highlighted 
within the literature non-adherence is conceptually hard to define and indeed measure. 
Therefore substantial effort was devoted to defining a group of patients with clinically 
significant fluid gain (IDWG, measured as a proportion of their ideal dry weight). Previous 
studies have failed to consider residual renal function (e.g. O’Connor et al., 2008) which 
may be a significant confound when defining non-adherence based upon weight gain. In 
the investigation of chapter 9, residual renal function was measured and controlled for in 
the analysis in an attempt to better define predictors of non-adherence.  
The findings of chapter 9 are the first to show that illness perceptions predict fluid non-
adherence in HD patients. This observation supports published data which reports an 
association between illness perceptions and maladaptive health care behaviours (Cooper et 
al., 1999; French, Cooper, & Weinman, 2006; Nouwen, Urquhart Law, Hussain, McGovern, 
& Napier, 2009). While more proximal perceptions pertaining to the actual behaviour (i.e. 
attitudes, treatment cognitions and self-efficacy) are likely to be important, the data here 
suggest that self-regulatory processes surrounding the interpretation of the illness can 
influence health behaviour. Indeed this notion is capsulated in the CSM operationalised as 
“IF THEN” rules, which are presumed to be embedded within the illness schema (e.g. 
Henderson et al., 2009). If the condition is not perceived to be as serious, then particular 
strategies or behaviours may not be salient to the individual and thus deemed not to be 
important.  
A limitation of chapter 9 is the cross-sectional design, which prevents temporal associations 
from being made. While it appears theoretically appropriate that illness perception should 
influence subsequent behaviour, it is plausible that non-adherent behaviour, and indeed 
“getting away with it”, may influence illness perceptions. Examining the temporal 
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association between illness perception and non-adherence would be of value, particularly 
considering an array of ESRD health behaviours including dialysis attendance and 
phosphate control.  
11.5 Clinical Outcomes 
The final chapter provided an evaluation of depression, illness perceptions and short-term 
survival among incident dialysis patients. The data here demonstrated that depression 
symptoms at a point soon after dialysis initiation predicted short-term survival, after 
controlling for potential co-variates including co-morbidity and age. Previous studies have 
also reported an association between depression and mortality in ESRD patients (Hedayati 
et al., 2005; Kimmel et al., 2000; Riezebos et al., 2010), yet it is my understanding than 
none have examined short-term survival in incident patients.  
Interestingly an evaluation of illness perceptions revealed that treatment control 
perceptions predicted mortality, an effect that was upheld even after controlling for 
depression. In addition illness coherence was found to predict mortality; however the 
effect was attenuated after controlling for depression, suggesting the depression mediated 
the association.  
In conclusion it has been demonstrated that greater depression symptoms and weaker 
perceptions of treatment control are predictors of survival among incident dialysis patients. 
While the mechanisms underlying these associations are not fully understood, non-
adherence and other maladaptive health behaviours appear obvious explanatory 
candidates. The quote provided at the beginning of chapter 2 appears extremely apt with 
regards to these data,  
“If you be sick, your own thoughts make you sick” 
 - Benjamin Jonson (1572-1637) 
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Taken together the final empirical section offers evidence that illness representations and 
depression are associated with adverse clinical outcomes in dialysis patients, thus the 
potential to improve the clinical sequel of patients by altering perceptions and treating 
depression remains substantial.  
11.6 Empirical Limitations 
It is acknowledged that the work here suffered some general limitations. Throughout the 
thesis depression symptoms were assessed using a severity measure and not by a 
diagnostic method. While assessing the relationship between illness perceptions and Major 
Depressive Disorder would be of interest, it was beyond the scope and practicalities of the 
investigations here. Adopting this approach would have certainly led to smaller sample 
sizes in the investigations reported due the fact that diagnostic enquiries cannot be easily 
conducted on-dialysis. Further, solely considering a diagnosis would have restricted the 
evaluation of the depression over time, which is better suited to the use of continuous 
data. Nevertheless examining illness perceptions in patients who meet a diagnosis of MDD 
would shed further insights into the relationship between perception, regulation and mood 
in ESRD. However it is envisaged that similar findings would be observed if diagnostic 
approaches were employed, as similar illness perceptions were associated with depression 
in the analyses here that treated depression both as a dichotomous variable (BDI≥16) and a 
continuous severity score.  
With regards to the patient demographic, the studies here were mostly restricted to HD 
patients. While the longitudinal study did include a sample of PD patients, comparisons 
between treatment modalities was not the main focus in these studies. However there 
does appear to be a literature bias for studying the psychosocial aspects of patients on HD 
and not PD, despite the fact that PD may offer several advantages with regards to Quality 
of Life (Brown et al., 2010). Extending the work here to include a representative PD patient 
sample would be of value, particularly as it would allow treatment specific differences in 
depression and illness representations to be identified and modelled over time.  
Although not of direct empirical interest here, it is acknowledged that some measure of 
coping may have added to the explanation of data presented, particularly in the studies 
that utilised SEM approaches. This would have allowed specific assumptions of the CSM to 
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be tested. However there is a growing literature that shows that coping does little to 
explain the association between illness perception and outcomes. While it is probable that 
conventional conceptualisations of coping may be inappropriate or even overlap with 
illness perceptions, it is clear that researchers need to define the specific mechanisms 
involved (e.g. coping procedures) that allow illness perceptions to translate into behaviour 
and outcomes. 
A final consideration concerns the IPQ-R. The symptoms that made up the identity subscale 
and the causal perception items were taken from the original questionnaire. Tailoring these 
items so there were renal specific may have better captured renal specific identity and 
causal attributions.  
11.7 Future Directions  
It is clear from the evidence presented in this thesis that depression is a significant extra-
renal co-morbidity that requires recognition and treatment, particularly given its 
association with increased mortality. Depression appears to be similar to other extra-renal 
co-morbidities because it requires some level of vulnerability and an activating event 
(stress or illness accompanied by its interpretation, c.f. Beck et al., 1967). Therefore like 
other co-morbidities it requires detection and management in ESRD patients. Accordingly 
initially work should be undertaken in order to test whether regular depression assessment 
increases diagnosis and referral for treatment. With regards to the later, future trials are 
needed to evaluate interventions to treat depression, particular at a point soon after 
dialysis. Currently there is no suitably powered RCT of anti-depressants in ESRD and only 
one trial of CBT (Duarte et al., 2009).  
While conventional treatments for depression including pharmacological and CBT 
interventions may be effective, the data presented here suggest the utility of targeting 
maladaptive illness representations. Indeed early work in the cardiac literature has shown 
the benefits of targeted illness perception inventions upon health related outcomes 
(Broadbent et al., 2009; Petrie et al., 2002). It is suggested that changing maladaptive 
illness perceptions early in the patient’s dialysis career could ultimately bring about lasting 
benefits with regards to mood and health care behaviour. Future interventions should 
ideally evaluate the potential benefits upon mood, behaviour and clinical outcomes. While 
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it is acknowledged that current research has not been able to consistently show that 
treating depression improves clinical outcomes, or have not directly tested the benefits 
upon clinical outcomes, it is envisaged that integrating depression and disease 
management strategies may help identify failures in self-regulation (Detweiler-Bedell et al., 
2008). Adopting this approach may help promote increased quality of life and improved 
outcomes in ESRD patients. 
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A - Revised Illness Perception Questionnaire (Moss-Morris et al., 2002) 
 
B- Beck Depression Inventory-II (Beck et al., 1996) 
 
C- Patient Questionnaire 
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